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Ab stract 
The adenomatous polyposis coli gene (APC) is located at human chromosome 5q21. 
Germline mutations in the APC gene characterise the Mendelian dominant inherited 
disorder, familial adenomatous polyposis coli (FAP). FAP patients develop numerous 
adenomas within the large intestine, some of which ultimately progress to carcinoma. A 
more general role for APC mutations in neoplasia is suggested by the fact that FAP 
patients are at risk of developing tumours of the brain, thyroid, bone and focal 
proliferative lesions ( "desmoid tumours ") of the connective tissue. Furthermore, 
mutations in the APC gene and / or loss of heterozygosity (LOH) at 5q21 have been 
reported in a range of sporadic tumours including tumours of the lung. 
This thesis firstly investigated the occurrence of LOH at chromosome 5q21 in subtypes of 
human non -small cell lung cancer (NSCLC). Allele loss was compared in adenocarcinoma 
(ADC) and squamous cell carcinoma (SCC), the most common forms of NSCLC. Further 
sub -classification of the ADC subgroup was carried out to compare ADC arising in the 
bronchus versus the parenchyma, as determined by histology. Four genetic 
polymorphisms in the APC and MCC (mutated in colorectal cancer) genes at 
chromosome 5q21 were analysed for LOH in 92 consecutive primary SCC and ADC of 
the lung. Loss of heterozygosity was identified in at least two polymorphic loci in 40% 
(27/68) of informative cases. There was no significant difference in the frequency of LOH 
between SCC and ADC cases (Chi- squared test, df=1, p= 0.446) or within the ADC 
subgroups; bronchial and parenchymal origin (Fisher's exact test; two -tailed test 
p= 0.237). Results revealed that the frequency of LOH within the SCC group and the 
ADC remained similar at each tumour stage, Fisher's exact test (two -tailed test; p >0.2 in 
all cases). This result suggests that loss of 5q21 does not promote metastatic spread in 
these histological groups. Following the subdivision of ADC into site of origin, results 
revealed that LOH was not associated with increasing tumour stage in the parenchymal 
or bronchial subgroups, as determined by Fisher's exact test (two -tailed test; p >0.2 in all 
cases), or that the frequency of LOH differed between subgroups at each tumour stage, 
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Fisher's exact test, two tailed test; p >0.2 in all cases. 
Thirty tumours showing LOH at one or more polymorphic sites were examined for 
mutations in the mutation cluster region (MCR) of APC by single- strand conformational 
polymorphism (SSCP) analysis. Mutations were not detected in any of these cases. These 
results suggest that it is likely that a tumour suppressor gene on 5q other than APC is 
involved in the pathogenesis of lung cancer. 
Secondly, this thesis examined ADC of parenchymal or bronchial origin by the 
independent criterion of K -RAS mutation, a known feature in pulmonary ADC. Sixty -five 
surgically resected primary pulmonary adenocarcinomas were screened for mutations at 
codon 12 of the K -RAS gene by a PCR based method. Mutations in position 1 or position 
2 of codon 12 were detected in 16 tumours (25 %). When analysed by site of origin, 
mutations were seen in 9/26 (35 %) parenchymal and in 0/12 bronchial ADC. This 
difference is significantly different, as determined by Fisher's exact test (two -tailed test; 
p= 0.0355). No association was noted between the presence ofK -RAS mutation at tumour 
stage, indicating that K -RAS mutations are not associated with metastatic spread. K -RAS 
mutations were also detected in 5 out of 32 foci of alveolar atypical hyperplasia (AAH), a 
lesion considered on histological grounds to be the precursor to parenchymal ADC. DNA 
sequencing showed that the great majority of mutations in both ADC and AAH were G -T 
transversions. These findings provide support for the classification of pulmonary ADC 
into bronchial and parenchymal subtypes and also provide molecular evidence to support 
the importance of AAH in the development of parenchymal cancers. 
Finally, this thesis described the generation and initial characterisation of a murine APC 
transgenic founder line designed as a model to investigate the effects of aberrant 
expression of APC. Several Apc mutant murine models of FAP already exist. These all 
carry a heterozygous mutation in the Apc gene. The Min mouse (multiple intestinal 
neoplasia) is an example and carries a mutation at codon 850. All current models 
however are of limited use as mice homozygous for Apc mutations die at approximately 
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6.6 days post coitum, limiting analysis to Apc heterozygotes. Homozygous loss of Apc 
therefore depends upon additional somatic events that are not under direct experimental 
control and this may be associated with additional, undisclosed genetic events. Here a 
transgenic approach was taken to generate animals where the expression of the APC 
transgene is conditionally inactivated using the Cre -loxP recombination system of the 
bacteriophage P 1. APC cDNA was flanked by loxP sequences and the promoter sequence 
of the ubiquitously expressed murine phosphoglycerate kinase (Pgk) gene cloned 
upstream of the APC cDNA to drive the expression of the transgene. Pro -nuclear 
injection was used to deliver the APC transgene into oocytes of wildtype mice (F1 
(C57BL /6 x CBA)). A transgene positive founder line was established and transcription 
of the APC cDNA confirmed in a wide variety of tissues using reverse transcription 
polymerase chain reaction (PCR). To date, transgene positive mice on an Apc wildtype 
background show no gross phenotype. Embryonic fibroblasts were derived and Cre- 
recombinase delivered by infection with a replication deficient adenovirus. APC cDNA 
excision was confirmed by PCR. The founder line was crossed with the C57BL /6 
Apc 
+/min 
line. Transgene positive Apc +Irvin mice were interbred and offspring screened to 
identify whether the APC transgene can rescue the Apc M II lethal phenotype. To date 
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Chapter 1: Introduction to the biology of non -small cell lung 
cancer 
1.1 Epidemiology of lung cancer 
1.1.1 Incidence 
Lung cancer is the most common diagnosed cancer worldwide. High incidences of the 
disease occur in developed countries, particularly in North America and Europe, and are 
less common in developing countries, including Africa and South America (Parkin et al., 
1992; 1994). From an international perspective, Scotland has a comparatively high 
incidence and lung cancer is the commonest cancer in men and the second most common 
cancer in women (Parkin et al., 1992; 1995; The Scottish Office, 1997). Statistics have 
shown that over a 10 year period (1986 -1995) the incidence in males has decreased by 
approximately 15% whilst in females it has dramatically increased by 27% (The Scottish 
Office, 1997). This contrasting trend between the sexes is probably a result of changing 
smoking habits, with women adopting the habit later than men. The incidence of lung 
cancer peaks between 60 and 70 years of age and five -year survival is 7 %, a figure that 
has remained relatively constant over the last 3 years (The Scottish Office, 1997; Scottish 
Health Statistics, 1998). 
1.1.2 Smoking and lung cancer 
Cigarette smoking is by far the leading cause of lung cancer, accounting for 
approximately 90% of lung cancer cases in countries where cigarette smoking is 
common, a fact that is reflected by the occurrence of lung cancer closely following trends 
in smoking (Peto 1994). The risk of lung cancer has been shown to increase with the 
duration of smoking and the number of cigarettes smoked per day (Doll and Peto 1978). 
Tobacco smoke contains thousands of components; to date 55 carcinogens have been 
identified and evaluated by the International Agency for Research on Cancer (Hoffmann 
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and HoíT'inann 1997). The mechanisms by which tobacco smoke causes carcinogenesis is 
not fully understood although major advances have been made in understanding 
carcinogen activation by cellular detoxification processes and how free radicals and 
oxidants, contained within the smoke, result in lung damage (reviewed in Hecht 1999). 
The major chemical classes of carcinogens in tobacco smoke are the nicotine -derived N- 
nitrosamines and polycyclic aromatic hydrocarbons (Hoffmann et al., 1983). Both require 
metabolic activation to exert their carcinogenic effects. 
During metabolic activation, carcinogens are enzymatically transformed to a series of 
metabolites in an attempt by the organ to convert them to forms that are more readily 
excreted. The cytochrome P450 enzymes encoded by the CYP family of genes usually 
carry out initial steps to oxygenate the substrate (Guengerich 1997). Other oxidative 
enzymes may be also involved but less frequently. The oxygenated intermediates formed 
may undergo further transformations by glutathione S- transferases, uridine-5- 
diphosphate- glucuronosyl transferases and other enzymes that detoxify the intermediate 
compound (Armstrong 1997; Burchell and Coughtrie 1997). The metabolic intermediates 
formed by the cytochrome P450s can form adducts with bases of DNA as well as yielding 
oxygen radicals which are also DNA damaging, producing DNA strand breaks in addition 
to modifications such as 8- hydroxyguanine, thymine glycol and 5- hydroxy methyl uracil 
(Kasai and Nishimura 1986; Imlay and Linn 1988). 
Carcinogen metabolites commonly form DNA adducts at guanine or adenine nucleotides 
(Hecht and Hoffmann 1988; Dipple 1995). The cellular mechanisms for DNA repair; 
direct, base excision and nucleotide excision repair, are important in determining whether 
DNA adducts persist (Pegg et al., 1995; reviewed in Sancar 1996; Singer and Hang 
1997). If DNA adducts are not repaired this can result in the miscoding of DNA during 
DNA replication. Analysis of mutations present in tumour suppressor genes and 
oncogenes in lung cancers typically exhibit a high frequency of mutations at guanine 
nucleotides (discussed further in section 1.3). 
Cigarette smoke also contains many oxidants and free radicals that are capable of 
initiating or promoting oxidative damage without the need for metabolic activation. One 
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such carcinogen, which is present in high concentrations, is nitric oxide. This oxidant can 
deaminate 5- methylcytosine residues of DNA to produce thymidine residues, resulting in 
nucleotide transition, cytosine to thymidine (Wink et al., 1991). 
1.1.3 Other hazards 
1.1.3.1 Occupational exposure 
Among cancers that have been associated with occupational exposures, cancer of the 
lung is the most common (Doll and Peto 1981). Several metallic compounds are proven 
lung carcinogens (Friberg and Cederlof 1978; Sunderman 1979); they include arsenic 
(Lee and Fraumeni 1969; Lloyd 1971), chromium (Alderson et al., 1981) and nickel 
(Kreyberg 1978). An increased risk of lung cancer has been identified in coke oven 
workers who are exposed to tar and soot, both of which contain benzo(a)pyrene (Lloyd 
1971). Miners are also at increased risk of lung cancer, possibly due to exposure to radon 
gas that leaks from igneous rocks (Radford and Renard 1984; Archer 1988). 
Asbestos is well established as an occupation carcinogen (Selikoff et al., 1976; 1980). 
The risk of lung cancer has been shown to increase with increased exposure. It is unclear 
whether asbestos acts directly as a carcinogen or through indirect mechanisms such as 
causing chronic inflammation (Brown 1986). 
1.1.3.2 Diet 
The link between diet and lung cancer, as with the majority of other cancers, is still 
poorly understood. In the majority of cases fruit and vegetables consumption has been 
observed to be inversely associated with lung cancer (Fraser et al., 1991; Knekt et al., 
1991; Candelora et al., 1992). Particular nutrients, retinol and carotene, and antioxidants 
within these foods have shown protective associations (Dartigues et al., 1990; Cooper 
1999). Dietary fat is thought to facilitate tumour growth but to date evidence correlating 
fat consumption and lung cancer risk have been inconsistent (Alavanja et al., 1996; 
Nyberg et al., 1998 a;b). 
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1.1.4 Genetic predisposition 
Environmental agents and cigarette smoking have been shown to cause lung cancer in 
only a minority of people exposed. Epidemiology studies have demonstrated a family 
history of lung cancer predicts increased risk. These studies support a genetic basis for 
lung cancer susceptibility. Possible mechanisms that result in lung cancer susceptibility 
include polymorphisms in genes that result in differential rates of activation and 
elimination of respiratory carcinogens and polymorphisms within oncogenes and tumour 
suppressor genes. 
1.1.4.1 Polymorphisms in genes involved in xenobiotic metabolism 
Polymorphisms in genes encoding cytochrome P450 and glutathione s- transferase 
enzymes have been investigated for possible genetic susceptibility to lung cancer. 
The cytochrome P450 enzymes, termed phase I enzymes, transform selected xenobiotics 
to intermediates that are detoxified by phase II enzymes which include the glutathione S- 
transferases. Many compounds in cigarette smoke e.g. polycyclic aromatic hydrocarbons 
and nitrosamines, are metabolised by the cytochrome P450 enzymes resulting in the 
production of intermediates that have carcinogenic effects (see section 1.1.2). Two 
cytochrome P450 enzymes, which are encoded by the genes termed CYPIAI and 
CYP2D6, have been investigated with respect to lung cancer risk as polymorphic variants 
have been shown to increase metabolic activation of carcinogens. 
Evidence that polymorphisms within CYPIAI are associated with increased risk of lung 
cancer has varied across populations. A particular polymorphism has been associated 
with increased risk in the Japanese population but not Brazilian or American populations 
(Nakachi et al., 1993; Shields et al., 1993; Sugimura et al., 1994). This difference 
between populations suggests that other genetic variations may be present which effect 
lung cancer susceptibility. 
Genotypic variants of CYP2D6 have been extensively investigated. This enzyme 
determines the phenotype for the metabolism of the anti -hypertensive drug debrisoquine. 
Individuals that are fast metabolisers of the drug were shown to have a 10 fold risk of 
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developing lung cancer (Gonzalez et al., 1988; Gough et al., 1990) conversely a case 
control study failed to support these findings (Shaw et al., 1995). Analysis of different 
genotypes have also generated inconsistent results (Bouchardy et al., 1996; Legrand et 
al., 1996; Christensen et al., 1997; London et al., 1997). 
The family of genes that encode glutathione S transferases (GSTs), phase II detoxifying 
enzymes, have also been extensively analysed. There are at least four genetically distinct 
classes of the glutathione S- transferases; GSM], GSTM3, GSTP1 and GSTT1. 
The presence of a polymorphic variant that encodes a deficient phenotype of GSTM1 
(present in 40% to 50% of the Caucasian population) reduces the efficiency of 
detoxification of carcinogens. Several groups have studied the distribution of the GSTMI 
null genotype to determine whether there is an association with susceptibility to smoking - 
related lung cancer but with contradictory results (McWilliams et al., 1995; Nyberg et al., 
1998c). Polymorphisms in other family members of the GST genes, GSTM3, GSTP1 and 
GSTT1 have also been reported. Saarikoski and co- workers (1998) studied the 
distribution of different genotypes in lung cancer patients and population controls and 
found no statistically significant effect on lung cancer risk. However, when GSTM3, 
GSTP3 and GSTT1 genotypes were analysed in combinations that included GSTM1 it was 
found that lack of GSTMI and GSTTJ genes led to an increased susceptibility to 
squamous cell carcinoma. Increased susceptibility to smoking related lung cancer through 
the presence of null alleles of GSTM1 and GSTT1 has been corroborated by Kelsey and 
coworkers (1997). 
Finally, N- acetyltransferases are involved in the activation and inactivation reactions of 
numerous xenobiotics. N- acetyltransferases are encoded by the NATI and NAT2 genes, 
of which there are several allelic variants that have different acetylation capacities. 
Reports have shown that NATI genotypes have a significant association with smoking 
related lung cancer whilst no significant association has been found with NAT2 
(Bouchardy et al., 1998; Abel -Rahman et al., 1998). 
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1.1.4.2 Inherited polymorphisms in oncogenes and tumour suppressor genes 
Polymorphic variants in well- characterised oncogenes and tumour suppressor genes have 
been implicated in lung cancer predisposition. 
The p53 protein (see section 1.3.2.2) exhibits a polymorphism at amino acid 72, resulting 
in either a proline or an arginine residue at this position. A proline residue would form 
part of a proline rich domain, which is ablated in the p53 arginine form, these isoforms 
differ in their abilities to activate transcription and induce apoptosis (Thomas et al., 
1998). Some studies have shown increased risk of non -small cell lung cancer (NSCLC) in 
proline /proline homozygotes whilst other studies implicate arginine /arginine 
homozygotes. As with the analysis of this polymorphism in other cancers, no consensus 
has been reached regarding predisposition to NSCLC (Weston et al., 1997; Tagawa et 
al., 1998 Auer et al., 1999). 
Inheritance of lung cancer susceptibility due to inherited polymorphisms in oncogenes is 
exemplified by polymorphic variants in H -RAS and L -MYC genes. The presence of a rare 
H -RAS allele containing an insertion/deletion polymorphism has been found to confer a 
relative risk to NSCLC in Caucasian and African American populations (Heighway et al., 
1986; White et al., 1990; Weston et al., 1992; 1997). In the Japanese population a 
restriction fragment length polymorphism in the L -Myc gene (see section 1.3.1.2) has also 
been associated with NSCLC, this polymorphism has also been shown to be a marker for 
metastatic potential (Kawashima et al., 1988; 1992; Weston 1997). Similar studies have 
been carried out on NSCLC samples from patients from Australia, Norway and North 
America (Fong et al., 1995b) and no increased risk of lung cancer has been associated 
with this polymorphism in these populations. 
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1.2 Lung cancer classification 
Bronchogenic carcinomas, malignant tumours of bronchial or bronchiolar epithelial 
origin, account for up to 95% of primary lung tumours. The remaining 5% are mostly 
bronchial carcinoids; these tumours may be malignant or benign and arise from mucous 
glands. Other tumours do occur, but are infrequent and are classified as miscellaneous 
tumours and include benign and malignant mesenchymal tumours, malignant lymphomas, 
lymphomatoid granulomatosis and hamartomas. 
According to the classification published by the World Health Organisation (WHO) 
(1982) lung cancers are classified into four major histological types; squamous cell 
carcinoma, adenocarcinoma, small cell carcinoma and large cell carcinoma (see table 1). 
Other tumours are classified into groups known as rare tumour types (miscellaneous) and 
tumours consisting of more than one histological type. 
For clinical, therapeutic and biological reasons, lung cancers are frequently classified into 
small cell (SCLC) and non -SCLC (NSCLC) groups. SCLC are rapidly growing, highly 
malignant tumours that arise within the central thorax. Usually the tumour has 
metastasised by the time of diagnosis therefore patients are often treated by 
chemotherapy. Five -year survival for patients with early stage tumours is approximately 
20% whereas in cases where there is extensive disease survival is less than 1 %. NSCLC 
account for 75 -80% of lung cancers. In comparison to SCLC, NSCLC grow more 
slowly, metastasise locally and regionally before widespread dissemination. If diagnosed 
within the early stage, patients may undergo curative surgery. Patients with later stages of 
NSCLC are treated with chemotherapy although only 30 -40% of tumours respond to this 
treatment. Survival is highly dependent on tumour staging, with a 5 -year survival of 65% 
in early stages and 1 -2% in the more advanced tumour stages. The currently used 
International Cancer Staging System (ISS) (Mountain, 1997) is shown in table 2. 
This thesis addresses the genetics of NSCLC, which from this point will refer to the 
three most common histological types ADC, LCC and SCC, other tumour types will 
not be discussed further. 
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Table 1. Classification of bronchogenic primary lung tumours and incidences according to 
the WHO (Yesner et al., 1982). 
Squamous cell carcinoma (35 -50 %) 
Adenocarcinoma (15 -35 %) 
a) Bronchial derived acinar; papillary; solid carcinoma 
b) Bronchioloalveolar cell carcinoma 
Small cell carcinoma 
a) Oat cell (lymphocyte -like) 
b) Intermediate cell (polygonal) 
c) Combined (usually with squamous) 
(20-25%) 
Large cell carcinoma (10 -15 %) 
a) Undifferentiated; giant cell; clear cell 
Combined squamous cell carcinoma and adenocarcinoma 
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Table 2: TNM lung cancer staging system (Mountain, 1997) 
TUMOUR 
TX: Demonstrable only by cytology of bronchopulmonary secretions 
Ti: Tumour <3cm without pleural or main stem bronchus involvement. 
T2: Tumour >3cm or involvement of main stem bronchus 2cm from carnis, visceral, 
pleural or lobular atelectasis. 
T3: Tumour with involvement of chest wall, diaphragm, mediastinal pleura, 
pericardium, main stem bronchus 2cm from carina, or entire lung atelectasis. 
T4: Tumour with invasion of mediastinum, heart, great vessels, trachea, oesophagus, 
vertebral body, or carina or with a malignant pleural effusion. 
NODE 
NO: No demonstrable metastasis to regional lymph nodes 
N1: Ipsilateral hilar or peribronchial nodal involvement 
N2: Metastasis to contralateral mediastinal or hilar lymph nodes, ipsilateral or 
contralateral scalene, or supraclavicular lymph nodes. 
Metastases 
MO: No (known) distant metastasis 
Ml: Distant metastasis present 
Using the above classification lung cancer stage is described as follows: 
Stage grouping 
Stage 1 a T1 NO MO 
Stage Ib T2 NO MO 
Stage Ila Tl N1 MO 
Stage IIb T2 N1 MO 
T3 NO MO 
Stage IIIa T1-3 N2 MO 
Stage IIIb Any T N3 MO 
T3 N1 MO 
T4 Any N MO 
Stage IV Any T Any N M1 
26 
1.2.1 Histology of NSCLC 
1.2.1.1 Squamous cell carcinoma 
Squamous cell carcinomas (SCC) form bulky grey -white necrotic intra -luminal masses as 
well as invading peri- bronchial and parenchymal tissues and regional nodes. 
Histologically, like SCC arising elsewhere, they contain stratified scale -like cells, attached 
together by well -formed uniformly distributed desmosomes (also referred to as prickles 
or intercellular bridges). SCC is further characterised by keratinisation and both individual 
cell and epithelial pearl formation. SCC can range from well differentiated to poorly 
differentiated which is reflected by the extent of keratinisation and desmosome formation. 
In poorly differentiated SCC, the histology appears towards that of the undifferentiated 
large cell carcinoma (LCC) pattern. A histological example of a SCC is shown in figure 
1 a. 
1.2.1.2 Adenocarcinoma 
Adenocarcinoma (ADC) may arise from the major bronchi or occur as peripheral, 
subpleural tumours. They are firm, grey- white, and may have a mucoid cut surface. The 
characteristic morphological features of ADC include cuboidal or columnar cells with 
prominent microvilli, forming gland -like structures. Intracellular mucin granules are 
present and mucin may be secreted, papillary structures may also be present. As with 
SCC the degree of differentiation varies considerably, with areas of poorly differentiated 
ADC often indistinguishable from LCC. Adenocarcinomas can be sub -classified into four 
groups according to their histological characteristics; acinar, papillary, and solid with 
mucin production and bronchioloalveolar carcinomas (WHO 1982). The former 3 groups 
are often termed bronchial derived adenocarcinomas, which is misleading as the majority 
arise in the periphery of the lung. Histological variability is described by the 3 subgroups. 
The bronchioloalveolar carcinomas (BAC) are a distinctive subtype which are thought to 
arise from the terminal bronchioles and alveoli. These tumours are diffuse and tend to 
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follow pre- existing alveolar structures, termed lepidic growth. Histologically BAC consist 
of tall, columnar to cuboid epithelial cells that line up along the alveolar septa and project 
into the alveolar spaces in numerous branching papillary formations. Glandular structures 
are rare. BAC are further classified into 3 groups: mucinous, non -mucinous and 
sclerosing (Clayton, 1988). Sclerosing BAC is thought to represent an advanced stage of 
non -mucinous BAC (Barsky et al., 1986). 
Even though the WHO classification is widely used, it has been criticised as poorly 
reproducible due to cell heterogeneity. In 1987, Edwards proposed a new classification 
for ADC based on cellular morphology and site. ADC were categorised as parenchymal 
(arising in the periphery of the lung from functional tissue rather than the supporting or 
connective tissue) and bronchial (arising at the hilum). Parenchymal tumours contain cells 
characteristic of goblet cells, Clara cells, type II pneumocytes and ciliated bronchiolar 
lining cells and occasionally neuroendocrine cells whilst ADC arising in the bronchi 
contain bronchial epithelial cells or bronchi glands (Bolen and Thorning, 1982; Raino, 
1983; Singh et al., 1984). A histological example of an ADC arising in the parenchymal is 
shown in figure 1 (b). 
1.2.1.3 Large cell carcinoma 
Large cell carcinoma (LCC) frequently present as large bulky peripheral tumours. These 
carcinomas contain cells with no differentiation pattern, they have large and vesicular 
nuclei with prominent nucleoli and abundant cytoplasm, which can be either clear or 
granular (figure lc). Some carcinomas contain large multinucleated cells and are 
classified as giant cell tumours (Nash and Stout, 1958), others with clear cytoplasm are 
termed clear cell carcinomas. It is thought that a number of LCC represent poorly 
differentiated SCC, ADC or SCLC as when cultured or xenografted most LCC 
developed differentiated features, especially those of adenocarcinoma. Some tumours 
remained undifferentiated and may represent a truly separate class of undifferentiated 
tumours (Gazdar and McDowell, 1988). 
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Figure 1: Three histological subtypes of non -small cell lung cancer 
a) Haematoxylin and eosin (H +E) stained section of a squamous cell carcinoma. 
The characteristic feature of cellular stratification can be observed in this figure. 
Magnification x 400. 
b) H +E stained section of a parenchymal adenocarcinoma. The arrow indicates the 
typical gland- forming characteristic of adenocarcinomas. Magnification x 400 
c) H +E stained section of a large cell carcinoma. Histological features include large 
vesicular nuclei with prominent nucleoli and abundant cytoplasm. Magnification 
x 400. 






1.2.2 Premalignant lesions of lung adenocarcinoma 
Morphological analysis has identified several stages of premalignant lesions in the 
development of SCC. The spectrum of histological changes in preneoplastic bronchial 
epithelium extends from basal cell hyperplasia through squamous cell metaplasia to mild, 
moderate and marked dysplasia, carcinoma in situ and finally invasive cancer (Auerbach, 
1957; 1961; Nasiell et al., 1987). In contrast to SCC, the premalignant lesions for ADC 
have been less well characterised. 
1.2.2.1 Pulmonary scars 
Some investigators proposed pulmonary scars, which are frequently associated with 
ADC, as possible precursor lesions, however evidence is conflicting (Shimosato et al., 
1982; Madri and Carter, 1984; Kung et al., 1985). Scars, identified by alveolar septate 
thickening and interstitial fibrosis, are often considered to be a result of healed 
tuberculous foci, healed or healing infarcts or due to pneumonia. The epithelium of small 
airways enclosed in the scar is thought to be particularly susceptible to malignant 
transformation (Madri and Carter, 1984). Shimosato and co- workers (1982) proposed 
that what had previously been regarded as a scar was in fact stroma induced by the 
growth of the ADC and suggested that ADC develop without any association with pre- 
existing scar tissue. Evidence to support this comes from the fact that in early -stage 
ADC, fibrotic foci are rarely detected. 
1.2.2.2 Alveolar atypical hyperplasia 
The best -known potentially premalignant lesions identified in the parenchyma of the lung 
are alveolar atypical hyperplastic lesions (AAH). These lesions have several synonyms; 
atypical epithelial proliferation, atypical alveolar cuboidal cell hyperplasia, 
bronchiolalveolar cell adenoma, alveolar adenomatous hyperplasia, atypical 
bronchiolalveolar cell hyperplasia ( Raeburn and Spencer, 1953; Meyer and Liebow, 1965; 
Shimosato et al., 1982; Kodama, 1986; Miller, 1988; Miller et al., 1990; Weng et al., 
1990; Carey et al., 1992). The term alveolar atypical hyperplasia or alveolar atypical 
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hyperplastic lesion (AAH) will be used from now on to describe these lesions. 
Unlike areas of alveolar hyperplasia, which are identified as areas of proliferation of type 
2 pneumocytes forming as a response to lung injury or part of the reparative process of 
the lung, AAH lesions are characterised by progressive cellular atypia of type II 
pneumocytes. Lesions are composed of a single row of atypical cuboidal cells with 
hyperchromatic nuclei and prominent nucleoli which line the alveolar walls in the absence 
of chronic inflammation (Nakanishi 1990; Carey et al., 1992; Rao and Fraire 1995). The 
alveolar septa lined by the atypical cells are often thickened by fibrosis (Figure 2). AAH 
lesions have been classified into three grades; low grade, high grade and AAH -like 
carcinoma (Kitamura et al., 1995;1996). Low -grade lesions are characterised by a single 
layer of round to cuboidal cells with low cellular density, small cell size, minimal variation 
in nuclear size and shape, and minimal thickening of the alveolar septa. In comparison, 
AAH lesions classified as high grade have increased cellular density, larger cell size, 
greater variation in cell size, shape, and mild fibrosis of the alveolar septa. The term 
AAH -like carcinoma is used to describe lesions that appear to represent a morphological 
transition between high -grade AAH and overt ADC. Morphological characteristics of this 
category consisted of lesions with high cellular density with stratification of epithelial 
cells, marked cytological atypia, and extensive thickening and fibrosis of the alveolar 
septa. 
AAH lesions tend to be incidental findings following lung resections from patients with 
primary ADC. The reported frequency of AAH foci from patients resected for ADC has 
varied from 5.7 -25% (Miller, 1990, Weng et al., 1992; Carey et al., 1992). Many lesions 
can be detected by gross examination of lung resections inflated by formalin or Bouin's 
fluid. Since AAH lesions are more difficult to identify grossly in routine specimens fixed 
by immersion, an underestimate of frequency is likely (Miller 1993), furthermore 
differential diagnosis between AAH and early invasive ADC with metastatic potential, 
such as BAC and papillary carcinomas with lepidic growth is extremely difficult. 
The histological analysis of ADC and AAH lesions by Miller and co- workers (1988; 
1990) led to the proposal that pulmonary ADC could follow a multistep progression from 
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precursor lesion to adenoma to carcinoma. Further to this, measurements of nuclear size 
as well as DNA content suggest a continuum from reactive hyperplastic type II cells to 
AAH and finally to ADC (Kodama et al., 1986; Nakanishi 1990; Nakayama et al., 1990; 
Kitamura et al., 1995;1996; Mori et al., 1996). To date there is no clear evidence that 
AAH lesions represent a neoplastic process rather than merely a reactive proliferation of 
non -neoplastic cells or that these lesions may be precursors of parenchymal ADC. The 
experimental work described in this thesis further defines AAH lesions through 
analysis of the proto -oncogene K -RAS, a gene that is mutated in a high portion of 
ADC. 
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Figure 2: Histology of normal alveolar and an area of alveolar atypical hyperplasia 
a) H +E stained section of alveolar in the normal lung. Magnification x 400 
b) H +E stained section of a focus of alveolar atypical hyperplasia (AAH). A 
single row of hyperplastic type II pneumocytes (arrow a) line the 
thickened alveolar septa (arrow b). Magnification x 400 





1.3 Molecular changes associated with NSCLC 
Lung carcinogenesis is a multistage process in which, by the time of clinical diagnosis, it 
is estimated that between 10 and 20 genetic alterations may have accumulated (Minna, 
1993; Gazdar and Carbone, 1994). The molecular events include activation or 
overexpression of dominantly acting oncogenes as well as loss or inactivation of tumour 
suppressor genes. The majority of NSCLC tumours exhibit aberrant expression of key 
genes involved in the regulation of cell proliferation and cell death. One pathway that has 
been elucidated in controlling these cellular responses is the p53 -RB pathway. This 
pathway is depicted in figure 3. 
This section describes some of the molecular changes associated with primary NSCLC 
and relates these events to the multistep development and progression of lung tumours. 
Particular emphasis is placed on the proto -oncogene K -RAS, previously shown to be 
mutated in NSCLC, as experimental work completed for this thesis addresses 
activation of this oncogene in subtypes of NSCLC and in alveolar atypical 
hyperplastic lesions. Furthermore, loss of heterozygosity at the chromosome region 
5q21, the site of the tumour suppressor gene APC, is also of particular interest as I 
investigate a possible role of APC in NSCLC. 
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Figure 3: The p53 -RB pathway 
The schematic representation in this figure outlines the regulation of cell proliferation, 
growth arrest and apoptosis through the interaction of a number of oncogenes and 
tumour suppressor genes. A further feature of this pathway is induction of GADD45 by 
p53 to initiate DNA repair, this is not represented in this figure. The interaction of these 
proteins and subsequent consequences of aberrant expression is discussed within the text 
of chapter 2. The analysis of NSCLC has determined that aberrant expression of 
protein/or proteins within this pathway is a characteristic of these tumours. 
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1.3.1 Proto- oncogenes and lung cancer 
Proto- oncogenes are often growth factors, growth factor receptors, intracellular signal 
transducers and transcription factors. When activated these genes can lead to increased 
cellular growth or enhanced cell survival. Activation of a proto -oncogene to an oncogene 
may occur via a variety of mechanisms including point mutations, overexpression or loss 
of normal cell cycle dependent regulation. Oncogenes are usually dominant, requiring 
only one of the alleles to sustain a mutation to lead to activation. Several oncogenes have 
been associated with lung cancer, these include the myc family of genes, c- ERB -BI and c- 
ERB-B2 , cyclin DI and BCL2. 
1.3.1.1 The ras genes 
The ras oncogenes were initially discovered as the transforming genes of the Harvey and 
Kirsten murine sarcoma viruses (Ha -MSV, Ki -MSV) (Harvey 1964; Kirsten and Mayer 
1967). Molecular analysis revealed that a non -transforming version of the ras gene was 
present in the eukaryotic genome and that the sequence of this gene differed from the 
gene with transforming properties by a single base pair change (Tabin et al., 1982; Reddy 
et al., 1982; Barbacid, 1987). The ras genes were the first oncogenes to be implicated in 
human cancer and following their initial discovery have been the focus of extensive 
investigations 
1.3.1.1.a Ras genes and their protein products 
The protein products of the ras genes are the prototype for the ras- related superfamily of 
proteins that share structural homology, this superfamily comprises over 60 mammalian 
members that have been divided into several subfamilies (ras, rho, rab, arf, ran and 
rad /gem), division that is based on sequence homology and biological activity. A 
discussion of these family members is not within the scope of this thesis but is reviewed in 
(Bourne et al., 1990; Bos 1997). 
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The ras family consists of the ras proteins (H -ras, K -rasA, K -ras B and N -ras), four rap 
proteins (rap 1 A, rap 1 b, rap2a and rap2b), 3 ras -like proteins (R -ras, TC21 and R- ras3), 
two ral proteins (ralA and ralB) and the newly identified rheb and M -ras proteins (Bos 
1997; Kimmelman et al., 1997; Matsumoto et al., 1997). The ras family is characterised 
by high similarity in the effector domain and the switch 1 region and all members exhibit 
GTPase activity (discussed in detail below). The cellular function of this family of 
proteins is diverse. This chapter will focus on the mammalian ras genes; H -ras, K -ras and 
N -ras. 
The H -ras, K -ras and N -ras genes encode proteins of very similar structure and function 
and are highly conserved between species (Barbacid 1987). These genes are composed of 
4 coding exons and 5 non -coding exons (introns); introns differ widely in size and 
sequence between family members. The human genomic sequences span 3 kb (H -RAS), 7 
kb (N -RAS) and more than 35 kb (K -RAS). Two isoforms of K -RAS exist as a result of 
exon 4 being alternatively spliced (K -RAS 4A and K -RAS 4B), these isoforms diverge at 
the COOH- terminal 25 amino acid sequence (Barbacid, 1987; Lowy and Willumsen 
1993). 
The protein product of each of these ras genes is approximately 21 kDa and consists of 
188 (H -RAS, K -RASA and N -RAS) or 189 (K -RASB) amino acids. These genes are 
ubiquitously expressed. The level of expression of each gene has been shown to vary in 
some murine adult tissues and stages of embryonic development and K -RasA exhibits a 
more restricted pattern of expression suggesting functional differences exist between 
different Ras proteins (Leon et al., 1987; Furth et al., 1987; Pells et al., 1997). Further 
evidence in support of functional differences include 1) different ras genes are activated 
in different human tumours suggesting cell -specific activities (Bos 1989; Rodenhuis 1992; 
discussed in section 1.3.1.1g) 2) regulation of ras activity and transduction of signals to 
signalling cascades has been noted to be modulated by different proteins i.e. some 
GTPase proteins and guanine exchange factors show varying affinities between ras 
proteins, and some effectors of ras exhibit higher affinity for specific ras proteins (Bollag 
and McCormick 1991; Mizuno et al., 1991; Jones and Jackson 1998; Hamilton and 
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Wolfman 1998), 3) H -and N -Ras knockout mice are completely viable whist K -Ras 
knock out mice die between day 12 and 14 of gestation (Johnson et al., 1997). 
1.3.1.1.b Ras proteins are GDP /GTP regulated switches 
Ras proteins function as guanosine diphosphate / guanosine triphosphate (GDP /GTP) 
regulated switches that transduce extracellular ligand mediated stimuli (growth factors, 
cytokines, hormones and neurotransmitters) to cytoplasmic signal transduction cascades. 
Ras proteins cycle between two conformations induced by the binding of either GDP or 
GTP. In the GTP bound conformation, ras is active binding to and activating effector 
proteins (see below). Ras proteins have low intrinsic hydrolytic activity limiting the rate 
of GDP /GTP exchange hence cellular control of GDP /GTP cycling is modulated by 
guanine nucleotide exchange factors (GEFs) and GTPase- activating proteins (GAPs). 
GEFs induce the dissociation of guanine nucleotides, and due to the relatively high 
concentration of cellular GTP to GDP (10:1), this reaction favours, at least initially, the 
active form of ras -GTP. In turn, ras -GTP is hydrolysed to GDP by intrinsic GTPase 
activity in combination with GAPs. To date, identified GEFs for ras proteins include 
sos1, sos2, cdc25, ras -GRF 2 and ras -GRP (reviewed in Malumbres and Pellicer 1998). 
At least six different GAPs have been identified in mammals: p120-GAP, the 
neurofibromatosis type 1 protein NF 1, GAP 1 m, GAP 11 p4BP, IOGAP1 and SynGAP 
(reviewed in Malumbies and Pellicer 1998). 
Analysis of the 3- dimensional protein structure of ras -GDP and ras -GTP in conjunction 
with the activity of ras proteins that harbour oncogenic mutations has facilitated an 
understanding as to how GDP /GTP cycling activates the protein. Amino acids 1 -164 
encode the highly conserved catalytic domain, encompassing the guanine binding site 
(constituted from amino acids 12 -18, 57 -63, 116 -119 and 114 -147) and two "switch" 
regions (amino acids 30 -38 and 60 -76). Conformational changes dependent upon GDP or 
GTP binding are within hydrophilic sites that are located on the external surface of the 
molecule (encoded by residues 30 -38 and 60 -76), these regions have been termed switch 
I and switch II respectively. 
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Effectors, GAPs and GEFs interact with ras through switch 1 and switch 2. Switch 1 
region is the main binding site of ras effector proteins, whilst the switch 2 region has been 
shown to be responsible for molecular recognition and the specificity of the interaction 
(Moodie et al., 1995; Nassar et al., 1996; Macara et al., 1996; Akasaka et al., 1996). 
GAPs and GEFs also interact with the switch regions (Crèchet et al., 1996; Boriack- 
Sjodin et al., 1998). In vitro studies have demonstrated that GAPs and GEFs compete 
with effector proteins for binding to GTP -ras and that effector protein binding inhibits the 
activity of GAPs and GTP nucleotide exchange (Marshall, 1996; Giglione and 
Parmeggiani 1998). 
Mutations in ras, which result in an oncogenic phenotype, encode proteins that remain in 
the active GTP -bound state (Scheele et al., 1995). Impaired intrinsic GTPase activity and 
resistance to GAP activity is associated with mutations at positions 12, 13, 59, 61 whilst 
mutations at positions 16, 17, 116, 117, 119, 144 and 146 result in increased guanine 
nucleotide exchange (Bollag and McCormick 1991; Lowy and Willumsen 1993). 
1.3.1.1.c Cellular signalling through ras 
A large variety of signals, such as growth factors, cytokines, hormones and 
neurotransmitters, activate ras. In most cases, this activation occurs through cell surface 
receptors with intrinsic or associated tyrosine kinase activity (Pronk and Bos 1994). In 
the case of receptors with intrinsic tyrosine kinase activity (RTK), ligand binding 
stimulates receptor homo- or hetero- dimerisation and /or a conformational change that 
typically result in autophosphorylation of multiple tyrosine residues in the cytoplasmic 
portion of the receptor (Pawson 1995). The resulting phosphotyrosine (PY) residues act 
as highly selective binding sites for so- called SH2' (Src homology domain 2) containing 
proteins, which include the ras specific GEF protein: sos and adaptor proteins GRB2 
(growth factor receptor bound protein 2) and SHC (Src homology and collagen) (Pawson 
1995; Schenk and Jagalska 1999). The PY residues form a docking site for GEF proteins 
directly or through binding of adaptor proteins. Protein interactions result in localisation 
of the GEF to the cell membrane and leads to the transient elevation of ras -GTP levels 
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(Schlessinger 1993). Activation of ras through RTK is shown in figure 4. 
Receptors not directly associated with tyrosine kinases, such as serpentine receptors are 
thought to activate ras indirectly through src -like kinases or ligand- independent activation 
of receptor tyrosine kinases (van Biesen et al., 1995; Lopez -Ilasaca et al., 1997). Calcium 
and diacylglyceral can activate ras directly by activation of specialised ras -specific GEFs 
(Farnsworth et al., 1995; Ebinu et al., 1998). 
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Figure 4: Activation of the ras protein by receptor tyrosine kinases (RTKs) 
Binding of ligand to a receptor with tyrosine kinase activity results in receptor 
dimerisation and autophosphorylation of tyrosine residues in the cytoplasmic portion of 
the receptor. Phosphorylation of tyrosine residues creates binding sites for SHC, which in 
turn becomes autophosphorylated and creates recognition sites for the SH2 domain of the 
adaptor protein GRB2. GRB2 is stably associated with the guanine exchange factor sos. 
These protein interactions result in the guanine exchange factor, sos, being localised to 
the plasma membrane, which leads to transient elevation of ras -GTP levels. When in the 
GTP -bound form, ras protein is active and forms a conformation -allowing interaction 
with effector proteins that relay the active ras signal downstream through cascades of 
cytoplasmic proteins. 
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1.3.1.1.d Effectors of ras 
Numerous proteins have been identified as putative ras effectors. These interact with the 
GTP -bound form of ras through the "effector loop" (amino acids 32 -40), flanking 
residues and the switch II region of ras protein (Fujita- Yoshigaki et al., 1995; 
Wittinghoefer and Nassar 1996; Katz and McCormick 1997). These interactions are only 
possible after the exchange of ras -GDP by GTP which result in a conformational change 
in switch I and II. Mutations in the ras effector region has been shown to impair binding 
of the effector proteins as discussed below. 
Through different effectors, ras signalling has been found to involve a complex array of 
signalling pathways involving cross -talk, feedback loops, branch points and multi - 
component signalling, controlling cell growth, differentiation and apoptosis (reviewed in 
Campbell et al., 1998). Two relatively well -characterised pathways are discussed below, 
the raf/MEK/ERK pathway and the ras/PI3K/PKB pathway. 
1.3.1.1.e Raf /MEK/ERK pathway 
The first effector to be identified in mammalian cells was the protein kinase raf -1, 
subsequently other family members have been identified (B -raf and A -raf). It is unclear by 
what mechanism raf effectors are translocated to the nucleus, or how following binding to 
GTP -ras, raf proteins become activated, although evidence suggests that activation 
involves a conformational change and modification by phosphorylation, both of which 
appear to be ras- independent (Stokoe et al., 1994; Morrison and Cutler 1997). Activation 
of the raf kinases leads to the activation of the MEK/ERK pathway. Following activation, 
raf phosphorylates and activates mitogen activated protein (MAP) -extracellular signal - 
related kinase (MEK), which in turn activates the two further extracellular signal - 
regulated kinases (ERKs), designated p42K/ERK2 and p44M`PK/ERK1. Once activated 
ERK kinases translocate to the nucleus and phosphorylate and activate a number of 
nuclear transcription factors including c -myc which in turn modulate a wide spectrum of 
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cell processes (Marais et al., 1993; Derijard et al., 1994), 
1.3.1.1. f Ras /PI3K/PKB pathway 
Another established effector of ras is phosphatidylinositol 3- kinase (PI3K). PI3K is a 
heterodimer consisting of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit 
that phosphorylates lipids (Kapeller and Cantley 1994). Interaction with ras -GTP is 
mediated through the binding of the catalytic subunit of PI3K and the effector region of 
ras (switch 1 region). Binding of PI3K activates the catalytic activity of the protein and 
also brings the active protein in close proximity to the plasma membrane. In this location 
it catalyses the phosphorylation of membrane bound phosphoinositides at the D -3 
hydroxyl of myoinositol, producing the second messengers phosphatidylinositol 3- 
phosphate (PIP), phosphatidylinositol (4,5) (PIP2) and phosphatidylinositol (3,4,5) 
triphosphate (PIP3). PI3K and the lipid products PIP3 and PIP2 act on pathways that 
control cell proliferation, cell survival and metabolic changes. PIP2 and PIP3 have several 
intracellular targets including the protein kinases, protein kinase B (PKB also known as 
AKT) (Burgering and Coffer 1995; Franke et al., 1995). Experiments have associated 
PKB kinase activity to the regulation of components of the apoptotic pathway, namely 
bad (reviewed in Coffer et al., 1998), Caspase -9 (Cardone et al., 1998) and FKHRL1, a 
member of the Forkhead transcription factor family (Brunet et al., 1999). 
A further substrate of PKB, which is of particular interest to this thesis, is glycogen 
synthase kinase 313 (GSK -313). Components of the wnt signalling pathway; proteins ß- 
catenin, adenomatous polyposis coli (APC), and Axin and one of the recently identified 
target genes of this pathway, cyclin D1 are all substrates for GSK -3ß. Phosphorylation of 
(3- catenin, APC and Axin mediate ß- catenin degradation whilst phosphorylation of cyclin 
D1 also mediates it's degradation (discussed in detail in section 2.6). In vitro experiments 
have shown that phosphorylation of GSK -3ß by PKB results in the inactivation of GSK - 
3ß kinase activity (Cross et al., 1995; Shaw et al., 1997). One may hypothesise that the 
oncogenic activation of K -ras can result in overexpression of PKB, which in turn may 
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lead to inactivation of GSK -3 f3 kinase activity. Inactivation of GSK -3 ß kinase activity 
could disrupt the degradation of 13- catenin resulting in increased transcription of target 
genes (in mammals: matrilysin, cyclin DI and c MYC) and in the case of cyclin D l result 
in increased protein stability. Aberrant expressions of these genes have been detected in 
NSCLC and are discussed fully in following sections. 
1.3.1.1.g Mutations in ras 
Ras can acquire transforming potential following point mutations that lead to amino acid 
changes at codons 12, 13 or 61 or through mutations at or near the GTP- binding domain, 
both of which result in enhanced ability to retain GTP leading to continuous ras signalling 
(Fayed and O'Brien, 1995). Mutations in the ras genes have been detected in a wide 
variety of tumours, the majority of which occur in the K-ras gene. 
RAS mutations are observed in approximately one third of cases of NSCLC (Rodenhuis 
et al., 1987; 1988 Suzuki et al., 1990). In the majority of these cases mutations are in the 
K -RAS gene ( >90 %) whilst mutations in H -RAS and N -RAS are relatively rare 
(Rodenhuis et al., 1988; Suzuki et al., 1990). The frequency of RAS mutations reported 
for NSCLC vary significantly and this may be a result of the relative proportion of 
different NSCLC subtypes within the cohort. The majority of publications report that K- 
RAS mutations occur primarily in the ADC histological subtype, the reported frequency 
varies between 20 -50% of tumours, whilst in SCC mutations are infrequent (0 -13% of 
cases) (Rodenhuis et al., 1988; Slebos et al., 1989; Reynolds et al., 1991, Mitsudomi et 
al., 1991; Slebos et al., 1991; Mills et al., 1995; Keohauana et al., 1996; Graziono et al., 
1999; Gealy et al., 1999). Conversely, some studies have reported that mutations occur 
in SCC with a similar frequency to ADC (Rosell et al., 1993; 1996; Gao et al., 1997). It 
is currently unclear why SCC are mutated in some cohorts but not others. Studies have 
analysed a full spectrum of SCC, different tumour stages and SCC obtained from 
smokers and non -smokers. One may suggest that variation in frequency may be a 
reflection of geographical differences. 
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The majority of mutations in the K -RAS gene occur at codon 12 and the mutation 
spectrum of this codon consisting of G -T transversions at position 1 (GGT -TGT) in 60% 
of cases, G -A transition at position 2 (GTT -GAT) in 20% cases and G -T transversion at 
position 2 (GGT -GTT) in 15% of cases (Rodenhuis et al., 1987; Rodenhuis et al., 1988; 
Reynolds et al., 1992; Slebos and Rodenhuis, 1992). The majority of mutations detected 
at codons 13 and 61 are also G -T transversions. The mutation spectrum is consistent with 
the formation of DNA adducts at guanine residues that can result from the carcinogenic 
properties of tobacco smoke (see section 1.1.2). In support of this, G -T transversions 
have been shown to occur more frequently in ADC of smokers than non -smokers 
(Reynolds et al., 1991), and this mutation is commonly seen in pulmonary ADC of mice 
treated with constituents of tobacco smoke (You et al., 1989; Belinsky et al., 1997; 
Nesnow et al., 1998). 
It is currently unclear whether mutations in K -RAS are an early event in lung 
carcinogenesis. Studies have shown a homogenous distribution of RAS mutation in 
early stage ADC, suggesting that the mutation is an early event occurring prior to 
clonal expansion of the tumour (Li et al.,1994a). Conversely, studies by Sugio and 
Co- workers (1994) suggest that K -RAS mutations are a relatively late event as gene 
mutations were detected infrequently in pre -neoplastic lesions associated with 
SCC; hyperplasia, metaplasia and dysplasia of the bronchioles and central airways. 
The experimental work carried out for this thesis aims to ascertain whether in our 
cohort of NSCLC cases there is a statistical significant difference between the 
frequency of K -RAS mutations occurring in ADC of parenchymal or bronchial 
origin. Furthermore, although analysis of preneoplastic lesions of SCC suggest that 
mutations are a late event in the development of SCC, this study will analyse AAH 
lesions, possible precursor lesions of ADC, for mutations within the K -RAS gene. 
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1.3.1.2 MYC 
1.3.1.2.a The C -MYC gene: structure and function 
The myc family includes three evolutionary conserved genes, c -, N- and L -myc, that have 
oncogenic potential. These family members are differentially expressed, with c -myc being 
most widely expressed in the majority of pre- and post -natal proliferating cells (reviewed 
in Marcu et al., 1992). Expression is strictly dependent upon mitogenic stimuli and is 
down regulated in many cell types when induced to terminally differentiate (Evan and 
Littlewood, 1993; Ryan and Birnie, 1997). Oncogenic activation is generally a result of 
their constitutive expression, and overexpression is noted in a large fraction of human 
malignancies (reviewed in Nesbit et al., 1999). Investigations into the cellular role of myc 
proteins have focused on the c -myc gene. Studies have demonstrated that deregulation of 
c -myc, rather than just overexpression is sufficient for oncogenic activation through the 
disruption of its role in the control of cellular proliferation, apoptosis and differentiation 
(Reviewed in Sakamuro and Prendergast 1999). 
The protein product encoded by the c -myc gene is a transcription factor. The protein can 
be divided into 3 regions; the N- terminal domain (NTD), central domain and carboxyl 
terminal domain (CTD), both the NTD and CTD are essential for transcriptional 
transactivation, proliferation and transformation whereas the central portion of the 
protein has been shown to be dispensable (Henriksson and Luscher 1996). 
The carboxyl terminus domain (CTD) contains a leucine zipper (Zip), a helix -loop -helix 
(HLH) motif and an adjacent domain rich in basic amino acids (Murre et al., 1989; 
Prendergast and Ziff, 1989; Blackwell et al., 1990). These motifs are contiguous and are 
referred to as the bHLHZip region (Henriksson and Luscher 1996). The HLHZip motifs 
mediate protein oligomerisation. Myc proteins do not homodimerise in vivo, but 
oligermerise with a number of other proteins that also contain HLHZip motifs. The first 
protein identified was max, a ubiquitously expressed protein that is comprised essentially 
of a bHLHZip domain (Blackwood et al., 1991). Heterodimerisation with max is 
necessary for c -myc to mediate gene transactivation, transformation, cell cycle 
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progression and apoptosis (Amati et al., 1993; Packham and Cleveland 1995). Included 
among the target genes transactivated by myc /max are cdc25a, cyclin A, cyclin E, a- 
prothymosin, lactate dehydrogenase A and orthinine decarboxylase (ODC) (reviewed in 
Grandori and Eisenman, 1997; Hoffman and Liebermann, 1998). 
In addition to max, several other proteins, including the tumour suppressor gene BRCA1, 
have been implicated in interactions with this region. All these proteins have been linked 
to transcriptional regulation (reviewed in Sakamuro and Prendergast, 1999). Unlike 
interaction with max, interaction of myc with these proteins results in inhibition of c -myc 
transactivation function. 
The N- terminus domain (NTD) acts as the transactivation domain. This NTD contains 
multiple phosphorylation sites and myc -homology Box 1 (MB 1) and Box 2 (MB2) 
domains that are implicated in the regulation of c -myc activity (Lutterbach and Hann 
1994; 1997; reviewed in Sakamuro and Prendergast, 1999). The NTD has been shown to 
interact with a number of proteins in vivo, to date seven proteins have been identified 
(reviewed in Sakamuro and Prendergast, 1999). The interaction of myc with these 
regulatory and effector proteins link c -myc to numerous cellular processes such as the 
cell cycle, chromatin modelling, apoptosis or cell fate signalling. 
1.3.1.2.b Myc genes in NSCLC 
Myc genes have been shown to be activated by a number genetic alterations including 
chromosomal translocations, proviral insertion, retroviral transduction and gene 
amplification (Ryan and Birnie, 1997). N -MYC and L-MYC do not appear to be 
deregulated in NSCLC but c-MYC, which is located at chromosome region 8q24, has 
been shown to be overexpressed in 50% of cases (Cline et al., 1987; Slebos et al., 1989; 
Paget 1989; Field and Spandidos 1990; Prins et al., 1993). The c-MYC gene has been 
shown to be amplified in 10% of these cases but in the remaining cases the mechanism of 
gene deregulation is unknown. C MYC is a target gene of the MEK/ERK pathway (see 
section 1.3.1.1.e), therefore gene expression may be deregulated due to activating 
mutations in ras or by deregulation of any other components of this pathway. 
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C -myc has recently been shown to be a target gene of the wnt signalling pathway (He et 
al., 1998). This discovery offered an explanation as to why c MYC was overexpressed in 
approximately 70% of colorectal cancer cases, and as with NSCLC, the frequency of 
gene amplification was low and no other genetic alterations had been detected (Erisman 
et al., 1985; Rothberg et al., 1985; Sikora et al., 1987). The majority of colorectal 
tumours contain mutations in either of two key components of this pathway, APC or 
catenin, mutations that result in increased expression of target genes, discussed in detail 
in section 2.6 (Sparks et al., 1998). To my knowledge there have been no reports 
regarding mutations in the wnt signalling pathway in NSCLC which may result in 
overexpression of c -MYC. However, loss of heterozygosity has been detected at 
polymorphic sites within the APC gene (discussed in section 1.3.3.3) and 
experimental work included in this thesis aims to determine whether the APC 
tumour suppressor gene has a role in NSCLC. 
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1.3.1.3. Protein Kinases 
NSCLC cases have been shown to overexpress the protein kinases c- ERB -B1, c- ERB -B2 
and c -MET. 
1.3.1.3a c -ERB family 
Erb-b1 and erb -b2 are members of the erb -b family of transmembrane receptor tyrosine 
kinases (Alroy et al., 1997). Signalling by these receptors, and two other family members 
(erb -b3 and erb -b4), can be stimulated by at least six different epidermal growth factor 
(EGF) ligands. Binding of extracellular ligand result in conformational alteration of the 
extracellular domain which induces receptor oligomerisation. Oligomerisation stabilises 
interactions between adjacent cytoplasmic domains and leads to elevated protein kinase 
activity and enhanced ligand- binding activity (Yarden and Schlessinger, 1987; 
Schlessinger, 1988). Following ligand binding, specific tyrosine residues within the 
carboxyl tail of the receptor are autophosphorylated and proteins containing SH2 
domains are recruited to the activated receptor. Specific SH2 proteins may be recruited 
depending upon which receptor family member is activated, for example 
autophosphorylation of erb -b3 recruits PI3K thus erb -b3 heterodimers will selectively 
activate the PI3K pathway (Carraway et al., 1995). Numerous signalling pathways can be 
activated in this way including pathways mediated by ras (see section 1.3.1.1). 
Erb -bl encodes the epidermal growth factor receptor (EGFR). This receptor has been 
shown to be overexpressed in approximately 45% of NSCLC, gene amplification is 
uncommon and the mechanism that results in deregulated expression is unclear (Kern et 
al., 1992; Volm et al., 1992; Rusch et al., 1993; 1995). Overexpression of the EGFR 
ligand, TGFa, has also been reported to occur in approximately 10% of NSCLC cases 
that do not aberrantly express EGFR, whilst overexpression of both EGFR and TGFa 
have been detected in 38% of cases. Cell type and stage do not influence differential 
expression of EGFR or TGFa, and studies have shown overexpression of EGFR in a 
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spectrum of preneoplastic lesions including metaplasia, dysplasia and carcinoma in situ 
(Rusch et al., 1995; 1997). Therefore, it appears that deregulation cellular signalling 
through EGFR is an early event in NSCLC. 
The transmembrane tyrosine kinase receptor encoded by erb -b2 (her2/neu) does not have 
a recognised ligand but has been shown to dimerise with other members of the erbb 
family and may be activated autonomously if receptor levels are high (Tzahar et al., 1994; 
Rachwal et al., 1995). Overexpression of ERB -B2 has been detected in NSCLC, with 
some studies suggesting a higher percentage of overexpression in ADC than in SCC 
(Kern et al., 1990; Tateishi et al 1991; Shi et al., 1992). ERB -B2 overexpression may be 
an early event in the development of ADC as in AAH lesions aberrant expression has 
been detected in 7 -35% of cases, this expression has been correlated with increase atypia 
(Kerr et al., 1994; Kitamura et al., 1996). 
1.3.1.2.b c -Met 
The c -niet gene encodes a membrane receptor tyrosine kinase that is activated by 
hepatocyte growth factor (HGF), a cytokine that is mitogenic and a motogenic factor for 
both cultured bronchial epithelial cells and non -small -cell carcinoma lines (Brinkmann et 
al., 1995; Singh -kaw et al., 1995). Overexpression of the receptor is observed in 
approximately 50% of NSCLC, of which overexpression is most frequent in ADC (30 %) 
and LCC (20 %) and is rare in SCC (Prat et al., 1991; Liu and Tsao 1993; Tsao 1998). 
HGF is also overexpressed in these NSCLC subtypes (Olivero et al., 1996). Among 
ADC, intermediate to high levels of c -MET immunoreactivity correlated with a greater 
degree of tumour differentiation. Furthermore, an accentuation of c -MET 
immunoreactivity was often noted in cancer cells at the advancing edge of tumours. 
These findings support a role for the c -MET tyrosine kinase receptor in lung cancer cell 
invasion and differentiation in vivo (Tsao et al., 1998). 
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1.3.1.4 BCL2 and apoptosis 
BCL2 was originally identified at the chromosomal breakpoint of t(14;18) in a 
lymphocytic B cell leukaemia (Tsujimoto et al., 1984; Cleary et al., 1986). Since its 
identification BCL2 has been shown to be one of a family of genes, of which there is at 
least 16 members in humans, that is involved in the regulation of apoptosis. Some family 
members enhance (e.g. BAX and BAD) and some negatively regulate apoptosis (e.g. 
BCL2 and BCLXL), reviewed in Kroemer, 1997. Bcl2 family members can form hetero- 
and homo- dimers and it has been postulated that the balance of pro- verses anti -apoptotic 
family members dictates cellular response. The current understanding as to how the bc12 
family regulate apoptosis is reviewed in Reed, 1998. 
Several studies have analysed the expression of BCL2 and found that protein 
overexpression is significantly associated with SCC (35 -59 %) and is less frequent in ADC 
(10 -28 %) and LCC (38 %) (Jiang et al., 1996; Higashiyama et al., 1997; Apolinario et al., 
1997; Laudanski., 1999; Dosaka -Akita., 1999). Aberrant expression of BCL2 is thought 
to be an early event in SCC as overexpression of the protein has been detected in 
dysplastic lesions (Walker et al., 1995). 
1.3.1.5 Cyclin Dl 
The CCNDI proto -oncogene, located on chromosome 11q13, encodes cyclin D1, a 
protein that is a major regulator of cell proliferation (reviewed in Sherr 1996 and 
discussed in sections 11.3.2.1 and 1.3.2.4). Following mitogen stimulation, cyclin Dl and 
other D -type cyclins are induced and assemble with their catalytic partners, cyclin 
dependent kinases, CDK4 and CDK6. These holoenzyme complexes enter the nucleus 
where following phosphorylation by a CDK- activating kinase (CAK), function to 
phosphorylate protein substrates. The major targets of the cyclin D -CDK complexes are 
the retinoblastoma family of proteins RB, p107, and p130 (see section 1.3.2.1). The most 
recognised function of cyclin -D dependent kinases is phosphorylation of the protein 
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product pRB that leads to further phosphorylation by other cyclin dependent kinases and 
results in hyperphosphorylation of the protein. Whilst hyperphosphorylated, the growth 
suppressive functions of RB are disrupted allowing transcription of a number of genes 
whose activities are required for DNA synthesis (reviewed in Dyson 1998; Nevins 1998). 
In vitro experiments implicate CCND1 as a proto -oncogene and studies have shown that 
cyclin Dl overexpression confers tumourigenicity (Musgrove et al., 1994). Elevated 
levels of cyclin D1 have been reported to occur in many types of human cancer including 
cancers of the breast, head and neck, colon and lung (Motokura and Arnold 1993; Hunter 
and Pines 1994; Hall and Peters, 1996). In some cases, overexpression of the gene has 
been shown to be a result of chromosomal translocations or gene amplification 
(Schuuring et al., 1992; Buckley et al., 1993; Zhang et al., 1993). Amplification of 
CCND1 has been detected in 5 -30% of NSCLC cases whilst overexpression of cyclin D1 
protein occurs in approximately 50% of cases (Betticher et al., 1996; Marchetti et al; 
1998; Reissmann et al., 1999; Mishina et al., 1999). Overexpression of cyclin Dl in cases 
of NSCLC that do not contain amplification of the CCNDI gene, may be a result of loss 
of RB expression (see section 1.3.2.1), disruption of wnt (see section 2.6.10.6) or ras 
signalling pathways (see section 1.3.1.1.f). 
No significant difference has been demonstrated between cyclin D 1 overexpression and 
histological subtype, and aberrant expression has been detected at all tumour stages 
suggesting cyclin D1 overexpression is an early event in NSCLC. 
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1.3.2 Tumour suppressor genes and lung cancer 
Tumour suppressor genes are cellular genes that inhibit or restrain the process of 
tumourigenesis. Knudson proposed the concept of tumour suppressor genes over 20 
years ago (Knudson 1978). By studying the inheritance patterns of retinoblastoma he 
concluded an inherited mutation in one allele of the tumour suppressor gene RB, 
predisposed the individual to the development of retinoblastoma. This mutation was 
recessive as development of the disease required the subsequent inactivation of the 
remaining allele i.e. by a somatic event resulting in deletion or mutation of the remaining 
`active' allele. In sporadic cancers two somatic events resulting in the inactivation of both 
alleles of a tumour suppressor gene are required, in most cases of sporadic cancer one 
allele is deleted whilst the other is inactivated through DNA mutation (Weinberg, 1991). 
This section reviews the tumour suppressor genes implicated in NSCLC. 
1.3.2.1 The retinoblastoma gene 
The retinoblastoma (RB) tumour suppressor gene, located on chromosome 13g14.11, 
was one of the first tumour suppressor genes identified (Knudson, 1978; Lee et al., 
1987). Individuals that harbour germline mutation within the gene are predisposed to the 
development of tumours of the retina (retinoblastoma), a small proportion of these 
individuals also develop osteosarcomas. The RB gene encodes a 105 kDa nuclear 
phosphoprotein (pRB) (Yunis and Ramsay, 1978). The protein functions to inhibit the 
cell cycle through the control of progression through late GI phase. pRB physically 
interacts with, and inhibits the action of cellular proteins, such as the E2F family of 
transcription factors, which function to activate genes required for DNA synthesis during 
the S phase of the cell cycle (Strauss et al., 1995; Bartek et al., 1996; Ikeda et al., 1996; 
Wang 1997; Herwig and Strauss 1997). The activity of pRB as a repressor of Gl 
progression is regulated by cycles of phosphorylation and dephosphorylation at multiple 
serine and threonine residues within the RB protein (Bartek et al., 1996; Wang 1997). 
53 
During GO /G1 phase of the cell cycle, pRB is hypophosphorylated and becomes 
phosphorylated by the cyclin D- dependent kinases, CDK4 and CDK6, as cells approach 
the G1 IS boundary prior to DNA synthesis. Phosphorylation of pRB leads to a release of 
active forms of the E2F family of transcription factors, which can in turn activate target 
genes such as cyclin E, cyclin A and many S phase -specific genes such as thymidine 
kinase and polymerase a (reviewed in Lavia and Jansen -Durr 1999). 
Mutations in the RB gene have been detected in a wide variety of sporadic cancers 
including lung carcinoma. In SCLC and NSCLC the inactivation of both RB alleles is well 
documented with loss of RB expression reported to occur in 17-41% of NSCLC tumours 
(Xu et al., 1991; 1994; Reissmann et al., 1993; Sakaguchi et al., 1996; Gorgoulis et al., 
1998; Tanka et al., 1998; Vonlanthen et al., 1998). Aberrant expression of the RB gene 
has been correlated with NSCLC stage, with 20% of stage I and II tumours and 60% of 
stage III and IV showing loss of expression (Xu et al., 1991). This suggests that RB may 
be important in cancer progression rather than initiation, a proposal that is supported by 
the fact that individuals heterozygous for mutations in RB do not have an increased risk 
of lung cancer. 
The RB protein is also thought to act as a positive transcriptional regulator of the cyclin 
Dl gene, CCND1, in some cell types (Muller et al., 1994; Lukas et al., 1995). Analysis of 
NSCLC has failed to correlate the presence of pRB with varying levels of cyclin D1 
detected in these tumours (Schauer et al., 1994). One may hypothesise that in NSCLC 
and possibly other tumour types the RB and cyclin D1 levels do not correlate due to 
deregulation of other pathways that influence the protein levels of these two genes, i.e. in 
the case of increased levels of cyclin D1 one could specify pathways such as MEK/ERK 
(see section 1.3.1.1.e), PI3K (see section 1.3.1.1.f) or wnt (see section 2.6.10.6). 
1.3.2.2 p53 
The p53 gene, located at chromosome 17p13.1, encodes a 53 kDa nuclear 
phosphoprotein which functions as a transcription factor that is involved in the regulation 
of a variety of cellular functions including DNA replication, transcription, cell cycle 
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progression, differentiation and apoptosis (Reviewed in Kirsch and Kastan 1998; Steele et 
al., 1998; Almog and Rotter 1998). The p53 gene has been termed "guardian of the 
genome" as following DNA damage the cell rapidly increases its level of p53 by a post - 
transcriptional mechanism which results in induction of cellular genes that induce G1 
arrest or programmed cell death (Lane 1992; Levine 1997). Further to this, inactivation 
of p53 has been shown to result in increased frequencies of gene mutations, chromosomal 
rearrangements and abnormal chromosomal segregation (Havre et al., 1995; Fukasawa et 
al., 1996; Bertrand et al., 1997). 
Germline mutations in the p.53 gene are found in patients with the autosomal dominant 
Li- Fraumeni cancer syndrome, whereby affected individuals have early onset of multiple 
tumours (Li et al 1988; Malkin et al., 1990; 1993; 1994). Somatic mutations have been 
detected in various cancers including pulmonary cancer (Takahashi et al., 1989; Hollstein 
et al., 1991). P53 mutations are of two types: dominant negative mutations that stabilise 
the protein and recessive null mutations. Usually within the cell the level of p53 is very 
low and difficult to detect by immunological techniques. In cells with dominant negative 
mutations that result in increased half -life of the protein, immunological techniques are 
able to detect the protein. 
Mutations within the p53 gene have been shown to occur in approximately 48% of 
NSCLC, with a significant difference between the frequency of mutations in SCC (67 %) 
and ADC (39 %) (Greenblatt et al., 1994, reviewed in Fujita et al., 1999). Most 
mutations, as with cancers at other sites, are located between codons 120 and 290, exons 
5 to 8 of the gene (Chiba et al., 1990; Greenblatt et al., 1994). This region of the gene 
encodes the central core domain and mutations in this region have been shown to lead to 
the loss of p53 DNA binding activity (Kern et al., 1992; Velculescu and El -Deiry, 1996). 
Within this region several mutational hotspots have been detected, these hotspots occur 
at codons 175, 248, 273 and 281/282 (Greenblatt et al., 1994). Mutations detected in 
NSCLC are commonly G -T transversions (Greenblatt et al., 1994; Huang et al., 1998; 
see section 1.1.2). 
Immunohistochemistry has been used to determine the timing of p53 alterations within 
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SCC tumourigenesis. Numerous studies have detected p53 protein in dysplastic lesions 
and the frequency of p53 detection correlates with increasing dysplasia and is reported to 
occur in over 70% of CIS, suggesting that aberrant expression of p53 is important in 
driving progression of severe bronchial dysplasia to an invasive SCC (Bennett et al., 
1993: Nuorva et al., 1993; Hirano et al., 1994). However, these data must be interpreted 
cautiously as p53 accumulation may be a reflection of initiation of G1 arrest or apoptosis 
following cellular damage. Confirmation that the p53 gene is mutated in dysplastic lesions 
has come from several studies (Sozzi et al., 1992; Chang et al., 1995; Franklin et al., 
1997). 
Due to the lack of identified precursor lesions, it is unclear whether mutation in the p53 
gene is an early event in ADC formation. Analysis of ADC has suggested that p53 
mutations may occur prior to clonal expansion, as determined by their homogeneous 
topographical distribution (Li et al., 1994a). Several groups have assessed p53 
accumulation in AAH lesions and reports show aberrant expression in 5 -58% of lesions 
(Kerr et al 1994; Kitamura et al., 1996, Cagle et al., 1996; Slebos et al., 1998), in several 
studies aberrant expression correlated with increased atypia. The large variation in 
reported frequency of aberrant expression could be due to several factors including 
antibody and immunohistochemical technique used, interpretation of positive staining and 
the relative percentage of lesions showing high grade and low grade atypia. 
1.3.2.3 The CDKN2 gene and its protein products p16 and p14`RF 
The CDKN2 gene, mapping to chromosome 9p21, has been termed a classic tumour 
suppressor gene. Germline mutations within the CDKN2 gene are associated with familial 
multiple -mole melanoma and the resulting tumours exhibit biallelic inactivation 
(Hussussian et al., 1994). The chromosome region 9p21 has also been shown to be 
frequently deleted in primary tumours and tumourigenic cell lines (Hussussian et al., 
1994; Nobori et al., 1994; Kamb et al., 1994; Testa, 1996). The region of loss identified 
within these tumours not only encompasses the CDKN2 gene but also the MTS 2/ INK4B 
(multiple tumour suppressor gene 2) (Xiao et al., 1995; Stone et al., 1995a;b). 
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The CDKN2 gene is very unusual in that it encodes two distinct proteins translated from 
alternatively spliced mRNA, each regulated by its own promoter (Harber, 1997). P16 
(p161rrx4a) is specified by a transcript containing exons 1, 2 and 3, and the alternative, or ß 
transcript containing exons 113, 2 and 3. The alternative, or ß transcript encodes the 
protein termed p19`ß in the mouse (Quelle et al., 1995) and p14'F in humans (Duro et 
al., 1995; Mao et al., 1995; Stone et al., 1995b). P16 and p14ARF have recently been 
identified as playing crucial roles in the regulation of the cell cycle; p16 is associated with 
the RB pathway (see section 1.3.2.1) whilst p14ARF is involved in the regulation of p53 
pathway (1.3.2.2). 
P16 consists of a 156 amino acid protein that functions as a cyclin dependent kinase 
inhibitor (CDI). P16 is representative of a class of CDIs with amino acid homology (p16, 
p15 (encoded by MTS2), p18, p19) that bind CDKs, inhibiting their ability to 
phosphorylate the RB protein and resulting in G1 cell cycle arrest (Hannon and Beach, 
1994). Evidence suggests that the RB protein negatively regulates p16 and an inverse 
correlation between alterations in these proteins has been determined in several tumour 
studies (Li et al., 1994b; Tam et al., 1994; Shapiro et al., 1995). 
CDKN2 also transcribes p 14 (alternative reading frame) which encodes, in humans, a 
15 kDa protein. P1 4A has only recently been described as having tumour suppressor 
functions. In NIH3T3 fibroblasts overexpression of the murine p19`ß homologue has 
been shown to induce G1 /S and G2/M cell cycle arrest (Quelle et al., 1995) whilst p19`ß 
knockout mice develop carcinogen- induced tumours at an accelerated rate (Kamijo et al., 
1997). 
The protein product p14ARF binds specifically to the protein MDM2. MDM2 is involved 
in the regulation of S phase transition through its ability to bind to the p53 protein 
preventing p53 mediated induction of genes required for G1 cell cycle arrest i.e. p21. 
MDM2 when in a protein complex with p14'ß can still associate with p53, however this 
protein complex (p53/MDM2 /p14') is more stable that the p53/MDM2 complex, which 
results in inhibition of G1 cell cycle arrest (Kamijo et al., 1997; Stott et al., 1998). 
Early analyses of the CDKN2 gene comment only on p16 as researchers were unaware of 
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p14w; therefore most data to date discuss mutations in relation to p16 and address the 
aberrant expression of p16 RNA and protein. 
P16 expression has been described in the normal lung, expression is nuclear with weaker 
cytoplasmic staining (Merlo et al., 1995; Kashiwabara et al., 1998; Gazzeri et al., 1998). 
Aberrant expression, as depicted by failure to detect protein product, has been frequently 
observed in NSCLC occurring in up to 66% of cases (Kratzke et al., 1996; Sakaguchi et 
al., 1996; Tanka et al., 1998; Gazzeri et al., 1998; Kashiwabara et al., 1998). The 
mechanisms by which p16 expression is lost include genomic alteration in exons la and 2 
(0 -14% of cases), homozygous deletions (45% of cases) and methylation of exon la. 
(30 -70 %) (Stirzaker et al., 1997; Tanka et al., 1998; Gazzeri et al., 1998). Loss of p16 
expression is associated more frequently with SCC than ADC (Kinoshita et al., 1996; 
Kratze et al., 1996; Sakaguchi et al., 1996; Kashiwabara et al., 1998) and has been 
correlated with degree of differentiation in ADC, with p16 expression more common in 
poorly differentiated than well -differentiated adenocarcinomas (Kashiwabara et al., 
1998). 
In the majority of human cell lines, large deletions have been shown to occur that 
encompass the coding region of p16 and p 14, although in a few cases, point mutations 
or small deletions that effect p16 only have been detected (Quelle et al., 1997). This may 
suggest that loss of both p16 and p 14w may favour tumour formation (Stone et al., 
1995b). 
1.3.3 Gross chromosomal abnormalities, fragile sites and loss of heterozygosity 
Cytogenetics and molecular biology techniques have demonstrated that NSCLC cases are 
often aneuploid and exhibit numerical and structural changes in chromosomes. These 
tumours may be described as exhibiting chromosomal instability (CIN), a phenotype 
originally described in colorectal cancers. Chromosomal instability is thought to be a 
result of abnormalities in genes that encode proteins that function in cell cycle check 
points, e.g. p.5.3 (Cahill et al., 1998). Numerous abnormalities occurring at specific 
chromosome regions are associated with NSCLC, some of these regions are known 
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"fragile sites ", i.e. sites that display a number of characteristics of unstable, highly 
recombinogenic DNA, and have been shown to be preferential sites for chromosomal 
deletion and rearrangement (Smith et al., 1998). Chromosomal amplifications and 
deletions associated with NSCLC are discussed below. 
1.3.3.1 Regions of DNA amplification 
Amplification of proto- oncogenes is a common feature of many solid tumours (Alitalo 
and Schwab, 1986; Schimke, 1988). Chromosomal regions of DNA amplification can be 
identified by the presence of double minutes or homogeneously staining regions or 
through the use of the relatively new technique comparative genomic hybridisation 
(CGH) analysis (reviewed in Houldsworth and Chaganti 1994). These techniques have 
been used to analyse primary NSCLC tumours and NSCLC cell lines (Balsara et al 1997, 
Taguchi et al., 1997). A high incidence of over representation of chromosome arms 3q 
(85 %), 5p (70 %), 7p (65 %) and 8q (65 %) were detected in these studies. DNA sequence 
amplification is most frequent at 3q26, the site of the PIK3CA gene that encodes the 
catalytic subunit of phosphatidylinositol- 3 kinase (see section 1.3.1.1.1), whilst 
chromosomal amplification at 8q24 (which harbours c-MYC; see section 1.3.1.2) was 
detected in 20% of cases. The chromosomal region 7p12, containing ERB -B1 was 
amplified in 50% of cases and of these cases, two thirds also exhibited chromosomal 
amplification at 2p13, a region containing the TGFa gene. (See section 1.3.1.3a). 
1.3.3.2 Regions of chromosomal loss 
Cytogenetic and comparative genomic hybridisation (CGH) studies report allelic loss at 
many chromosomal regions in NSCLC cases. The use of molecular techniques has been 
used to narrowly define the critical regions of loss. Initial analysis utilised polymorphic 
loci based on restriction fragment length polymorphisms (RFLP). These polymorphic 
sites however were at uncertain sites throughout the chromosome and most were of low 
informity (i.e. the polymorphic variants occurred at a very low frequency). A further 
drawback was that RFLP were detected by southern blotting which required large 
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amounts DNA. Since these initial studies, the number and informativeness of RFLP 
markers has increased dramatically and information has been further enhanced by new 
types of markers utilising highly polymorphic DNA sequences, such as variable number of 
tandem repeat (VNTR) loci (Nakamura et al., 1987), microsatellite repeats containing 
variable copy numbers of cytosine and adenosine repeats ((CA)n) (Weber and May 1989) 
and tri or tetranucleotide repeats (Gastier et al., 1995; Dubovsky et al., 1995). These loci 
have multiple alleles resulting in a frequency of heterozygosity that can be 80% or higher. 
With the introduction of polymerase chain reaction (PCR) and the development of PCR- 
based polymorphic markers, it is now possible to detect genetic change even in the 
smallest number of cells. This is further refined by microdissection, which allows 
purification of tumour cells from normal stromal cells. Using these refined techniques 
more than 30 regions of deletion, either loss of heterozygosity (LOH) or homozygous 
deletions, dispersed on 21 different chromosome arms have been defined in NSCLC 
(Reviewed in Kohno and Yokota 1999), the majority of these deletions occur within 
common fragile sites (Smith et al., 1998). 
The most common losses identified in NSCLC lie on chromosome 3p, 13q and 17p, 
frequency of loss has been detected in >70% of cases. Loss of heterozygosity include 6q, 
9p and 19p in >60% cases. Tumour suppressor genes have already been identified on 13q 
(RB), 17p (p53) and 9p (CDKN2), and have been discussed in detail in previous sections. 
These studies analysed multiple polymorphic sites along the chromosome arm and 
demonstrated multiple regions of loss; further studies are now needed to elucidate tumour 
suppressor gene in these regions. 
The allelotypes of SCC and ADC have been shown to vary (Sato et al., 1994). Loss of 
heterozygosity is more frequent in SCC than in ADC as determined by the analysis of 36 
chromosomal arms. In SCC most frequent losses are seen at chromosome 17p (88- 
100%), 3p (82- 100 %), 9q (67 %) and 13q (60 %), whilst in ADC loss at 17p (51 %), 3p 
(40 %), 9p (36 %) and 8q (32 %) are most frequent (Tsuchiya et al., 1992; Sato et al., 
1994). The frequencies of LOH on chromosomes 17p and 3p are significantly different 
between SCC and ADC, whilst LOH on chromosome 2q has been reported to only occur 
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in ADC (Tsuchiya et al., 1992; Sato et al., 1994). These data suggest that different 
tumourigenic mechanisms may be involved in histological types of NSCLC. 
Losses of 3p, 13q and 17p have been associated with stage 1 primary NSCLC. A study 
specifically addressing early genetic events in SCC analysed normal epithelium, 
preneoplasia (hyperplasia, metaplasia and dysplasia) and carcinoma in situ (CIS), from 
smokers, for LOH at 10 chromosomal regions frequently deleted in NSCLC. These 
chromosomal regions were: 3p12, 3p14.2 -21.3, 3p21, 3p22 -24, 3p25, 5q22 (region of 
the APC and MCC genes, see below), 9q21 (CDKN2), 13q14 (RB) and 17p13 (p53). 
These studies determined that LOH at 3p21, 3p22 -24, 3p25 and 9p21 were the most 
frequent events and occurred in the earliest detectable lesions, in fact they were also 
detected in histologically normal epithelium. The incidence of LOH within a sample 
increased with increasing morphological change i.e. dysplasia and CIS demonstrated a 
significant increased overall incidence of LOH than normal epithelium or metaplastic 
lesions, falling in line with the theory that a sequence of molecular events precedes the 
development of cancer. Losses at other regions of 3p and the 17p13 (p53 gene) were 
present mainly in histologically advanced lesions (dysplasia and CIS). In contrast 
deletions at chromosome 5q22 and 13q (near the APC and RB genes) were mainly 
associated with invasive lesions (Wistuba et al., 1999). 
1.3.3.3 LOH at 5q21 
Several groups have reported genetic loss at chromosome 5g21 in NSCLC (Ashton - 
Rickardt et al., 1991; D'Amico et al., 1992; Tsuchiya et al., 1992; Horri et al., 1992a; 
Hosoe et al., 1994; Wieland and Bohm 1994, Fong et al., 1995). These studies report 
LOH in 20 -71% of cases. The varying frequency of LOH may be a reflection of different 
histological types within cohorts as a number of studies have revealed that ADC and SCC 
exhibit differences in allelotypes (see section 1.3.3.2). Tumour stage may also be a cause 
for this variation, as discussed in the previous section the analysis of different stages of 
SCC has determined that different genetic events occur at different stages of tumour 
development. This phenomenon has been well described during pathogenesis of colon 
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cancer where both the accumulation of mutations and the order have been shown to be 
important in the colon tumourigenesis (Fearon and Vogelstein 1990; Kinzler and 
Vogelstein 1996). 
Two studies have reported a correlation between LOH at 5q21 and ADC and SCC 
histological types, however the results from these groups were conflicting 
(Tsuchyiya et al., 1992; Fong et al., 1995). Fong and co- workers also reported that 
LOH at 5q21 occurs more frequently in late stage tumours, suggesting that loss of 
this chromosomal region is a late event in the tumourigenesis of NSCLC. 
1.3.3.3.a Putative tumour suppressor genes: APC and MCC 
Several genes have been identified that reside within the chromosomal region 5g21. 
These genes are FER, TBI, MCC, TB2, SRP19 and APC (Kinzler et al., 1991a,b; Joslyn 
et al., 1991). Chromosome region 5q21 was initially investigated to identify the tumour 
suppressor gene responsible for the inherited disorder, familial adenomatous polyposis 
coli (FAP). FAP is a disease whereby multiple polyps develop within the colon 
predisposing the affected individual to colonic carcinoma and increased risk of cancers of 
the brain, thyroid, bone and focal proliferative lesions of the connective tissue (Bodmer et 
al, 1987; Leppert et al., 1987; Dunlop et al., 1990). FAP kindred's were screened for 
mutations within the six identified genes, mutated in colorectal cancer (MCC), TB I, 
SRPJ9, TB2 and the adenomatous polyposis coli gene (APC). 
Mutations in the MCC gene were detected in sporadic colon tumours (Kinzler et al, 
1991 a) although further larger studies failed to show mutations within this gene (Curtis et 
al., 1994; Cripps et al., 1995). No mutations were detected in the TBI, SRP19, TB2 
genes (Nigro et al., 1989; Nishisho et al., 1991). Germline mutations were detected in 
the gene that was subsequently termed the APC gene. In the majority of familial and 
sporadic colorectal cancer cases both APC alleles were shown to be inactivated either by 
gene mutation alone or by loss of one allele and mutation within the remaining allele 
(Nishisho et al., 1991; Groden et al., 1991). Biallelic inactivation of APC has also been 
reported in sporadic gastric (Tamura et al., 1994) and hepatic cancers (Oda et al., 1996; 
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Imai et al., 1997), suggesting that inactivation of the APC gene may be a critical step in 
the genesis of several types of tumours. It is unknown whether biallelic inactivation of 
APC is a feature of NSCLC. One study consisting of 7 NSCLC cases, that displayed 
LOH at 5q21, detected no mutations in the remaining APC allele (Horri et al., 1992b). 
Therefore, experimental work undertaken for this thesis investigates whether 
biallelic inactivation of the APC gene is a feature of NSCLC. 
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Chapter 2: The APC gene 
This chapter reviews the current knowledge on the expression of APC and its protein 
structure. Several proteins have been identified that interact with APC whilst other 
interactions are still putative. These protein/protein interactions are discussed and 
possible cellular functions are addressed. The mutation spectrum identified within the 
APC gene in both familial and sporadic colorectal cancer and in other sporadic cancers is 
reviewed. Publications have described the identification and characterisation of 
homologues of APC, these homologues are discussed in detail in section 2.5. 
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2.1 APC expression 
The APC gene was originally identified to encode a 2843 amino acid polypeptide with a 
predicted molecular weight of 310 kDa ( Groden et al., 1991; Kinzler et al., 199la). 
Recent investigations have revealed that several isoforms of APC exist (discussed in 
section 2.2) and protein products of various molecular weights have been identified 
(Santoro and Groden 1997; Pyles et al., 1998). 
APC is expressed in both epithelial and mesenchymal lineages and particularly high 
expression has been noted in the central nervous system (CNS) (Smith et al., 1993; Bhat 
et al., 1994; Miyashiro et al., 1995; Senda et al., 1996; Midgley et al., 1997; Senda et al., 
1998). 
Bhat and Co- workers (1994) demonstrated high levels of APC mRNA throughout the 
brain of embryonic and early postnatal rats which, with the exception of the olfactory 
bulb, decreased 6 weeks after birth and remained low in adult rats. Relatively high levels 
of mRNA were noted in the hippocampus and cerebellum and in layers containing newly 
formed postmitotic neurones, lower levels were observed in proliferative zones where 
neurogenesis occurs. The expression pattern seen throughout the developing tissue 
suggested that APC might contribute to suppressing neuronal proliferation during brain 
development. 
Senda and Co- workers (1998) analysed the localisation of Apc in the mouse CNS. This 
study showed Apc expression in neurones and nerve fibres in some but not all nervous 
tissues. Apc was shown to be concentrated in the terminal plexus of the basket cell fibres 
around Purkinje cells. This is also a location of postsynaptic densities (PSD) which are 
proposed to have several functions, including the stabilisation of synaptic junctions and 
regulation of neurotransmitter receptors (reviewed in Kennedy et al., 1993). APC was 
shown to co- localise at these sites with ß- catenin and the human homolgue of the 
Drosophila tumour suppressor, Dlg (lethal (1) disc -large) (Lue et al., 1994; Hunt et al., 
1996; Makino et al., 1997; discussed in detail in section 2.3.5).The co- localisation of 
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these proteins to PSD implicates their involvement in signal transduction between basket 
cell fibres and Purkinje cells. 
Apc was also shown to localise to perivascular astrocytic "endfeet ". Astrocytes, one of 
the glial cells, surround and extend along neurones (both their cell bodies and their 
processes) and themselves extend processes that are expanded into "endfeet" which, 
linked by cell junction complexes form a sealed barrier at the external surface of the 
central nervous system. Astrocyte processes and endfeet act as the sites for cell adhesion 
and intercellular signalling (Kimelberg et al., 1989; Walz and Wuttke, 1989). The 
localisation of Apc suggests it may have a role in the regulation of intracellular signal 
transduction and structural maintenance of astrocyte endfeet. f3- catenin or DLG did not 
co- localise with APC in astrocytic processes and endfeet, this may suggest a different 
mechanism of signal transduction in astrocytes. 
In summary investigations of Apc localisation and expression levels within the CNS may 
suggest a role for Apc in neuronal cell signalling and cellular proliferation in some but not 
all cell types. APC is a negative regulator of wnt /ß- catenin signalling pathway (discussed 
fully in section 2.6). One may hypothesise that mutations in the APC gene, that result in 
the perturbation of wnt signalling, may lead to aberrant cellular signalling and neuronal 
proliferation. It is therefore interesting to note that individuals with germline mutations 
within APC are associated with Turcots syndrome, a syndrome characterised by not only 
colonic adenomas but also neuroepithelial tumours. Futhermore, murine models with 
targeted disruption of the proto -oncogene Int- 1/Wntl that results in the absence of 
signalling are characterised by severe brain development abnormalities (Thomas and 
Capecchi 1990). 
In numerous mouse tissues APC expression has been shown to vary in its subcellular 
location in individual cell types of the same tissue. The level of expression also varies and 
studies have shown increased expression in cells where cell replication has ceased and 
terminal differentiation is established (Miyashiro et al., 1995; Midgley et al., 1997). This 
is shown to be the case in enterocytes of both the small and large intestine, with Apc 
expression increasing from the base of crypts to the luminal surface (as cells become 
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differentiated and no longer undergo mitosis). Diffuse cytoplasmic staining seen in the 
lower portion of the crypts becomes localised to lateral and sub -apical cell membranes. In 
the small intestine, enterocytes that have migrated to the luminal surface show strong 
accentuation of staining along their apical surfaces, this apical staining is maintained as 
cells migrate up the villi. Apc co- localises with both a- and 3- catenin at the lateral 
membranes but this co- localisation does not occur at apical surfaces (Miyashiro et al., 
1995; Senda et al., 1996) supporting additional functions of APC independent of its 
association with ß- catenin. Interestingly, the apical region of epithelial cells contain ends 
of microtubules. APC has been shown to promote microtubule assembly in vitro and co- 
localisation studies reveal that APC is localised in clusters near ends of microtubules that 
protrude into actively migrating membrane structures (Munemitsu et al., 1994; Smith et 
al., 1994; Näthke et al., 1996; discussed in section 2.3.4). Therefore, the localisation of 
APC to the apical surface of the cell may reflect a role in cell migration. The lateral and 
sub -apical membranes are typically sites for adhesion junctions; junctions that are 
required not only for intercellular adhesion, but also for intercellular signalling and cell 
polarity. The role of APC in cell adhesion is discussed in section 2.7. 
Within murine lung tissue, APC expression is described as showing a diffuse cytoplasmic 
pattern with linear membranous staining of the bronchial epithelial cells (Midgley et al., 
1997). 
Immunohistochemical studies have generally described APC expression as either diffuse 
or punctate in the cytoplasm with occasional nuclear staining (Miyashiro et al., 1995; 
Midgley et al., 1997). From early immunohistochemical studies, it was unclear whether 
nuclear staining was specific. APC nuclear localisation has since been confirmed by cell 
fractionation techniques and experiments have demonstrated that the ability to clearly see 
the nuclear component of APC is highly dependent on protocol details e.g. the use of 
paraformaldehyde versus formaldehyde in cell fixation (Neufeld and White, 1997). Two 
putative nuclear localisation sequences have been identified within APC. These sequences 
begin at amino acids 1773 and 2054. The significance of nuclear localisation of APC has 
not been determined although current knowledge on the interaction of APC with other 
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cellular proteins does raise some interesting proposals. APC is a negative regulator of the 
wnt signalling pathway, functioning to negatively regulate the level of ß- catenin in the 
cytoplasm (reviewed in section 2.6). The association of f3- catenin with APC, Axin and 
glycogen synthase kinase 3ß leads to ß- catenin phosphorylation and the subsequent 
degradation by the ubiquitin -proteosome system. The accumulation of free ß- catenin (not 
in a complex with cadherin) in the cytoplasm results in translocation to the nucleus where 
it associates with members of the lymphocyte enhancer binding factor or T -cell factor 
(LEF -1 /TCF) family of transcription factors. As ß- catenin and APC interact in the 
cytoplasm and both proteins have been shown to localise to the nucleus, this raises the 
possibility of interactions between these two proteins occurring in the nucleus. It is 
unknown whether APC can interact with ß- catenin whilst it is in a complex with LEF -1/ 
TCF, or if the ß- catenin complex is stable, but one could speculate that APC may further 
negatively regulate wnt signalling at the nuclear level. 
ß- catenin can be imported into the nucleus and evidence suggests it may also be exported 
from the nucleus (Fagotto et al., 1998; Prieve and Waterman, 1999), the mechanism of 
translocation and exportation are unknown as is the nuclear function of uncomplexed 13- 
catenin, it may be possible that APC could have a role in these processes. 
The detection of APC in the nucleus may suggest a functional role in mitosis (see section 
2.3.4). Studies have shown interactions with microtubules, a key component of the 
mitotic spindle, and the EB 1 family of proteins, proteins that in yeast have been 
suggested to function as a cell checkpoint mechanism prior to mitosis, whilst 
immunohistochemical analysis suggests that APC is a negative regulator of cell 
proliferation. 
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2.2 Alternative splicing of the APC gene 
The APC gene was originally reported to contain an open reading frame that encoded a 
2843 amino acid sequence. The gene was described as containing 15 exons, exon 1 
contained a translation initiation codon and exon 9 was shown to be alternatively spliced 
and was designated exon 9 and 9A (Groden et al., 1991). To date 5 additional exons 
have been identified. Four exons are located 5' of exon 1 and are designated (from 5' -3') 
0.3, BS (for brain specific), 0.1 and 0.2 (Horii et al., 1993; Thliveris et al., 1994). 
Transcripts containing the BS exon were originally thought to be only expressed in the 
brain, this is now known not to be the case. One exon has been identified 3' to exon 1 
and is designated exon 10A. Exons 0.3, BS, 0.1, 0.2, 9 and l0A are alternatively spliced 
to produce at least 16 different transcripts (Santoro and Groden 1997). As with exon 1, 
exons 0.3, BS and 0.2 also contain a translation initiation codon that is inframe with exon 
2. Exons are depicted in figure 5a. 
Transcripts that contain exons upstream of exon 1 have been identified, some transcripts 
encode exon 1 whilst others do not. Sequence analysis revealed a stop codon located 6 
base pairs 5' to the exon 1 initiation codon. It is predicted that translation initiated 5' to 
exon 1 will cease at the stop codon in exon 1 and be reinitiated by the exon 1 initiation 
codon. Thus only transcripts lacking exon 1 have the ability to encode differentially 
expressed APC peptides with novel amino terminal domains ( Thliveris et al., 1994; 
Santoro and Groden, 1997; Pyles et al., 1998). 
In transcripts identified with exons upstream of exon 1 all were shown to exist in APC 
isoforms both with and without exon 9 in all cell lines and tissues examined (Santoro and 
Groden, 1997). This study did not examine the presence of the alternatively expressed 
exon 10A. 
Elevated levels of transcripts lacking exon 1 have been identified in postmitotic and 
terminally differentiated tissues and can be induced in cell culture systems where cells are 
driven to differentiate (Santoro and Groden, 1997). This may suggest that different APC 
isoforms may be involved in the physiology of cell cycle cessation. 
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Analysis of the DNA and amino acid sequence of APC revealed that exon 1 encodes the 
amino terminus of the oligomerisation domain (discussed in detail in section 2.3.1). The 
predicted structure of proteins encoded from transcripts without exon 1 suggests that 
these proteins would lose their ability to dimerise or interact with other proteins through 
this domain. Further to this, Pyles and co- workers (1998) have shown that APC protein 
encoded by transcripts lacking exon 1 can not dimerise to APC isoforms that contain 
exon 1 encoded sequence. 
In summary, it is likely that different isoforms of APC specify various cellular functions 
thereby adding a new dimension to the cellular role of APC. 
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Figure 5: The APC gene: exons and protein structure 
(a) Twenty -one exons have currently been identified within the AP« gene. These exons 
are alternatively spliced to produce numerous transcripts. Translation initiation codons 
have been identified in four exons and translation stop codons in 3 exons. 
(b) A schematic representation of the APC protein highlighting sites of protein/protein 
interaction. A number of domains have been identified throughout the APC protein. 
Some of these domains have been shown to mediate interactions with other cellular 

























































































































































































































































































































































































2.3 Identified functional domains 
Nucleotide and amino acid analysis and immunoprecipitation studies have identified a 
number of domains in APC that are thought to interact with various proteins. Some 
domains are binding sites of proteins of known function whilst in other cases the 
functions of interacting proteins are unclear. Each identified domain and interacting 
protein is discussed in this section and depicted in figure 5b. 
2.3.1 The oligomerisation domain 
The first 900 amino acids at the amino terminus of the APC protein contain a series of 
heptad amino acid repeats that are involved in APC oligomerisation (Groden et al., 1991; 
Joslyn et al., 1991; Kinzler et al., 1991a). These repeat sequences have hydrophobic side 
chains that form a hydrophobic streak on one side of the protein helix thereby allowing 
hydrophobic interactions between similar streaks on other helices promoting association 
of the two helices into a coiled -coil (Traub 1985; Bourne 1991a; 1991b). Oligomerisation 
may occur between two of the same type of proteins; homo- dimerisation or between two 
different proteins with oligomerisation domains; hetero -dimerisation. To date the APC 
protein has not been shown to interact with any other proteins through its oligomerisation 
domain, however APC has been shown to homo -dimerise (Su et al., 1993). 
Using in vitro expression and immunoprecipitation Su and co- workers (1993) showed 
that the first 171 residues of APC are sufficient for homo- dimerisation. Further 
experiments using lymphoblastoid cell lines, that co- express wildtype and truncated forms 
of APC, revealed that wildtype and truncated protein products could homo- dimerise in 
vitro. The majority of germline and somatic mutations that have been detected within the 
APC gene lead to the production of a truncated protein product, these products 
commonly have an intact oligomerisation domain (discussed in detail in section 2.4). 
Thus, these truncated products have the ability to dimerise to wildtype APC 
demonstrating the potential for dominant interference by the truncated mutant protein 
(Joslyn et al., 1993; Su et al., 1993). Interference of the mutant protein upon the normal 
function of the wildtype protein is often referred to as a dominant negative effect 
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(Herskowitz 1987). The hypothesis behind the dominant negative effect is that protein 
oligomerisation creates a functional complex, if the protein dimerises with a mutant 
protein then the complex may not be functional. Thus, the wildtype protein is essentially 
being inactivated. 
2.3.2 Armadillo repeats 
The armadillo motif is a 42 amino acid sequence that was originally identified in the 
Drosophila segment polarity gene product armadillo, the motif is repeated 12 times in 
tandem in the central region of the protein (Riggleman et al., 1989). The armadillo motif 
has also been identified in the vertebrate homologues I3-catenin (McCrea et al., 1991) and 
plakoglobin (y- catenin) (Franke et al., 1989) and in a number of other proteins with 
diverse cellular functions. Disparate activities, including nuclear transport, cell adhesion, 
cell cycle control and microtubule stability, have been ascribed to the armadillo containing 
proteins and it is thought that the armadillo domain represents a site of protein -protein 
interaction (reviewed in Hatzfeld, 1999). The specificity of protein -protein interactions 
could be determined by either individual or small groups of motifs as each motif within a 
protein is generally only 30% identical. Individual motifs are highly conserved during 
evolution presumably reflecting well -conserved interactions with target proteins (Peifer 
and Wieschaus 1990). 
APC also encodes the armadillo motif, which is repeated 7 times in tandem; this domain is 
situated at amino acids 453 -767 (Kinzler et al., 1991a; Groden et al., 1991; Peifer et al., 
1994). APC interacts directly with the armadillo repeat domain of f3- catenin although this 
interaction is not through APC's armadillo repeat domain (Su et al., 1993; Rubinfeld et 
al., 1993). APC does not associate directly or indirectly with cadherins (Rubinfeld et al., 
1993; 1995) and to date no proteins have been identified that bind to APC's armadillo 
domain and so the function of APC armadillo motifs remain elusive. 
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2.3.3 ß- catenin binding sites 
ß- catenin binding sites have been identified in the APC protein. The interaction of APC 
and (3- catenin was reported by two groups who used immunoprecipitation to identify 
cellular proteins that interacted with APC (Su et al., 1993; Rubinfeld et al., 1993). Two 
proteins, p95 (95 kDa) and p100 (100 kDa) were co- precipitated with APC and were 
subsequently identified as f3- catenin and a- catenin respectively. APC was found to 
preferentially interact with ß- catenin. These interactions were through amino acids 1014 
to 1210 of the APC protein, this region harbours 3 imperfect repeats of 15 amino acids. 
Each 15 amino acid motif was shown to be capable of binding both a- catenin and ß- 
catenin. 
Rubinfeld and co- workers (1993) identified a second ß- catenin binding motif, a 5 amino 
acid sequence, serine -leucine -serine -serine -leucine, that is also present in the ß- catenin 
binding domain of E- cadherin. This sequence formed part of the of the 20 amino acids 
motif described by Groden et al., (1991), which is repeated 7 times within amino acids 
1034 and 2130 of the APC protein. 
The 15 and 20 amino acid motifs share some sequence homology but are distinct 
sequences. Experiments have demonstrated that in order for the 20 amino acid repeat 
domain to bind ß- catenin this region must be phosphorylated (Rubinfeld et al., 1996), 
discussed fully in section 2.6. Hence this f3- catenin binding domain is often referred to as 
the kinase- regulated binding domain whereas the 15 amino acid repeat domain is referred 
to as the constitutive binding domain. The kinase regulated binding domain has been 
shown to down regulate f3- catenin levels (Rubinfeld et al., 1993; Su et al., 1993; 
Munemitsu et al., 1995). It is currently unclear how this region leads to this function but 
it is interesting to note that interspersed between motifs are SAMP (Ser -Ala- Met -Pro) 
sequences, these sequences are situated downstream of motif number 3, 4 and 7. The 
protein Axin has been identified and implicated in the negative regulation of ß- catenin, 
evidence suggests that Axin interacts with APC through APC's latter five 20 amino acid 
motifs and that this interaction requires SAM' sequences (Behrens et al., 1998; Hart et 
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al., 1998; Nakamura et al., 1998). Interactions between APC, Axin and ß- catenin are 
discussed fully in section 2.6.6 
The identification of distinct ß- catenin binding domains in APC raised considerable 
interest and investigators explored possible cellular functions of the APC and 13- catenin 
interaction. Two major cellular functions were determined 1) the interaction of APC and 
ß- catenin in the wnt signalling pathway and 2) the influence of APC on ß- catenin 
mediated cell adhesion. The functional role of APC in these systems is discussed in detail 
in sections 2.6 and 2.7. 
2.3.4 The basic domain and EB1 protein interactions 
The carboxyl -terminal third of the APC protein contains a stretch of approximately 200 
amino acids that is referred to as the basic domain. This domain is defined as amino acids 
2200 -2400 (Groden et al., 1991). Analysis of the basic domain reveals a sequence 
enriched in serine- proline and threonine -proline motifs, motifs that have been shown to 
exist in phosphorylated and unphosphorylated states (Bhattacharya and Boman, 1995). 
The basic domain has amino acid sequence homology to many microtubule associated 
proteins (MAPs), these proteins play a role in modulating the functions of microtubules. 
This may suggest that APC may also have a function in microtubule dynamics. Recent 
investigations have supported this theory. 
Microtubule associated proteins through the modulation of microtubules (MTs) influence 
cell polarity, the internal and external shape of the cell and are also involved in cell 
migration (reviewed in Wadsworth 1999; Waterman- Stoner and Salmon 1999). 
Microtubules also play a crucial role in chromosome and spindle movement in meiosis 
and mitosis (Hyman and Karsenti 1996; Vernos and Karsenti 1996) and in the transport 
of vesicles and movement of organelles (reviewed in Lane and Allan 1998). 
Investigations into the localisation of APC revealed that full -length APC protein and 
fragments containing the carboxyl- terminal of APC associate along the length of 
cytoplasmic microtubules in vivo. APC protein lacking the carboxyl terminal region did 
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not result in this filamentous pattern of staining and was found to be distributed in 
deposits throughout the cell cytoplasm (Munemitsu et al., 1994; Smith et al., 1994). 
Wildtype and carboxyl protein fragments were also shown to promote the assembly of 
microtubules in vitro. These results suggested that mutations within APC that result in 
the truncation of APC prior to the basic domain could have an effect on important 
microtubule processes. As these experiments were carried out on cell lines that were 
transfected with plasmids overexpressing fragments of APC, the pattern of protein 
expression might not reflect the localisation of endogenous levels of APC. Näthke and 
co- workers (1996) examined the localisation of endogenous APC in MDCK and IEC -6 
cells and determined that APC protein is localised in punctate clusters near the ends of 
microtubules that protrude into actively migrating membrane structures. These finding 
support previous experiments showing that APC protein associates with microtubules and 
further suggests a role in microtubule dependent cell migration. It could be hypothesised 
that APC is localised to sites of cell migration and is involved in the bundling of 
microtubules, forming structures that stabilise the direction of migration. Alternatively, 
the increased level of APC detected at these sites could lead to a reduction in cell -cell 
adhesion due to increased turnover of ß- catenin leading to a reduction in cadherin/catenin 
complexes (discussed in section 2.7). Further to this, Näthke and co- workers detected 
APC clusters at the outer boundary of cell -cell contacts where membranes are moving 
past each other. The importance of APC in cell migration has recently been elucidated by 
the analysis of murine models. Mice that harbour a germline mutation at codon 850, a 
mutation that results in the production of a truncated protein product lacking the basic 
domain, have been shown to exert a dominant negative effect on the migration of 
enterocytes in colonic crypts (Mahmoud et al., 1997). 
2.3.4.1 APC, EB1 and microtubules 
Using the yeast two -hybrid system with a fragment of APC encompassing amino acids 
2167 -2843 as bait, Su et al., (1995) identified a cDNA encoding a novel protein termed 
EB1 that could associate with APC in vivo and in vitro. The functions of EB 1 and EB 1- 
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APC interactions are currently unclear. 
EB I has been found to localise, in mammalian cells, to sections of microtubule filaments, 
in particular to leading edges of cell membranes and the periphery of stained fibres. 
Perinuclear staining was present with intensive staining at the microtubule organising 
centres (MTOC). During mitosis, EB 1 localised to spindle microtubules and centrosomes 
and was strongly associated with midbody microtubules during cytokinesis. Analysis of 
the localisation of EB 1 in the colorectal carcinoma cell line SW480, which encodes a 
truncated APC protein lacking the EB1 binding domain, revealed that EB 1 localisation to 
microtubules and the centrosomes was preserved. This demonstrated that cellular 
distribution of EB 1 does not depend on the carboxyl terminus of APC (Morrison et al., 
1998; Berrueta et al., 1998). 
Shortly after the identification of EB1, Renner et al (1997) published details of a gene 
RP1 that was shown to be rapidly up regulated following T -cell activation and that was 
expressed in cell lines, derived from a spectrum of tumours, that were rapidly 
proliferating but not cells blocked in G,. The expression pattern of RPl in activated T 
cells, i.e. rapid up- regulation peaking after 4 hours prior to a decline in expression, 
suggested that RPI might be a member of the immediate -early gene family. Immediate - 
early genes and the proteins encoded by these genes can act as pleiotrophic regulators of 
cell activation, and include transcription factors and proteins involved in signal 
transduction cascades (Kelly and Siebenkist 1995). RPI had significant homology to EB1 
and experiments revealed specific binding to wildtype but not to truncated APC protein. 
Two further genes with high homology to RPI were identified using the technique of 
RACE (rapid amplification of cDNA ends), these genes were designated RP2 and RP3. 
Together these genes presently constitute the EBI gene family. 
Homologues of EBI /RP have been identified in mice and rats at both the nucleotide and 
protein level, and in yeast homologues Mal3 (Schizosaccharomyces pombe) and Bimlp 
(Saccharomyces cerevisiae) have recently been identified (Schwartz et al., 1997; 
Beinhauer et al., 1997). The human EB/RP proteins and the yeast Mal3 /Bim1p proteins 
have been shown to bind to cytoplasmic and nuclear microtubules in vivo suggesting 
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conserved function (Schwartz et al., 1997; Beinhauer et al., 1997; Berrueta et al., 1998; 
Morrison et al., 1998; Juwana et al., 1999). The analysis of yeast cells harbouring deleted 
Bimlp or Mali reveal that these proteins play a critical role in microtubule dynamics and 
may function as a cell checkpoint mechanism during mitosis (Schwartz et al., 1997; 
Beinhauer et al., 1997; Muhua et al., 1998). Mal3 deletion mutants showed condensed 
chromosomes suggesting a delay in mitosis whilst in Bimlp deleted cells the mitotic 
spindle was abnormally short. Furthermore, in cells harbouring a mutation in act5 (gene 
encoding for the motor protein dynein) that results in the mis- positioning of the nucleus, 
Bimlp was shown to block cytokinesis. No yeast homologue of APC has been identified 
therefore, these experiments can not be expanded to examine the role of APC in yeast 
cytokinesis. 
In summary the EB/RP family have been shown to interact with the C- terminal domain of 
the APC protein however at present the significance of this interaction is unclear. 
2.3.5 Disc large proteins 
The tumour suppressor gene dlg -A (lethal (1) discs -large) was originally identified in 
studies of Drosophila. Germline mutations within dlg -A resulted in neoplastic 
overgrowth of the imaginal disc epithelium, loss of apical- basolateral polarity and 
disruption of normal cell -cell adhesion (Stewart et al., 1972; Woods and Bryant, 1989). 
This phenotype suggested that the function of wildtype dlg -A protein may be concerned 
with maintaining normal epithelial structure and possibly with regulating cell division and 
differentiation (Woods and Bryant, 1991). 
Dlg -A is the founding member of an expanding group of proteins referred to as the 
MAGUK (membrane- associated guanylate kinase) family. MAGUK proteins are typically 
localised to various cell junctions and play an important role in maintaining junction 
structure and signalling properties. These functions are achieved through three distinct 
structural domains that mediate specific protein/protein interactions. The structural 
domains of the protein are: an N- terminal segment comprising one or more discs -large 
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homologous regions (DHRs); a Src oncogene homology motif 3 (SH3); and a C- terminal 
domain with homology to guanylate kinase (GUK). 
Homologues of Drosophila dlg -A have been identified; h -DLG and NE -DLG (highly 
expressed in neuronal and endocrine tissues) are human homologues (Lue et al., 1994; 
Makino et al., 1997); m -Dlg and synapse- associated protein 97 kDa (Sap -97) have been 
identified as mouse and rat homologues respectively (Muller et al., 1995; Lin et al., 
1997). 
The analysis of vertebrate homologues show that Dlg is a ubiquitously expressed, with 
highest levels noted in the central nervous system (CNS) (Muller et al., 1995; Lin et al., 
1997; Makino et al., 1997). The protein localises to regions of cell -cell contact and in 
stratified epithelium has been shown to be specific to non -proliferating cells. Within the 
CNS, is concentrated at synaptic junctions (within postsynaptic densities) in dendrites and 
cell bodies. Postsynaptic densities (PSDs) function to stabilise synaptic junctions and 
regulate neurotransmitter receptors (reviewed in Kennedy et al., 1993). MAGUKs 
localised to PSDs, including SAP -97, have been shown to bind N- methyl -D- aspartate 
(NMDA) receptors, Shaker -type potassium channels, and brain nitric oxide synthase 
through the interaction of the DHR region in the MAGUK protein and the (T /S)XV 
(threonine or serine, any amino acid, valine) motif located at the C- terminus of the target 
proteins (Niethammer et al., 1996; Doyle et al., 1996; Brenman and Bredt, 1997). The 
human homologues of dlg interact with an (T /S)XV motif located at the C- terminal 15 
amino acids of the APC protein via the DHR region (Matsumine et al., 1996; Makino et 
al., 1997). 
The function of APC /dlg protein interactions is currently unknown. Both proteins 
function to suppress tumourigenesis. They co- localise to regions associated with adherens 
junctions (Matsumine et al., 1996; Midgley et al., 1997) and are both likely to interact 
with a number of other proteins associated with cell signalling and junction formation. 
One could hypothesise that dlg and other MAGUK proteins may compete for the binding 
of APC's carboxyl terminal (T /S)XV motif, and its localisation to cell -cell contacts may 
suggest interaction with proteins such as the zonula occludentes proteins (zo -1, zo -2 and 
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zo -3). These proteins are associated with intercellular adhesion being localised at tight 
junctions, adherens junctions and desmosomes where they appear to function as cross - 
linkers between occludin and actin filaments in epitheliaUendothelial cells or between a- 
catenin and actin filaments in non -epithelial /endothelial cells (Itoh et al., 1997; Haskins et 
al., 1998; Itoh et al., 1999). 
Within the CNS, one may speculate that APC could compete with NMDA receptors and 
shaker -type potassium channels for binding of dig and regulate the clustering of receptors 
and channels thereby influencing their functions. 
2.4 Mutations in the APC gene 
Over 1,000 mutations have been identified in the APC gene, the majority from the 
analysis of FAP and sporadic colorectal cancer cases. Somatic mutations have been 
described in other neoplasms; pancreas (Yashima et al., 1994; Horn et al., 1992a), 
stomach (Horri et al., 1992b; Nakatsuru et al., 1992; 1993; Tamura et al., 1994), 
oesophagus (Powell et al., 1994; Gonzalez et al., 1997) liver (Oda et al., 1996; Imai et 
al., 1997) and prostate (Watanabe et al., 1996). The frequency of somatic APC 
mutations within oesophageal, prostate and pancreatic cancer is less than 10 %, stomach 
cancers is approximately 20% and hepatoblastomas 61 %. 
Of the mutations identified, the vast majority ( >98 %) lead to the premature truncation of 
the APC protein (See Laurent -Puig et al., 1998). More than 98% of all mutations are 
frameshift mutations or nonsense mutations (two thirds are frameshift mutations whilst 
one third are nonsense mutations). 
In colorectal cancer, missense point mutations were initially thought to be extremely rare 
however recent reports have described germline missense mutations that confer an 
increased risk to colorectal cancer (White et al., 1996; Laken et al., 1997; Frayling et al., 
1998). The mutations detected in the APC gene in hepatoblastomas differs from other 
neoplasms with the majority of mutations being missense mutations (90 %) with only 10% 
of cases featuring a frameshift mutation (Oda et al., 1996; See Laurent -Puig et al., 1998). 
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Frameshift mutations, insertions or deletions of one or more base pairs, may result from 
chemical mutagens that intercalate in DNA. The effect of these mutations is to alter the 
reading frame in translation unless an integral multiple of 3 is inserted or deleted. 
Missense and nonsense mutations occur due to the substitution of one base for another. 
These mutations may result from spontaneous deamination of cytosine and failure of 
DNA repair systems to correct the error leading to C/G to T/A nucleotide transition, both 
mutations could occur at an equal frequency. However, 98% of mutations are C -T 
transitions and only 2% are G -A transitions. This bias is thought to be due to the fact that 
most transitions occur at CGA codons and a C -T transition results in a nonsense mutation 
TGA which signals translation to stop. Thus, this mutation reflects selection pressure for 
making a truncated protein. 
Alternatively, these mutations may result from mutagens that chemically modify the DNA 
base resulting in an unidentifiable base, which can not be duplicated during replication. 
DNA polymerase will incorporate a base into the daughter strand, in most instances this 
base tends to be a thymine. This substitution can result in a change in the amino acid 
(missense mutation) or a codon that does not encode an amino acid leading to the 
premature termination of translation (nonsense mutation). 
Almost all germline and somatic APC mutations occur in the 5' half of the open reading 
frame (see figure 6). Germline mutations at codon 1061 and 1309 are extremely frequent 
and account for about 30% of cases. The majority of mutations at these sites involve 
5 bp deletions that result in the production of a premature stop codon. Somatic mutations 
most commonly occur at codons 1309 (7 %) and 1450 (8 %) and mutations cluster in a 
region referred as the mutation cluster region (MCR), located between codons 1286 and 
1513 (Miyoshi et al., 1992b). The location of these mutation hotspots and the MCR is 
within the kinase regulated ß- catenin binding domain, and these mutations are likely to 
disrupt the function of this domain. Also, as the majority of mutations result in premature 
stop codons all downstream domains are usually lost (see figure 6). 
Following the analysis of colorectal adenomas arising in FAP patients it has been shown 
that patients with a germline mutation in the APC gene which resides within a small 
81 
region (codons 1194 -1392), mainly show allelic loss in their colorectal adenomas in 
contrast to other FAP patients, whose second hit tends to occur by truncating mutations 
in the mutation cluster region (Lamilum et al., 1999). This study suggests that different 
APC mutations provide cells with different selective advantages. 
The location of the APC germline mutation is also associated with severity of polyposis 
and the presence of extracolonic manifestations, namely congenital hypertrophy of the 
retinal pigment epithelium (CHRPE), desmoid tumours, oesteomas and epidermoid cysts 
(Nagase et al., 1993; Olschwang et al., 1993; Wallis et al., 1994; Bunyan et al., 1995; 
Caspari et al., 1995; Dobbie et al., 1996). Different phenotypes may be due to loss of 
various functional domains, dominant negative effects of wildtype and mutant protein 
interactions. However, germline deletions of APC lead to classical FAP and attenuated 
FAP, and the extracolonic manifestations, desmoid, oesteomas and epidermoid cysts have 
all been detected. This suggests that factors additional to the location of the germline 
mutation are of importance and to this effect. A modifier locus, MOM -1 (modifier of 
Min) has been mapped in the mouse model of FAP to the region of murine chromosome 
4 (Dietrich et al., 1993; MacPhee et al., 1995; Luongo and Dove, 1996; Shoemaker et 
al., 1996). This murine chromosomal region has synteny to human chromosome 1p35 -36 
and a study of a large FAP kindred, in which patients harbour the same germ -line 
mutation but show markedly different disease characteristics, is supportive of a 
phenotype -modifying locus within this chromosomal region (Dobbie et al., 1997). The 
secretary type II phospholipase gene (Pla2g2a) has been suggested as a candidate gene 
which may modify the FAP phenotype. This gene is located in mice and humans within 
the chromosome regions identified as harbouring the modifier locus, MOM -1 (Praml et 
al., 1995; MacPhee et al., 1995; Tomlinson et al., 1996a). Pla2g2a functions in the 
cleavage of fatty acids from lipids and is expressed in the small intestinal crypts (McPhee 
et al., 1995), therefore expression of Pla2g2a is thought to alter the cellular 
microenvironment within the intestinal crypt. Overexpression of the gene has been shown 
to reduce tumour multiplicity and size within a murine model of FAP (Cormier et al., 
1997). MOM -1 sensitive strains are thought to be null for Pla2g2a protein, C57BL /6 is a 
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sensitive strain for MOM -1. 
The human PLA2GA gene has been sequenced and polymorphic variants detected in a 
study of FAP patients. No associations were found between severity of polyposis and 
PLA2GA variants (Tomlinson et al., 1996b) and to date there is no data to support 
PLA2GA as a modifier of FAP in Homo sapiens. 
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Figure 6: Functional domains within the APC protein and distribution of mutations 
identified 
Analysis of familial and sporadic colorectal cancers and other sporadic tumours has 
revealed the mutation spectrum that is depicted in figure 6. The majority of mutations 
identified occur within the 5' portion of the protein and usually result in the production of 
a truncated protein product. The region most commonly mutated is referred to as the 
mutation cluster region (MCR). This region spans the kinase- regulated ß- catenin binding 
domain. Tumours that produce APC protein that encompasses the kinase regulated ß- 
catenin binding domain are extremely rare. From this evidence, it appears that this domain 
is crucial in tumour suppression. The kinase regulated ß- catenin domain has been shown 
to down regulate (3- catenin levels. Accumulation of ß- catenin within the cytoplasm 
results in the transcriptional activation of target genes of the wnt signalling pathway. A 
number of these genes have already been described as oncogenes. See section 2.6 for full 
discussion. 
A: A linear diagram showing identified functional domains in the APC protein. 
B: Distribution of germline and somatic mutations identified in the APC gene relative to 
protein domains shown in 6a. 
Figure: 6 
A: A linear diagram showing identified functional domains within the APC protein. 
B: Distribution of germline and somatic mutations identified in the APC gene relative to 
protein domains shown in 6a. 
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2.5 Identification and characterisation of APC homologues 
The APC gene has been shown to exhibit a high degree of homology across species 
( >86 %). Homologues of the human APC gene (h -APC) have been identified in mouse 
(Su et al., 1992), Drosophila (Hayashi et al., 1997; Yu et al., 1999; Hamanda et al., 
1999), Xenopus (Vleminckx et al., 1997) and C.elegans (Rocheleau et al., 1997). 
Recently, new homologues of h -APC gene have been reported in man (van Ets et al., 
1998; Nakagawa et al., 1998). 
Hayashi and coworkers (1997) identified the first Drosophila homologue (D -APC). 
Investigations revealed a 2416 amino acid protein that was expressed at low levels in the 
developing embryo and at high levels in the CNS during late stages of development. 
Analysis of embryos null for the D -APC gene revealed that there was no defect in 
Armadillo (Drosophila homologue of ß- catenin) distribution. This suggested that the 
APC gene may not be crucial in the regulation of levels of Armadillo, or that protein 
levels were regulated by maternally derived APC. However, a second Drosophila 
homologue of APC has recently been reported (Yu et al., 1999; Hamanda et al., 1999). 
This homologue, termed E -APC, has an open reading frame of 1,067 amino acids and has 
been shown to be ubiquitously expressed in all stages of Drosophila development, with 
particularly high levels in epithelial cells. Subcellular and co- localisation studies reveal 
that E -APC is localised to sites of adherens junction assembly and is maintained within 
these regions with E- cadherin and Armadillo. The identification of this second APC 
homologue suggests that there may be redundancy between the two APC proteins and 
could explain the control of Armadillo levels in embryos null for D -APC. 
D -APC, E -APC, the murine homologue of APC and h -APC all encode a protein with an 
armadillo repeat domain, 15 amino acid motif (h -APC seven repeats, D -APC one repeat 
and E -APC two repeats), the 20 amino acid motifs (D -APC and E -APC encode five 
repeats whereas h -APC encodes seven repeats). Functional analysis revealed that D -APC 
and E -APC associate with ß- catenin in vitro, further experiments have shown that 
E -APC also interacts with the Drosophila homologue of GSK -3 ß (sgg) in vitro. 
Transfection of D -APC into an APC null colon carcinoma cell line showed that D -APC 
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could down regulate the intracellular concentration of ß- catenin. Analysis of these 
binding domains suggests that these two Drosophila homologues have similar functions 
to those carried out by h -APC and murine APC. 
D -APC, like its human and murine counter parts, also contains a basic domain which is 
thought to be capable of binding microtubules. However, the carboxyl terminus of the D- 
APC lacks the X (S /T)XV motif, a motif previously been shown to be required for the 
interaction of APC with dlg. E -APC also diversifies at this point from human and mouse 
homologues and initial analysis suggests that in Drosophila APC will not bind 
microtubules or dig -A. 
The APC homologue that has been identified in Xenopus, XAPC (Vleminckx et al., 1997) 
has been shown to be found primarily in a complex with ß- catenin. Analysis of the 
overexpression of XAPC in ventral blastomeres did not result in changes in ß- catenin 
levels, but resulted in a phenotype, development of a second axis, which is typical of 
overexpression of the wnt signalling pathway. This study suggested that XAPC might 
have a positive signalling role in the wnt signalling pathway. Analysis of the C.elegans 
APC homologue, APR -1, support studies in Xenopus (Rocheleau et al., 1997), whereas 
experiments in other species had indicated that APC negatively regulated the wnt 
signalling pathway, discussed in detail in section 2.6. 
Two recent reports have been published which describe the identification and initial 
characterisation of two new APC protein homologues in homosapiens. APC2 was 
described by van Ets and co- workers (1998) whilst APCL was described by Nakagawa 
and colleges (1998). Both APC2 and APCL map to human chromosome 19p13.3. 
APC2 is a 2274 amino acid protein, whilst APCL encodes a protein of 2303 amino acids. 
It is likely that these two proteins are isoforms. The two homologues show different 
expression patterns with APC2 being ubiquitously expressed, with highest levels detected 
within the CNS, whereas APCL2 is described as brain specific. 
Analysis of the two homologues revealed that both encode the same protein binding 
domains. As detected in the original human APC protein (h -APC) the protein structure of 
the homologues consists of an N- terminal oligomerisation domain and an armadillo 
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domain (which is 76% homologous to h -APC). Downstream of these domains in h -APC 
lies the constitutive (3- catenin binding domain encoded by 3 repeats of a 15 amino acid 
motif. This domain was not present within the human APC homologues. The kinase- 
regulated ß- catenin binding domain, consisting of 7 repeats of a 20 amino acid motif 
identified in h -APC, differs in the homologues in that only 5 repeats are present. 
Secondly, this domain varies as only 2 SAMP repeats are interspersed thoughout these 
repeats as opposed to 3 SAMP repeats. Analysis of the carboxyl terminus of the 
homologues revealed that the X (S /T)XV motif, a motif previously shown to be required 
for the interaction of h -APC with DLG, is not present. It is interesting to note that the 
structure of the APC homologues is extremely similar to the Drosophila homologues of 
APC, containing only 5 repeats of the 20 -amino acid motifs and also lacking the DLG 
binding region (Hayashi et al., 1997; Yu et al., 1999). 
Functional analysis of homologues have shown interactions with ß- catenin through the 
kinase- regulated 13- catenin binding domain (20 amino acid repeats) and that through this 
interaction APC homologues decrease the intracellular concentration of f3- catenin. 
APC -2 interacts with conductin (homologue of Axin) and both APC homologues inhibit 
ß- catenin/TCF mediated wnt signalling in vitro. 
The identification of APC homologues within species adds a new dimension to all 
previous investigations. It is likely functional redundancy exists between proteins and 
further research is now need to determine the unique functions of these genes within the 
cell. 
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2.6 APC and the wnt signalling pathway 
The wnt signalling pathway is required for a diverse range of biological processes such as 
embryonic patterning, determination of cell fate and cell proliferation (reviewed in 
Wodarz and Nusse, 1998; Dierick and Bejsovec 1999). This diversity is reflected in the 
complex nature of the pathway. The current model of wnt signalling via the ß- catenin 
mediated pathway suggests that in the absence of a wnt signal, the serine /threonine 
kinase, glycogen synthase kinase-3I3 (GSK -3 ß), phosphorylates ß- catenin if associated 
with the multiprotein complex, which contains APC /ß- catenin/GSK -3 ß /Axin and possibly 
other components that regulate 13-catenin phosphorylation. Phosphorylation targets ß- 
catenin for ubiquitin- mediated degradation. When the wnt signalling pathway is activated, 
via ligand binding to Frizzled receptors, GSK -3ß function is inhibited and ß- catenin 
accumulates and translocates to the nucleus where it interacts with LEF -1 /TCF 
transcription factors. Interaction of 13- catenin with these transcription factors is thought 
to relieve LEF -1 /TCF transcriptional repression and in turn results in the transactivation 
of genes that encode LEF -1 /TCF binding sites within their promoters. A model for wnt 
signalling is depicted in figure 7. 
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Figure 7: Wnt/(3- catenin signalling 
A simplified canonical pathway of wnt signalling is represented by figure 7. 
a) in the presence of wnt ligand 
Wnt ligand binds to the Frizzled receptor that transduces a signal to Dishevelled (Dsh). 
Dsh inhibits the kinase activity of GSK -3 ß. Inactivation of GSK -313 kinase activity 
inhibits phosphorylation of ß- catenin and other components that are required to 
negatively regulate 13-catenin levels. Thus 13- catenin accumulates in the cytoplasm and 
subsequently translocates to the nucleus. In the nucleus, ß- catenin interacts with the 
transcription factors of the LEF -1 /TCF family following the displacement of co- 
repressors. ß- catenin, whilst in a complex with LEF -1 /TCF transactivates target genes of 
the wnt signalling pathway. 
b) In the absence of wnt ligand 
In the absence of wnt ligand, GSK -3 ß is active. APC, Axin and 13-catenin form a trimeric 
complex, whilst GSK -313 binds to Axin and phosphorylates all 3 components. 
Phosphorylated ß- catenin is then targeted for degradation by the ubiquitin- proteosome 
pathway. LEF -1 /TCF located in the nucleus is thought to repress expression of target 































































































































































Many components of the wnt signalling pathway appear structurally and functionally 
conserved thus studies from Drosophila, Xenopus, Caenorhabdiiis elegans and mammals 
have all contributed to the understanding of this pathway. Identified components of f3- 
catenin mediated wnt signalling in vertebrate and invertebrates are listed in table 3. 
Table 3. Wnt signalling components in vertebrates and invertebrates. Multiple 
homologues have been identified in all cases unless indicated by an asterisk 
Generic Mammalian Drosophila C. elegans Xenopus 
wnt Wnt D -wnt 









Dvl Dsh -1* Putative genes 
identified 
Xdsh 
GSK -3 GSK -3 a and 
ß- isoforms 






Daxin Non described XAxin 
APC APC D -APC APR -1 XAPC 
f3- catenin ß- catenin Arm* WRM -1 ß- catenin 
TCF TCF/LEF dTCF /pangolin POP -1 XTCF 
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2.6.1 Wnt ligands 
The wnt proteins comprise a highly conserved, multi- member ligand family (Nusse and 
Varmus, 1982; Nusse et al., 1984; Wainwright et al., 1988; Gavin et al., 1990; Gavin and 
McMahon, 1992). Wirt genes encode secreted glycoproteins, usually 350 -400 amino 
acids in length, which contain a conserved pattern of 23 -24 cysteine residues in addition 
to other invariant amino acids. Secreted wnt proteins associate with the extracellular 
membrane where they may interact with proteoglycans (see below). 
2.6.2 Frizzled receptors 
Wnt proteins have been shown to bind to the extracellular domain of Frizzled receptors. 
Genetic screening in Drosophila identified the first Frizzled (fz) gene. Mutations in this 
gene resulted in a defect in tissue or planar polarity, phenotypically expressed as 
disruption in the alignment of wing hairs, direction of bristles on the notum and legs and 
disorientation of the ommatidia comprising the insect compound eye (Zheng et al., 1995). 
Frizzled proteins are characterised by a large cysteine -rich extracellular domain (CRD) 
that spans approximately 120 amino acids and contains 10 cysteine residues. The CRD is 
located at the N- terminal of the protein and this region is the site of wnt binding (Ingham, 
1996; Bhanot et al., 1996; Orsulic and Peifer, 1996; Wang et al., 1997b). The CRD is 
followed by seven putative membrane -spanning domains and a cytoplasmic C- terminal 
tail. Many Frizzled proteins contain within the carboxyl terminal tail an X(T /SX)V motif, 
this motif can interact with DHRs (discussed further below and in section 2.3.5) (Chan et 
al., 1992; Wang et al., 1996). 
A number of wnt ligands and Frizzled receptors have been identified and analysis in 
Drosophila has revealed that some receptors are capable of binding different D -wnt 
ligands and that many members of the D -wnt ligand family will bind to multiple receptors. 
Endogenous D -wnt expression patterns in many tissues overlap, this raises the possibility 
that different D -wnt proteins may functionally substitute for each other in vivo (Gavin et 
al., 1990; McMahon et al, 1992). Redundancy of receptor binding may be the 
explanation as to why developmental defects in Wnt null mice occur in only a subset of 
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the regions in which the Witt is expressed (McMahon et al., 1992; Takada et al., 1994; 
Stark et al., 1994; Parr and McMahon, 1995). 
2.6.3 Frizzled related proteins 
In addition to the integral membrane Frizzled proteins, Xenopus and other vertebrates 
produce several secreted proteins, called FRPs (Frizzled related proteins) that contain a 
CRD that is very similar to those in Frizzled proteins. These molecules lack the 7 
transmembrane sequence, but encode a stretch of charged residues with homology to 
netrins; exon guidance proteins found in the developing vertebrate spinal cord (Shirozu et 
al., 1996; Leyns et al., 1997; Rattner et al., 1997; Wang et al., 1997). FRPs have been 
shown to complex with wnt ligands and frizzled receptors and in vitro experiments reveal 
that FRPs antagonise wnt signalling (Leyns et al., 1997; Wang et al., 1997; Bafico et al., 
1999). 
2.6.4 Association with proteoglycans 
As previously mentioned, wnt proteins associate with proteoglycans at the cell surface 
(Schryver et al., 1996). Proteoglycans function as low affinity cell surface receptors for a 
variety of ligands (Schlessinger et al., 1995). It is thought that proteoglycans may 
increase the local concentration of wnt proteins leading to increased avidity and /or 
receptor clustering (Reichsman et al., 1996), or may be required for the transduction of 
wnt signals. 
2.6.5 Transduction of signals via frizzled; G-proteins and Dishevelled 
It is likely that the recruitment or release of intracellular signalling molecules transmits 
wnt signals as no enzymatic motifs have been identified in the Frizzled receptors. 
Candidate molecules that could interact with Frizzled include heterotrimeric G- proteins 
and the protein Dishevelled (Dsh). 
Heterotrimeric G- proteins have previously been shown to couple numerous receptors that 
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contain 7 transmembrane sequences to a range of intracellular signalling pathways 
(reviewed in Knall and Johnson, 1998; Simonds, 1999). Despite only minimal homology 
between Frizzled proteins and other known G- protein coupled receptors (Mukoyama et 
al., 1993), there is some evidence to suggest that Frizzled receptors may transmit signals 
via G- proteins (Slusarski et al., 1997). 
The Dsh protein has been shown to be required for wnt signalling in many tissues (Lecuit 
and Cohen, 1997; Neumann and Cohen, 1997). Several mammalian Dsh homologues 
(Dvl) have been identified revealed and an overlapping pattern of expression of proteins 
have been detected suggesting redundancy in function between these protein homologues 
(Sussman et al., 1994; Klingensmith et al., 1996; Tsang et al., 1996). Further to this, 
murine gene knockout models, null for one Dvl gene, do not have phenotypes typical of 
loss of wnt signalling (Sussman et al., 1994; Pizzuti et al., 1996; Lijam et al., 1997). 
Amino acid sequence comparison of all known Dsh molecules revealed 3 highly 
conserved regions thoughout the species: an N- terminal Dsh homology domain, a DHR 
domain and a DEP (Dsh/egl -10 /pleckstin) domain. The Dsh homology domain shares 
homologies to a newly identified protein, Axin, and these two proteins have recently been 
shown to interact. Axin is thought to play an important role in the negative regulation of 
wnt signalling and is discussed further in section 2.6.6 (Zeng et al., 1997; Ikeda et al., 
1998; Sakanaka et al., 1998; Behrens et al., 1998). The Dsh domain is now referred to as 
the DIX domain (Dishevelled and Axin). Schematic representation of Dsh and Axin is 
depicted in figure 8. 
The DHR domain located in the central region of the Dsh/Dvl proteins is also found in a 
number of other proteins including dig and zo -1 (Ponting et al., 1997). Structural analysis 
has shown that the DHR domains within some proteins are able to bind four residue C- 
terminal peptides with the motif X(S /T)XV (section 2.3.5). The Frizzled receptors have 
been shown to encode this motif in their cytoplasmic C- terminal tails, however, the Dsh 
DHR falls into the non -binding class (Songyang et al., 1997; Doyle et al., 1996; Morais 
Cabral et al., 1996). In keeping with this, experiments have failed to detect interactions 
between any Frizzled proteins and Dsh proteins (Nusse et al., 1997). At the C- terminal 
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side of the DHR domain is the DEP domain. This domain is approximately 80 amino 
acids in length and has been detected in a number of other proteins including the guanine 
nucleotide dissociation and GTPase- activating protein families (Ponting and Bork, 1996). 
The molecular mechanism by which Dsh transduces wnt signals is unknown. Dsh is a 
phosphoprotein that localises predominantly in the cytoplasm of cells (Yanagawa et al., 
1995). Exogenous expression of wnt ligands in mammalian and Drosophila in vitro cell 
culture systems results in a fraction of Dsh protein localising to the cell membrane 
(Yanagawa et al., 1995; Steitz et al., 1996). This change in compartment location 
suggests that the membrane fraction of protein is active in signalling. In Drosophila, the 
Dsh -1 protein that is translocated to the cell membrane is hyperphosphorylated 
(Yanagawa et al., 1995). Phosphorylation is thought to be by casein kinase II (CKII) as 
Dsh has been found in a complex with CKII and is phosphorylated by CKII in vitro 
(Willert et al., 1997). It is currently unclear whether phosphorylation of Dsh is a 
consequence of or is required for wnt signalling. 
Recent studies have identified interactions between Axin and Dsh suggesting that Dsh 
may transduce wnt signals by interacting with the multiprotein complex that is required 
for ß- catenin phosphorylation (discussed further in section 2.6.7). 
2.6.6 GSK -3 J3 and wnt signalling 
Studies in Drosophila revealed that mutations within the gene zeste white -3 (zw3) 
resulted in phenotypes consistent with the constitutive activation of wit signalling (Peifer 
et al., 1994). The ß isoform of glycogen synthase kinase -3 (GSK -30) was identified as 
the mammalian homologue of zw3 (Plyte et al., 1992). Glycogen synthase kinase -3 is a 
widely conserved serine threonine protein kinase, which is constitutively active in 
unstimulated cells and is inhibited by signal transduction pathways responding to various 
growth factors in different systems (Kim et al., 1998; Marcus et al., 1998). Data from 
studies in Drosophila and Xenopus demonstrate that GSK -3ß kinase activity is negatively 
regulated by and negatively regulates wnt signalling (He et al., 1995; Dominguez et al., 
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1995; Pierce and Kimelman, 1995). 
Wnt signalling is thought to mediate inhibition of GSK -3 ß kinase activity through 
Dishevelled (Dv1-1), although a mechanism has not yet been determined. GSK -3ß kinase 
activity is revoked by incubation with serine /threonine phosphatases and recent 
investigations demonstrate that Axin interacts with protein phosphatase 2A in vitro, 
suggesting that this may be a mechanism of negative regulation (Hsu et al., 1999), 
discussed further in section 2.6.7.5. 
Analysis of Drosophila and Xenopus embryos revealed that inactivation of Zw3 /GSK -3/3 
results in the accumulation of the protein f3- catenin/armadillo (Peifer et al., 1994; Hinck 
et al., 1994; Yost et al., 1996). GSK -3 3 phosphorylates ß- catenin at a conserved N- 
terminal site and mutations within 3- catenin at these sites of phosphorylation results in a 
more stable form of ß- catenin (Rubinfeld et al., 1996). GSK -3 ß also phosphorylates 
APC and numerous studies have shown that site specific phosphorylation of APC within 
the kinase regulated ß- catenin binding domain is crucial for the binding of ß- catenin to 
this domain and subsequently degradation of f3- catenin (2.3.3 and 2.6.7.2). Axin is also 
phosphorylated by GSK -313, discussed in 2.6.7.3. 
GSK -3 ß, Axin, ß- catenin and APC are thought to form a tetrameric complex allowing 
efficient phosphorylation of these GSK -30 targets mediating degradation of 13- catenin. 
Axin can be viewed as the scaffolding protein to these interactions as all components bind 
to this protein directly, depicted in figure 8. 
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Figure 8: Axin is the scaffolding protein in a protein complex that regulates ß- catenin 
stability. 
Figure 8a depicts protein- binding domains identified within the APC, ß- catenin and Dsh 
proteins. Figure 8b represents the protein complex that is thought to form to down 
regulate the level of cytoplasmic f3-catenin. 
The binding domains and protein interactions are fully described within the text of section 
2.6. 
Figure 8: Axin is the scaffolding protein in a protein complex that 
regulates 13- catenin stability 
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2.6.7 GSK -313/Axin /13- catenin and APC 
2.6.7.1 Axin 
Axin was originally identified as a product of the mouse Fused gene (Zeng et al., 1997). 
Some spontaneously occurring alleles of the Fused gene, when exhibited homozygously, 
resulted in embryos with a duplication of the embryonic axis, suggesting a role for this 
gene in embryonic axial development and as a negative regulator of wnt signalling 
(Jacobs -Cohen et al., 1984; Perry et al, 1995). The cDNA of the locus has since been 
sequenced and the Fused gene was renamed Axin (Perry et al., 1995; Vasicek et al., 
1997; Zeng et al., 1997). The murine Axin gene is ubiquitously expressed in wildtype 
embryos and adult tissues, and encodes 3 mRNA transcripts. Protein isoforms differ by 
the presence or absence of a 36 amino acid sequence at position 856 encoding proteins of 
either 956 or 992 amino acids. 
Homologous proteins have been identified in rat (rAxin and Axil /conductin (Axin like) 
and Drosophila (D -Axin) and Axin appears to be structurally and functionally conserved 
across species (Behrens et al., 1998; Yamamoto et al., 1998; Hamanda et al., 1999). The 
protein structure includes an N- terminal region which shows homology to the regulator 
of G protein signalling (RGS) domain, the central domain contains sites shown to interact 
with ß- catenin, GSK -313 and protein phosphatase 2A, and the carboxyl terminal contains 
a DIX domain. 
2.6.7.2 The RGS domain and APC 
The RGS domain of Axin (amino acids 220 -340) binds APC at the kinase regulated 13- 
catenin binding domain (see section 2.3.3). This domain consists of seven motifs 
encoding 20 amino acid repeats. Axin binding requires only the latter five motifs which 
contain the interspersed SAMP domains suggesting that the SAMP domains mediate this 
interaction (Behrens et al., 1998; Ikeda et al., 1998; Kishida et al., 1998; Hart et al., 
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1998; Fagotto et al., 1999). 
A second APC binding domain within Axin has been recently identified, the region 
between amino acids 96 -253 can directly bind to the NH2- terminal region of APC which 
encodes the Armadillo motifs and the constitutive 13- catenin binding domain (Fagotto et 
al., 1999). In the absence of the RGS domain APC /Axin interactions were not detected 
suggesting that this may be a secondary binding site for already bound APC. It is unclear 
whether Axin and ß- catenin compete for APC binding. 
2.6.7.3 Axin and GSK313 
Several immunoprecipitation studies have identified direct interactions between Axin and 
GSK -3 ß, although experiments have failed to detect the interaction of Drosophila 
homologues, zw -3 and D -Axin (Hamanda et al., 1999). The region of Axin required for 
GSK -3ß binding is located between amino acids 497 -552 (Ikeda et al., 1998; Kishida et 
al., 1998; Fagotto et al., 1999; Smalley et al., 1999). In vitro studies elucidated that 
catalytically inactive mutants of GSK -3 ß are unable to interact with Axin suggesting that 
prior phosphorylation of Axin is required for the interaction of these two proteins 
(Kishida et al., 1998). Furthermore, in vivo experiments have shown that binding of 
GSK -3 ß to Axin is required for GSK -3 ß mediated phosphorylation of APC ( Fagotto et 
al., 1999). 
2.6.7.4 Axin and ß- catenin 
In vitro studies have determined that Axin and its homologues Axil/conductin can interact 
with the Armadillo repeat domain of (3- catenin, and this interaction is mediated through a 
highly conserved region present in Axin and its homologues (Zeng et al., 1997; Behrens 
et al., 1998; Ikeda et al., 1998; Sakanaka et al., 1998; Yamamoto et al., 1998; Kishida et 
al., 1998; Itoh et al., 1998; Hamanda et al., 1999). Interactions between f3- catenin and 
either rAxin or Axil promotes GSK -313 dependent phosphorylation of ß- catenin (Ikeda et 
al., 1998; Yamamota et al., 1998). 
The Armadillo repeat domain of ß- catenin is also the site of interaction with APC, a- 
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catenin, cadherin and the LEF -1 /TCF family of proteins (Hülsken et al.,1994a; Funayama 
et al., 1995; Behrens et al., 1996; Molenaar et al., 1996; Polakis et al., 1997). APC binds 
(3- catenin between armadillo motifs 2 and 10 whilst rAxin binds I3-catenin within the 
region of motifs 2 and 7. As previously discussed in section 2.3.2, armadillo motifs are 
not 100% homologous, therefore different motifs or groups of motifs may represent 
different sites of protein interaction. As Axin has distinct binding sites for APC (RGS 
domain) and 13- catenin (ß- catenin binding domain) and APC has distinct binding sites for 
Axin and [3-catenin these proteins are thought to form a ternary complex. Further 
evidence that these components exist in a ternary complex comes from 
immunoprecipitation studies using site specific mutants (Ikeda et al., 1998; Kishida et al., 
1998; Fagotto et al., 1999). 
2.6.7.5 Axin, phosphatase 2A and the carboxyl terminal domain 
Amino acids 632 -836 of the Axin protein bind to the catalytic subunit of the Ser /Thr 
protein phosphatase 2A (PP2A) (Hsu et al., 1999). The binding of PP2A to Axin may 
suggest that PP2A could positively regulate wnt signalling by opposing the action of 
GSK -313. Studies have demonstrated that unphosphorylated Axin is less stable than when 
in a phosphorylated form (Yamamoto et al., 1999). One could hypothesise that PP2A 
could promote destabilisation of Axin and the Axin based protein complex resulting in 
increased J3- catenin levels and wnt signalling or equally, modification of APC and /or (3- 
catenin phosphorylation could result in the same effect. 
A role for the PP2A binding in the negative regulation of wnt signalling is supported by 
the phenotype seen in mice that harbour the spontaneous Fused alleles (see section 
2.6.7.1). Fused (Axin'u) and Knobbly (AxinKB) encode proteins with C- terminal 
truncations that are predicted to retain binding domains for APC, GSK -3 ß and fl-catenin, 
but reduce or abolish the PP2A binding site. The phenotype seen in these mice is typical 
of overexpression of the wnt signalling pathway. 
Analysis of the C- terminal domain of Axin revealed a self binding domain located within 
the terminal 100 amino acids of the protein (Hsu et al., 1999; Sakanaka and Williams 
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1999). This fragment contains the DIX domain, a 51 amino acid region of similarity 
between Axin and Dsh proteins (Hsu et al., 1999). Therefore, Axin may have the ability 
to homo- or hetero- dimerise with different Axin isoforms or even the closely related 
protein Axil /conductin (Behrens el al., 1998; Yamamoto et al., 1998). It is unclear what 
function Axin homodimerisation could play, but possibly dimerised molecules could 
further regulate ß- catenin signalling, enhancing interactions between proteins within the 
complex or in some way regulate phosphorylation. 
Dsh has been shown to interact with Axin through the Dsh DIX domain, see section 2.6.5 
(Kishida et al., 1999; Smalley et al., 1999), however, Smalley and co- workers 
demonstrated that this interaction does not require the DIX domain of Axin. 
2.6.8 ß- catenin degradation via the ubiquitin -proteosome pathway 
Studies have shown that ß- catenin is a target for the ubiquitin -proteosome pathway and 
that phosphorylation of serine /threonine residues at positions 29,33,37,41 and 45 by 
GSK -3ß appear to be a prerequisite for ubiquitination (Aberle et aí.1997; Orford et al., 
1997). The ubiquitin proteosome pathway plays a critical role in diverse biological 
processes though the rapid elimination of many important regulatory proteins. Ubiquitin 
mediated proteolysis (reviewed in Hochstrasser, 1995) involves a cascade of ubiquitin 
transfer reactions in which the ubiquitin- activating enzyme El uses ATP to form a high 
energy thiolester bond with ubiquitin which is then transferred to members of the E2 
ubiquitin- conjugating enzyme family. Ubiquitin is then transferred to lysine residues in the 
target though E3- ubiquitin ligases, which can be either a single polypeptide, or, in many 
cases, a protein complex. E3 serves as an adapter that interacts with both the target 
protein and the appropriate E2 enzyme thereby providing specificity to the ubiquitin 
transfer reaction. Multiple rounds of ubiquitination lead to poly -ubiquitination, which 
targets the protein for proteolysis by the 26S proteosome. 
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2.6.9 ß- catenin LEF/TCF 
Wnt signalling inhibits ß- catenin degradation, and ß- catenin accumulates within the 
cytoplasm. ß- catenin is subsequently translocated to the nucleus (reviewed in Kuhl and 
Wedlich 1997). ß- catenin does not encode a recognised nuclear localisation sequence 
(NLS) but can be imported into the nucleus by binding directly to the nuclear pore 
machinery (Fagotto et al., 1998). In the nucleus ß- catenin associates with lef -1 /tcf family 
members. 
Tcf -1 and lef -1, the two founding members of the small subfamily of vertebrate high - 
mobility group (HIVIG) box transcription factor genes were originally defined as 
lymphoid -specific transcription factors. This was based on their affinity for the enhancers 
of CD3c and the T -cell receptor a genes respectively. Both genes were later found to be 
expressed in largely overlapping complex patterns during mouse embryogenesis (Sawada 
and Littman 1991, Travis et al., 1991; Waterman et al., 1991; van de Wetering et al., 
1992, Oosterwegel et al., 1993; Carlsson et al., 1993). To date four members of this 
family have been identified in mammals: lef -1, tcf -1, tcf -3 and tcf-4 (Travis et al., 1991; 
Waterman et al., 1991; van de Wetering et al., 1992; Carlsson et al., 1993; Morin et al., 
1997), one member in Drosophila: D- tcf/Pangolin (van de Wetering et al., 1997) and 
one member in C.elegans; POP -1 (Lin et al., 1995). 
All proteins contain a highly homologous ß- catenin binding domain located at the amino 
terminal, a carboxyl HMG DNA binding domain and a central contex dependent 
activation domain (CAD) that is divergent between members. The ß- catenin binding 
domain of Lef -1 /tcf interacts with ß- catenins armadillo repeat domain, and armadillo 
repeats 1 -7 have been shown to be required for this interaction (Behrens et al., 1996; Hsu 
et al., 1998). The HMG DNA binding domains, comprise three a- helices arranged in an 
L -shape which binds to highly similar AT -rich DNA motifs or a more conserved 
11 bp motif encoded by promoters of target genes (van wetering et al., 1997). 
Transcriptional activation function is mediated by the CAD, although the mechanism of 
transcriptional transactivation is unclear. Within the lef -1 /tcf and ß- catenin complex, the 
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amino terminal 131 residues and the carboxyl terminal region of ß- catenin is thought to 
confer transcriptional transactivation. 
Analysis of dominant negative forms ofLef -1 /Tcf, that lack the ß- catenin binding domain, 
block signalling mediated by ß- catenin or wnt (Molenaar et al., 1996; van de Wetting, 
1997; Kengaku et al., 1998; Dorsky et al., 1998) and loss of function mutants of D -tcf in 
Drosophila have shown that D -tcf is required for downstream effects of wnt signalling 
(van de Wetering, 1997; Brunner et al., 1997). Analysis of Lef -1 /Tcf mutations in the 
mouse has resulted in diverse phenotypes. Targeted mutations of the Lef -1 gene results in 
developmental abnormalities of multiple organs including hair follicles, the mammary 
glands and teeth (van Genderen et al., 1994), whilst mutations in Tcf -1 impairs T -cell 
differentiation (Verbeek et al., 1995). Mice null for Tcf -4 have defects in colonic stem 
cell proliferation (Korinek et al., 1998). These phenotypes suggest that specific Lef -1 /Tcf 
members are critical in different tissues /cell types, although it is possible there is 
functional redundancy between Lef -1 /Tcf transcription factors and this is supported by 
the overlapping expression pattern detected in mouse embryos (Oosterwegel et al., 1993; 
Korinek et al., 1998). Furthermore, recently it has been documented that mice null for 
both Lef -1 and Tcf -1 exhibit defects in mesoderm specification that are virtually identical 
to those observed in Wnt3a deficient mice (Galceran et al., 1999). 
In the absence of wnt signalling and stabilisation of ß- catenin, lef -1 /tcf proteins actively 
repress transcription of wnt responsive genes. Ultrabithorax (ubx) and Siamosis are 
genes that are responsive to wnt signals in Drosophila and Xenopus respectively. 
Mutations within the lef -1 /tcf binding region of these genes resulted in ectopic gene 
expression, this lead to the proposal that lef -1 /Ttcf proteins act as repressors (Riese et 
al., 1997; Brannan et al., 1997). Further to this, lef -1 /tcf proteins have been shown to 
interact with the transcription corepressor Groucho and CBP (CREB binding protein) 
(Roose et al., 1998; Cavallo et al., 1998; Waltzer and Bienz, 1998). 
2.6.9.1 Transcription corepressors 
Promoter activity in eukaryotic cells is regulated to a certain degree by coactivators and 
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corepressors (reviewed in Kadonaga et al., 1998). These factors modulate rates of 
transcription by a variety of mechanisms, they do not have the ability to bind DNA on 
their own, but are recruited to target promoters by protein -protein interactions with 
DNA -binding transcription factors. 
Groucho is the founding member of a family of transcriptional corepressor proteins that 
contain a highly conserved N- terminal region (the effector of repression) and multiple 
tandemly repeated copies of a 40 amino -acid motif known as the WD40 repeat 
(Reviewed in Parkhurst, 1998; Fisher and Caudy, 1998). The WD40 repeat domain 
interacts with WRPW ( Tryptophan -Arginine -Proline -Tryptophan) and WRPY (Y- 
Tryrosine) motifs that are present in a number of transcription factors. 
Evidence suggests that the interaction of lef -1 or tcf with Groucho results in repression of 
lef -1 /tcf target genes. When ß- catenin enters the nucleus it forms a complex with lef -1 /tcf 
transcription factors and target genes are transactivated. It could be hypothesised that 13- 
catenin displaces Groucho and relieves repression of transcription. 
CBP, a histone acetyltransferase (reviewed in Imhof et al., 1997), is a modulator of tcf/ß- 
catenin binding. In vitro, CBP has been shown to bind the HMG domain of D -tcf, which 
results in the acetylation of lysine residues in the f3- catenin binding region of tcf. 
Acetylation lowers the affinity of the interaction between ß- catenin and tcf, this 
modification is thought to inhibit signalling until the levels of Armadillo reaches a 
threshold (Waltzer and Bienz, 1998). 
2.6.10 Responsive genes of Wnt /ß- catenin signalling 
Based on genetic evidence, overexpression studies and promoter sequence analysis, 
target genes have been identified in Drosophila; Ultrabithorax (Riese et al., 1997; van de 
wetering et al., 1997); Xenopus: Siamosis, and nodal- related -3 (Brannon et al., 1997; 
Mckendry et al., 1997) and mammals: connexin 43: CCNDI, c IvfYC and matrilysin (van 
der Heyden et al., 1998; Tetsu et al., 1999; Shtutman et al., 1999; He et al., 1998). The 
identification of these genes now provides a link with the diverse biological processes 
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associated with the wnt signalling pathway. 
2.6.10.1 Ultrabithorax 
Ubx is a member of the family of homeobox transcription factors expressed in 
Drosophila. Ubx functions to signal endoderm induction and cell type specification 
during gut development (Bienz and Tremml, 1988; Bienz, 1994). Reciprocal inductive 
interactions between different tissues that result in differentiation and organisation of cells 
into organs are crucial for morphogenesis of vertebrates and invertebrates. Analysis of the 
Ubx promoter sequence revealed a lef -1 /tcf binding motif and investigations have 
demonstrated that lef -1 can activate ubx transcription (Riese et al., 1997). Mice deficient 
for Lef -1 exhibit defects in organs that require inductive epithelial -mesenchymal 
interactions during organogenesis, specifically mutant mice lack teeth, mammary glands, 
whiskers and body hair (van Genderen et al., 1994). 
2.6.10.2 Siamosis 
Siamosis is a homeobox gene that is expressed in the dorsal vegetal cells soon after the 
start of zygotic transcription. Ectopic expression of siamosis induces complete axis 
duplication in xenopus (Lemaire et al., 1995) The siamosis promoter has been shown to 
be a direct target of the 13- catenin/ X -tcf -3 complex and multiple binding sites for X -tcf -3 
have been identified within the promoter (Brannon et al., 1997). Furthermore, 
investigations have demonstrated that X -tcf -3 is a repressor of the siamosis promoter 
(Brannon et al., 1997). 
2.6.10.3 nodal -related 3 
Nodal- related 3 (Xnr3) is a key regulator of Xenopus development (Smith et al., 1995; 
McKendry et al., 1997). Xnr3 encodes a protein related to members of the TGFI3 family 
of signalling molecules and is specifically expressed in the epithelial layer of the spemann 
organiser (a broad zone on the dorsal side of the embryo) during gastrulation (Smith et 
al., 1995). Xnr3 has both inductive and morphogenic activity in the gastrula embryo 
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(Hansen et al., 1997). The Xnr3 promoter was shown to confer wnt inducible 
transcription of a reporter gene. Two distinct regulatory sequences were identified, both 
mediated wnt responsiveness. One regulatory element was identified as the binding site of 
the LEF -1 /TCF family of transcription factors, whereas the other sequence element 
interacted with an unknown protein from Xenopus gastrulae. 
2.6.10.4 Connexin 43 
Connexin 43 (Cx43) is one of a family of proteins controlling the permeability of gap 
junctions (reviewed in Goodenough et al., 1996). Gap junctions are intercellular channels 
that permit exchange of ions, small metabolites and low molecular mass signalling 
molecules (Goodenough et al., 1996). Cx 43 was identified as a target gene of wnt 
signalling following overexpression of Wntl in a rat neuronal cell line (PC -12) (Bradley et 
al., 1995). Overexpression of Wntl resulted in a tendency for cells to grow in highly 
connected groups, indicating that wnt signalling can result in increased cellular adhesion. 
Further studies revealed that this phenotype was a result of increased coupling by gap - 
junctions, measured by enhanced chemical and electrical gap junction communication. 
Subsequent experiments revealed elevated levels of Cx43 (van der Heyden et al., 1998), 
and this phenotype was also noted following experiments on a mammary epithelial cell 
line. Multiple lef -1 /tcf consensus binding sequences are present in rat; human and murine 
CX43 promoters. 
Van der Heyden and co- workers (1998) also demonstrated that treatment of cells with 
lithium, an inhibitor of GSK -313 kinase activity, resulted in increased transcription from 
the CX43 promoter, further associating Cx43 with wnt signalling pathway. It is 
interesting to note that mice deficient in Wnt -1 or which overexpress Cx43 both exhibit 
severe brain defects (Thomas and Capecchi 1990; Nusse and Varmus 1992; Ewart et al., 
1997). 
105 
2.6.10.5 c -MYC 
c -MYC plays a role in both positive and negative growth through its influence on 
proliferation, differentiation and apoptosis (Reviewed in Hoffinan and Liebermann 1998; 
discussed in detail in section 1.3.1.2). Using serial analysis of gene expression (SAGE), a 
technique that allows the quantitative evaluation of cellular mRNA (Velculescu el al., 
1995), investigators evaluated gene expression in the colon carcinoma cell line HT29, a 
cell line that contains truncating mutations within the APC gene, following exogenous 
expression of an inducible APC construct. Several transcripts were shown to be 
overexpressed (14) and repressed (16) by APC induction. As APC represses 13- 
catenin/TCF-4 mediated transcription (Korinek et al., 1997), repressed transcripts were 
analysed further. One highly repressed transcript was identified as c -MYC mRNA. This 
repression was confirmed at the mRNA and protein level by northern blot and 
immunoblot analysis respectively. In the human colon cancer cell line SW480 (a cell line 
also encoding only truncated APC), expression of the inducible APC construct was 
shown to significantly repress the transcriptional activity of a c-MYC reporter plasmid (c- 
MYC promoter inserted upstream of a luciferase reporter gene). Conversely, expression 
of a mutant form of ß- catenin, that rendered the protein insensitive to 
GSK -3f3 phosphorylation and subsequent degradation, when expressed in the human 
kidney cell line 293, resulted in significant activation of the c-MYC reporter plasmid. 
Analysis of the c-MYC promoter sequence revealed two putative TCF binding sites. 
Mutations within either of these sites reduced activity of the c-MYC promoter by 50 %. 
Deletion of both sites removed APC repression and ß- catenin activation of the c-MYC 
reporter plasmid. 
The exact mechanisms by which c -MYC mediates cell proliferation, apoptosis and 
differentiation are still unclear but numerous investigations both in vivo and in vitro have 
demonstrated that deregulation of cMYC can result in tumourigenesis. C-MYC is 
overexpressed due to genetic alterations including chromosomal translocations, proviral 
insertion, retroviral transduction and gene amplification (Ryan and Birnie, 1997). 
However, c MYC is overexpressed in colorectal cancers and NSCLC cancers that do not 
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exhibit gene amplification. In the cases of colorectal cancers, where overexpression of c- 
MYC is reported to occur in approximately 70% of cases (Sikora et al., 1987), mutations 
within the APC or the ß- catenin genes occur in the majority of cases (Sparks et al., 
1998). The identification of c-MYC as a target gene of wnt signalling could therefore 
explain aberrant expression. 
In NSCLC, LOH at 5q21, the location of the APC gene, is relatively common although 
studies have not fully addressed the possibility of biallelic inactivation of the APC gene 
(see section 1.3.3.3). No reports of mutations in other components of the wnt signalling 
pathway have been reported. As previously discussed, activation of the proto -oncogene 
K -RAS occurs in approximately one third of NSCLC cases, as c-MYC is also one of the 
target genes of the MEK/ERK signalling pathway then this may also be a mechanism by 
which c-MYC is deregulated (see section 1.3.1.1). 
2.6.10.6 Cyclin D1 
Cyclin D1 is a major regulator of the progression of cells into the proliferative stage of 
the cell cycle (reviewed in Sherr 1996; discussed in section 1.3.1.4) and has recently been 
identified as a target of wnt signalling (Tetsu and McCormick 1999; Shtutman et al., 
1999). Four LEF /TCF consensus sequences have been identified in the promoter region 
of the CCNDI gene. All sites were shown to confer cyclin D1 activation in vitro and 
inactivation of increasing numbers of sites resulted in a gradual reduction in 
responsiveness to ß- catenin. 
Overexpression of cyclin D1 has been reported to occur in approximately 50% of 
NSCLC cases, of which amplification of the CCNDI accounts for around 2 -30% cases 
(see section 1.3.1.4). Oncogenic activation of K -RAS resulting in transcriptional 
activation of cyclin D1 via the MEK/ERK and PI3K pathways is thought to contribute to 
cyclin D1 expression seen in a high proportion of these cases. Alternatively, deregulation 
of cyclin D may be a result of loss of RB expression (see section 1.3.2.1). The 
identification of Cyclin D1 as a target gene in the wnt signalling pathway now adds 
another pathway to be investigated. 
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2.6.10.7 Matrilysin 
Greater than 90% of colonic adenomas that harbour germline mutations in the APC gene 
(in both human and mice) have been shown to overexpress matrilysin (Wilson et al., 
1997; Fingleton et al., 1999). Matrilysin was therefore considered a possible target gene 
of 13- catenin/tcf transactivation. Crawford and co- workers (1999) confirmed this in a 
series of experiments. In murine intestinal adenomas and ADC, matrilysin transcripts 
were shown to co- localise with areas of ß- catenin protein accumulation. The mouse 
matrilysin promoter was cloned and sequenced and revealed a single canonical Tcf -4 
binding site. Using electrophoretic mobility shift assays (EMSA), the Tcf motif was 
shown to interact with Tcf -4 and the ß- catenin/Tcf bipartite complex, these interactions 
were eliminated by the introduction of a 2 base pair mutation within the Tcf binding 
motif. Further in vitro experiments demonstrated that the Tcf -4 binding site exhibited 
transcriptional repressor properties and that formation of the ß- catenin/Tcf complex 
relieves gene repression mediated by Tcf only, but does not directly act as a 
transcriptional activator of the Tcf binding site (Crawford et al., 1999). 
The matrix metalloproteinases (MMPs) are a family of secreted, zinc -dependent enzymes 
known to degrade components of the extracellular matrix (Reviewed in Matrisian, 1992). 
Members of the metalloproteinase family can be divided into three categories depending 
on substrate specificity; the collagenases, gelatinases and stromelysins. Matrilysin is a 
member of the stromelysin category that has been shown to degrade proteoglycans, 
gelatins, elastin and glycoproteins such as fibronectin, laminen and entactin (Matrisian 
1992). The regulation of MMPs is complex with selective expression in specific cell types 
being induced by a variety of growth factors, cytokines and hormones. MMP expression 
can alter the integrity of the extracellular matrix (ECM) surrounding the cell and in turn 
affect cellular morphology and cellular processes such as proliferation, migration or 
differentiation (reviewed in Matrisian 1992). In vivo experiments have demonstrated that 
expression of MMPs can induce tumour phenotypes in well -differentiated cells (Witty et 
al., 1994). Virtually all members of the MMP family have been shown to be 
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overexpressed in malignant neoplasm of various origins, in most cases overexpression has 
been associated with the invasive and metastatic stages of tumour progression (Matrisian, 
1992). MMPs are thought to facilitate tumour invasion and metastasis by breaking down 
membrane and underlying stroma, however, evidence suggests that matrilysin 
overexpression is not sufficient for tumour invasion and metastasis, and other factors are 
involved (Lochter et al., 1997). 
Matrilysin is distinct from other MMPs in its expression pattern, localising to the 
epithelial component of ADC (Pajouh et al., 1991; McDonnell et al., 1991; Newell et al., 
1994) whereas other MMP transcripts generally localise to the stromal components 
(Muller et al., 1993; Newell et al., 1994; reviewed in Powell and Matrisian 1996). A role 
for matrilysin in colorectal carcinogenesis has been demonstrated through the analysis of 
Min (multiple intestinal neoplasia) mice. Min mice harbour a germline mutation in Apc 
gene that results in the FAP phenotype. When Min mice were crossed to matrilysin 
deficient mice, fewer and smaller colorectal adenomas were detected (Wilson et al., 
1997). 
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2.7 APC and cell adhesion 
Adhesive interactions between cells and the interaction of cells with the extracellular 
matrix play a critical role in a number of biological activities including embryonic and 
organ development and maintenance of tissue integrity (Takeichi 1995; Gumbiner 1996; 
Vleminckx 1999). Cell adhesion is mediated by a number of different molecules that 
include members of the integrin, cadherin, immunoglobulin and proteoglycan protein 
families. Integrins and proteoglycans can execute cell -matrix, as well as cell -cell 
interactions whilst adhesion via cadherins appears to be strictly intercellular. Cadherins 
are of particular interest as they complex with (3-catenin. Thus 13-catenin functions in both 
wnt signalling and cell adhesion. 
The term cadherin denotes calcium -dependent intercellular adhesion molecules. Classical 
cadherins are defined by their characteristic and highly conserved cytoplasmic domain and 
include E- (epithelial), N- (neuronal) and P- (placental) cadherin which are primarily 
found at the adherens junctions of adjacent cells (Kemler 1992; Yap et al., 1997). 
Cadherins exist at the cellular membrane as parallel dimers consisting of the same family 
members. The extracellular segment consists of 5 cadherin repeats, EC1 -EC5; these 
repeats contain calcium binding sub -domains. Calcium is critical for cadherin function and 
serves to maintain the structural integrity of the transmembrane protein. Different family 
members express various EC -1 subunits and cells adhere preferentially to cells expressing 
the identical family member. The highly conserved cytoplasmic tail of the classical 
cadherins serves as a link to the cytoskeleton of the cell through specific interactions with 
the intracellular proteins a -, ß- and y- catenin (Gumbiner 1993; Ranscht 1994). 13- and y 
catenin share a high degree of homology and interact with the cytoplasmic tail of cadherin 
through armadillo repeat sequences located in the central portion of the proteins (Hülsken 
et al., 1994a; Funayama et al., 1995). (3- catenin and y- catenin interact with a- catenin 
linking the cadherin- catenin complex, either directly or indirectly is the actin binding 
proteins a -actin or vinculin, to the actin filament network (Rimm et al., 1995; Knudsen et 
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al., 1995; Weiss et al., 1998). This interaction is essential for cell -cell adhesion, and its 
regulation is critical for the highly dynamic nature of cellular junctions during for 
example, embryonic development or wound healing where junctions have to be rapidly 
disassembled and reassembled (Angres et al., 1996; Marrs and Nelson 1996). 
Another catenin that associates with the cadherin adhesion complex is p120" (Reynolds 
et al., 1994; Aghib and McCrea 1995; Shibamoto et al., 1995; Staddon et al., 1995). 
P120" appears to have a distinctive biological role from 13- catenin and y- catenin. P120`' 
binds to a more proximal region of the cadherin cytoplasmic tail than f3- and y- catenin 
(Yap et al., 1998). Data implicate a role in cell mobility (Riehl et al., 1996; Chen et al., 
1997) and in cadherin clustering and adhesive strengthening (Yap et al., 1998). 
Besides physically linking cadherin to the cytoskeleton, the cytoplasmic domain of 
cadherins can interact, either directly or indirectly (through the catenins) with other 
proteins that have potential signal transducing activities. These interacting proteins 
include the receptor tyrosine kinases erb -bl and erb -b2, the cytoplasmic kinases (such as 
SRC) and the adaptor protein SHC (Daniel and Reynolds 1997; Xu et al., 1997). How 
cadherins modulate cellular signalling is generally unclear but this signalling in addition to 
the mechanism of cell adhesion, are thought to mediate cellular responses associated with 
cadherin proteins such as cell proliferation, apoptosis and cell differentiation (reviewed in 
Vleminckx and Kemler, 1999). 
2.7.1 Interaction of 0-catenin with cadherins and the wnt signalling pathway 
13-catenin plays a crucial role in both cadherin- mediated cell -cell adhesion and wnt signal 
transduction. Three proteins that facilitate these functions are APC, Lef -1 and cadherin, 
which mediate r3-catenin degradation, activation of gene transcription and cell adhesion 
respectively. All three proteins bind to the armadillo repeat region of f3-catenin. The 
binding sites of these proteins have been shown to partially overlap and experiments have 
demonstrated that proteins compete for mutually exclusive binding of I3-catenin (Hülsken 
et al., 1994b; Rubinfeld et al., 1995; Behrens et al., 1996; Huber et al., 1996; Orsulic and 
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Peifer, 1996; Orsulic et al., 1999). 
In a simple cellular model, ß- catenin is sequestered and stabilised at the cell membrane, 
non -sequestered or free 3- catenin can bind APC and forms a complex with Axin, this 
complex is phosphorylated by GSK -313 and ß- catenin is targeted for degradation. In the 
presence of wnt signals, GSK -30 activity is inhibited and 13- catenin levels rise saturating 
cadherin molecules, excess ß- catenin then translocates to the nucleus and activates target 
genes. 
Several in vivo studies have demonstrated that cadherins can antagonise wnt signalling by 
competing for ß- catenin binding (Sanson et al., 1996; Fagotto et al., 1996; Torres et al., 
1996). Recently, Orsulic and co- workers (1999) have also demonstrated that loss of E- 
cadherin, an event that is commonly associated with the progression of the majority of 
epithelial tumours, mimics wnt signalling (Behrens et al., 1989; Vleminckx et al., 1991; 
Birchmeier and Behrens, 1994). Therefore, it could be hypothesised that loss of E- 
cadherin could promote tumourigenesis not only as a result of deregulated cellular 
adhesion, but also by the promotion of transcription of wnt responsive .genes such as 
CCND1, c MYC and matrilysin. Alternatively, one could consider deregulation of ß- 
catenin levels, accumulation of ß- catenin within the cytoplasm may lead to increased 
cellular adhesion in cases where E- cadherin expression is not lost, i.e. in the early stages 
of tumourigenesis. 
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Chapter 3: Loss of heterozygosity at chromosome 5q21 and gene 
mutation in the APC gene in NSCLC 
3.1 Introduction 
The functional inactivation of tumour suppressor genes is a common event in neoplasms. 
According to Knudson's hypothesis, tumour suppressor genes act recessively at the 
cellular level so that both copies of the gene must be inactivated for growth suppressive 
functions to be eliminated (Knudson 1978). In hereditary syndromes, generally a germline 
mutation in one allele predisposes an individual, and following inactivation of the 
remaining wildtype allele (by mutation or allele loss through partial arm deletion or 
mitotic recombination) gives rise to a phenotypic effect. In sporadic neoplasms, 
inactivation of a tumour suppressor gene requires two genetic events to occur (Weinberg, 
1991). Previous chapters have discussed several tumour genes that are inactivated in 
NSCLC. 
The chromosomal region 5q21 is deleted in numerous neoplasms including NSCLC 
where results have shown loss in up to 70% of cases (Ashton -Rickardt et al., 1991; 
D'Amico et al., 1992; Tsuchiya et al., 1992; Horri et al., 1992a; Hosoe et al., 1994; 
Wieland et al., 1994; Fong et al., 1995a). Within NSCLC, a common region of 
chromosomal deletion has been identified (Wieland et al., 1994). This region spans 3 -5 
megabases and harbours numerous genes including the tumour suppressor gene APC. 
Germline mutations within the APC gene predisposes individuals to FAP, a disease 
whereby multiple adenomas develop within the colon predisposing the individual to 
colorectal cancer and in some instances extracolonic manifestations (see section 2.4). 
Analysis of subsequent tumours reveals mutation or loss of the remaining APC allele. 
Biallelic inactivation of the APC gene has also been reported in sporadic colorectal cancer 
cases (Nishisho et al., 1991; Groden et al., 1991) and gastric and hepatic cancers 
(Tamura et al., 1994; Oda et al., 1996; Imai et al., 1997). 
Gene mutations have also been detected in pancreatic (Yashima et al., 1994; Horri et al., 
113 
1992a), oesophageal (Powell et al., 1994; Gonzalez et al., 1997) and prostate cancers 
(Watanabe et al., 1996). In these neoplasms, only one APC allele has been shown to be 
inactivated and it is unclear whether APC has a role in promoting tumourigenesis. If 
Knudson's hypothesis were to be up held then inactivation of one allele would not result 
in a phenotypic change. However, in the cases were the allele has been subject to a 
mutation, rather than loss of the whole gene, then one must consider the possibility of a 
dominant negative effect (see sections 2.3.1 and 2.4). 
Previous publications report that LOH within the chromosomal region 5g21 occurs in 20- 
70% of NSCLC cases. Several factors could be responsible for the variability in 
frequency between cohorts. Firstly, some studies included NSCLC cell lines, the results 
from these studies can be unreliable as often during culturing cell lines acquire genomic 
aberrations. Secondly, the relative percentages of histological subtypes (SCC, ADC and 
LCC) vary. A previous investigation reported that ADC and SCC exhibit different 
allelotypes (Sato et al., 1994) suggesting that different genes may be involved in driving 
tumourigenesis in these different histological groups. Two studies have analysed the 
frequency of LOH at 5q21 in ADC and SCC. Results were conflicting with one group 
reporting that LOH at 5q21 is more frequent in ADC than SCC whilst the other reported 
LOH to be more frequent in SCC (Tsuchiya et al., 1992; Fong et al., 1995a). Conflicting 
results between these studies may be due to the frequency of different grade tumours as 
Fong and co- workers (1995a) showed that LOH at 5q21 was more common in advanced 
stage NSCLC suggesting that LOH at 5q21 is a late event in NSCLC tumourigenesis. 
114 
3.2 Aims 
In the following study, my aim was to determine whether the APC tumour suppressor 
gene has a role in the tumourigenesis of NSCLC. Initial investigations analysed the 
frequency of LOH at 5g21 in a cohort of well- characterised NSCLC cases. This was 
carried out through the analysis of polymorphic sites within the APC and MCC genes. 
Secondly, I analysed the frequency of LOH at 5q21 in ADC and SCC subtypes. LOH at 
5q21 was also analysed following the subclassification of ADC into parenchymal and 
bronchial origin, as described by Edwards (1987), discussed in section 1.2.1.2. 
Thirdly, the frequency of LOH at 5q21 was analysed with respect to tumour grade. 
These initial studies address LOH at 5q21 and analyse results with respect to histological 
subtype and tumour grade. The final aim of this investigation was to determine whether 
biallelic inactivation of the APC gene is a characteristic of NSCLC. NSCLC cases shown 
to exhibit LOH at 5q21 were subject to mutational analysis of the APC gene. Two 
methods of analysis were chosen. The first method was single stranded conformation 
polymorphism analysis (SSCP). This is a relatively quick method to screen fragments of 
DNA for mutations. As the majority of mutations, both sporadic and germline, have been 
shown to occur within the mutation cluster region (MCR) of the APC gene, SSCP was 
used to analyse this region. As SSCP analysis is not 100% reliable and because mutations 
may also occur outwith the MCR, NSCLC cases were also subject to 
immunohistochemical analysis. An antibody raised to the carboxyl terminal region of the 
APC protein was used in this technique as the majority of mutations result in the 
production of a truncated protein product. 
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3.3 Materials and Methods 
3.3.1 Tissue collection 
A retrospective analysis of paraffin embedded non -small cell lung cancer ( NSCLC) 
biopsies was carried out. A total of 99 surgically resected lung cancers were analysed, 
consisting of 33 consecutive squamous carcinomas and 59 consecutive adenocarcinomas 
and seven additional bronchial adenocarcinomas. The additonal bronchial adenocarcinmas 
were included to improve statistical analysis between parenchymal and bronchial 
adenocarcinomas as bronchial adenocarcinomas occur less frequently (Dr. F. Carey, 
personal communication, Edwards 1987). For each NSCLC case, consecutive sections of 
3 and 1Opm were cut using a microtome, and placed onto glass slides. Between samples, 
the microtome blade was replaced to prevent cross contamination. One 3µm section was 
stained with haematoxylin and eosin and examined histologically to determine areas of 
tumour with minimal stromal and inflammatory cell contamination. The selected area was 
removed from the 10µm section using a sterile scalpel to scrape the tissue into a 
microfuge tube. For each NSCLC case to be analysed 10µm sections from lung tissue or 
lymph node, previously examined histologically and shown not to contain tumour 
(`normal'), were also cut and placed directly into microfuge tubes for DNA extraction. 
3.3.2 DNA extraction from paraffin embedded tissue 
DNA was extracted from the paraffin embedded tissue sections using the method of Levi 
and co- workers (1991), with slight modifications. For sections isolated from slides the 
method of DNA extraction was as follows; samples were microfuged briefly to pellet the 
tissue section and 400µ1 of lysis buffer and 254l of proteinase K (20 mg/ml) added (see 
appendix A). The samples were incubated for a period of 1 hour at 55 °C, gently vortexed 
then incubated for a further 3 hours. Following incubation, sterile EDTA, pH 8.0 was 
added to a final concentration of 1 mM to prevent bacterial growth in the sample and 
prevent digestion of DNA by nucleases. 
Sections of normal tissue were dewaxed before following the above extraction protocol. 
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To dewax, 1 ml of xylene was added, and the section vortexed and left to stand for 2 
minutes at room temperature (RT). The samples were centrifuged at 16,000 rpm for 2 
minutes, the supernatant discarded and the pellet resuspended in 1 ml of xylene and 
centrifuged as previously described. Finally, 1 ml of absolute ethanol was added and 
samples left for 2 minutes at RT. The samples were centrifuged again, the supernatant 
removed, and this step was repeated. The pelleted tissues were air -dried and the protocol 
for DNA extraction outlined above was followed. All samples were aliquoted and stored 
at -20 °C. 
3.3.3 Determination of DNA concentration using ethidium bromide plates 
Ethidium bromide plates were prepared by adding 1g of agarose into 100 ml of lx TBE 
buffer. Agarose was dissolved in the TBE by slowly microwaving. Once the solution had 
cooled to approximately 50°C, ethidium bromide solution (an intercalating dye that 
fluoresces under ultraviolet light) was added to give a final concentration of 0.1 mg/ml. 
The solution was poured into petri dishes and allowed to cool until set. Plates were 
stored at 4°C until required. 
To determine the concentration of a DNA sample, 11.1l of the sample and 1µ1 of each 
concentration of a standard DNA, ranging from 3 ng/µl to 125 ng/µl, were pipetted onto 
the plate. Plates were incubated at room temperature for 25 minutes and viewed under 
ultraviolet light. Concentrations of unknown samples were determined by eye by 
comparing with florescence of the known standards. 
3.3.4 Analysis of polymorphic sites within APC and MCC genes for loss of 
heterozygosity 
Loss of heterozygosity (LOH) in the APC and MCC genes was determined using PCR 
amplification of intragenic sequences containing known polymorphisms. Following PCR 
amplification restriction fragment length polymorphisms (RFLPs) in the 3' untranslated 
region (UTR) (Heighway et al., 1991) and exon 11 of the APC gene (Groden et al., 
1991) and the 3' UTR of the MCC gene (Heighway et al., 1992) were analysed using 
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restriction endonucleases Sspl, Rsal and Mae111, respectively. All enzymes were 
purchased from Boehringer Manheim. A fourth polymorphism, a length polymorphism in 
exon 10 of the MCC gene (Miyoshi et al., 1992a) was also analysed. 
3 3 4 1 Amplification of intragenic sequences containing known polymorphisms 
Intragenic sequences were amplified using polymerase chain reaction (PCR). PCR 
reactions were carried out in l00111 volumes. Each reaction mix consisted of 0.1 -1µg 
DNA, 2.5 units Tag polymerase (Gibco BRL), 0.2 mM of each dNTP (dATP, dCTP, 
dTTP, dGTP) (Pharmacia Biotech.), 1.5 mM MgC12 (Gibco BRL), 10µl of 10 X PCR 
buffer (200 mM Tris -HC1 pH 8.0, 500 mM KCI. Gibco BRL) and 0.5µM of each primer 
(Oswell DNA Services). PCR was performed in a Hybaid Omni Gene DNA thermocycler. 
Primers used for the amplification of the intragenic sequences have been published 
(Heighway et al., 1991,1992, Groden et al., 1991 and Miyoshi et al., 1992a) with the 
exception of a primer used for the amplification of the 3' UTR of the APC gene. Here the 
previously published upstream primer was replaced with a new primer to produce a 
smaller PCR product that was easier to amplify from archival paraffin- embedded tissue. 
Primers, specific PCR annealing conditions and cycle number for each set of primers is 
shown in table 4. The following standard PCR cycling program was used in all cases; 
initial denaturation step of 5 minutes at 94 °C followed by a cycling program of 
denaturation at 94 °C for 1 minute, annealing conditions see table 4, and an extension step 
of 72 °C for 1 minute with the exception of MCC exon 10 which had a 2 minutes 
extension time. A final extension step of 72 °C for 9 minutes was also included. 
Ten microlitres (approximately 0.2 µg) of each PCR product was electrophoresed 
through a 3% agarose gel (see below) to ensure amplification of the template. 
3.3.4.2 Agarose gel electrophoresis 
To prepare a 3% agarose gel, 4.5 grams of agarose was weighed out into a flask and 
150 
ml of 1xTBE buffer added. The agarose solution was gently heated in a 600W 
microwave 
for 2 minutes or until all the agarose powder was dissolved. A magnetic bar 
was added to 
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the agarose solution and the flask was placed on a magnetic stirrer for 5 minutes. 
Ethidium bromide was added to the agarose to give a final concentration of 0.1 mg/ml. 
The agarose gel was poured into a cast and left to set at 4 °C. 
100 of each PCR product was mixed with 111l of 10X gel loading buffer (Appendix A) 
and the solution loaded into the wells of the agarose gel. Gels were run at 100 V in 1 X 
TBE buffer. Following electrophoresis PCR product was visualised by illuminating the 
gel with ultraviolet light. 
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Annealing Temp./Time Program 
cycles 
APC 3' UTR U - ATGACCACCAGGTAGGTGTATT 
D - GAAGAGACTGCAATGTCTAAGAA* 
OR 
D -GCATTAAGAGTAAAATTCCTCTTAC 
55 °C 30 seconds. 30 
OR 
*54 °C 30 seconds. 30 
APC EXON 11 U- GGACTACAGGCCATTGCAGAÁ 
D -GGCTACATCTCCAAAAGTCAA 
59 °C 1 minute. 34 
MCC 3' UTR U- CCAATGAAACTTCGCTTTAATCAG 
D -CTGGATACAGTCCACAATGACAC 
52 °C 1 minute. 36 
MCC EXON 10 U- CACTTCTACCCTGAAGTAGCTCC 
D ATGACCTCCTGACCATAACCTTG 
55°C 1 minute. 30 
*New Primer, U- upstream primer, D- downstream primer 
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3 3 4 3 Restriction endonuclease cleavage of PCR products 
Approximately 0.2µg of each PCR product was incubated in a total volume of 20µ1 
containing 2 units of the appropriate restriction endonuclease and 1 x restriction enzyme 
buffer for 2 hours at the recommended temperature. In the case of APC exon 11 and 
MCC 3' UTR, a control DNA fragment (internal control) containing the appropriate 
restriction site was included to ensure restriction enzyme cleavage. In these cases the 
incomplete cleavage of the PCR product may lead to incorrect interpretation of results as 
the sample would be scored as either non -informative or as informative with loss of the 
second allele. 
3.3.4.4 Analysis of polymorphic sites 
Following restriction enzyme cleavage, the tumour and `normal' PCR product pairs were 
electrophoresed through a 3% agarose gel in lx TBE running buffer until the different 
size alleles were separated. Molecular weight markers (marker V, Boehringer Manheim) 
were included on each gel. Samples were scored as informative (polymorphic between 
alleles) or non -informative (no- polymorphism between alleles). LOH in informative cases 
was defined by a reduction in the intensity, as determined by eye, of an allele band of the 
tumour in comparison with its corresponding normal. PCR product and RFLP sizes are 
shown in table 5. 
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Allele size (bp) 
Following enzyme cleavage 
Internal Control (bp) 
APC 3' UTR Sspl 850 580 +270 A 1 
580 +135 +135 A2 
APC 3' UTR Sspl 318 270 +48 Al 
135 +135 +48 A2 
PUC 19 
APC exon 11 RsaI 132 132 Al PCR product size 103 
87 + 45 A2 Cleavage 71 
32 
APC 3' UTR 
MCC 3' UTR Mael ll 210 210 Al PCR product size 850 
189 +21 A2 Cleavage 700 
150 
MCC exon 10 Not applicable 175 175 Al 
161 161 A2 
- Internal Control 
Al /A2- Allele bands 1 or 2. 
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3.3.5 Single strand conformational polymorphism analysis of the MCR of the APC 
gene 
All cases showing LOH at 5q21 were screened for mutations in the mutation cluster 
region (MCR) of the remaining allele of APC. The method used was single strand 
conformational polymorphism (SSCP); a method designed to detect unknown point 
mutations. The method was originally described by Orita et al., (1989) and involves 
amplification of DNA using PCR and electrophoresis of denatured product on a 
polyacrylamide gel under non -denaturing conditions. The electrophoretic mobility of the 
single stranded DNA is dependent on the size and the folded secondary structure of the 
DNA. The secondary structure of the DNA is stabilised by intra- strand nucleotide 
interactions determined by the base sequence of the strand. 
3.3.5.1 Amplification of DNA fragments spanning the mutation cluster region 
The MCR of the APC gene lies between codons 1268 and. 1513 (nucleotides 3717 -4614) 
(Miyoshi et al., 1992). Amplification of DNA fragments spanning the MCR was carried 
out using polymerase chain reaction (PCR). Primers used to span the MCR were as 
previously reported (Curtis et al., 1994) but modified to produce PCR products less than 
300 bp long (suitable for amplification of DNA extracted from paraffin embedded tissue). 
Nucleotide location, PCR product size, primers and PCR annealing temperatures are 
noted in table 6. Cycling conditions consisted of an initial denaturation step of 5 minutes 
at 94 °C, followed by 36 cycles of 30 seconds denaturation at 94 °C, 30 seconds at 
appropriate annealing temperature, and 60 seconds extension at 72 °C, with a final 
extension step of 10 minutes at 72 °C. 
To ensure that the PCR reaction had been successful, PCR products were analysed on 
3% agarose gels using the method described in section 3.3.3.2. 
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PRIMERS 5' -3' Annealing 
Temperature 
°C 
1 3735 -3991 256 U- TGGAACTTCGTCACAGGAT 
D- AAGTGGTCAGCCTCAAAAGG 
58 
3888 -4181 292 U- TCAGACGACACAGGAAGCAG 
D- GTACATCTGCTAAACATGAGTGGG 
56 
4150 -4441 291 U- CAGGAGACCCCACTCATGTT 
D- CAGCATTTACTGCAGCTTGC 
56 
4 4408 -4612 203 U- AGAGTGGACCTAAGCAAGCT 55 
D -A rrrl CCTGAACTGGAGGC 
U- Upstream Primer, D- Downstream Primer 
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3.3.5.2 Single strand conformational polymorphism gels 
PCR products were denatured by the addition of 1111 of denaturing solution (Appendix A) 
to 511l (approximately 0.1µg) of PCR product. Samples were incubated for 5 minutes at 
50 °C, then 3111 of stop solution (Appendix A) was added to each sample. Nine microlitres 
of sample was loaded onto a non -denaturing 0.7% MDE gel (AT Biochem, PA. USA) 
containing 5% glycerol and 1xTBE. The gel was run for 2 -3 hours in lx TBE running 
buffer at 25 °C at 25W using a LKB Bromma 2001 vertical electrophoresis unit. Tumour 
and normal DNA pairs were loaded side by side, and DNA from colorectal 
adenocarcinomas previously shown to harbour mutations in the MCR of APC were 
included as positive control on some gels. 
3.3.5.3 Silver staining and gel analysis 
Gels were silver stained according to the manufacturer's instructions (Bio -Rad 
Laboratories Ltd., UK). This involved fixing the gels by washing in 40% methanol / 10% 
glacial acetic acid (v /v) for 1 hour, followed by two 30 minute washes in 10% ethanol / 
5% glacial acetic acid (v /v). The gels were then incubated at RT on a rocking platform 
for 10 minutes in oxidising solution, which contained potassium dichromate and nitric 
acid, and washed in double distilled water (DDW) for 2 minutes. The DDW water was 
removed and the washing repeated at least 12 times until the yellow coloration had been 
removed from the gels. Gels were incubated at RT on a rocking platform in silver nitrate 
solution for 30 minutes. The gels were then washed for 2 minutes in DDW and 
transferred to developer solution, which contained sodium carbonate and 
paraformaldehyde. Initially 200 ml was added and immediately poured off. A further 200 
ml was added and the gels incubated at RT until brown DNA bands appeared on the gel, 
usually after 5 minutes. Developer was then removed and 5% glacial acetic acid (v /v) 
added for approximately 15 minutes to fix the gel. Gels were then dried on 3M Whatman 
paper and laminated. Gels were examined for the presence of band mobility shifts 
between normal and tumour DNA samples. Mobility shifts were seen in all positive 
control samples. 
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3.3.6 APC immunohistochemistry 
All cases showing LOH at 5q21 were analysed by immunohistochemistry using a rabbit 
polyclonal antibody raised to the carboxyl terminus (C- terminal) of the APC protein to 
determine whether full length APC protein was being translated from the remaining APC 
allele. This APC antibody was produced within the department and is fully described in 
Midgley et al., 1997. Three micron sections from paraffin- embedded tissues were 
dewaxed and hydrated by incubating for 10 minutes in xylene followed by 2- minutes each 
in absolute alcohol, and graded aqueous alcohol (95% and 70 %). Slides were washed for 
2 minutes in tap water and incubated for 15 minutes in 3% (v /v) hydrogen peroxide 
solution diluted in water to block endogenous peroxidase activity. Slides were washed in 
running tap water for 5 minutes and incubated in 2 changes of phosphate buffered saline 
(PBS) with 0.1% (v /v) Tween -20 for 5 minutes. Sections were incubated for 20 minutes 
with 10011l of PBS containing 20% normal donkey serum (Dako, UK) and 0.1% Tween- 
20 (NDSPT). Following incubation slides were washed with PBS/ 0.1% Tween -20 and 
then 10011l of APC C- terminal antibody, diluted 1/50 (a dilution previously determined) 
in NDSPT, was added to each tissue section. Slides were incubated overnight at 4 °C in a 
humidifying chamber. Slides were then washed for three 5- minute washes in PBS/ 0.1% 
Tween -20 and sections were incubated for 30 minutes in a humidifying chamber with 
10011l of horseradish peroxidase conjugated donkey anti -rabbit secondary antibody 
(Dako, UK), diluted 1/400 in PBS /0.1% Tween -20. Again slides were washed for three 5 
minute washes PBS / 0.1% Tween -20. For detection of immunoperoxidase activity, 
freshly prepared diaminobenzidine (DAB) solution (Appendix A) was applied to the 
slides for 5 minutes. Slides were washed in water for a further 5 minutes and nuclei were 
counter -stained with Mayer's haematoxylin for 5 seconds. After a further wash in running 
tap water, the sections were transferred through graded aqueous alcohol solutions to 
absolute ethanol and then through 3 changes of xylene. Cover slips were mounted using 
DPX (BDH, UK) mounting fluid. Control slides from `normal' lung tissue were included 
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as 1) a positive control slide to confirm APC staining 2) a negative control which was 
incubated with NDSPT instead of APC antibody. 
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3.4 Results 
3.4.1 LOH at 5q21 
Ninety -nine NSCLC cases were examined for LOH at polymorphic sites within the APC 
and MCC genes. NSCLC cases consisted of 33 consecutive SCC, 59 consecutive ADC 
and 7 additional non -randomly selected ADC of bronchial origin. The latter cases were 
included to enhance cases for statistical analysis between ADC of parenchymal and 
bronchial origin (see section 1.2.1.2 and 3.3.1) but were not included in the initial analysis 
of frequency of LOH in our consecutive cohort, as seen in table 7a. 
Four genetic polymorphisms in the APC and MCC genes were analysed. Following PCR 
amplification and subsequent incubation with the appropriate restriction endonuclease (if 
required), the polymorphic sites within tumour and normal tissue pairs for each NSCLC 
cases were viewed under ultraviolet light following electrophoresis through a 3% agarose 
gel containing ethidium bromide (see section 3.3.4). 
Normal tissue samples from each NSCLC cases were viewed to determine whether 
polymorphic sites were non -informative, i.e. no polymorphic variation between alleles, or 
informative i.e. showed polymorphic variation between alleles. Tumour and normal tissue 
pairs of cases shown to be informative were then scored as informative retained, the 
tumour sample retained both alleles, or informative with LOH, one allele was absent or 
was noted to be of decreased intensity when compared to the corresponding allele within 
the normal tissue sample. Example of cases showing non -informative, informative 
retained and informative with LOH for each site are shown in figures 9 and 10. 
Unlike in the analysis of tumour cell lines, DNA extractions from tumour tissue contain 
non -tumour DNA derived from stromal tissue and infiltrating inflammatory cells. This can 
make the interpretation of results difficult and subjective. To try and eliminate 
misinterpretation, Dr VJ Bubb and myself independently scored results. In cases where 
there was disagreement, DNA was re- extracted from the tissue trying to further minimise 
the amount of stromal material. As a further precaution, only cases informative at two or 
more loci were subject to statistical analysis. 
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Figure 9: Analysis of restriction fragment length polymorphisms (RFLP) within the APC 
gene 
a) This figure shows the analysis of a polymorphic site within the 3' untranslated region of the 
APC gene. DNA extracted from tumour (T) and normal (N) tissue for each NSCLC case was 
subject to PCR to amplify a 318 bp product which encorporated the polymorphic site. PCR 
products were incubated with the restriction endonuclease S'spl to identify polymorphic variants 
which would yield fragments of 270 + 48 bp or 135 + 135 + 48 bp. Following incubation with 
S'spl, PCR products were electrophoresed on a 3% agarose gel. PCR product not incubated with 
S'spl was also loaded on the gel to indicate the migration of undigested PCR product. this lane is 
indicated as "U ". The 48 bp restriction fragment can not be visualised on this gel. 
Case 1 is an individual who is heterozygous for this polymorphism and exhibits loss of one APC 
allele in the tumour sample (loss of heterozygosity). Case 2 is an individual who is heterozygous 
for this polymorphism and both alleles are retained in the tumour and normal samples 
(informative retained).Case 3 is an individual who is homozygous (non -informative). MV 
indicates molecular weight marker V (Boehringer Manheim). 
b) This figure shows the analysis of a polymorphic site within exon 11 of the APC' gene. PCR 
amplification of DNA samples yields a 132 bp product which when incubated with the restriction 
endonuclease Rsal identifies the two polymorphic variants yielding fragments of 132 bp or 87 + 
45 bp. Internal controls to ensure enzymatic cleavage were required (see section 3.3.4.3). PCR 
amplification of the internal control DNA yields a product of 103 bp that is cleaved by Rsal to 
give fragments of 71 + 32 bp. The 32 bp fragment can not be visualised on this 3% agarose gel. 
Following incubation with Rsal, PCR products from tumour (T)and normal (N) tissue for each 
case were electrophoresed on a 3% agarose gel. PCR product not incubated with Rsal were 
loaded onto the gel to indicate the migration of the 132óp PCR product, indicated on the figure as 
U. Lanes C 1 and C2 correspond to PCR amplification of the internal control uncleaved and 
cleaved with Rsal respectively. 
Case 1 is an individual who is heterozygousi for the polymorphism and exhibits loss of one of the 
APC alleles within the tumour sample. Cases 2 and 3 are individuals who are informative for the 
polymorphism and both alleles are retained in the normal and tumour samples. MV indicates 
molecular weight marker V. 
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Figure 10: Analysis of polymorphic sites within the MCC gene 
a) This figure shows the analysis of a RFLP within the 3' untranslated region of the MCC gene. 
DNA extracted from tumour (T) and normal (N) tissue for each NSCLC case was subject to 
PCR to amplify a 210 bp product, which encompassed the polymorphic site. PCR products 
were incubated with the restriction endonuclease Maelll, which identifies the two 
polymorphic variants yielding fragments of 210 bp or 189 +21 bp. Internal controls to ensure 
enzymatic cleavage were required (see section 3.3.4.3). Amplification of the internal control 
yielded a PCR product of 850bp, which when incubated with MaeIII yielded fragments of 700 
and 150 bp. Lane marked C in the figure conatins both the PCR product from the 
amplification of the RFLP in the MCC gene and the internal control. Following incubation 
with Mael11, PCR products were electrophoresed through a 3% agarose gel. The 21 bp 
fragment can not be visualised on this gel. 
Case 1 is an individual who is heterozygous for the polymorphism and both alleles are 
retained in the tumour and normal tissue. Case 2 is an individual who is homozygous for the 
polymorphism (non -informative). Case 3 is an individual who is heterozygous for this 
polymorphism and exhibits loss of one of the APC alleles within the tumour sample (loss of 
heterozygosity). MV indicates molecular weight marker V (Boehringer Manheim). 
b) This figure shows the analysis of a length polymorphism within exon 10 of the MCC gene. 
Amplification of a fragment of DNA encompassing the polymorphic site identifies the two 
polymorphic variants, yielding products of 175 bp or 161 bp. 
Case 1 is an individual who is homozygous for this polymorphism. Case 2 is an individual 
who is heterozygous for the polymorphism and exhibits loss of one of the APC alleles within 
tumour tissue. Case 3 is an individual who is heterozygous for the polymorphism and both 
APC alleles are retained in tumour and normal tissue. MV indicates molecular weight marker 
V ( Boehringer Manheim). 











All case data and histological information is shown in Appendix C. Summary of results is 
shown in table 7 a -d. 
Sixty -eight of the 92 consecutive NSCLC cases were informative at two or more loci. 
Cases that contained informative polymorphisms in both the APC and MCC genes 
exhibited no discordance between genes with respect to the allele being retained or lost. 
Eleven out of 24 informative SCC (46 %) and 16/ 44 informative ADC (36 %) exhibited 
LOH. Statistical analysis indicated no significant difference in the frequency of LOH 
between SCC and ADC (x2= 0.0.582, df l; P= 0.446). See table 7a. 
Within the consecutive ADC series with the additional non -randomly selected bronchial 
ADC, 5/9 (56 %) of informative bronchial ADC whilst 6/20 (30 %) informative 
parenchymal ADC exhibited LOH. Nineteen ADC could not be clearly described as 
arising in the bronchus or the parenchyma. Of these cases, termed of uncertain origin, 
8/19 (42 %) showed LOH. Fisher's exact test was applied to these results and 
demonstrated that there was no statistically significant difference between ADC of 
parenchymal or bronchial origin with respect to LOH at 5q21 (Two -tailed analysis; 
p= 0.237). See table 7b. 
To determine whether LOH at 5q21 is an early or late event in NSCLC, the cases 
analysed above were subject to analysis following segregation into tumour stage 
according to the international staging system, as outlined in section 1.2 (Mountain 1997). 
No significant difference was seen between tumour stages with respect to LOH at 5g21 
(Fisher's exact test; Two -tailed test; p >0.2 in all cases). Therefore, one may conclude at 
this point, that loss of 5g21 is not associated with tumour progression. When the NSCLC 
group was subdivided into the histological groups ADC and SCC, results revealed that 
the frequency of LOH within the SCC group remained similar at each tumour stage, and 
statistical analysis showed that there was no significant difference between tumour stage 
and LOH, the same was shown for the ADC group, Fisher's exact test, Two -tailed test; 
p >0.2. See table 7c. No significant difference was seen in the frequency of LOH between 
SCC and ADC groups at each stage, Fisher's exact test p >0.2. 
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Following the subdivision of ADC into site of origin, results revealed that LOH was not 
associated with increasing tumour stage in the parenchymal or bronchial subgroups, as 
determined by Fisher's exact test (two- tailed test; p >0.2 in all cases). The group of 
tumours designated of uncertain origin followed the same pattern of loss as the ADC of 
parenchymal origin. See table 7d. 
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Table 7 a) Analysis of consecutive NSCLC cases for LOH 
Histology No. of informative cases No. of informative cases 
exhibiting LOH 
( %) 
SCC 24 11 (46 %) 
ADC 44 16 (36 %) 
Ninety -nine consecutive NSCLC cases were analysed for LOH, 68 cases were shown to 
exhibit loss of heterozygosisty at more than one loci. Statistical analysis indicated no 
significant difference in the frequency of LOH between SCC and ADC (x2= 0.582, df=1; 
p= 0.446). 
Table 7 b) Analysis of ADC cases for LOH following subclassification into site of origin 




Parenchymal 20 6 (30 %) 
Bronchial 9 5 (56 %) 
Uncertain origin 19 8 (42 %) 
Fourty -four ADC cases identified in the initial consecutive NSCLC cohort, plus 7 non- 
consecutive bronchial ADC, which were selected to improve statistical analysis, were 
analysed. Four of the seven bronchial ADC were informative, of which three exhibited 
LOH. Statistical analysis indicated no significant difference in the frequency of LOH 
between ADC of parenchymal and bronchial origin, Fisher's exact test, two -tailed test; 
p=0. 237. 
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Table 7 c) Analysis of tumour stage and LOH in ADC and SCC subtypes 
Tumour 
stage 
Total no. of cases 
exhibiting LOH / 
informative cases 
No. of SCC 
exhibiting LOH / 
informative cases 
No. of ADC 
exhibiting LOH / 
informative 
cases 
Ia +Ib 16/37 (43 %) 5/9 (56 %) 11/28 (39 %) 
IIa + IIb 8/23 (35 %) 3/10 (30 %) 5/13 (38 %) 
IIIa + IIIb 6/12 (50 %) 3/5 (60 %) 3/7 (43 %) 
All cases were analysed to determine if there was any significance difference between the 
frequency of LOH with tumour stage for the ADC and SCC groups. No significant 
difference in LOH between tumour stages was seen for SCC, nor for ADC, Fisher's exact 
test, Two -tailed test; p >0.2 in all cases. 
Table 7 d) Analysis of tumour stage and LOH following subdivision of ADC into 
parenchymal and bronchial subtypes. 
Tumour 
stage 













Ia +Ib 2/10 (20 %) 5/8 (62 %) 4/11 (36 %) 
IIa + Mo 3/7 (43 %) 0 2/4 (50 %) 
IIIa + II% 1/3 (33 %) 0/1 (0 %) 2/4 (50 %) 
No statistically significant difference was seen in frequency of LOH between tumor 
stages, in either the bronchial or parenchymal ADC groups, was seen as determined by 
Fisher's exact test, two -tailed test; p >0.2 in all cases. Comparison of LOH revealed no 
significant difference in the frequency of LOH between ADC arising in the bronchus or 
parenchyma at each tumour stage, Fisher's exact test, two -tailed test; p= >0.2 in all cases. 
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3.4.2 Mutational analysis of the APC gene 
NSCLC cases shown to exhibit LOH at 5q21 (n =30) were subject to mutation analysis. 
Single strand conformation polymorphism analysis was used to screen for mutations 
within the MCR of the APC gene. PCR was used to amplify the MCR, in several 
overlapping fragments, using DNA extracted from tumour and normal tissue of each 
NSCLC case. For each MCR fragment, PCR products from tumour and normal tissue 
were loaded side by side onto an SSCP gel, subject to electrophoresis and then silver 
stained to visualise the PCR products (see section 3.3.5). 
As positive controls, DNA extracted from colorectal ADC cases known to harbour 
mutations within the MCR of the APC gene, were also amplified by PCR and included on 
the gel. In all cases, positive controls showed a shift in band mobility when compared to 
the NSCLC test samples. No shift in band mobility was seen between tumour and 
corresponding normal tissue from individual NSCLC cases, or between all NSCLC cases. 
Examples of SSCP gels are shown in figure 11. 
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Figure 11: Single strand conformational polymorphism analysis of the mutation cluster 
region of APC 
Primers were designed to amplify the mutation cluster region (MCR) of the APC gene. 
Following amplification of a fragment of the MCR by PCR, PCR products were 
electrophoresed though an SSCP gel and subsequently silver stained. For each NSCLC 
case, previously shown to exhibit LOH at 5q21, tumour (T) and normal (N) tissue was 
compared. Figures 1 la -1 ld are examples of the analysis of the MCR fragments 1 -4 
respectively. On each gel, 3 NSCLC cases are represented (1 -3). Control samples, shown 
in the figure in lanes marked C, were also analysed, these cases were tissue from 
colorectal cancer cases previously shown to harbour a mutation within that region of the 
MCR. A shift in band mobility is noted for both of these positive control cases. No shifts 
in band mobility are noted in any of the tumour or normal tissue pairs or between NSCLC 
cases. Lane M denotes a molecular weight marker V (Boehringer Manheim). 
Figure 11: Single strand conformational polymorphism analysis of the 
mutation cluster region of APC 
a) b) 
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3.4.3 APC immunohistochemistry 
Tumour tissue from NSCLC cases shown to exhibit LOH at 5q21 (n =30) were subjected 
to immunohistochemistry using a polyclonal antibody raised to the carboxyl terminal of 
the APC gene (Midgley et al., 1997). NSCLC were scored as positive by the presence of 
a brown coloration within the cell, reflecting the diaminobenzidine substrate, which was 
used for visualisation of the immunohistochemical reaction. A1130 cases showing LOH at 
5g21 were positive for APC staining. Diffuse staining was noted in the cytoplasm of cells 
throughout the tumour, with the exception of areas of necrosis where staining was 
absent. Some tumour cells exhibited nuclear staining in conjunction with cytoplasmic 
staining. 
Normal lung tissue sections were included as positive controls. APC was ubiquitously 
expressed in all cell types, as seen in the tumour samples. APC was present within the 
cytoplasm of cells and in some cases within the nucleus. Intense staining was noted at the 
apical and lateral borders of the epithelial cells lining the bronchioles. Negative controls, 
normal lung tissue sections incubated with NDSPT instead of APC antibody, were 
included and in all cases shown no brown coloration. Figure 12 shows APC 
immunohistochemistry in tumour and non -tumour lung cases. 
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Figure 12: APC protein expression in normal and tumour tissue of the lung 
Immunohistochemical staining of formalin fixed paraffin embedded lung tissue with a 
polyclonal antibody raised to the carboxyl terminal of the APC protein. The method used 
was indirect immunoperoxidase using diaminobenzidine substrate for visualisation. Slides 
were lightly counter stained with haematoxylin. APC protein was detected in all cells 
types; diffuse cytoplasmic staining was noted with occasional nuclear staining within 
some cells. 
a) This section shows APC protein expression in the bronchial epithelium. Arrow a 
indicates intense apical and lateral staining of the epithelial cells lining the bronchioles 
(cuboidal ciliated cells and columnar Clara cells). Arrow b indicates staining within 
the submucosal gland. Magnification x 200. 
b) APC protein expression in alveolar epithelial cells (type I and type II Clara cells). 
Magnification x 400. 
c) APC protein expression in a bronchial adenocarcinoma (area a). This case showed 
loss of heterozygosity (loss of one APC allele) as determined by restriction fragment 
polymorphism analysis. Staining of the tumour indicates expression of full- length 
protein from the remaining APC allele. Magnification x 400. 







Polymorphic sites within the APC and MCC genes were analysed to determine the 
frequency of LOH at chromosome 5q21 in a series of NSCLC cases. DNA was extracted 
from tumour and normal tissue derived from each NSCLC case. Areas of tumour tissue 
were examined histologically and an area of tumour tissue carefully selected with a 
minimal amount of stromal tissue and infiltrating inflammatory cells. Tissue selection was 
necessary to minimise contamination of the tumour DNA with non -tumour DNA as this 
can make the interpretation of results difficult and subjective. Following PCR, and if 
required, subsequent treatment with the appropriate restriction endonucleases, 
polymorphic sites within the tumour and normal samples were analysed for LOH. In the 
majority of cases that exhibited LOH a reduction in the intensity of an allele band in the 
tumour sample compared to the normal sample was noted. It was rare for the allele band 
to be completely absent. This is indicative of contaminating non -tumour tissue within the 
sample. To overcome the problem of contamination, one could use a more stringent 
dissection technique; microdissection can be used to select single cells from which DNA 
can be extracted and subject to PCR. To obtain enough PCR product for analysis, a high 
number of PCR cycles would be needed, often in these circumstances nested PCR is 
used. A problem with this protocol may arise if there is heterogeneity within the tumour. 
This may occur if the cells that exhibit LOH have not reached clonal dominance. 
In this study, results were independently scored (Dr VJ Bubb and myself) to try to 
eliminate misinterpretation due to non -tumour contamination. In cases where there was 
disagreement, DNA was re- extracted from the tissue trying to further minimise the 
amount of contaminating material. As a further precaution, only cases informative at two 
or more loci were subject to statistical analysis. 
The initial aim of this study was to determine the frequency of LOH at 5q21 in the 
NSCLC subtypes; SCC and ADC. Previous studies have analysed the frequency of LOH 
at 5q21 in NSCLC and reported that LOH occurs in between 20 -70% of cases. The 
variation in frequency of loss seen between these studies suggested that LOH may be 
more common in different NSCLC subtypes or associated with different tumour stages, 
139 
as these were variables between these studies. 
This study has shown that in this consecutive cohort of NSCLC cases, LOH at 5g21 is a 
frequent event. In the SCC group LOH was detected in 11/24 (46 %) informative SCC 
cases and 16/44 (36 %) informative ADC cases (Table 7a). Statistical analysis reveals that 
there is no significant difference in the frequency of loss in ADC and SCC subtypes. This 
result is supported by two smaller studies (Ashton -Rickardt et al., 1991; Tsuchiya et al., 
1992). Conversely, two studies have reported that LOH at 5q21 occurs more frequently 
in SCC than ADC, in both studies results were statistically significant (Fong et al., 1995; 
Sanz -Ortega et al., 1999). 
The differences seen between cohorts may have been a reflection of the number of early 
and late stage tumours. However, in this study, SCC of all tumour stages exhibited 
similar frequencies of LOH (stage I: 5/9 (56 %); stage II: 3/10 (30 %); stage III: 3/5 
(60 %)), as seen in table 7c. Stataistical analysis of the data revealed that there was no 
association between tumour stage and frequency of LOH, Fisher's exact test. Two -tailed 
test; p >0.2 in all cases, and suggested that LOH at 5q21 is not associated with tumour 
progression. This result is in keeping with two recently published studies (Sanz -Ortega et 
al., 1999; Wistuba et al., 1999) but is contrary to studies by Fong and Co- workers 
(1995a). 
Analysis of LOH and tumour stage for ADC cases also revealed that the frequency of 
LOH did not increase with tumour progression, stage I: 11/28 (39 %), stage II: 5/13 
(38 %) and stage III: 3/7 (43 %), data shown in table 7c..Using Fisher's exact test, the 
frequency of LOH at 5g21 between tumour stages was shown not to be statistically 
significant, two -tailed test; p >0.2 in all cases, thus indicating that LOH at 5q21 is not 
associated with tumour progression. 
Subdivision of ADC into site of origin (see table 7b) revealed no significant difference in 
the frequency of LOH occurring in ADC of parenchymal or bronchial origin (Fisher's 
exact test, two -tailed test; p= 0.237). Statistical analysis was then used to determine 
whether the frequency of LOH in parencymal and bronchial subgroups varied with 
tumour stage (data shown in table 7d), no significant difference was determined, Fisher's 
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exact test, two- tailed test; p >0.2 in all cases. Analysis of the frequency of LOH exhibited 
by bronchial and parenchymal ADC at each tumour stage revealled that the frequency of 
loss was similar (see table 7d) and statistical analysis revealed no significant difference, 
Fisher's exact test p >0.2 in all cases. Therefore, through the analysis of individual ADC 
subgroups, it appears that LOH at 5g21 is not associated with tumour progression within 
either subgroup and that the frequncy of LOH exhibited by the two subgroups is not 
significantly different. 
In summary, this study has shown that there is no statistically significant difference in the 
frequency of LOH at 5q21 in the NSCLC histological subgroups ADC and SCC and that 
LOH is not associated with tumour progression in these groups. These results suggest 
that with respect to LOH at 5q21, ADC and SCC may follow the same genetic pathway 
to tumourigenesis and that LOH of heterozygosity at 5q21 does not promote tumour 
progression. Therefore, one may speculate that LOH at 5q21 may be important in the 
initiation of tumourigenesis. Analysis of ADC cases of bronchial and parenchymal origin 
revealed that the frequency of LOH is not significantly different between these subgroups 
and that frequency of loss does not increase significantly with tumour stage. This 
suggests, as with ADC and SCC, that LOH is not associated with tumour progression in 
either of these subgroups and that LOH at 5q21 may be important in the initiation of 
tumourigenesis. 
There are currently no publications, which identify the point at which LOH at 5q21 
occurs. It is also still unclear as to why the frequency of LOH at 5q21 varies to such an 
extent. Despite carrying out statistical analysis using the Fisher's exact test which allows 
for small numbers, I think that it may be worth increasing the numbers of cases within this 
study, in particular the number of later stage tumours. This will be difficult as in most 
cases NSCLC are detected and surgical procedures are immediately implemented before 
the tumours can progress. Alternatively, a study of advanced tumours may be carried out 
through the production of xenografts using murine hosts. 
In NSCLC, the region of chromosomal loss at 5q21 spans 3 -5 megabases and harbours 
numerous genes including the tumour suppressor gene APC and the MCC gene (see 
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section 1.3.3.3a). These two genes lie approximately within 500 kb of each other. 
Initially, MCC was thought to also be a tumour suppressor gene as mutations were 
detected in a series of colorectal cancer cases (Kinzler et al, 1991a). Subsequent studies 
where undertaken to determine the frequency of gene mutations in a larger series of 
colorectal cancer cases and these studies revealed no mutations in the MCC gene (Curtis 
et al., 1994; Cripps et al., 1995). The protein encoded by the gene has since been shown 
to be a negative regulator of the cell cycle (Matsumine et al., 1996) however, there have 
been no publications reporting biallelic inactivation of this gene. 
The analyses of polymorphic sites within the MCC gene were included in this study to 
increase the number of informative cases. In all cases that were informative for both APC 
and MCC; loss or retention was always seen in both genes i.e. there were no cases 
showing discordance between the two genes, indicating that this was a minimum area of 
loss. 
To further investigate the role of APC in NSCLC tumourigenesis, cases that exhibited 
LOH at 5q21 were screened for mutations within the APC gene. It is unknown whether 
biallelic inactivation of APC is a feature of NSCLC. One study consisting of 7 NSCLC 
cases that displayed LOH at 5q21 detected no mutations in the remaining APC allele 
(Horri et al., 1992b). 
Lung cancer is associated with cigarette smoking, the carcinogen metabolites that are 
produced commonly form DNA adducts at guanine or adenine nucleotides and analysis of 
mutations present in tumour suppressor genes and oncogenes in lung cancers typically 
exhibit a high frequency of mutations at guanine nucleotides (discussed in section 1.1.2, 
and 1.3). One may therefore expect to see a high level of G -T transversions or A -T 
transversion mutations in lung cancer cases from individuals who smoked. Throughout 
the APC gene, there are numerous codons that may give rise to stop codons following the 
production of DNA adducts at a guanine or an adenine residue. One may predict that 
these codons could become mutation hotspots in lung cancer arising in smokers. 
The coding region of the APC gene is 8529 nucleotides, to sequence the whole length of 
the gene for mutations would be extremely expensive and time consuming. Therefore, in 
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this study I decided to analyse the MCR of the gene as the importance of this region in 
tumour suppression had been reflected by previous mutation studies in other neoplasms. 
The method used to screen this region for mutations was single strand conformational 
polymorphism analysis (SSCP), a relatively quick and simple screening method. No 
mutations were detected in the 30 cases analysed. This negative result may raise 
questions on the sensitivity of this method despite all colorectal cancer cases with known 
mutations, which were used as positive controls, being detected by this method. SSCP 
analysis has been shown to detect >90% of single base substitutions in PCR fragments of 
200 bp and >80% in fragments of 400 bp in size (Suzuki et al., 1990; Gaidano et al., 
1991; Hayashi 1991; Hayashi and Yandell 1993). In this study the MCR was amplified by 
PCR in fragments ranging from 200 -300 bp (see section 3.3.4.1), therefore one may 
assume a detection rate of between 80 -90 %. Other than the size of the fragment, one 
must consider that the position of the mutation may influence whether the mutation is 
detected since sequences neighbouring the mutation have been shown to affect 
conformation and hence mobility within the gel (Sheffield et al., 1993; Glavac and Dean 
1993). Another consideration is the presence of normal DNA present within the extracted 
tumour DNA samples. In the case of normal DNA contamination, detection of the 
mutation within the tumour DNA will depend on the degree of separation that can be 
achieved between wildtype and mutant bands. Therefore, in this study samples were 
electrophoresed to the bottom of the gel to ensure maximum separation . 
Despite the possible false negatives that may occur using this method, I feel that from the 
absence of mutations within these 30 cases one can say that mutations within the MCR of 
the APC gene are rare. 
Immunohistochemistry was then used to detect mutations throughout the whole of the 
APC gene. Tissue sections were screened for full- length protein by 
immunohistochemistry using an antibody raised to the carboxyl terminus of the APC 
protein. This method also has its limitations with only mutations leading to the truncation 
of the APC protein being detectable. 
Immunohistochemical studies had previously reported that APC protein is ubiquitously 
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expressed within the lung (Midgley et al., 1997). The analysis of normal lung tissue in 
this study confirmed these results with a diffuse cytoplasmic staining pattern being noted 
in the majority of cells. Interestingly, previous reports have indicted that APC expression 
is restricted to regions where cell replication has ceased and terminal differentiation is 
established (Miyashiro et al., 1995; Midgley et al., 1997), and within the lung mitotic 
index is very low. Relatively high levels of protein were detected within the epithelial cells 
lining the bronchioles with accentuated staining at the lateral and apical surfaces. The 
lateral membranes are typically sites for adhesion junctions; junctions that are required 
not only for intercellular adhesion, but also for intercellular signalling and cell polarity. 
APC has been shown to co- localise with both a- and ß- catenin at the lateral membranes 
of colonic epithelium, therefore it would be interesting to confirm whether APC co- 
localises with these proteins within the lung. Apical staining has also been noted in 
colonic epithelium and co- localisation studies have shown the absence of a- and 
f3-catenin but co- localisation with actively growing microtubules, suggesting APC plays a 
role in cell migration (discussed in section 2.3.4). Again, studies are needed to explore 
the co- localisation of APC with other proteins within the lung. 
In some cells, the APC protein was detected in the nucleus. The nuclear localisation of 
APC has been previously reported using immunohistochemical techniques and confirmed 
by subfractionation experiments (Neufeld and White, 1997). Two putative nuclear 
localisation sequences have been identified within APC, these sequences begin at amino 
acids 1773 and 2054. The significance of nuclear localisation of APC has not been 
determined. 
Full length APC protein was detected in all NSCLC cases that exhibited LOH at 5q21. 
As seen in normal lung tissue, APC protein was detected in both the cytoplasm and in 
some cells within the nucleus. These results reveal that the remaining APC allele is 
producing full length APC protein. Thirty cases were analysed, therefore one could state 
that mutations that result in the production of a truncated APC protein are rare in ADC 
and SCC of the lung. The detection of full length APC in these cases also suggests that 
epigenetic factors do not lead to loss of APC expression in these cases. Hypermethylation 
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of the APC promoter has previously been reported to occur in patients with colorectal 
carcinoma and it is thought to be involved in the progression of colorectal cancer 
(Hiltunen et al., 1997). 
According to Knudson's hypothesis tumour suppressor genes act recessively at the 
cellular level so that both copies of the gene must be inactivated for growth suppressive 
functions to be eliminated (Knudson 1978). LOH has been detected in a proportion of 
NSCLC cases but in all cases showing LOH, no mutations have been detected within the 
remaining ARC allele and full length protein is produced. The methods used in this 
research have not eliminated the possibility of mutations outside the MCR (the remaining 
1/3 of the gene) that do not result in the production of a truncated protein product. These 
mutations may be detected by sequencing the remaining portion of the APC gene or 
alternatively carrying out protein function tests such as electrophoresis mobility shift 
assays (EMSAs) however, both these methods are expensive and time consuming. 
Considering all the results within this study and research that has examined the APC gene 
in other types of cancers, I feel that it is unlikely that the APC gene is inactivated in ADC 
and SCC of the lung. 
Failure to detect mutations within the APC gene may be a reflection of mutations in other 
components of the wnt signalling pathway. The presence of mutations within other 
components of the wnt signalling pathway may also explain the overexpression of two 
wnt target genes, CCND1 (Cyclin D1) and c-MYC, in NSCLC (see sections 1.3.1.2b, 
1.3.4.2, 2.6.10.5 and 2.6.10.6). Overexpression of cyclin Dl has been reported to occur 
in approximately 50% of NSCLC cases, of which amplification of the CCNDI accounts 
for around 2 -30% cases, whilst c-MYC is overexpressed in 50% of cases and has been 
shown to be amplified in 10% of these cases. In the remaining cases, the mechanism of 
gene deregulation is unknown. Both CCND1 and c MYC are also activated by pathways 
controlled by K -RAS (MEK/ERK and PI3K), therefore gene expression may be 
deregulated due to activating mutations in RAS or by deregulation of any other 
components of these pathways (see section 1.3.1.1). 
If mutations in components of the wnt signalling pathway, other than APC, are present 
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then subsequent mutations within the APC gene may not give rise to an increased growth 
advantage. This has been noted in colorectal cancer where cases have only been shown to 
harbour a mutation in the f- catenin gene or APC but never both genes (Sparks et al., 
1998). To date no publications have reported the status of the genes WNT, .frizzled, 
dishevelled, Axin or f -catenin in lung cancer. 
If the APC gene did play a role in lung carcinogenesis, one would expect individuals with 
germline mutations in the APC gene to be at increased risk of lung cancer, this is not the 
case. 
LOH at 5q21 is clearly a relatively common and relatively early event in pulmonary ADC 
and SCC tumourigenesis. The data presented here suggest that it is unlikely that APC 
plays a role in these cancers, therefore investigations should now concentrate on the 
identification and characterisation of other putative tumour suppressor genes within the 
5q21 region. The MCC gene was initially considered as a putative tumour suppressor 
gene although further studies have not supported this theory. Other known genes within 
this region include the FER, a tyrosine kinase homologous to SRC, TBI which shares 
similarities with ADP, ATP carrier/ translocator protein family, TB2 with no similarities 
with other known genes; and the SRPI9 gene (Joslyn et al., 1991; Kinzler et al., 1991; 
Kinzler et al 1991). These genes are currently being fully characterised, to date no 
mutations within these genes have been reported. 
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Chapter 4: K -RAS mutations in adenocarcinoma and alveolar 
atypical hyperplastic lesions of the lung 
4.1 Introduction 
Multiple genetic alterations are involved in lung tumourigenesis and include the activation 
of oncogenes and inactivation of tumour suppressor genes. The proto -oncogene K -RAS, 
which encodes a protein that functions as a guanosine diphosphate /guanosine 
triphosphate (GDP /GTP) regulated switch transducing extracellular stimuli to 
cytoplasmic signal transduction cascades, has been shown to be frequently mutated in 25- 
50% of NSCLC. 
The majority of publications report that K -RAS mutations occur primarily in the ADC 
histological subtype. The reported frequency varies between 20 -50% of tumours, whilst 
in SCC mutations are infrequent (0 -13% of cases) (Rodenhuis et al., 1988; Slebos et al., 
1989; Reynolds et al., 1991, Mitsudomi et al., 1991; Slebos et al., 1991a; Mills et al., 
1995; Keohavong et al., 1996; Graziano et al., 1999; Gealy et al., 1999). Conversely, 
some studies have reported that mutations occur in SCC with a similar frequency to ADC 
(Rosell et al., 1993; 1996; Gao et al., 1997). It is currently unclear why SCC are mutated 
in some cohorts but not others. Studies have analysed a full spectrum of SCC; different 
tumour stages and SCC obtained from smokers and non -smokers. One may suggest that 
variation in frequency may be a reflection of geographical differences. 
The majority of K -RAS mutations detected in pulmonary ADC and SCC occur at codon 
12 (80 %), with a lower frequency occurring at codons 13 and 61. Mutations at these sites 
result in the production of a protein product that remains in the active GTP -bound state, 
which results in constitutive signalling leading to an oncogenic phenotype (discussed in 
detail in section 1.3.1.1b). The majority of studies report that the mutation spectrum seen 
at codon 12 in ADC and SCC, consists of G -T transversions at position 1 (60% of cases), 
G -A transition at position 2 (20% of cases) and G -T transversion at position 2 (15% of 
cases) (Rodenhuis et al., 1987; Rodenhuis et al., 1988; Reynolds et al., 1992; Slebos and 
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Rodenhuis, 1992; Vachtenheim et al., 1995). One study does differ and reports that 
within SCC, the majority of mutations at codon 12 position 1 and position 3 are A -T 
transversion (Gao et al., 1997). The mutation spectrum seen in the K -RAS gene is 
consistent with the formation of DNA adducts at guanine or adenosine residues. These 
adducts can result from the carcinogenic properties of tobacco smoke, and as expected, 
the presence of K -RAS mutations has been significantly associated with tobacco exposure 
(see section 1.1.2; Rodenhuis et al., 1988; 1992; Slebos et al., 1991b; Westra et al., 
1993; Gealy et al., 1999 and references therein). Interestingly, a high frequency of G -A 
transitions has been noted in non - smokers with Goa and co- workers (1997) reporting 
that 11 /11 tumours exhibited this mutation. 
A spectrum of well -defined histological lesions have been associated with the 
development of several epithelial tumours. The analysis of these lesions have aided the 
understanding of the molecular events underlying tumourigenesis. In pulmonary SCC the 
progressive morphological changes include goblet cell hyperplasia, basal cell hyperplasia, 
squamous cell metaplasia, atypia or dysplasia, carcinoma in situ (CIS) and invasive cancer 
(Saccomanno et al., 1974). Wistuba and co- workers (1999) have recently carried out an 
extensive analysis of the molecular abnormalities involved in the pathogenesis of the 
multistep development of pulmonary SCC. The investigators showed that there was an 
increase in the frequency of LOH with increasing severity of histopathological changes. 
The earliest and most frequent regions of allelic loss occurred at 3p21, 3p22 -24 3p25 and 
9p21 (reviewed in section 1.3.3.2). Loss of heterozygosity within the p53 gene was seen 
dysplastic lesions and CIS, suggesting that p53 mutation is a relatively late event in SCC 
tumourigenesis (see section 1.3.2.2). 
Even though many genetic changes have been identified in pulmonary ADC, little is 
known about the chronology of their development due to the absence of well - 
characterised premalignant lesions. Furthermore, as ADC differs significantly in their 
histology, it is likely that different premalignant lesions exist. Areas of alveolar atypical 
hyperplasia (AAH) are considered as potential premalignant lesions of ADC. These 
lesions arise in the periphery of the lung (within the alveolar compartment) and are 
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characterised by progressive cellular atypia of type II pneumocytes (discussed in detail in 
section 1.2.2). 
Immunohistochemical analysis of AAH lesions have shown that these lesions overexpress 
the tyrosine kinase receptor ERB -B2 (see section 1.3.I.3.a), exhibit high levels of p53 
protein (see section 1.3.2.2) and carcinoembryonic antigen (Hamanda et al., 1995 
Nakanishi, 1990; Carey et al., 1992; Kitamura et al., 1996). Aberrant expression of these 
proteins has been reported in pulmonary ADC, therefore one may suggest that aberrant 
expression of these genes is an early event in ADC tumourigenesis with AAH lesions 
representing preneoplastic lesions. 
Oncogenic activation of K -RAS has been reported to be an early event in the multistep 
process of colorectal and pancreatic cancer. K -RAS mutations have been detected in 
colorectal adenomas and in aberrant crypt foci (possible precursor lesions of colorectal 
ADC) (Pretlow 1993; Yamashita et al., 1995; Losi et al., 1996; Shivapurkar et al., 
1997). Within the pancreas mutations have been detected in small pancreatic adenomas 
(Schaeffer 1994) and in atypical hyperplastic lesions and non -neoplastic (hyperplastic and 
metaplastic) ductal cells of patients with pancreatic cancer (Tabata et al., 1993; Sugio et 
al., 1997; Matsubayashi et al., 1999; Luttges et al., 1999). 
Investigations have shown that K -RAS codon 12 mutations are present in foci of non- 
invasive carcinoma (CIS) and are homogeneously distributed throughout small ADC (Li 
et al.,1994a; Sugio et al., 1994). These results suggest that K -RAS mutations are an early 
event occurring prior to clonal expansion of the tumour and due to the absence of 
recognised precursor lesions it has been difficult to further define the timing of K -RAS 
mutations. Investigations have reported that there is no significant difference between the 
frequency of K -RAS mutations and tumour stage, this suggests that K -RAS mutations are 
not associated with tumour progression (Sugio et al., 1992; Rodenhuis 1992). 
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4.2 Aims 
The research described in this chapter aimed to determine firstly, the frequency of K -RAS 
codon 12 mutation in a series of ADC cases. Secondly, determine whether there was an 
association between K -RAS mutations and the site of origin of the ADC; a comparison 
between parenchymal ADC arising in the distal parenchyma and bronchial ADC taking 
origin (like squamous and small cell tumours) from the bronchi. Finally, AAH lesions 
were examined to identify whether these lesion harbour K -RAS mutations. 
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4.3 Materials and methods 
4.3.1 Collection of ADC cases and extraction of DNA 
Collection of ADC and extraction of DNA has previously been described within section 
3.1.1. 
4.3.2 Identification of alveolar atypical hyperplastic lesions and extraction of DNA 
Alveolar atypical hyperplastic lesions were identified in non -tumour parenchyma from 
patients previously diagnosed with ADC and also patients who had been biopsied for 
possible lung cancer. Ten -micron sections from biopsies containing areas of AAI-I were 
cut and de- paraffinised as described in section 3.3.2. To visualise areas of AAH, sections 
were incubated for 3 minutes in eosin and then rinsed twice in sterile DDW. Slides were 
examined under the microscope and areas of AAH marked using a permanent marker pen 
on the underside of the slide. The area of AAH was isolated by gently scraping away 
surrounding tissue using a sterile scalpel then pipetting 2 -5µl of DNA lysis buffer 
(Appendix A) onto the lesion and drawing up the tissue in the buffer. The buffer was then 
pipetted into a sterile eppendorf containing 50 -100111 of lysis buffer, the volume 
dependent on the size of the lesion. Proteinase K (20 mg/ml) was then added to give a 
final concentration of 1.25µg/1.11. The samples were incubated for a period of 1 hour at 
55 °C, gently vortexed and incubated for a further 3 hours. Following incubation, sterile 
EDTA, pH 8.0 (100 mM stock solution) was added to a final concentration of 1 mM to 
prevent bacterial growth in the sample and prevent digestion of DNA by nucleases. DNA 
samples were aliquoted into 501.1l samples and frozen at -20°C until required. 
4.3.3 Detection of K -RAS codon 12 mutations 
PCR was applied to tumour and normal DNA extracted from ADC and AAH lesions to 
amplify a 157 base pair product encompassing codon 12 of the K -RAS gene. The primers 
used have been described previously and incorporate nucleotide changes designed 
to 
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create two BstN1 restriction endonuclease sites (CCTGG) in the amplified sequence 
(Jiang et al., 1989). 
Primer sequences were: 
Upstream 5' ACTGAATATAAACTTGTGGTAGTTGGACCT 3' within exon 1. 
Downstream primer 5' TCAAAGAATGGTCCTGGACC 3' within intron 1. 
The exon 1 primer was degenerate, substituting guanine with cytosine (bold) at the first 
position of codon 11, creating a BstN1 restriction endonuclease site (underlined) that 
extends into position 1 and 2 of codon 12 (outside the primer sequence). Mutations in 
either of the first two positions of codon 12 result in loss of this restriction site, and 
following incubation with BstN1 can be identified by gel electrophoresis. The 
downstream intron 1 primer contained a BstN1 restriction endonuclease site that acted as 
a cleavage control, cleaving a 14 bp fragment. Figure 13 shows the primer locations and 
the possible PCR product fragment sizes that are seen in the case of mutation or no 
mutation within position 1 or 2 of codon 12 following incubation with BstN1. 
PCR reactions were prepared as described in section 3.3.4.1, and subject to PCR cycling 
parameters of 94 °C for 5 minutes followed by 34 cycles of 94 °C for 30 seconds to 
denature, 55 °C for 30 seconds to anneal and 72 °C for 30 seconds for extension. A final 
extension time of 10 minutes at 72 °C was also included. To ensure amplification of the 
fragment had been successful, the PCR products were electrophoresed through a 3% 
agarose gel containing 0.1 mg/ml of ethidium bromide in 1 x TBE running buffer and 
visualised under ultra -violet light (described in section 3.3.4.2). Approximately 0.2µg of 
PCR product was added to 2 units of BstN1 restriction endonuclease and 211l of 
restriction enzyme buffer. The volume was adjusted using sterile DDW to 201.11. 
Endonuclease reaction mixes were incubated for 2 hours at 60 °C. Following incubation 
samples were again analysed on a 3% agarose gel and the size of the cleaved products 
determined using a molecular weight marker V (Boehringer Manheim). 
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Figure 13: Detection of mutations within codon 12 of the K -RAS gene 
A PCR fragment of 157 bp, which encompassed codon 12 of the K -RAS gene, was 
amplified using PCR. One primer was situated within exon 1 (upstream primer) and 
contained a degenerate nucleotide, a cytosine substitution corresponding to the first 
position of codon 11, thus creating a BstN1 recognition site (CCTGG) extending into 
position 1 and 2 of codon 12, nucleotide positions outside the primer sequence. The 
BstN1 restriction site is only present if there are no mutations within position 1 or 2 of 
codon 12. The down stream primer was situated within intron 1 and also contained a 
BstN1 site, this primer was not degenerate. Primers are shown in figure 13 (a). 
Following amplification of the 157 bp fragment, PCR products were incubated with the 
restriction endonuclease BstN1. In the case of no mutations within codon 12, the PCR 
product yielded 3 fragments of 114 bp, 29 bp and 14 bp, as exemplified in figure 13 (b). 
If a mutation was present in position 1 or 2 of codon 12 the upstream BstNl restriction 
site is lost (29 bp fragment) therefore yielding protein products of 143 bp and 14 bp, 
exemplified in figure 13 (c). 
Figure 13: Detection of mutations within codon 12 of the K -RAS gene 
A) Exon 1 primer 
GGA CCT 
GGA GCT GGT 
codon 10 11 12 
Cl 
Intron 1 primer 
29 bp 14bp 
114bp - 




B) DNA with no codon 12 mutation at position 1 or 
2 
C) DNA with a codon 12 mutation at position 1 or 2 
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4.3.4 Sequencing codon 12 of the K -RAS gene 
4.3.4.1 Pre s aration of sin le stranded PCR s roduct usin . D nabeads 
DNA from samples shown to carry codon 12 mutations by BstNJ restriction analysis 
were sequenced to determine nucleotide change. DNA samples were re- amplified by PCR 
using a biotinylated upstream primer 5' GACTGAATATAAACTTGTGG 3' (exon 1) 
and the previous described intron 1 downstream primer (see section 4.3.3) to amplify a 
145 bp fragment which encompassed codon 12. Conditions for PCR were as previously 
described in section 4.3.3. Single stranded DNA was isolated using streptavidin coated 
magnetic beads (Dynabeads M -280) and the Dynal magnetic particle concentrator (MPC) 
according to manufacturer's instructions (Dynal, UK). Briefly, 30p1 of Dynabeads were 
pipetted into a microfuge tube and washed three times with 3000 of PBS with 0.1% 
bovine serum albumin (BSA) using the Dynabeads MPC. For each wash, the beads were 
pipetted up and down in the wash solution and then the microfuge tube was placed in the 
MPC so that the coated magnetic beads were drawn to the wall of the microfuge. The 
wash solution was then removed by careful pipetting. The microfuge tube was removed 
from the MPC and the next wash carried out. Beads were equilibrated with 30011l of two 
times binding wash (Appendix A). Five hundred -one thousand nanograms of PCR 
product (determined by ethidium bromide plates, section 3.3.3) was added to the beads. 
The sample volume was adjusted to 1001a1 with sterile DDW and l00111 of 2 times binding 
wash was added. Samples were incubated at RT for 30 minutes to allow the biotinylated 
PCR products to bind to the streptavidin coated beads. Following incubation, the bound 
PCR product was denatured by washing the beads with 150µ1 of 0.15M NaOH, addition 
of a further 15041 of NaOH and incubation at RT for 15 minutes. The NaOH was 
removed and the remaining biotinylated single strand DNA was washed twice with 15011l 
PBS / 0.1% BSA, and twice with 150µl of sterile DDW. Finally, the beads were 
resuspended in 711l of sterile DDW and the DNA template stored at 4°C until required. 
4.3.4.2 Sequencing PCR product 
DNA sequencing was carried out using the Sequenase Version II sequencing 
kit 
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(Amersham, UK). The sequencing protocol is based on the chain termination method 
originally described by Sanger et al. (1977). To the 7p1 of template, previously prepared 
using Dynal beads, 1pl (1 pM) of sequencing primer, namely the downstream intron 1 
primer, and 2µ1 of reaction buffer (Appendix A) were added. Reactions were placed in a 
beaker of water at 65 °C, which was left to cool on the bench to 35 °C over a period of 15 
to 30 minutes. This allowed the primer to anneal to the template. Reactions were 
microfuged briefly and placed on ice. One hundred millimolar dithiothreitol, 2p1 labelling 
mix (Appendix A), SµCi (35S) dATP and 2µl (3.25 units) of Sequenase enzyme were 
added. Samples were vortexed gently and the labelling reaction was carried out at RT 
(24 -26 °C) for 5 minutes. Termination of the sequencing reaction was carried out by the 
addition of 3.5111 of labelling reaction to 2.5111 of each of the dideoxynucleotides (ddATP, 
ddCTP, ddGTP, ddTTP) which had been preheated to 37°C, the termination mix was 
incubated for 5 minutes at 37°C. Four microlitres of sequencing stop solution (Appendix 
A) was added to the termination reactions following the 5 minute incubation. 
Sample were denatured by incubating at 95 °C for 5 minutes then 41l of the sample was 
loaded onto a 6% polyacrylamide, 8M urea sequencing gel (Appendix A) which had been 
pre -run to warm to 50 °C. The samples were electrophoresed at 70 W, for 2 hours in 1 x 
TBE running buffer. Following electrophoresis gels were fixed for 5 minutes in 10% (v /v) 
methanol / 10% (v /v) glacial acetic acid. Fixed gels were blotted onto Whatman 3MM 
paper and dried under vacuum at 120 °C for 2 hours, then exposed to Kodak Biomax MR 
autoradiograph film at RT within a radioactive cassette for 2 -3 days. Autoradioactive film 
was subsequently developed using an automated film developer and the DNA sequence 
read. 
4.3.5 Conformation of G -T transversion at position 1 and 2 within an alveolar 
atypical hyperplastic lesion 
Following DNA sequencing one AAH lesion was shown to harbour two nucleotide 
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substitutions, G -T transversions at position 1 and 2 of codon 12 (see results section 
4.4.2). To determine whether this mutation was present within an individual cell or was a 
result of a mixed population of cells, the PCR product was cloned and then the cloned 
product sequenced. Cloning was carried out using the Original TA Cloning Kit 
(Invitrogen). This kit was selected as amplified PCR products could be cloned directly 
into the pCR2.1 plasmid vector supplied with the kit without need to enzymatically 
modify the PCR product. This is possible if Taq polymerase is used to amplify the 
product. Taq polymerase has a non template- dependent activity that adds a single 
deoxyadenosine (A) to the 3' ends of the PCR products, the linearised plasmid vector 
pCR2.1 has single 3' deoxythymidine (T) residues, which provide complementary ends 
for ligation with the PCR product. 
The pCR2.1 plasmid vector contains the ampicillin resistance gene, therefore following 
transformation into competent cells, in this case INVaF' cells which do not contain 
ampicillin resistance (Invitrogen), only cells which contain the vector will be able to grow 
when plated onto Luria -Bertani (LB) plates containing the antibiotic. The colonies on 
these plates may contain the vector with the PCR product inserted or may be self -ligated 
vector (see below). The colonies growing on the plates can be screened for these two 
possible outcomes using the chromogenic substrate 5-bromo-4- chloro -3- indolyl -ß -D- 
galactoside (X -gal). X -gal is cleaved by f3- galactosidase, releasing a blue indolyl 
derivative. The pCR2.1 vector harbours the ß- galactosidase gene, the gene promoter and 
lacZa fragment of the gene are situated 5' to the linearisation site (site of PCR product 
insertion) whilst the remaining proportion of the gene is situated 3' to the linearisation 
site. Following self -ligation, the fragments of the ß- galactosidase gene are within a 
continuous trans -position and the 3- galactosidase enzyme is produced. In this case, in the 
presence of X -gal, colonies turn blue. When the PCR product is inserted into the 
linearisation site, the ß- galactosidase gene is interrupted and ß- galactosidase is not 
produced, therefore no chromogenic substrate is produced in the presence of X -gal and 
colonies remain white. 
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4.3.5.1 Ligation reactions 
According to manufacture's directions, PCR products which were less than 1 day old (as 
single 3'A- overhangs on the PCR product degrade with time) were used to set up 
ligation reactions. Ligation reactions contained PCR product and vector at a molar ratio 
of 1:1, see section 5.3.1.1.e for formula. Two nanograms of PCR product (as determined 
by ethidium bromide plates, see section 3.3.3) was mixed with 50 ng of pCR2.1 vector 
and 1µl of 10x ligation buffer (Appendix A) and 411 T4 DNA ligase (4.0 Weiss units) 
was added. The volume of the ligation mix was adjusted to 10111 by the addition of sterile 
DDW. 
A control ligation reaction was also prepared to detect false positive colonies. As seen 
with the 3' A overhangs present on PCR products the 3'T- overhangs present on the 
vector may also be lost, this has been shown to be a result of time or due to incorrect 
storage or repeated freezing and thawing. Loss of the 3'T- overhangs can result in blunt - 
ended self -ligation of the vector. This can cause a frameshift of the lacZ gene, which 
prevents or reduces ß- galactosidase production, therefore white or light blue colonies 
that do not contain the insert may be detected. To control for this event, a ligation 
reaction was set up that contained no PCR product. 
Ligation reactions were incubated at 14°C overnight. Ligations were then stored at 
-20°C prior to transformation. 
4.3.5.2 Transformation into INVaF' competent cells 
Competent cells were removed from -70 °C and thawed on ice. Fifty microlitres of cells 
were placed in a pre -chilled 15 ml Falcon tubes and ß- mercaptoethanol (supplied with the 
cells) added to give a final concentration of 25 mM. Cells were incubated for 10 minutes 
on ice then 41l of ligation mix added and the tubes incubated on ice for a further 30 
minutes. Tubes were placed in a 42 °C water bath for 45 seconds and then immediately 
placed on ice for 2 minutes. Nine hundred microlitres of preheated (42 °C) SOC medium 
(Appendix A) was added and the tubes incubated at 37°C for 1 hour shaking in an orbital 
shaker at 225 rpm. 
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One hundred microlitres and 200111 of each transformation was spread onto separate LB 
agar plates containing X -Gal and 501..tg/ml of ampicillin (see Appendix A). The 
transformation solution was left to absorb into the agar plate for approximately 5 minutes 
and then plates were inverted and placed at 37°C for at least 18 hours. Plates were then 
placed at 4°C for 2 -3 hours to allow development of the colony colour. 
4.3.5.3 Bacterial cultures and plasmid isolation 
Individual white colonies (clones) from the agar plates were transferred into 3 mis of LB 
broth supplemented with 5011g/ml ampicillin (Appendix A) and incubated shaking at 225 
rpm at 37 °C overnight. Plasmid DNA was purified using the WizardTM plus Minipreps 
DNA Purification System (Promega UK). The protocol was as follows; 1.5 ml of 
bacterial culture was centrifuged at 13,000 rpm to pellet the cells. The supernatant was 
discarded and the cell pellet resuspended in 2004l of cell resuspension solution (Appendix 
A) and transferred into a 1.5 ml microfuge tube. Two hundred microlitres of cell lysis 
solution (Appendix A) was added and the suspension mixed by gently inverting the tube. 
Two hundred microlitres of neutralisation solution (Appendix A) was added and the 
solution mixed by inverting the tube. The tubes were microfuged at 13,000 rpm for 5 
minutes to pellet the cell debris and protein. The cell lysate was then loaded onto a 
minicolumn/syringe assembly containing 1 ml of resin. The lysate was drawn down the 
column via vacuum and the column washed with column wash solution (Appendix A). 
Plasmid DNA was eluted from the minicolumn by the addition of 5011l of sterile DDW, 
preheated to 65 °C, and microfuging at 13,000 rpm for 20 seconds. Plasmid DNA was 
collected in a sterile 1.5 ml microfuge tube and stored at 4°C. 
4.3.5.4 Sequencing plasmid DNA 
Plasmid DNA was sequenced using the T7 Sequenase quick denature plasmid sequencing 
kit (Amersham Life Sciences). The sequencing protocol is based on the chain termination 
method originally described by Sanger et al. (1977) and has been previously described 
in 
section 4.3.3. The production of single stranded DNA differs in this protocol, in 
the 
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previous case Dynal beads were used. To obtain single stranded DNA, NaOH was added 
to 0.5 -3µg of plasmid DNA to give a concentration of 0.2M, the reaction mix was 
adjusted to 8µ1 with the addition of sterile DDW. Two picomole of sequencing primer 
was added to each sample and left to anneal to the template DNA for 10 minutes at 37 °C, 
then placed on ice. The sample was neutralised by the addition of HC1 to a final 
concentration of 0.2M. Two microlitres of plasmid reaction buffer (Appendix A) was 
added and samples left to anneal at 37 °C for a further 10 minutes then chilled on ice. One 
hundred millimoles of dithiothreitol, labelling mix (Appendix A), 5p.Ci (35S) dATP and 
Sequenase enzyme were added. Samples were vortexed gently and labelled reactions 
were carried out at RT for 5 minutes. Three and a half microlitres of the labelling reaction 
was then added to 2.51A1 of each of the dideoxynucleotides at 37 °C for 5 minutes. The 
reaction was terminated by addition of 411l of sequencing stop solution (Appendix A). 
Samples were loaded onto a DNA sequencing gel and electrophoresed using conditions 
described in section 4.3.4.2. Sequencing gels were subsequently dried and exposed to x- 
autoradiograph film as described in section 4.3.4.2. 
159 
4.4 Results 
4.4.1 Mutations at codon 12 of the K -RAS gene in adenocarcinomas 
Mutations in codon 12 of the K -RAS oncogene were detected using a combination of 
PCR amplification and restriction endonuclease cleavage analysis (Jiang et al., 1989). 
This method is highly specific, with loss of a BstNJ restriction endonuclease recognition 
site being diagnostic for the presence of mutations at position 1 or 2 of codon 12. An 
additional BstNJ restriction endonuclease recognition site offers a control for the 
restriction endonuclease cleavage . 
Sixty -five ADC samples were assayed for the presence of mutations in codon 12 (Data 
are shown in Appendix D). Mutations in codon 12 were detected in 16 cases (25 %). 
There was no statistically significant difference between the presence of K -RAS mutation 
and tumour stage, Fisher Exact Test p >0.2 in all cases (see table 8a). Examples of normal 
and tumour DNA pairs analysed for mutations in codon 12 of the K -RAS gene by 
restriction endonuclease cleavage are shown in figure 14 (a). 
DNA from tumours showing mutation were sequenced. Nine tumours harboured G -T 
transversions at position 1 of codon 12, 6 tumours G -T transversions at position 2 and 
one tumour a G -A transition at position 2. Sequencing gels from two cases with 
mutations at codon 12 are shown in figure 14 (b)(c). 
Sub -classification of ADC into bronchial and parenchymal origin revealed that 9/26 
(35 %) of parenchymal ADC contained mutations in position 1 or 2 of codon 12 whilst 
0/12 bronchial ADC were mutated at these positions, see table 8b. This difference was 
shown to be statistically significant by Fisher's exact test (two- tailed test; p= 0.0355). 
There was no statistically significant difference between the presence of K -RAS codon 12 
mutation and tumour stage in parenchymal subtypes, as determined by Fisher's exact test 
(two -tailed test;p >0.1). 
Twenty seven of the 65 ADC cases screened for mutations could not be classified into 
either of the two subgroups, of these 6 (22 %) contained a mutation at codon 12. 
160 
Table 8a: Analysis of K -RAS codon 12 mutations with tumour stage in ADC 
Tumour Stage No. of tumours with K -RAS 
mutations /total number of 
tumours 
Stage 1 11/38 
Stage II 3/15 
Stage 111 2/12 
Statistical analysis shows there is no statistically significant difference between the 
presence of K -RAS codon 12 mutation and different tumour stages as determined by 
Fisher's exact test (two -tailed; p >0.2 in all cases). 
Table 8b: Analysis of the presence of K -RAS codon 12 mutations in relation to origin of 
ADC 
Origin Mutation No mutation 
Bronchial 0 12 
parenchymal 9 17 
Statistical analysis shows that there is a statistically significant difference between the 
presence of K -RAS codon 12 mutation and the origin of the ADC. Fisher's exact test, 
two -tailed analysis, p= 0.0355. 
Table 8c: Analysis of K -RAS codon 12 mutation and tumour stage in parenchymal ADC 
Tumour stage No. of parenchymal ADC with K -RAS 
mutations/ total number of parenchymal 
ADC 
Stage I 7/14 
Stage II 2/9 
Stage III 1/3 
There was no statistically significant difference between the presence of K -RAS codon 12 
mutation with different tumour stages in the parenchymal subtypes, as determined by 
exact test (two -tailed test; p >0.1 in all cases). 
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Figure 14: Mutational analysis of K -RAS codon 12 
Figure 14 a) Paired tumour (T) and normal (N) DNA samples were subjected to PCR to 
amplify a fragment of the K -RAS gene encompassing codon 12. PCR products were 
incubated with the restriction endonuclease BstNI and then electrophoresed through a 
3% agarose gel. PCR product not subjected to restriction endonuclease cleavage and 
molecular weight markers were also loaded onto the gel, lanes U and M respectively. 
Case I is an example of an ADC which harbours a mutation at position 1 or 2 of codon 
12. Restriction endonuclease analysis of the amplified tumour DNA results in cleavage of 
the 157 bp PCR product to yield 143 bp and 14 bp fragments (the latter fragment is not 
visible on this gel). 
The PCR product amplified from normal DNA of this patient is cleaved to give a 
114 bp, 29 bp and 14 bp fragments (the latter two fragments are not visible on this gel), a 
restriction pattern indicative of no mutations at positions 1 or 2 of codon 12. 
Within the tumour sample a faint band is also detected at 114 bp and is a result of 
incomplete cleavage or contaminating normal DNA. 
In case 2, following incubation with BstNl, the PCR products of both normal and tumour 
DNA are cleaved to give 114 bp, 29 bp and 14 bp (the latter two fragments are not 
detected on this gel). This restriction pattern is indicative of no mutations at position 1 or 
2 in codon 12. 
Figure 14 b) and c) Following the identification of mutations within codon 12, through 
the use of PCR and restriction endonuclease cleavage, DNA from cases shown to be 
mutated were amplified by PCR and the product sequenced. Figure 14b is an example of 
an ADC, which harbours a G -T transversion at position 1 of codon 12. Figure 14c shows 
an ADC case with a G -T transversion at position 2 of codon 12. In both examples, the 
normal DNA base (G) can be seen as a faint band on the gel. This is a result of 
contaminating normal DNA. 
Figure 14: Mutational analysis of codon 12 of the K -RAS gene 
a) 
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4.4.2 Mutations at codon 12 of the K -RAS gene in alveolar atypical hyperplastic 
lesions 
Alveolar atypical hyperplastic lesions were identified in parenchymal tissue of patients 
previously diagnosed with ADC and also patients who had been biopsied for possible 
lung cancer. Foci of AAH were available from 16 patients yielding a total of 32 lesions, 
with between one and six distinct foci per case. Analysis of each case is summarised in 
table 9. 
Five atypical hyperplastic lesions were shown to harbour mutations within position 1 or 2 
of codon 12. In case 1, two out of the 5 lesions examined contained codon 12 mutations. 
One lesion harboured a G -A transition at position 1, whilst within the second lesion two 
nucleotide changes were noted; a G -T transversion at position 1 and a G -T transversion 
at position 2. As there have been no reports of two nucleotide changes occurring within 
K -RAS codon 12, the DNA of this case was cloned to rule out the possibility that this was 
a result of a mixed population of tumour cells. Cloning confirmed that within a single 
strand of DNA two nucleotide changes had occurred. This case also contained an ADC, 
no mutations were detected in this tumour. 
Case 7, consisted of 6 lesions, again this case contained an ADC. Mutation was only 
detected in 1 lesion, this was a G -T transversion at position 2. No mutation was detected 
within the corresponding ADC. 
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Table 9:K -RAS mutational analysis in ADC and alveolar atypical hyperplastic lesions. 
_Cas e NQ 
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G-A transition pos.l 


































































































13 AAH + G-T transversion pos.1 
14 AMI - - 
15 AMI + G-T transversion pos. 1 
16 AMI - - 




A retrospective analysis of a series of pulmonary ADC cases revealed that 25% (16/65) 
of tumours harboured a mutation at either position 1 or 2 of codon 12 of the K -RAS 
gene. This mutation frequency is similar to previous published studies, which have 
reported a mutation frequency of between 20 -50% (see section 1.3.1.1g and 4.1). It is 
currently unclear as to why the reported frequency of mutation varies so significantly 
between cohorts. Mutations within the K -RAS gene is thought to be a relatively early 
event, occurring prior to clonal expansion and the presence of K -RAS mutation does not 
increase significantly with tumour stage (Sugio et al., 1992; Rodenhuis et al., 1992; Li et 
al., 1994a; Sugio et al., 1994). It is therefore unlikely that the number of different stage 
tumours within each cohort is a governing factor in frequency variation. Analysis of this 
series of ADC also revealed no association with tumour stage (see Table 8a, Fisher's 
exact test, two -tailed test; p >0.2 in all cases). 
Ninety -four percent (15/16) of mutations were G -T transversions, 56% (9/16) occurred 
at position 1 of codon 12 and 38% (6/16) at position 2. The only other mutation to be 
detected was a single G -A transition at position 2 (frequency of 6 %). G -T transversion 
have been reported by numerous studies to be the most common mutation within the K- 
RAS gene in pulmonary ADC, occurring in approximately 80% of cases (see section 4.1). 
Guanine to thymine transversions are typical of the production of DNA adducts at 
guanine residues. The formation of DNA adducts results in the failure of the DNA 
polymerases to identify the base and during DNA replication, in the majority of cases, the 
guanine is substituted for a thymine residue in the daughter strand (see section 1.1.2, 
1.3.1.1.g and 2.4). The production of DNA adducts at guanine residues has been shown 
to be associated with the carcinogens derived from cigarette smoking (see section 1.1.2). 
In accordance with this, numerous studies have reported that G -T transversions in K -RAS 
occur more frequently in pulmonary ADC of smokers than non -smokers (Rodenhuis et 
al., 1988; 1992; Slebos et al., 1991; Reynolds et al., 1991; Westra et al., 1993; Gealy et 
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al., 1999 and references therein). Furthermore, G -T transversions are commonly seen in 
pulmonary ADC arising in mice which have been treated with constituents of tobacco 
smoke (You et al., 1989; Belinsky et al., 1997; Nesnow et al., 1998). Information 
regarding the patients smoking habits was not available for this study, but it is likely that 
ADC from non -smokers were included. If this is the case, this study would suggest that 
G -T transversions are also a common occurrence in ADC of non -smokers. The presence 
of G -T transversions in non -smokers may be a result of passive smoking or implicate 
other environmental pollutants that result in guanine DNA adducts. 
The subclassification of ADC into bronchial and parenchymal origin showed that 
mutations were significantly associated with ADC of parenchymal origin, as determined 
by Fisher's exact test (two -tailed test; p= 0.0335) and that within the parenchymal 
subgroup there was no association between K -RAS mutation and tumour stage (Fisher's 
exact test, two -tailed analysis; p >0.1). This is the first reported genetic difference 
between these two histological subtypes and suggests that different genetic pathways may 
be involved in the development of these tumours. This may not be entirely unexpected as 
investigations have already shown that the genetic events involved in tumourigenesis of 
different histological types of pulmonary cancer vary. For example SCC and ADC exhibit 
different allelotypes, the K -RAS oncogene is frequently mutated in ADC but is infrequent 
in SCC, and the aberrant expression of several oncogenes and tumour suppressor genes 
are often reported to be associated more frequently with either of these subtypes 
(reviewed in section 1.3). Parenchymal and bronchial ADC are histologically different, 
with parenchymal ADC containing cells characteristic of goblet cells, Clara cells, type II 
pneumocytes and ciliated bronchiolar lining cells and occasionally neuroendocrine cells 
whilst bronchial ADC contain bronchial epithelial cells or bronchi glands (see section 
1.2.1.2). Bronchial ADC are also reported to be more aggressive than pulmonary ADC 
(Edwards 1987) suggesting that specific mutations may occur in bronchial ADC which 
promote metastatic spread. It is interesting to note that like bronchial ADC, SCC and 
SCLC, that also arise in the central portion of the lung and are associated with smoking, 
are not frequently characterised as having K-RAS mutations. 
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In this study, I have screened positions 1 and 2 of codon 12 of the K -RAS gene in a series 
of ADC to determine the frequency of mutation and have shown that mutations are 
associated with parenchymal but not bronchial ADC subtypes. This however does not 
rule out the possibility that mutations are not present at other sites within the gene. 
Mutations in the K -RAS gene have also been reported to occur at codons 13 and 61, with 
the frequency of mutation at either of these two sites reported to be less than 20% (see 
sections 1.3.1.1g). It is possible that mutations are present at either of these codons or in 
fact at other sites that may result in the oncogenic activation of the K -RAS gene 
(discussed in section 1.3.1.1b). Further mutation analysis could be carried out and initial 
analysis should focus on codons 13 and 61, and may be extended to screening all exons 
of the genes using a relatively quick and simple method such as SSCP analysis. 
Mutations within the K -RAS gene are thought to be an early event in the tumourigenesis 
of pulmonary ADC, however, as preneoplastic lesion have not been identified, it is 
unclear at exactly what stage these mutations occur. There is evidence to suggest that 
alveolar atypical hyperplastic lesion is precursor lesion to parenchymal ADC (see section 
1.2.2.2). Unlike areas of alveolar hyperplasia, which are identified as areas of 
proliferation of type 2 pneumocytes forming as a response to lung injury or part of the 
reparative process of the lung, AAH lesions consist of hyperplastic type II pneumocytes 
which exhibit atypical cytological features. These lesions are identified in the absence of 
any inflammatory reaction and tend to be incidental findings following lung resections 
from patients with ADC. Reports suggest these lesions occur in 5 -25% of primary ADC 
cases, areas of AAH have also been detected in biopsies taken from patients without 
ADC (Miller, 1990, Weng et al., 1992; Carey et al., 1992). 
In pulmonary ADC, p53 gene mutations are thought to occur prior to clonal expansion of 
the tumour, therefore if alveolar atypical hyperplastic lesions are precursor lesions to 
ADC one may expect p53 mutations to be present. The p53 protein product has been 
detected in 5 -58% of lesions, this figure shows significant variation which is thought to 
be a result of methodology and antibody used within each study (Kerr et al 1994; 
Kitamura et al., 1996, Cagle et al., 1996; Slebos et al., 1998).Slebos and co- workers 
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(1998) have recently reported that p53 gene mutations are an extremely rare occurrence 
in AAH and that accumulation of p53 is significantly associated with the grade of the 
lesion, i.e. low- grade, high grade or AAH -like carcinoma, as defined in section 1.2.2.2. In 
this study Slebos and co- workers carried out immunohistochemical analysis on 37 AAH 
lesions and paired overt ADC. DNA from all lesions and tumours exhibiting p53 protein 
accumulation were sequenced, sequencing was limited to the region within exons 5 to 
exon 9, a region previously shown to encompass the majority of mutations found in 
several types of cancer (see section 1.3.2.2). Four AAH lesions, identified in 4 patients 
were shown to exhibit p53 accumulation. Interestingly, these lesions had been graded as 
AAH -like carcinoma, which may represent a stage of transition from benign to 
malignant. It is interesting to note that in SCC, mutations within the p53 gene are also 
common in the late pre- invasive stage of SCC formation and are thought to be important 
in driving progression of severe bronchial dysplasia to an invasive SCC (see section 
1.3.2.2). In two of the cases shown to harbour an AAH lesion with p53 protein 
accumulation, protein accumulation was also detected within the carcinoma. DNA 
sequence analysis showed that only one of the 4 lesions harboured a mutation within the 
analysed region of p53. In this case, the p53 protein has also been detected within the 
carcinoma. The AHH lesion and the carcinoma both harboured missense mutations within 
exon 7, however, the mutation within the AAH lesion was an A -G transition at codon 
239 and in the carcinoma a C -T transversion at position 250. This result makes it unlikely 
that AAH lesions are a result of metastatic spread and suggests that AAH lesions may 
result from field cancerization of the bronchial epithelium (discussed in detail below). 
In this study, I aimed to determine whether areas of AAH, putative preneoplastic lesions 
of parenchymal ADC, contained mutations within codon 12 of the K -RAS gene. Previous 
investigations suggest that K -RAS mutations are an early event in ADC tumourigenesis, 
occurring prior to clonal expansion of the tumour, therefore identification of mutations 
within the K -RAS gene in areas of AAH would add molecular evidence to support their 
role as preneoplastic lesions. 
DNA was extracted from 32 lesions identified in sixteen patients, 10 of these patients 
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harboured an ADC, and DNA was also extracted from the tumour. Mutations within 
codon 12 were detected in 5 AAH lesions (16 %). Two positive lesions were identified in 
case 1, which contained 5 lesions plus an ADC. No mutations were detected in the ADC 
and different mutations were detected within the two AAH lesions (G -A transition pos. l 
and a G -T transversion at position 1 and 2). In case 7, one out of 6 AAH lesions 
harboured a K -RAS codon 12 mutation, no mutation was detected in the corresponding 
ADC. In cases 13 and 15, which consisted of only one lesion and no ADC, mutations 
were also detected. 
From the different genetic backgrounds, one may argue that AAH lesions are independent 
entities, independent of ADC and of other lesions, and may result due to a phenomenon 
known as field carcinogenesis. The field cancerization effect was originally described by 
Slaughter and colleges over 40 years ago, who reported the development of multiple 
primary head and neck cancers in heavy smokers (Slaughter et al., 1953). Two distinct 
theories have been proposed to explain the occurrence of multiple primary and secondary 
tumours and preneoplastic lesions in the aerodigestive epithelium, however, from current 
data it is unclear which mechanism is involved and it is possible that a combination of 
both theoretical mechanisms are responsible for lung carcinogenesis. The monoclonal 
neoplasia theory proposes that the progeny of a single transformed cell can spread to 
form multiple pre- invasive lesions and tumours. Evidence for this mechanism would 
include the occurrence of a common mutation within multiple lesions. In support of this 
phenomenon, analysis of multifocal lesions often present in patients with oesophageal 
ADC (Barrett's oesophagus) revealed that ADC and synchronous premalignant lesions 
frequently harboured the same genetic aberrations (Gleeson et al., 1998). Within the 
lung, identical abnormalities have been found in SCC and adjacent non -malignant 
epithelium, these mutations include LOH of chromosome 3p (Sundaresan et al., 1992; 
Hung et al., 1995; Chung et al., 1995; Kohno et al., 1999), and 9p (Kishimoto et al., 
1995; Kohono et al., 1999) and point mutations in the p53 tumour suppressor gene 
(Sundaresan et al., 1992; Sozzi et al., 1992; Mao et al., 1994; Chung et al., 1995; 
Franklin et al., 1997). From the analysis of AAH lesions within this study, it is difficult to 
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determine whether AAH lesions are a result of monoclonal neoplasia. Firstly, in several 
cases K -RAS mutations were only present in one or two lesions. However, one may 
argue that lesions are a result of spread of progeny from a single progenitor cell and that 
mutation of the K -RAS gene is an additional genetic event, this phenomenon has been 
referred to as subclonal drift (Nowell, 1976). 
The second theory suggests that continued exposure of the aerodigestive epithelium to 
carcinogens predispose the entire epithelium to develop multiple, independent pre - 
invasive lesions that can develop into tumours or which may regress, the field 
cancerization theory. This theory has been supported by numerous studies that have 
analysed mutations within the p53 gene in multiple pre- invasive lesions and multiple 
primary tumours of the lung and head and neck. These studies revealed that lesions and 
tumours harbour different genetic mutations (Nees et al., 1993; Chung et al., 1993; 
Noguchi et al., 1993; Sozzi et al., 1995; Lavieille et al., 1998). Within my study, case 1 
was shown to harbour two lesions with different K -RAS mutations, this may support the 
field cancerization theory, although it does not rule out the possibility of subclonal drift. 
The mutation spectrum seen within AAH lesions consisted of 7 cases of G -T 
transversions and only one lesion with G -A transition, this spectrum is consistent with 
mutations detected in parenchymal ADC further strengthening the proposal that AAH 
lesions are precursors of parenchymal ADC. The high frequency of G -T transversions is 
also indicative of exposure to cigarette smoke. An unusual double mutation was noted in 
one lesion, a G -T transversion at position 1 and 2 of codon 12. Initially it was not clear 
whether different genetic populations were present within the lesion, some cells 
harbouring a mutation at position 1 and some at position 2. To rule out this possibility, 
the DNA from the lesion was cloned and the result revealed that mutations at position 1 
and position 2 existed within the same DNA strand. As far as I am aware, there are no 
other reports of two mutations occurring within the K -RAS gene. Because of the nature 
of the oncogenic activation of K -RAS, i.e. one mutation with codon 12 leads to 
constitutive activation of the K -RAS gene, and the rarity of such a double mutation, one 
may assume that the presence of two mutations does not give the cell a proliferative 
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advantage. 
Since the initiation of this work two studies have reported the presence of K -RAS 
mutations within areas of AAH ( Ohshima et al., 1994; Westra el al., 1996). Ohshima and 
co- worker analysed 20 AAH lesions from 6 patients, all of which had undergone a lung 
resection for ADC. It is likely that in this study lesions identified as areas of AAH were in 
fact a result of spread of the ADC since it was stated that lesions were generally 
contiguous with the carcinoma. K -RAS mutations were detected in 9 AAH lesions from 2 
patients (8 from one patient and 1 from the other patient). These investigators did not 
identify what mutation had occurred at codon 12. 
A second study, by Westra and co- workers, analysed 41 solitary lesions identified in 18 
patients for mutations at codon 12. Sixteen lesions (37 %) from 11 patients harboured a 
mutation, this frequency of mutation is similar to that reported to occur in ADC but is 
much higher than the frequency detected within my study (16 %). The mutation spectrum 
consisted of 62% G -T transversions, 24% G -A transitions and 12% G -C transversions. 
Different K -RAS mutations were detected in AAH lesions within one patient, this may 
support the theory of field cancerization. This case also confirmed that it is unlikely that 
AAH lesions are a result of metastatic spread since different K -RAS mutations were 
detected in AAH lesions compared to a synchronous ADC (Westra et al., 1996). 
Included in this cohort were 2 patients with LCC, one with a SCC and 1 with a carcinoid 
tumour, of these cases no mutations were detected within tumour tissue. One LCC 
harboured a G -A transition at position 2 within the only identified AAH lesion, and a 
G -T transversion was identified in one of 2 lesions present within the patient with SCC. 
AAH lesions and ADC analysed in the study by Westra and co- workers were 
subsequently classified according to the degree of cellular atypia, grades were low grade 
AAH, high -grade AAH, AAH -like carcinoma and carcinoma (described in section 
1.2.2.2). Statistical analysis revealed that there was no significant difference in the 
frequency of K -RAS mutation with increasing lesion grade. This suggests, assuming that 
AAH lesions are true preneoplastic lesions, mutations within K -RAS gene are a very early 
event in the development of parenchymal ADC. 
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A recent study has reported LOH at 3p and 9p in AAH lesions (Kohno et al., 1999),In 
this study Kohono and co- workers analysed 20 AAH lesions identified in 26 patients, all 
of which harboured a synchronous ADC. Mutational analysis of the p53 gene was also 
carried out. Genetic events were detected in three cases. Two cases exhibited LOH at 3p, 
in the single identified AAH lesion, LOH was present in the corresponding ADC in both 
cases. In the third case, consisting of an ADC and a single AAH lesion, a mutation within 
exon 8 of p53 was detected in both the AAH lesion and ADC, the mutational event was 
not identified. This case also exhibited LOH at 9p in the AAH and ADC. The frequency 
of allelic loss at 3p and 9p was extremely low, 10% and 5% of AAH lesions respectively, 
compared to that seen in ADC 40% and 36 %. This may suggest that LOH at these sites is 
a relatively late event in ADC tumourigenesis, however as the lesions within this study 
were not graded no conclusion can be made. 
Previous studies have determined that mutations within the p.5.3 gene are a relatively late 
event in the pathway of AAH through to overt ADC. To determine whether other key 
genes in cell cycle regulation were disrupted in AAH lesions Kurasono and co- workers 
(1998) investigated Cyclin D1, RB and p16. Cell cycle regulation is reviewed in figure 3. 
Investigations revealed that cyclin D1 was overexpressed in 47% of low grade AAH, 
89% of high grade AAH, 28% CIS and 35% of overt ADC. These results suggested that 
overexpression of cyclin D1 is a common occurrence in AAH. From these data, one may 
hypothesise that if AAI-I lesions are precursor lesions of ADC then cyclin DI 
overexpression is not required for the maintenance of the malignant phenotype. If this 
was the case then one may expect to see a disruption in a component of the RB pathway 
downstream of cyclin DI e.g. actually within the RB gene or within a cyclin dependent 
kinase inhibitor such as p16. In this study analysis of lesions for the RB protein by 
immunohistochemistry revealed that loss of expression is associated with the progression 
of CIS to overt ADC and may therefore reflect mutations within the gene. Loss of p16 
expression was shown to be infrequent in AAH lesions, CIS and overt ADC, results 
that 
support previous findings that loss of p16 is associated with metastatic spread (Okamoto 
et al., 1995; discussed in section 1.3.2.3). An alternatively theory would be that 
increased 
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levels of cyclin D1 may be a result of growth arresting conditions rather than growth 
promoting conditions, since p53 has been shown to induce cyclin DI synthesis through 
p21 (Chen et al., 1995). This theory is however not supported by immunohistochemical 
studies. 
Due to the absence of identifiable preneoplastic lesions in pulmonary ADC the genetic 
pathway of pulmonary ADC was unclear. The proposal that areas of AAH are 
preneoplastic lesions of parenchymal ADC has changed this and since the completion of 
my work, the genetic profile of AAH lesions has been extensively analysed. From these 
studies, one may propose a genetic pathway for parenchymal ADC. Research has shown 
that the oncogenic activation of K -RAS and overexpression of cyclin D1 and ERB -B2 are 
early events in ADC tumourigenesis, occurring in low grade AAH lesions. Inactivation of 
the RB gene is thought to occur at a CIS stage whilst mutations within the p53 gene and 
allelic loss at 3p and 9p are late events occurring in overt ADC. Loss of p16 expression is 
associated with metastatic spread. 
Despite the identification of known tumour markers in AAH lesions, one must be 
cautious and cannot still with certainty say that AAH lesions are preneoplastic lesions. 
The adenoma -carcinoma sequence seen in colorectal cancer has been extensively analysed 
and evidence suggests that both the accumulation of mutations and the order are 
important in tumourigenesis (Fearon and Vogelstein 1990; Kinzler and Vogelstein 1996). 
Mutations within the K -RAS gene have been reported to occur in normal colonic 
epithelium and in foci of hyperproliferating cells that do not lead to colorectal neoplasia 
(Pretlow et al., 1993; Jen et al., 1994), subsequently Kinzler and Vogelstein proposed the 
theory of gatekeeper genes. A gatekeeper gene may be described as a gene responsible 
for maintaining constant cell number in renewing cell populations and ensuring the cell 
responds to situations requiring net cell growth. Mutation in the gatekeeper gene leads to 
an imbalance of cell proliferation over cell death. Prior to mutations in the gatekeeper 
gene, mutations in other genes do not lead to sustainable growth perpetration. In the case 
of colorectal cancer, the gatekeeper gene is considered to be the APC gene. Therefore, in 
the proposed AAH- parenchymal ADC sequence one may question whether K -RAS 
is a 
173 
gatekeeper gene or if mutation within another oncogene or a suppressor gene is required 
before the presence of K -RAS mutations can drive tumourigenesis. Unlike in colorectal 
cancer, where inactivation of the APC gene occurs in >98% of carcinomas (Nishisho et 
al., 1991; Groden el al., 1991), K -RAS is oncogenically activated in approximately one 
third of parenchymal ADC, this suggests that K -RAS is not the gatekeeper gene. 
The question of whether these lesions are neoplastic or reactive proliferation of non - 
neoplastic cells is still unclear despite mounting genetic and morphological studies. 
Without longitudinal studies to assess the biological and clinical progression of AAH no 
conclusion can be made. 
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5. A transgeneic murine model for the analysis of APC function 
5.1 Introduction 
The APC gene is located on human chromosome 5q21. Germline mutations in the APC 
gene characterise the Mendelian dominant inherited disorder, familial adenomatous 
polyposis coli (FAP) ( Bodmer et al, 1987; Leppert et al., 1987; Dunlop et al., 1990; 
Kinzler et al., 1991b). FAP patients develop numerous adenomas within the large 
intestine, some of which ultimately progress to carcinoma. FAP patients are at increased 
risk of cancers of the brain, thyroid, bone and focal proliferative lesions of the connective 
tissue "desmoid tumours ", suggesting that the APC gene may have a more general role in 
neoplasia. 
In the majority of familial and sporadic colorectal cancer cases both APC alleles are 
shown to be inactivated either by gene mutation alone or by loss of one allele and 
mutation in the remaining allele (Nishisho et al., 1991; Groden et al., 1991). Biallelic 
inactivation of the APC gene has also been reported in sporadic gastric (Tamura et al., 
1994) and hepatic cancers (Oda et al., 1996; Imai et al., 1997). Furthermore, loss of 
heterozygosity at 5q21 has been observed in sporadic tumours of the breast, ovary, lung 
and oesophagus (Boynton et al., 1992; Thompson et al., 1993; Kashiwaba et al., 1994). 
Therefore, it appears that the inactivation of the APC gene may be a critical step in the 
genesis of several types of tumours. This is supported by the fact that the APC gene is 
expressed in a wide range of epithelial, mesenchymal and neuronal cell types (reviewed in 
section 2.1). 
It is currently unclear what precise role APC plays in carcinogenesis. The gene encodes a 
large protein of 2843 amino acids in which numerous functional domains have been 
identified (reviewed in chapter 2). The protein can homodimerise, it contains armadillo 
repeat sequences that are thought to represent a site of protein -protein interaction, two 
ß- catenin binding domains; the constitutive binding domain (consisting of 3 amino acid 
repeat motifs) and the kinase- regulated binding domain (consisting of 7 amino acid repeat 
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motifs). Interspersed between motifs within the kinase- regulated binding domain is 
SAMP (Ser -Ala- Met -Pro) motifs and evidence suggests that the protein Axin interacts 
with APC through APC's latter five 20 amino acid motifs and that this interaction 
requires SAMP motifs. The C- terminal portion of the protein contains binding sites for 
tubulin and EB 1, for which a role has been proposed in maintaining microtubule integrity 
and spindle alignment during cell division and cell movement. APC has also been shown 
to interact with the human homologue of the Drosophila Disc large tumour suppressor 
protein, which is associated with maintenance of cellular adhesion and possibly with the 
regulation of cell division and differentiation. 
In summary, the APC protein appears to have multiple functions within the cell which 
involve the regulation of cell proliferation and differentiation, cell adhesion and signalling, 
and cell movement. 
5.1.1 Current murine models for the analysis of APC function 
In order to understand the role of APC in tumourigenesis, several different murine 
models of FAP have been generated. The first model was generated using a random 
mutagenesis protocol employing ethylnitrosurea, a point mutagen (Moser et al., 1990). 
Following the treatment of mouse strain C57BL /6 with the mutagen, one mouse 
displayed an anaemic phenotype which was traced to bleeding from multiple adenomas 
(in excess of 50) in the intestine. A murine line was established and named Min (multiple 
intestinal neoplasms). Subsequent characterisation revealed that this mouse harboured a 
nonsense mutation at codon 850 in the mouse APC homologue (Su et al., 1992). The 
protein product, which would be translated from an Apc gene harbouring a truncating 
mutation at codon 850, would contain only the homodimerisation domain and the 
armadillo repeats. All ß- catenin binding domains would be lost, as would domains for 
interactions with EB 1, microtubules and DLG. Mice which were heterozygous for the 
mutation (Apc +lm'n) had a life span of approximately 5 months, after which time the 
secondary effects of the tumours, anaemia and intestinal blockage, resulted in death 
(Moser et al., 1990). Breeding Min mice onto different genetic backgrounds revealed that 
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a smaller number of tumours developed and therefore mice lived longer (Dove et al., 
1994; Bilger et al., 1996). This suggested the presence of modifier loci. One modifier loci 
has been identified and this locus, sited at the distal end of mouse chromosome 4, was 
termed the MOM -1 locus (modifier of Min) and is discussed in section 2.4. Recent 
positional cloning experiments have shown that a secretory phospholipase 2 group 2a is a 
candidate modifier gene situated in the MOM -1 locus (MacPhee et al., 1995; Cormier et 
al., 1997). The protein product of Pla2g2a functions in the cleavage of fatty acids from 
lipids and is therefore thought to effect the cellular microenvironment within the intestinal 
crypt. MOM -I sensitive strains are thought to be null for Pla2g2a protein whereas in 
resistant strains the protein is present (Cormier et al., 1997). C57BL /6 is a sensitive strain 
for MOM -1. 
The phenotype displayed by Min mice differs from the human FAP phenotype. In Min 
mice tumours appear in the small intestine, whereas in human FAP, the majority of 
mutations are within the large intestine (Bilger et al., 1996). Secondly, a small proportion 
of female mice exhibit mammary adenomas and ancanthomas (approximately 5 %) (Moser 
et al., 1993; van der Houven et al., 1995). This is not a phenotype of human FAP, and 
may suggest mutations in genes in the Min mice other than Apc. Alternatively, the 
susceptibility to breast cancer due to germline mutations in the APC gene in humans is 
not significantly increased above the incidence in the general population. 
Desmoid tumours and epidermal cysts are detected in Min mice. These are phenotypically 
associated with human FAP, however other extracolonic manifestations such as osteomas 
of the skull and mandibles and hypertrophy of retinal pigment epithelium are not seen in 
this murine model. The reason for this may be related to the position of the germline 
mutation (codon 850) since there is some evidence to suggest that the particular site of 
the APC mutation correlates with extracolonic manifestations seen in FAP patients 
(Nagase et al., 1993; Olschwang et al., 1993; Wallis et al., 1994; Bunyan et al., 1995; 
Caspari et al., 1995; Dobbie et al., 1996). Alternatively, the different phenotypes 
displayed between the human and murine model of FAP may suggest that genes other 
than APC may be involved in tumourigenesis of some of the extracolonic manifestations. 
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Analysis of colorectal tumours which developed in the small intestine of Min mice 
revealed that the remaining wildtype Apc allele was lost (Luongo et al., 1994; Levy et al., 
1994). Loss of the remaining wildtype allele or inactivation by gene mutation is also 
reported to occur in the majority of tumours from FAP patients (Nishisho et al., 1991; 
Groden et al., 1991; Ichii et al., 1992; Nagase et al., 1993). 
The study of Min mice has also shown that Apc is important in development since 
homozygosity for the mutated Apc allele (ApcM"'`M'n) leads to embryonic lethality (Moser 
et al., 1990; Dove et al., 1994; Moser et al., 1995). Analysis of embryos from Min 
crosses (Apc+ `n X Apc +im`n) showed that by 6.5 days post coitum (dpc) abnormalities 
could be clearly seen in 25% of embryos and genotyping demonstrated that that 
abnormalities were associated with homozygosity for the mutated Apc allele. Close 
inspection of 6.5 dpc embryos and more mature embryos demonstrated that the 
development of the primitive ectoderm fails prior to gastrulation and embryos die before 
day 8 gestation. By mid gestation (approximately 10 dpc) homozygotes consist of a mass 
of trophoblast giant cells with an additional cluster of much smaller embryonic cells. This 
phenotype is similar to that seen in both ß- catenin and c- cadherin null embryos (Haegel et 
al., 1995; Lame et al., 1994). 
Murine models of FAP have also been generated using gene targeting methods (Fodde et 
al., 1994; Oshima et al., 1995). Oshima and co- workers designed a targeting cassette, 
which was inserted into exon 15 of the mutine Apc gene by homologous recombination in 
embryonic stem (ES) cells. Embryonic stem cells and subsequently a mutine founder line 
were generated which expressed the mutant Apc gene and encoded a protein product 
truncated at residue 716. Mice heterozygous for the mutated allele developed multiple 
adenomas throughout the entire intestinal tract, with the majority occurring within the 
small intestine. The number of polyps detected within these mice were more numerous 
(three to five times) than seen in Min mouse model, although both mice are on a 
C57BL /6 background. The difference may be a result of the fact that in Oshima's model 
an additional 133 amino acids of the Apc protein is transcribed compared to the Min 
mouse. No specific binding domain has been identified within this region. 
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As seen with the Min model, the colorectal tumours that develop have lost the remaining 
wildtype Apc allele and mice homozygous for the mutated allele (Apc716 1716) die in utero 
before day 8 gestation. In this model, there have been no reports of extracolonic 
manifestations and this may support the hypothesis that additional genetic events are 
required for the development of these tumours. 
Fodde and workers have also generated a murine model for FAP. The Apc 1638N model 
carries a targeted frameshift mutation which results in the production of a premature stop 
codon at codon 1638 (Fodde et al., 1994). The protein translated from an Apc gene with 
a truncating mutation at codon 1638 would retain homodimerisation sites, the armadillo 
repeat sequences as well as both ß- catenin binding domains. However, analysis of 1638N 
mice failed to detect the predicted 182 kDa truncated protein by western blotting 
technique, therefore suggesting that this protein was unstable. Previous studies of 
mutations within the APC gene, in both mice and humans, have shown that mutations 
upstream of codon 1400 result in the production of a stable protein. In these cases high 
numbers of intestinal adenomas have been detected with a low incidence of extracolonic 
manifestations (Fodde and Khan, 1995). Mutations beyond codon 1600 do not result in a 
stable protein and are generally associated with a reduced number of intestinal adenomas 
and severe extracolonic lesions, a phenotype termed attenuated FAP (Scott et al., 1995; 
Eccles et al., 1996; VanderLuijt et al., 1996; Friedl et al., 1996; Scott et al., 1996). 
There is no current explanation for these phenotypic differences, but one may suggest 
that these phenomena may be a result of tissue specific differences relating to APC 
function or tumour initiation. Further studies are required, especially in light of the recent 
identification of APC homologues (see section 2.5). 
The Apc 1638N model is characterised by the attenuated FAP phenotype, a low number 
of adenomas (5 -6 adenomas per animal) are detected within the intestine, and unlike the 
Min or 716 model, the majority exist in the large intestine. Several other extracolonic 
manifestations, associated with human FAP have been noted, these include osteomas, 
dental abnormalities, lipomas and retinal pigment epithelium. Additionally, mammary 
tumours and trichofolliculmas have been observed sporadically (Fodde et al., 
1994; Smits 
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et al., 1998). This murine model is also on a C57BL /6 background. 
Loss of the wildtype Apc allele has been observed in intestinal tumours although 
interestingly the frequency at which the wildtype allele is lost in desmoid tumours and 
cysts is 42% and 53% of cases respectively. The remaining Apc allele may be inactivated 
by a point mutation within the gene or alternatively these results may suggest that the 
complete inactivation of Apc may not be necessary for desmoid tumour or cyst formation. 
As seen in the Min and 716 models for FAP, homozygosity for the 1638N truncating 
mutation results in embryonic lethality before day 8 of gestation. 
Following the generation and characterisation of the 1638N murine model, Fodde and co- 
workers then went on to generate the Apc 1638T murine model, which was characterised 
by a stable 182 kDa truncated Apc protein comprising the amino- terminal 1683 amino 
acids (Smits et al., 1999). The investigators used gene targeting, using the same cassette 
used to generate the 1638N mice, but with the selectable marker within the cassette 
which lay in the same transcriptional orientation as Apc. Targeted ES cells and 
subsequently murine founder lines expressed a stable 182 kDa truncated Apc protein. 
Analysis of mice heterozygous for 1638T did not show an increased tumour 
predisposition when compared to wildtype animals and furthermore, mice homozygous 
for 1638T were viable. 
The lack of FAP phenotype indicates that deletion of the carboxyl -terminal domains that 
bind tubulin, DLG and EB -1 does not predispose to tumour development. The protein 
produced from 1638T harbours the homodimerisation domain, the armadillo repeats and 
constitutive ß- catenin binding domain and three of the seven motifs within the ß- catenin 
kinase regulated domain, which contain one of the three Axin- binding SAMP motifs. 
Analysis of 1638T homozygous ES cells and embryonic fibroblasts showed that the 
regulation of 13- catenin appeared to be normal whereas in compound heterozygotes 
1638T/1638N and cells homozygous for 1638N, 13- catenin levels are deregulated. 
Therefore, it appears that the multiprotein complex of APC /Axin, GSK -3 ß and ß- catenin 
is necessary for regulation of intracellular 13- catenin levels (see section 2.6.7) and this 
regulatory activity is the main tumour suppressing function of APC. 
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Mice which were homozygous for the Apc 1638T mutation were characterised by 
developmental abnormalities such as growth retardation, behavioural abnormalities, 
reduced postnatal viability in the absence of preputial glands and the formation of nipple - 
associated cysts. This phenotype may be a reflection of the loss of function of the C- 
terminal domains. 
5.1.2 Generation of murine models using Cre/lox technology 
Several murine models of FAP have been generated either by random chemical 
carcinogenesis or conventional gene targeting (see section 5.1.1). Different phenotypes 
have been noted in each model enabling further understanding of Apc's role in the 
tumourigenesis of colorectal cancer and extracolonic manifestations associated with the 
FAP phenotype. Furthermore, these models have revealed that the (3- catenin binding 
domains are crucial to the tumour suppressing functions of Apc and that the Apc protein 
plays a crucial role in development. However, the analysis of Apc function in these 
models is limited due to embryonic lethality. To overcome this problem, murine models 
need to be generated which allow inactivation of the Apc gene in a temporally controlled 
In such a model, Apc could be inactivated in the adult mouse, therefore 
bypassing embryonic lethality. Secondly, the gene could also be inactivated during stages 
of embryogenesis to further examine the role of Apc in development. Such a model can 
be generated using the Cre -loxP recombination system of the bacteriophage P1 
(Sternberg, 1981). 
5.1.2.1 Cre recombinase mediated DNA excision and inversion 
Bacteriophage P1 encodes Cre recombinase (cyclization recombination), a 38 kDa 
enzyme, which is a member of the integrase family of recombinases. Cre is a site specific 
recombinase which functions within the bacteriophage to cyclize P1 DNA after infection 
(Segev and Cohen 1981; Hochman et al., 1983) and enhance P1 plasmid stability in 
bacterial lysogens by resolving dimeric plasmids prior to bacterial division (Austin et al., 
1981). Cre recombinase recognises a 34 bp sequence on the P1 genome called loxP 
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(locus of X -over of P1). The consensus sequence for the loxP sequence, shown in figure 
15a, catalyses reciprocal conservative DNA recombination between pairs of loxP sites. 
Resultant DNA structure is dependent upon the orientation of loxP sites. Direct repeats 
of loxP dictate excision of intervening sequences whereas inverted repeats specify 
inversion of the intervening DNA sequence (Abremski et al., 1983). Cleavage and joining 
of DNA is confined to discrete positions within the core region of the loxP sequence (the 
spacer region) and proceeds one strand at a time by way of a transient phosphotyrosine 
DNA -recombinase complex. In the case of DNA excision, one loxP sequence is also 
removed, in fact this is composed of half of each of the two loxP sequences which are 
each cleaved within the spacer region. Excision is reversible and the excised fragment can 
be reinserted, however, excision is much more efficient than reinsertion (reviewed in 
Torres and Kuhn, 1997). Inversion is also reversible and occurs at a similar frequency in 
both directions (reviewed in Torres and Kuhn, 1997). Figure 15b depicts Cre 
recombinase mediated DNA excision and inversion. Unlike many recombinases of the Int 
family, no host factors are needed for efficient Cre- mediated DNA recombination, 
therefore the functions of this recombinase can be put to use in the genomic manipulation 
of eukaryotic cells (Sauer 1987). 
The loxP sequence consists of two inverted 13 bp repeat sequences that flank an 8 bp- 
spacer sequence (see figure 15a). Not all 34 bp are essential for efficient recombination. 
The first 4 bp of either of the 13 bp inverted repeats (as read from each end of the 
sequence) can be modified without significant loss of recombination proficiency or 
fidelity, each 13 bp sequence binds a single Cre monomer. The asymmetrical 8 bp- spacer 
region is the site of cleavage and strand exchange of recombining loxP sites (Hoess and 
Abremski 1985). Experiments have shown that base substitutions can be made within the 
spacer sequences (Hoess et al., 1986). The following points have been made. Firstly, for 
efficient recombination to occur between two loxP sites, the spacer region of each loxP 
sequence must be homologous. Secondly, a base change at position +1 of the spacer 
region drastically reduces recombination, even between two homologous loxP sequences. 
Thirdly, if base substitutions are such that the spacer region becomes symmetrical then 
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these sites undergo both excision and inversion at an equal frequency. 
LoxP sequences with a substituted base within the spacer region are of particular use if 
one is designing an experiment where other genes are also activated and /or inactivated by 
the use of Cre recombinase. For example, a model may be made whereby two separate 
genes are "floxed" (insertion of LoxP sites to flank the DNA sequence of interest) and are 
to be excised following the administration of Cre recombinase. If genes are on the same 
chromosomal strand then several possible excisions or recombination events may occur, 
due to the presence of 4 loxP sites. If one gene harbours loxP sites with a base 
substitution within the spacer region then recombination/excision will occur between this 
pair and not with either of the loxP sequences containing the consensus sequence. Cre 
recombinase also catalyses intermolecular recombination resulting in integration and 
translocation. Therefore, even if the floxed genes are not on the same DNA strand care 
must be taken in design of the experiment. 
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Figure 15: The Cre /IoxP recombination system 
Figure 15a: The consensus sequence for loxP sites. 
Cre recombinase recognises a 34 bp sequence called loxP (locus of X -over of P1) and 
catalyses reciprocal conservative DNA recombination between pairs of loxP sites. The 
sequence consists of two inverted repeat sequences that flank an 8 bp spacer sequence. 
Cre recombinase binds to the DNA at the inverted repeat sequences; each repeat 
sequence binds one Cre monomer. The spacer sequence determines the orientation of the 
loxP sequence and is the site of enzymatic cleavage and strand exchange of recombining 
loxP sites. 
Base changes within the first 4 bp of either of the inverted repeat sequences (as read from 
the end of each sequence) or within positions -1, -2 -3 or +2, +3 of the spacer region still 
result in high recombination proficiency and fidelity. In the case of a degenerate sequence 
within the spacer region, efficient recombination only occurs if this sequence is 
homologous in both loxP sites. 
Figure 15b: Cre /IoxP recombination reactions 
The resultant DNA structures following Cre mediated recombination, is dependent upon 
the orientation of loxP sites (as determined by the spacer region, see above). Direct 
repeats of loxP dictate excision and recirculation of intervening sequences, leaving one 
loxP site on each product. Excision is reversible with the excision reaction being more 
efficient than reinsertion. Inverted repeats specify inversion of the intervening DNA 
sequence, this reaction is reversible and occurs at an equal frequency in both directions. 
Figure 15: The Cre/loxP recombination system 
15a: Consensus sequence for loxP sites 
Inverted repeat 
--> 
Spacer Inverted repeat 
3 2 1 1 2 3 
5'-ATAACTTCGTATA GCATACAT TATACGAAGTTAT- 3' 
3'-TATTGAAGCATAT CGTATGTA ATATGCTTCAATA- 5' 
15b: Cre/loxP recombination reactions 
Cre mediated deletion Cre mediated inversion 
loxP loxP loxP loxP ® Exo Exo 
loxP loxP loxP 
noxE 
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5.1.2.2 Delivery of Cre recombinase 
Following the generation of a mouse line which harbours the floxed gene, gene 
expression can be controlled by Cre recombinase. Two systems are currently in use to 
deliver the Cre gene into the tissues of mice bearing floxed alleles. The first system to be 
discussed is the generation of transgenic mice which expresses Cre recombinase under the 
control of selected promoters, the second system is viral delivery. 
5.1.2.2a Transgenic animals 
Several transgenic animals have been derived which either express Cre recombinase 
globally or in a tissue specific and /or temporal manner. Cre transgenic mice can be 
crossed with the floxed transgenic mice, and the gene of interest controlled in doubly 
transgenic progeny. 
For global expression of Cre, the gene is driven by promoter sequences from ubiquitously 
expressed genes or from viral promoters (Schwenk et al., 1995; Lakso et al., 1996; Saki 
and Miyazaki 1997). Transgenic mice have also been generated which express Cre 
recombinase in a tissue specific manner. These models have utilised tissue specific 
promoter sequences to drive expression of the Cre -recombinase gene. Currently, 
transgenic mice are available with tissue specific expression within the eye (Lakso et al., 
1992); thymocytes (Orban et al., 1992); brain (Tsien et al., 1996); adipose tissue (Barlow 
et al., 1997); mammary gland (Wagner 1997; Seibert et al., 1998); basal cells of the skin 
(Tarutani et al., 1997), heart (Agah et al., 1997), muscle (Bruning et al., 1998; Miniou et 
al., 1999), [3-cell-specific (Ray et al., 1999) and small intestine and colonic epithelium 
(Saam and Gordon 1999). 
Controlling activity at a post -transcriptional level can control Cre activity in a temporally 
regulated manner. Using this approach, Cre recombinase is expressed as a chimeric 
protein, and is fused to the ligand- binding domain (LBD) of a steroid receptor. In the 
absence of ligand, heat shock protein is bound to the LBD preventing enzymatic activity 
of the Cre protein. Upon administration of ligand, heat shock proteins dissociate and Cre 
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activity is restored. To further control Cre activity and eliminate activity of the enzyme in 
the presence of endogenous steroid, the LBD may be mutated so that it has a very low 
affinity for the natural ligand but can bind to synthetic steroids. This system has been 
successfully used in ES cells and transgenic mice with the LBD of oestrogen and 
progesterone receptors (Kellendonk et al., 1996; Zhang et al., 1996; Feil et al., 1996). 
Schwenk and co- workers (1998) have generated a transgenic model whereby Cre activity 
is both tissue specific and temporally -regulated. In this model, a B -cell specific promoter 
is used to limit the expression of a Cre- oestrogen receptor fusion protein to B- 
lymphocytes. This model exhibits both temporal and tissue specific control of Cre 
recombinase. 
5.1.2.2b Viral delivery 
An alternative approach for the delivery of the Cre gene into tissues involves the use of 
replication deficient recombinant viruses. Viral delivery of the Cre recombinase gene into 
selected tissues is a much more rapid approach than crossing transgenic lines (as 
described above). A number of Cre- expressing adenovirus vectors have been generated 
(Anton and Gramham 1995; Sakai et al., 1995; Kanegae et al., 1995; Wang et al., 1996b; 
Rohlmann et al., 1996). Adenovirus is able to infect a range of cell types making it a 
powerful vehicle for gene delivery (Brody and Crystal 1994; Smith et al., 1995). 
Adenovirus may be administered by intravenous injection, studies have shown this route 
of administration results on high levels of recombination within liver and spleen, with 
lower levels in the kidney, heart and lung (Wang et al., 1996b). High levels of infection in 
specific tissues are thought to be a result of some cell types being particularly susceptible 
to adenovirus infection. In these studies only trace levels of adenovirus were detected in 
the brain, presumably because the brain -blood barrier blocks viral particles (Doran et al., 
1995; Wang et al., 1996b). The expression of Cre may be controlled by placing the gene 
under a tissue specific promoter, as discussed above, or alternatively the adenovirus may 
be injected directly into the organ of interest (Wang et al., 1996b; Agah et al., 1997; Stec 
et al., 1999). 
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This method of Cre delivery does have some problems, adenovirus can be antigenic and 
cause cellular immune responses against the viral particles and viral infected cells (Kass - 
Eisler et al., 1994). 
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5.2 Aims 
In the following sections, I describe the generation and initial characterisation of a new in 
vivo model for the analysis of APC function, which utilises a transgenic Cre/Lox 
approach. This novel model will allow the analysis of : 
1) APC transgenic mice on a murine wildtype Apc background. These mice will 
ubiquitously express the APC transgene, and transcription of APC will be controlled 
by the murine phosphoglycerate kinase gene promoter. Essentially the APC tumour 
suppressor gene will be overexpressed throughout the mouse. 
2) the ability of the transgene to rescue the embryonic lethal phenotype of mice 
homozygous for the Min mutation. 
3) the temporal and spatial deletion of the APC transgene. 
The APC transgene will be engineered so that expression can be conditionally inactivated 
using the Cre -lox P recombination system of the bacteriophage P 1 (Sternberg et al, 
1981). The transgene constructed for this study requires the incorporation of loxP sites 
upstream and downstream of the APC cDNA sequence, which has previously been cloned 
into a plasmid. Two loxP sequences will be inserted in the same relative orientation into 
the plasmid backbone to allow excision of the APC cDNA following administration of 
Cre recombinase. LoxP sequences will harbour a base substitution within the spacer 
region. 
The expression of the transgene will be controlled by the promoter sequence of the 
murine phosphoglycerate kinase (Pgk) gene. The Pgk gene is a housekeeping gene and 
encodes a key enzyme required for glycolysis. This gene is ubiquitously expressed, and 
particularly high levels are noted in early embryonic cells that are rapidly proliferating, 
and much lower levels are seen in many differentiated cells (Riele et al., 1990; Mortensen 
et al., 1991; McBurney et al., 1991; 1994; Sutherland et al., 1995). The murine Pgk 
promoter sequence will be cloned upstream of the APC cDNA but downstream of the 
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first loxP sequence. 
Following the construction of the transgene, a prokaryotic system will be used to confirm 
that the APC cDNA can be excised from the construct in the presence of Cre 
recombinase. Pro -nuclear injection will be used to deliver the APC transgene into oocytes 
of wildtype mice. Mice produced as a result of pronuclear injection will be screened for 
the presence of the transgene and these founder mice will be employed in a breeding 




5.3 MATERIALS AND METHODS 
Construction of the floxed APC transgene involved numerous techniques. Each technique 
will be addressed individually. 
5.3.1 Ethidium bromide plates 
Ethidium bromide plates were used to determine the concentration of DNA. Preparation 
of plates and method is as previously described in section 3.3.3. 
5.3.2 Agarose gel electrophoresis 
All agarose gels were prepared and analysed according to the protocol previously 
described in section 3.3.4.2 
5.3.3 Restriction endonuclease cleavage 
Plasmid DNA was cleaved with the appropriate restriction endonuclease required for the 
cloning step. Reaction mixes were prepared as described in section 3.3.4.3. 
Concentrations of DNA to be cleaved varied and subsequently the amount of enzyme and 
volume of the reaction was increased proportionately. 
5.3.4 Polymerase chain reaction 
Reaction mixes for PCR were prepared as previously described in section 3.3.4.1 
5.3.5 Extraction of DNA fragments from agarose gels 
Following PCR or restriction endonuclease cleavage, it was sometimes necessary to 
isolate a particular fragment of DNA from other DNA within the reaction. The required 
fragments were isolated from the agarose gel and then purified using the Qiaexll gel 
extraction kit (Qiagen Ltd.). The appropriate fragments were cut from the agarose gel 
using a sterile scalpel blade and placed into a pre- weighed 1.5 ml microfuge tube and 
190 
microfuged at 13,000 rpm for 2 minutes. The microfuge tube was then re- weighed to 
determine the weight of the gel slice. Three hundred microlitres of QXl buffer was added 
per 100 mg of gel slice to solubilise the agarose, dissociate DNA binding proteins from 
the DNA fragment and give a suitable pH to allow absorption of the DNA fragment to 
the Qiaexll silica particles. Ten microlitres of Qiaex II particles were added and the 
sample incubated at 50 °C for 15 minutes. Particles were washed with QX 1 buffer and PE 
buffer. The pelleted particles were air -dried and the DNA fragment eluted with 2O111 of 
sterile DDW. 
5.3.6 Dephosphorylation of vectors 
The 5' terminal nucleotide of linearised vectors were dephosphorylated using shrimp 
alkaline phosphatase (Amersham, UK). One unit of shrimp alkaline phosphatase was 
added to the 100 ng of linearised vector in reaction buffer (20 mM Tris -HC1 pH 8.0, 10 
mM MgC12). The reaction was incubated at 37 °C for 1 hour then heated to 65 °C to 
inactivate the enzyme. This step was included to increase ligation efficiency by preventing 
re- circularisation of the vector. 
5.3.7 Ligation reactions 
Concentrations of both vector and insert were estimated using ethidium bromide plates 
(see section 3.3.3). Ligations were prepared using 100 ng of vector and various molar 
ratios of insert generally 1:1 or 1:3, vector to insert. Conversion of molar ratio to mass 
ratio was calculated using the following equation: 
100 ng of vector x kb size of insert 
kb size of vector 
x molar ratio of insert = ng of insert 
vector 
To each ligation, l µl of 10x ligation buffer (Appendix A) and 10 T4 DNA ligase (4.0 
Weiss units) (Gibco BRL) was added. The volume of the ligation mix was adjusted 
to 
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14tl by the addition of sterile DDW. Ligation reactions were incubated overnight at 
16 °C. Ligation controls were also set up, these reactions contained no insert but only 
dephosphorylated vector. 
5.3.8 Transformations 
Transformations were carried out using Epicurian Coli SURE competent cells 
(Stratagene Ltd., Cambridge, U.K.). The protocol was according to Stratagene 
instructions. Competent cells were removed from -70 °C and thawed on ice. Fifty 
microlitres of cells were placed in a pre -chilled 15 ml Falcon tubes and ß- 
mercaptoethanol (supplied with the cells) added to give a final concentration of 25 mM. 
Cells were incubated for 10 minutes on ice then 1 -2p1 (5 -8µg of DNA) of ligation mix 
added and the tubes incubated on ice for a further 30 minutes. Tubes were placed in a 
42 °C water bath for 45 seconds and then immediately placed on ice for 2 minutes. Nine 
hundred microlitres of preheated (42 °C) SOC medium (Appendix A) was added and the 
tubes incubated at 37°C for 1 hour shaking in an orbital shaker at 225 rpm. One hundred 
microlitres and 2001Al of each transformation was spread onto separate LB (Luria - 
Bertani) agar plates containing 501.1.g/m1 of ampicillin (Appendix A). Ampicillin selects for 
bacterial colonies that have successfully been transformed with the plasmid as the plasmid 
contains the ampicillin resistance gene. The transformation solution was left to absorb 
into the agar plate for approximately 5 minutes and then plates were inverted and placed 
at 37°C for at least 18 hours. Plates were then placed at 4 C. 
5.3.9 Bacterial cultures and plasmid isolation 
To screen for colonies which had been transformed with the plasmid and contained the 
appropriate insert, individual colonies (clones) from the agar plates were transferred into 
3 mis of LB broth supplemented with 50µg/m1 ampicillin (Appendix A) and incubated 
shaking at 225 rpm at 37 °C overnight. Plasmid DNA was purified from 2.75 mls of the 
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bacterial culture using the WizardTM plus Minipreps DNA Purification System (Promega 
>). This protocol is outlined in section 4.3.5.3. The concentration of the plasmid DNA 
was estimated using ethidium bromide plates (section 3.3.3). 
5.3.9.1 Bacterial streak plates and glycerol stocks 
Bacterial streak plates and glycerol stocks were prepared from the remaining 250µl of the 
3 ml cultures. Bacterial plates were prepared for short-term storage of clones. A 
biological loop was inoculated with the culture then streaked across LB (Luria -Bertani) 
agar plates containing 5014/m1 of ampicillin (Appendix A). The plates were incubated 
overnight at 37 °C and then stored at 4 °C. For long term storage of clones, 0.1 ml of the 
culture was pipetted into an eppendorf and 0.1 ml of sterile glycerol added. The cell 
culture and glycerol were gently mixed and the eppendorf was frozen at -70 °C. 
5.3.10 Large scale preparation of plasmid 
To obtain a large volume of the plasmid for further restriction analysis, cloning steps or 
plasmid sequencing, a single clone was removed from the streaked agar plate (see section 
5.3.9.1) and used to inoculate 3 mls of LB broth supplemented with 504ml ampicillin 
(Appendix A). The bacterial culture was incubated shaking at 225 rpm at 37 °C overnight. 
This culture was then used to inoculate 3 -100 ml of culture medium, the volume of 
culture used was 1 /100`h the volume of new culture medium. The inoculated medium was 
then incubated shaking at 225 rpm at 37 °C overnight and WizardTM midiprep columns 
were used to isolate plasmid DNA. The protocol is as described in section 4.3.5.3 but 
with solution volumes scaled up. 
5.3.11 Sequencing plasmid DNA 
The procedure used to sequence plasmid DNA is described in section 4.3.5.4. Samples 
were loaded onto a DNA sequencing gel and electrophoresed using conditions described 
in section 4.3.4.2. Sequencing gels were subsequently dried and exposed to x- 
autoradiograph film as described in section 4.3.4.2. 
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5.4 Construction of the APC transgene 
The construction of the APC transgene is described in the following sections and each 
step is depicted in figure 16. 
5.4.1 APC cDNA 
The human APC cDNA sequence was originally generated by screening cDNA libraries 
with genomic DNA segments from a contig of yeast artificial chromosome (et al., 
199 lb). The APC cDNA sequence is 8532 bp in length, and contains a methionine codon 
(ATG) at the 5' end of the sequence. This initiation codon is situated two codons from an 
in -frame stop codon conforming to the Kozak translation initiation consensus (Kozak, 
1984). Multiple translation stop sequences are present in all frames over the final 1.8 kb 
within the 3' open reading frame. Since the isolation of the APC cDNA sequence, the 
sequence has been cloned into the plasmid pGEM -3ZF( +) (p -GEM) by S. White 
(unpublished). The APC cDNA, cloned into the BamH1 restriction site within the 
multiple cloning site of pGEM -3ZF( +), was available in our department for this project, 
as shown in figure 16a. This construct formed the backbone to the APC transgene. 
5.4.2 Addition of the SV40 poly -adenylation sequence 
A poly -adenylation sequence was not present at the 3' terminus of the APC cDNA 
sequence. This nucleotide sequence results in the transcription of 100 -200 residues of 
adenylic acid (poly -A tail) to the 3' end of the RNA chain in order to complete the RNA 
transcript. The function of the poly -A tail is not known for certain but is thought to play a 
role in the export of mRNA from the nucleus and also to stabilise mRNA molecules by 
retarding their degradation in the cytoplasm. 
The first step was to clone in a poly -adenylation sequence. PCR was used to amplify the 
SV40 poly -adenylation (poly -A) sequence from the plasmid pUHD 10 -3 (constructed by 
M. Gossen, Heidelberg, unpublished). Degenerate primers were designed 
which 
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incorporated Mlul sites into the amplified fragment to generate compatible ends for the 
cloning of the poly -A sequence into a unique Mlul site situated 3' to the APC cDNA 
stop codon, see figure 16b. 
Primers were designed by S. White and resulted in the production of a 480 bp PCR 
fragment. Primers are stated below. 
Forward 5'- GGCGACGCGTAGACATGATAAG 3' 
Reverse 5' - ATCGACGCGTAAGCTTGGTCGA 3' 
The underlined nucleotides indicate SV40 sequence, italics indicates Mlul restriction 
recognition sequence. PCR conditions for these primers were: initial denaturation of 5 
minutes at 94 °C, and then 30 cycles of 94 °C for 1 minute, 60 °C for 30 seconds and 72 °C 
for 1 minute, the final extension time was 72 °C for 8 minutes. Reaction mixes for PCR 
were as previously described in section 3.3.4.1 with the exception of the use of Expand 
high fidelity PCR system (Boehringer Manheim). Expand high fidelity PCR system was 
used in order to minimise the possibility of polymerase errors within the PCR product. 
The Expand high fidelity PCR system utilises thermostable Taq DNA and Pwo DNA 
polymerases (Barnes, 1994). Due to the 3' -5' exonuclease proofreading activity of Pow 
DNA polymerase, the fidelity of the DNA synthesis is increased 3 fold compared to Taq 
DNA polymerase alone. 
Two Mlhil restriction endonuclease reactions were prepared, one containing the PCR 
amplified poly -A sequence, the other the APC cDNA construct (as seen in figure 16a). 
Following restriction endonuclease cleavage, ligation reactions were prepared (see 
section 4.3.5.1) and subsequently transformed into Epicurian Coli SURE competent cells 
(Stratagene Ltd., Cambridge, U.K.) as described in section 5.3.8. Plasmid DNA was 
isolated from bacterial clones, sees section 4.3.5.3, and screened for the presence of the 
poly -A sequence. Screening was carried out by incubating the plasmid preparations with 
the restriction endonuclease BstEl. The restriction endonuclease site is unique to the 
poly -A sequence. Therefore, following incubation with the restriction endonuclease, if the 
poly -A sequence is present, one would expect the plasmid to linearise to give a 12 kb 
fragment whilst in the absence of the sequence the plasmids remains circularised. 
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Restriction endonuclease reactions were loaded onto a 0.7% agarose gel, a molecular 
weight marker was also loaded. Marker XII (Boehringer Manheim) was used as this 
contained a DNA fragment of 12 kb. The samples were electrophoresed until the marker 
DNA had been separated. Plasmid preparations which linearised were identified. 
To determine the orientation of the poly -A sequence, linearised plasmid (previously 
incubated with BstNI) were incubated with the restriction endonuclease Sall. A Sall 
restriction endonuclease site is present within the p -GEM plasmid backbone. If the poly - 
A sequence was inserted in the correct orientation, the Sall cleavage site would be 
approximately 380 bp downstream of the BstNI cleavage site. However, if the poly -A 
sequence has been cloned into the plasmid in the incorrect orientation the Sall site would 
be situated 80 bp downstream of the BstNI restriction site. Therefore, following 
incubation with Sall samples were electrophoresed through a 3% agarose gel. All 
plasmid preparations showing a fragment of 380 bp were selected. 
One hundred millilitre cultures were grown and plasmid isolated for each selected clone 
as described in section 5.3.10. Plasmid DNA was sequenced (see section 4.3.5.4) to 
confirm the presence of the poly -A sequence and its orientation. Sequencing was initiated 
from the universal M13 reverse sequence situated approximately 80 bp downstream of 
the poly -A sequence within the p -GEM plasmid backbone. The universal M13 reverse 
primer sequence was as follows: 5' CAGGAAACAGCTATGAC 3'. 
5.4.3 Addition of LoxP sequence 
Oligonucleotides were designed which contained a 34 bp loxP sequence with a base pair 
change at position 2 of the spacer region (discussed in section 5.1.2.1) and compatible 
ends for sub -cloning into the APC cDNA constructs as shown in figure 16b. The 
first 
loxP (Lox P 1) to be inserted into the construct was to be cloned into a unique 
Sall 
restriction endonuclease site situated within the p -GEM plasmid backbone downstream 
of 
the poly -A sequence, see figure 16c. The oligonucleotide Lox P 1 
was designed to 
include a unique restriction site, Pacl, which would enable screening of clones 
and also 
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Sall cohesive ends to allow easy cloning of the oligonucleotide into the Sall restriction 
site of the APC cDNA construct. Oligonucleotide sequences are shown in table 10. The 
Lox P 1 oligonucleotides were made doubled stranded by mixing an equal molar ratio of 
each oligonucleotide and heating to 75°C, mixes were left to cool at RT for 
approximately 15 minutes. 
The APC cDNA construct, as seen in figure 16b, was incubated with the restriction 
endonuclease Sall. Ligation reactions were prepared using the cleaved APC cDNA 
construct and the annealed Lox P 1 oligonucleotides. Ligation mixes were subsequently 
transformed, bacterial cultures grown and plasmid DNA isolated using the previously 
described standard methodology. Plasmid DNA was subjected to restriction endonuclease 
cleavage using the enzyme Pad. Restriction endonuclease reactions were then 
electrophoresed through a 0.7% agarose gel. Plasmid preparations viewed as a 12.2 kb 
linear fragment were sequenced to ensure the oligonucleotide had not integrated as a 
concatamer and to determine orientation. Sequencing was carried out using the M13 
reverse primer previously described in section 5.4.2. 
A second Lox P oligonucleotide was designed to be cloned into the Sacl restriction 
endonuclease site present within the p -GEM plasmid backbone upstream of the APC 
cDNA sequence, see figure 16d. This oligonucleotide (Lox P 2) was designed with Sacl 
cohesive ends and an Apal restriction site downstream of the 34 bp loxP consensus 
sequence, see table 10. The APC cDNA construct, as seen in figure 16c, was incubated 
with the restriction endonuclease Sacl. Ligation reactions were prepared using the 
cleaved APC cDNA construct and annealed Lox P 2 oligonucleotides (see above for 
oligonucleotide annealing conditions). Ligation, transformations and DNA plasmid 
preparations were carried out as described for Lox P 1. Isolated plasmid DNA was 
incubated with the restriction endonuclease Sacl and electrophoresed through a 
0.7% 
agarose gel. Plasmid preparations that linearised, giving a 12.2 kb fragment, harboured 
the Lox P 2 sequence. These plasmid preparations were sequenced 
to ensure the 
oligonucleotide had not integrated as a concatamer and to determine 
orientation. 
Sequencing was carried out using the M13 universal 
forward primer (5' 
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GTTTTCCCAGTCACGAC 3') which was situated 74 bp upstream of the inserted Lox P 
2 sequence. 
Table 10. Oligonucleotide sequences for Lox P 1 and Lox P 2 
Oligonucleotide sequences and orientation within plasmid 
Lox P 1: 3' to the APC cDNA 
Inverted Repeat Spacer Inverted Repeat 
Sall cohesive ends 
Pact restriction site 
5' GTATTGAAGCATAT TACATATG ATATGCTTCAATAAATTAATTCAGCT 3' 
3' TCGACATAACTTCGTATA ATGTATAC TATACGAAGTTATTTAATTAAG 5' 
Lox P 2: 5' to the APC cDNA 
-> 
Inverted Repeat Spacer Inverted 
Sad cohesive ends 
Apal restriction site 
5' CCGGCCGATAACTTCGTATAATGTATACTATACGAAGTTATGGGCCCGAGCT 3' 
3' TCGAGGCCGGCTATTGAAGCATATTACATATGATATGCTTCAATACCCGGGC 5' 
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5.4.4 Addition of the murine phosphoglycerate kinase gene promoter sequence 
The final step in constructing the APC transgene was the addition of the 
phosphoglycerate kinase (Pgk) gene promoter sequence. The murine Pgk promoter 
sequence was available in our department within a 4 kb construct, Puc19 -Pgk, previously 
prepared by S. White. The 900 bp Pgk promoter sequence could be excised from the 
Puc19 -Pgk plasmid by incubation with the restriction endonucleases BamHI and Pstl. 
The Pgk sequence was to be cloned into the unique Apal restriction endonuclease site 
within the APC construct as shown in figure 16d. Therefore, to aid cloning, two sub - 
cloning steps were carried out. One microgram of the Puc19 -Pgk plasmid was linearised 
using the restriction endonuclease BamHl and ligated with Apal /BamHI linkers. 
Apal /BamHI linkers are oligonucleotides consisting of the endonuclease recognition 
sequences for BamHl and Apal. The oligonucleotide sequence consisted of 
BamHI /Apal /BamHI nucleotide sequences. Oligonucleotide sequences were made 
double stranded as described in section 5.4.3, and the ligation reaction between the 
linearised Puc19 -Pgk plasmid (incubated with BamHI) and oligonucleotides carried out. 
Following the ligation reaction, the mixes were transformed, colonies selected, bacterial 
cultures prepared and plasmid DNA isolated, using standard methodology. Each plasmid 
preparation was screened for the presence of the linker by incubation with Apal. Plasmid 
DNA from clones containing the linker linearised with Apal. 
Plasmid DNA, from a clone containing the Apal linker, was then cleaved with the 
restriction endonuclease Pstl and an Apal /Pstl linker, (nucleotide sequence 
Pstl /Apal /Pstl) cloned into the plasmid as previously described above. Plasmid DNA 
from clones were screened by Apal cleavage, excising the 900 bp Pgk promoter 
sequence with Apal cohesive ends. For clones shown to harbour the Pgk promoter, 
large -scale plasmid preparations were prepared (10 ml), as described in section 5.3.10. 
The 900 bp Pgk promoter sequence was isolated from the PUC 19 plasmid backbone (size 
3 kb) by incubating 1 pg of the isolated plasmid with Apal and electrophoresis through a 




The isolated Pgk sequence containing Apal cohesive ends was sub -cloned into the APC 
construct at the Apal site, using standard techniques. To select for clones that contained 
the Pgk promoter sequence, plasmid preparations were screened by incubating with 
Apal. Positive clones were detected by gel electrophoresis (0.7% agarose gel), a 
fragment of approximately 900 bp corresponded to the presence of the Pgk promoter 
sequence and a 12 kb fragment the APC construct as seen in figure 16d. Plasmid DNA 
from clones containing the Pgk promoter sequence were screened by Pstl cleavage to 
determine the orientation of the promoter sequence. The Vector NTI software package 
was used to determine the predicted pattern of plasmid fragments that would be 
generated following incubation with Pstl. The fragment pattern expected from Pstl 
cleavage is shown below. 








Plasmid preparations were subsequently incubated with Pstl and reaction mixes 
electrophoresed through a 0.7% agarose gel. One plasmid preparation containing the Pgk 
promoter sequence in the correct orientation was identified, as seen in figure 16f, and this 
construct is the completed APC transgene. To produce large amounts of the transgene, 
four 100 ml bacterial cultures were set up and plasmid isolated according 
to the method 




Figure 16: Construction of the APC transgene 
Each cloning step is described within the text 
of section 5.4.1- 5.4.4. 
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Figure 16: Continued from overleaf 
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Figure 16 continued: Construction of the APC transgene 
Each cloning step is described within the text of section 5.4.1- 
5.4.4. 
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5.5 Analysis of the APC transgene 
The construction of the APC transgene is described in sections 5.4.1 -5.4.4. Restriction 
endonuclease reactions and /or DNA sequencing was carried out following each cloning 
step to ensure the presence of the DNA sequence being inserted and to determine the 
orientation of the insert. In the case of the addition of oligonucleotide sequences (Lox P 
sequences and linkers) DNA sequencing was carried out not only to determine 
orientation but to also eliminate the presence of oligonucleotide concatamers which 
would not be detected by fragment sizes following agarose electrophoresis. An example 
of DNA sequencing is given in figure 17. 
The final construct, the APC transgene, was then incubated with a number of different 
restriction endonucleases to confirm the relative positions of the cloned fragments. 
Digestion patterns were analysed on a 0.7% agarose gel and compared to the expected 
pattern determined by building the construct on the Vector NTI software package. All 
fragment sizes were as predicted. 
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Figure 17: Example of DNA sequencing 
The Lox P 1 sequence was cloned into the Sall restriction endonuclease site within the 
APB' construct as seen in figure 16c. Clones containing the sequence were identified by 
restriction endonuclease cleavage with Pact. Plasmid DNA was subsequently sequenced 
to determine the orientation of the Lox P 2 sequence and to ensure that concatamers had 
not been formed. 
Prior to insertion of the Lox P 2 sequence the DNA sequence encoded Sphl, Pst], Sall 
and Xbal restriction endonuclease recognition sequences. Following the cloning of the 
Lox Pl sequence into the Sall restriction site, Svhl, Psi] and Xbal surround one copy 
of the Lox P 1 sequence. 






GTC GA C Sall 
CTGCA G Fstl 
GCATGCA 411 hl 
















5.5.1 Excision of APC by Cre -recombinase in prokaryotic cells 
To test whether the DNA sequence (Pgk promoter sequence, APC cDNA and poly -A 
sequence) situated within the two loxP sequences could be excised from the transgene in 
the presence of Cre -recombinase, the transgene was transformed into the E. Coli strain 
BNN132, which constitutively expresses Cre recombinase (MoBiTech, GmbH). 
For this experiment, three controls were also carried out. Firstly, the APC transgene was 
transformed into Epicurium Coli Sure competent cells (Stratagene), to demonstrate that 
recombination of the transgene, as seen in BNN132 cells, was a result of Cre 
recombinase. In the second and third controls, incomplete construct containing only one 
loxP site, Lox P 1 (as seen in figure 16c) was transformed into BNN132 cells and 
Epicurium Coli Sure cells. These controls would show that for recombination to occur, in 
the presence or absence of Cre recombinase, two loxP sites must be present. Following 
transformation, individual colonies were cultured and plasmid DNA isolated using 
standard methodology. Restriction endonuclease reactions were prepared using the 
enzyme Hindlll and subsequently analysed on a 0.7% agarose gel to identify excision of 
the intervening sequences. Following excision of the sequence between lox P sites, 
incubation with Hindlll would result in the production of a single fragment of 3.2 kb. 
One Hindlll restriction site is present within the recombined construct and is situated 
within the p -GEM plasmid backbone. The predicted fragment sizes for the APC 
transgene in the absence of Cre recombinase (control 1) are 6.382, 3.863, 2.630, 0.276 
and 0.096 kb, as predicted using the Vector NTI software. The control construct, in the 
absence of recombination, would be cleaved to yield fragments of 5.420, 3.863, 2.630 
0.27 and 0.096 kb. 
Ten plasmid preparations were analysed for each transformation, in all preparations 
following incubation with the restriction endonuclease Hindlll the appropriate sized 
fragments were generated. These results show that the DNA sequence between the loxP 
sequences can be efficiently excised from the transgene in the presence of Cre - 
recombinase. Figure 18a shows examples of the DNA fragments identified. 
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Figure 18a: Cre mediated excision of the foxed APC construct in a prokaryotic 
system 
Figure 18a shows that the DNA sequence between the loxP sequences can be efficiently 
excised from the ARC transgene in the presence of Cre recombinase. 
Lane 1 shows the DNA fragments generated following Hindlll cleavage of plasmid 
preparations generated from the transformation of the APC transgene into Epicurium coli 
Sure cells, this strain does not express Cre recombinase. Fragments of approximately 6.3, 
3.8 and 2.6 kb are seen. Further fragments of 276 and 96 bp are generated but are not 
detected on this agarose gel. 
Lane 2 shows the DNA fragments generated following Hindlll cleavage of plasmid 
preparations generated from the transformation of the APC transgene into an E. coli 
strain (BNN132) which constitutively expresses Cre recombinase. Following Cre 
mediated excision, a 3.199 kb construct is generated, and this construct contains a single 
Hindlll site, following incubation the construct is linearised. 
Lane 3 and 4 show the DNA fragments generated when a control construct, containing 
only one loxP site, is transformed into Epicurium sure cells (lane 3) and BNN132 cells 
(lane 4). These lanes show that in the absence or presence of Cre recombinase this 
construct does not undergo recombination. In both lanes, as predicted, DNA fragments 
of 5.4, 3.8 and 2.6 kb are seen. 
Figure 18b: Cre mediated excision of the floxed APC construct in an eukaryotic system 
Transgene positive embryonic fibroblasts were derived and infected with a replication 
deficient adenovirus that either expressed Cre recombinase (flask 1), or ß- galactosidase 
(flask 2). Flask 4 was not infected with adenovirus. 
DNA was extracted from each flask and subject to PCR to amplify a 240 bp fragment of 
the transgene. Primers were situated within the poly A sequence and the p -GEM plasmid 
backbone. Following Cre mediated excision of the foxed sequence, the poly A sequence 
would not be present and no PCR product would be produced. Results are shown in 
figure 18b (i). A 240 bp PCR product was detected in lanes 1,2 and 3 (flask 1, flask 2 and 
flask 4 respectively). No band was seen in lane 4, the PCR with no DNA template 
control. The presence of a 240 bp PCR product in lane 1 indicated that Cre mediated 
recombination may not have occurred or was not 100% efficient. Alternatively, 
reinsertion of the excised fragment had occurred. 
DNA was then subject to PCR to determine whether the transgene had under gone Cre 
mediated excision. The primers used spanned the floxed sequence, if excision had 
occurred, a 190 bp fragment would be amplified. Results are shown in figure 18b (ii). A 
190 bp fragment was detected in lane one; DNA extracted from flask 1; infected with 
adenovirus expressing Cre recombinase. No band was detected in lanes 2,3 and 4, 
infected with adenovirus expressing ß- galactosidase not infected and PCR no template 
control. 
Figure 18a: Cre mediated excision of the floxed APC construct in a 
prokaryotic system 
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5.6 Generation and analysis of transgenic mice 
The following sections describe the generation and analysis of a murine ARC transgenic 
founder line. The procedure involved linearisation and purification of the transgene, 
which was to be microinjected into the pronuclei of fertilised oocytes at the one -cell 
stage. The transgene will randomly integrate into the murine genome, and may integrate 
as multiple tandemly repeated copies and at multiple sites. Injected oocytes were placed 
within the oviducts of surrogate female mice who carried the developing pups. Following 
birth, each pup was analysed for the presence of the transgene using PCR to amplify a 
region of the transgene; DNA extracted from tail biopsies was used as template. Southern 
blotting was used to confirm the presence of the transgene and to determine the transgene 
copy number. Expression of the transgene was analysed by reverse transcription PCR. 
Transgene positive mice were bred to establish APC transgenic founder lines. Transgene 
positive mice essentially overexpress APC, therefore, tissues were analysed to detect any 
phenotype associated with aberrant expression. 
Transgenic founder lines were used in a breeding program with the aim of generating 
transgene positive mice on a Apc Min/Min background, i.e. the transgene will rescue of the 
embryonic lethal phenotype of Apc M`n/M`n mice. 
5.6.1 Preparation of transgene for pronuclear injection 
The first step was to linearise the transgene as it has been shown that linear DNA 
integrates into the host genome fivefold more efficiently than supercoiled DNA (Townes 
et al., 1985). One hundred and eight micrograms of the APC transgene was linearised in a 
total volume of 1 ml using the restriction endonuclease AspEl. The nucleotide sequence 
recognised by AspEl endonuclease is situated at position 11380 of the APC transgene, 
see figure 16f. Following overnight incubation at 37°C, heating the reaction mix 
to 65°C 
for 15 minutes inactivated the restriction endonuclease. The APC transgene 
was purified 
by phenol chloroform extraction and ethanol precipitation. The first step 
was to add an 
equal volume (1m1) of phenol: chloroform: isoamyl alcohol (25:24:1) 
solution to the 
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sample. The solution was mixed well, then microfuged at 13,000 rpm for 1 minute. The 
aqueous phase (upper layer) was pipetted into a clean microfuge tube whilst the cloudy 
interface, containing the proteins and the lower organic phase, was discarded. An equal 
volume of chloroform was then added and the sample spun at 13,000 rpm for 1 minute. 
The upper phase, containing the transgene, was pipetted into a clean microfuge tube and 
the organic lower phase discarded. The purified transgene was then concentrated and 
sterilised by ethanol precipitation. For ethanol precipitation, 2 volumes of ethanol and 
1 /10`h the volume of 3M sodium acetate pH 5 were added to the DNA solution. The 
sample was placed at -20 °C for at least 1 hour and then centrifuged at 13,000 rpm in a 
microfuge for 20 minutes. Ethanol was poured off and the pellet washed with 1 ml of 
70% (v /v) ethanol. The sample was centrifuged for 15 minutes and the wash step 
repeated. The transgene was resuspended in sterile injection buffer (10 mM Tris, 0.1 mM 
EDTA) at a concentration of 6pg/ml. The resuspended transgene was then dialysed 
against a large volume of injection buffer for 4 days at 4 °C; the buffer was changed daily. 
This step was carried out to remove all contaminating solutes and solvents that might be 
deleterious to the oocyte. Following dialysis, the concentration of the transgene was 
adjusted to 10 p.g/ml and was stored at -20 °C in 20111 aliquots. 
5.6.2 Collection of fertilised oocytes and pronuclear injection 
Dr. Alistair Mackenzie carried out this work in the MRC Transgenic Facility, Edinburgh. 
The first step was to treat a 4 -5 week old female mice, strain C57BL /6, with follicle 
stimulating hormone (FSH) (Sigma, UK) and human chorionic gonadotrophin (hCG) 
(Sigma, UK) to induce superovulation. Mice were injected intraperitoneally 
(ip) with 
10011l of 50 IU /ml FSH (ie 5 IU /mouse). Between 46 -48 hours later, the 
mice were 
injected ip with l00µ1 of 50 IU /ml hCG (ie 5 IU /mouse). The female mice 
were then 
placed with a stud male, murine strain CBA. C57BL /6 strain was not 
used, as males tend 
to be less fertile than other strains. The following morning, females 
were examined for the 
presence of a copulatory plug and plugged females were killed by 
cervical dislocation. 
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The oviducts were removed and placed into a petri dish containing M2 medium (Sigma, 
UK) which had been equilibrated to RT. The ampulla, which contains the cumulus mass 
(numerous fertilised eggs surrounded by cumulus cells), was located by examining the 
oviducts under a dissection microscope. The ampulla was teased out of the oviduct and 
the cumulus mass and any isolated fertilised eggs transferred using a pipette containing 
M2 medium into a second dish of M2 medium. The cumulus masses were mixed with 
5011l of hyaluronidase solution (10 mg/ml of hyaluronidase in M2 medium) for a period of 
2 -3 minutes; this step separated the fertilised eggs from cumulus cells. Fertilised eggs 
were transferred, using a transfer pipette, to a petri dish containing droplets of M2 
medium and washed by repeatedly collecting and transferring to a new droplet of medium 
in the dish, they were then transferred to a dish containing M16 medium (Sigma, UK) 
which had been equilibrated to 37°C in a CO2 incubator. Fertilised eggs were washed 
twice in M16 medium, as described above, and subsequently placed at 37°C in 5% CO2 
until required for microinjection (usually within an hour, within this time the transgene is 
equilibrated to RT and the micro -manipulator prepared). 
The transgene, prepared as described in section 5.6.1, was equilibrated to RT. Fertilised 
eggs were transferred into M2 medium which had been equilibrated to RT and the 
transgene was injected into a pronuclei of the fertilised egg using a micro- manipulator. 
For an in depth description of the use of a micro- manipulator see Hogan et al (1994). 
Briefly, the transgene DNA is forced into one of the two pronuclei of the fertilised egg at 
the one -cell stage via an injection needle linked to a simple system consisting of an air 
filled tube connected to a 50 ml syringe. Usually the male pronuclei are targeted, as they 
tend to be larger than female pronuclei. Enough transgene was injected to see the 
pronuclei swell but not burst. 
Injected eggs were then transferred into equilibrated M16 medium and placed at 
37°C in a 
5% CO2 incubator. The following day embryos which were at the two 
cell stage were 
selected and transferred into the oviducts of 0.5 day post -coitum pseudo -pregnant 
mice. 
These mice were prepared by hormonal treatment as described for 
superovulation, but 
mature females were used that had already successfully raised a litter 
of pups. Following 
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hormone treatment, females were placed with vasectomised males, these males leave a 
copulatory plug after mating but fail to transmit sperm. Pseudo -pregnant recipient 
females were anaesthetised and embryos transferred into the ampullae by the oviduct 
transfer procedure as described in Hogan et al (1994). Between 10 -18 embryos were 
transferred to each oviduct in an attempt to generate litter sizes of 5 -10 pups. Usually less 
than a third of transferred embryos result in the production of a live pup. Following this 
procedure, the mice were returned to a cage and left undisturbed to recover from the 
anaesthetic. In this experiment, 110 two cell stage embryos were transferred into four 
recipients. 
Recipient mice gave birth to a total of 13 pups, unfortunately two litters (six pups) were 
lost due to water run outs within the cages. The remaining 7 pups were subsequently 
screened for the presence of the transgene. 
5.6.3 Screening for transgenic mice 
5.6.3.1 Extraction of DNA from mouse tails 
Tail biopsies were taken from mice of 3 weeks of age and DNA extracted using the 
following method. Tails were incubated shaking overnight in 504t1 of lysis buffer 
(Appendix A) with 3011l of proteinase K (stock solution of 20 mg/ml). The DNA was 
purified by phenol extraction. Five hundred microlitres of TE saturated phenol was added 
and the tube shaken vigorously. The sample was then microfuged for 3 minutes and the 
aqueous phase carefully removed to a clean microfuge tube, avoiding the lower phenol 
phase and material at the interface. This procedure was followed again for 5000 of 
phenol: chloroform (1:1) and then 500µ1 of chloroform. DNA was precipitated by the 
addition of 200111 of 7.5M ammonium acetate and 3.75 ml of absolute alcohol. The 
samples were shaken and a glass rod was used to spool out the DNA. Excess alcohol 
was 
allowed to evaporate from the DNA before it was transferred to 50011l of 
TE buffer 
(Appendix A). DNA samples were stored at 4 °C. 
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5.6.3.2 PCR protocol 
PCR was carried out on the extracted DNA samples to identify mice that contained the 
APC transgene. To control against false negatives, all DNA extracts were initially 
subjected to PCR to amplify a 144 bp fragment of the murine Apc gene. Primers and PCR 
conditions have previously been published (Luongo et al., 1994). 
To detect the presence of the transgene, primers were designed that would amplify a 240 
bp fragment by PCR. The forward primer was situated in the transgene poly -A sequence 
and the downstream primer was the universal M13 reverse primer situated within the p- 
GEM plasmid part of the transgene (see section 5.4.2). 
Primers were: forward 5' CTCTTCATCGGGAATGC 3' 
reverse 5' CAGGAACAGCTATGAC 3' 
PCR cycling conditions were 94 °C for 5 minutes for 1 cycle, 34 cycles of 94 °C for 1 
minute, 55 °C for 30 seconds and 72 °C for 30 seconds. Final extension time was 8 minutes 
at 72 °C. 
5.6.3.3 Results 
Of the 7 pups screened, two were positive for the APC transgene, see figure 19. 
Unfortunately, one transgene positive pup was found dead (pup 7). This pup died aged 4 
weeks and had been noted to phenotypically resemble a runt. It was not possible to 
histologically analyse this pup, as when it was found the tissues were substantially 
decayed. Thus, there was only one founder mouse to establish one transgenic line. 
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Figure 19: Detection of APC founder lines 
The progeny of surrogate mothers, who under went oviduct transfer for oocytes injected 
with the APC transgene, were screened for the presence of the transgene. DNA was 
extracted from tail biopsies of the 7 pups and subject to PCR to amplify a 240 bp 
fragment of the transgene. PCR reactions were electrophoresed through a 3% agarose gel 
containing ethidium bromide. Lanes 1 to 7 represent PCR reactions for progeny 1 to 7, 
Lane 8 is a no DNA template control for the PCR reaction and lane M contains DNA 
molecular weight marker V. Two of the seven progeny were shown to be transgene 
positive (lanes 2 and 7). 
Figure 20: Detection of RNA transcribed from the APC transgene 
RNA was extracted from numerous tissues of transgene positive mice. RNA was subject 
to reverse transcription (rt) to generate cDNA, and samples treated with DNase to 
remove any contaminating DNA. To determine whether rt had been successful, a 
fragment of the [3-actin gene was amplified by PCR; presence of cDNA resulted in a 
460 bp PCR product. PCR reaction mixes were electrophoresed through a 3% agarose 
gel containing ethidium bromide. Figure 20a shows that in all tissues analysed, a PCR 
product of 460 bp was present. Lanes were as follows: 





5: large intestine 







13: mammary gland 
14: salivary gland 
15: positive control cDNA 
16: negative control; cDNA derived from the tail of a non -transgenic animal 
To detect transcription from the APC transgene, cDNA was subject to PCR to amplify a 
137 bp fragment encompassing the 3' terminus of the APC gene and the transcribed 
region of the poly A sequence. To control for amplification of contaminating genomic 
DNA, which would also yield a PCR product of 137 bp, for each tissue a control sample 
was also analysed. In these samples the cDNA had not been subjected to rt. Reverse 
transcribed and non rt samples were loaded adjacent to each other on a 3% agarose gel. 
A 137 bp PCR product was detected for each tissue sample that was subject to rt whilst 
no bands were detected in the corresponding control samples, as seen in figure 20b and c. 
Lanes 1 -14 are loaded as described for figure 20a. M represents molecular weight marker 
V. 
Figure 19: Detection of APC founder lines 
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5.6.4 Determination of transgene copy number by Southern blotting 
Prior to microinjection into fertilised oocytes, the transgene was linearised (see section 
5.6.1). Injection of a linearised DNA constructs results in the DNA being integrated 
randomly into the genome, the DNA may integrate as a single copy or as multiple 
tandemly repeated copies, furthermore integration may occur at multiple sites. To 
determine the transgene copy number and whether integration had occurred at multiple 
sites the Southern blot protocol was used. This method would also confirm the presence 
of the transgene to support the PCR result that may give rise to false positives despite 
negative controls being incorporated. 
5.6.4.1 DNA digestion and Southern transfer 
Twenty micrograms of DNA, extracted from the tail biopsy of the founder mouse, was 
digested with the restriction endonuclease Pmll (methods described in section 5.6.3.1). A 
single enzyme recognition sequence is present within the transgene at position 3165. 
Following restriction endonuclease cleavage of the murine DNA with Pmll and following 
the Southern blotting protocol and subsequent probing of the Southern blot with a 
radiolabelled DNA sequence (see below), one can detect the transgene. Fragments of 
13.2 kb and a further fragment of unknown size, which is determined by the distance to 
the first Pml restriction site in the murine genome from where the transgene has 
integrated, will be detected using the probe. The fragment of unknown size can be used 
as an internal control indicating, by the intensity of the band, one copy of the transgene. 
However, as the size of the fragment is unknown it may not be possible to detect. In this 
experiment, to indicate the intensity of bands in relation to transgene copy number, 201Ag 
of wildtype DNA was spiked with transgene linearised with AspEl to give 1, 10 or 100 
copies of transgene per copy of mouse genome. 
Transgene copy number control samples and the 20µg of the founder DNA cleaved with 
Pmll were electrophoresed through a 0.5% agarose gel as described in section 5.3.2 
with 
the exception that electrophoresis was carried out overnight at 25 volts. DNA 
molecular 
weight marker XII was also electrophoresed through the gel to indicate 
the position of 
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the 13.2 kb fragment. The agarose gel was then placed on an UV transilluminator to 
ensure that all the DNA, and particularly the high molecular weight DNA, had migrated 
into the gel and was significantly separated. A photograph was taken of the gel with a 
ruler placed beside the molecular weight marker lane so that following blotting and 
probing the Southern blot the size of bands detected could be determined. 
The following day DNA within the gel was transferred onto a Nylon hybridisation 
membrane following a modified protocol previously described by Southern (1975). The 
gel was washed in 0.2M HC1 for 10 minutes. This step was incorporated to depurinate 
the DNA to enable better transfer of the high molecular weight DNA. The gel was rinsed 
in DDW and then denatured by washing in 0.4M NaOH for 40 minutes, rinsed and 
washed for 2x 20 minutes in 1M Tris pH 7.2. DNA was transferred from the gel to a 
nylon membrane by capillary action using the following apparatus. A tray was filled with 
20 times SSC (Appendix A) and a perspex plate suspended over the reservoir. A piece of 
Whatman 3MM paper was cut to the width of the gel and laid over the perspex plate. The 
length of the paper was such that it acted as a wick dipping into the SSC solution. The 
gel was placed reverse side up on top of the wick and a piece of Nylon membrane, the 
same size of the gel pre- soaked in 2x SSC, placed on top. Two pieces of Whatman 3MM 
paper were then placed on top of the membrane followed by about 2 inches of paper 
towels. A 1 kg weight was placed on top and the blotting apparatus left overnight. The 
following day the membrane was marked for orientation and washed in 2 X SSC and 
baked for 15 minutes at 100 °C. The membrane was then stored at RT until it was probed. 
5.6.4.2 Labelling DNA probes 
The PCR amplified Poly -A sequence (see section 5.4.2) was used to probe 
the 
membrane. The PCR product was purified though a wizard clean up column to remove 
any unincorporated nucleotides. One microlitre of Wizard clean up resin was pipetted 
into a 1.5 ml microcentrifuge tube and 51.ig of PCR product added. The 
resin and PCR 
product were mixed by gently inverting the tube several times. The 
solution was then 
pipetted into a syringe barrel, which was attached to the Wizard 
minicolumn. The syringe 
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plunger was inserted into the barrel slowly, pushing the solution into the column. Two 
millilitres of 80% (v /v) isopropanol was added and pushed through the column using the 
syringe plunger. The syringe barrel was then removed from the minicolumn, and the 
column seated in a 1.5 ml microcentrifuge tube. The minicolumn was centrifuged at 
13,000 rpm for 2 minutes and then transferred to a new microfuge tube. Fifty microlitres 
0 
of prewarmed (65-70C) TE buffer (Appendix A) was added to the column. Following a 
period of approximately 1 minute, the minicolumn was centrifuged for 20 seconds at 
13,000 rpm to elute the bound DNA fragment. The concentration of the PCR product 
was determined and adjusted to a concentration of 200 ng/µl. The purified PCR product 
was radiolabelled using High Prime kit (Boehringer Mannheim). High prime is a random 
primer DNA labelling method originally developed by Feinberg and Vogelstein (1983) 
whereby a complementary DNA strand is synthesised by Klenow polymerase using the 
3'0H termini of random oligonucleotides as primers and a labelled deoxyribonucleoside - 
triphosphate. 
Seven hundred and fifty nanograms of purified PCR product was denatured by boiling for 
15 minutes and chilling on ice. The volume was adjusted to 111Al and 4tl of high prime 
mix (Appendix A) and 51.1l of 32P dCTP added. The reaction mix was incubated at 37 °C 
for 10 minutes. The labelling reaction was stopped by the addition of 2p1 of 0.2M EDTA 
(pH 8.0). 
5.6.4.3 Hybridisation of Southern membranes 
Hybridisation was carried out in a Hybaid hybridisation oven with rotisserie. Membranes 
were placed in the Hybaid bottles and incubated for 2 hours at 65 °C in 15 ml of pre - 
hybridisation solution (Appendix A) containing 100 tg/ml of denatured sonicated salmon 
sperm DNA. The probe was then denatured by boiling for 5 minutes and placed on ice 
prior to being added to the pre- hybridisation solution to hybridise overnight. Following 
incubation, the hybridisation solution was discarded and the membranes washed at 
65 °C 
with the following different stringency washes; 2 x 15 minutes with 
wash 1, lx 30 
minutes with wash 2 and 1 x 10 minutes with wash 3. For auto radiography 
the membrane 
215 
was wrapped in Saran Wrap and exposed to Kodak Biomax MR film at 
-70 °C for a period of between 1 -4 weeks. Autoradioactive film was subsequently 
developed using an automated film developer. 
5.6.4.4 Southern blot results 
Using the protocol described in preceeding sections I could not determine the transgene 
copy number or confirm the presence of the transgene. No bands were seen in the lane 
loaded with the founder line DNA and no bands were seen in the transgene control copy 
numbers 1 and 10. A band of approximately 13 kb was seen in the lane containing the 
transgene control copy number 100 lane. This indicated that the sensitivity of this 
protocol was not capable of detecting less than 100 copies of transgene and that the 
founder line probably contained less than 100 copies. Increasing amounts of DNA were 
subject to restriction endonuclease cleavage and loaded onto gels (40µg and 60µg). The 
only band to be detected again was a 13 kb band in the transgene control copy number 
100 sample. 
Southern blotting and probing using a 32P radionucleotide probe of between 400 -6000 bp 
has been reported to easily detect single -copy genes in 10µg of human DNA and in 
practice detection in 0.5µg of total DNA is possible (Old and Primrose 1989). It is 
currently unclear why this protocol was unsuccessful and this issue will be discussed 
further in section 5.7. 
5.6.5 Establishing the APC transgene line 
The APC transgene positive mouse (the founder mouse) was used to establish the 
APC 
transgenic line. Initially, the founder mouse, a female, was mated with a 
male mouse 
heterozygous for the Min mutation (Apc+ ' °; see section 5.1.1). Eleven 
progeny were 
produced which consisted of four transgene positive (Tg +) mice, three of 
which were 
homozygous for wildtype Apc (ie Tg +, Apc 
+1 
+), one which was heterozygous for 
the 
Min allele (ie Tg +, Apc + /m1°). F1 Tg+ mice were then utilised in a 
breeding program to 
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`° generate Tg +, Apc mice, which were subsequently interbred in an attempt to 
generate Tg +, Apc 
Min/Min 
mice. The result of this breeding program are presented and 
discussed in section 5.6.9. 
5.6.6 Analysis of transgene expression in transgene positive mice 
Whilst the breeding program was underway, experiments were carried out to determine 
whether RNA was being transcribed from the transgene. Three F 1 mice with the 
genotype 3 Tg +; Apc + 
/+ 
were culled at the age of 2 months. Mice were dissected and 
tissue taken for RNA extraction. Tissue was placed immediately in liquid nitrogen. A 
sample of each tissue was also taken for histological analysis and was placed directly in 
formalin prior to paraffin embedding. 
5.6.6.1 RNA extraction from mouse tissues 
To prevent degradation of RNA, in the following protocol all solutions used are RNAase 
free. Double distilled water has been treated with DEPC (see appendix A) and where 
possible tissues and extracted samples are maintained at 4°C. All equipment that came 
into contact with the tissue or extract was new or had been treated with DEPC water. 
Each tissue for RNA extraction was placed, still frozen, into 1 ml of TRIzol Reagent 
(Life technologies). TRIzol reagent is a mono -phasic solution of phenol and guanidine 
isothiocyanate, which maintains the integrity of the RNA while disrupting cells and 
dissolving cell components. Tissues were homogenised and incubated for 5 minutes at 
RT. Two hundred microlitres of chloroform was added and the tubes shaken vigorously 
for 15 seconds and incubated at RT for 3 minutes. The samples were centrifuged at 
13,000 rpm for 15 minutes at 4 °C, and the aqueous phase containing the RNA was 
removed to a clean tube. Five hundred microlitres of isopropanol was added to each tube 
and the samples incubated at RT for 10 minutes. Precipitated RNA was recovered by 
centrifugation at 13,000 rpm for 15 minutes at 4 °C. The RNA pellet was washed 
in 1 ml 
of 75% ethanol (prepared with DEPC treated water), centrifuged at 6,500 rpm 
for 5 
minutes at 4 °C and the supernatant discarded. The pellet was air dried for 
10 minutes and 
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resuspended in 5000 of DEPC treated DDW and incubated for 10 minutes at 55 °C. 
The yield and purity of the extracted RNA was determined using a spectrophotometer. 
The yield was determined at 260nm where 1 absorbance unit (A260) = 40µg /ml of RNA 
and purity was estimated by the absorbance ratio at 260nm/280nm. An absorbance ratio 
between 1.7 -2.0 was considered acceptable. To ensure there was no contaminating DNA, 
each sample was treated with DNase (Gibco, UK). The protocol was as follows. Two 
micrograms of RNA was incubated for 15 minutes at RT with 2µl of 10X DNase reaction 
buffer (Appendix A), 2µl (1 unit /µl) of DNase 1 enzyme and DEPC treated DDW to a 
final volume of 201.11. DNase was inactivated by the addition of 2µl of 25 mM EDTA and 
incubation at 65 °C for 10 minutes. Samples were centrifuged and placed on ice. 
5.6.6.2 Reverse transcription for the production of cDNA 
One microlitre of oligo (dT) primer (500pg/ml) (Gibco) was added to 141l of the DNase 
treated RNA and the sample heated to 70 °C for 10 minutes then placed on ice. Four 
microlitres of 5x first strand buffer (Appendix A), 211l of 0.1M dithiothreitol and 411 
dNTPs (10 mM each deoxynucleotide) were added and samples heated to 42 °C for 2 
minutes. Two microlitres of superscript II enzyme (200u /µ1) (Gibco) was added and 
incubated at 42 °C for 50 minutes then 70 °C for 15 minutes. 
5.6.6.3 PCR to detect transcription of the APC transgene 
Prior to PCR amplification of the APC cDNA, to control against false negative results, all 
samples were subjected to PCR using primers that would amplify a 460 bp fragment of (3- 
actin cDNA. The primers span an intron and if DNA were amplified rather than 
cDNA 
then a 1 kb PCR product would be generated. The PCR cycling conditions 
used for 
amplification of the cDNA are such that DNA is not amplified. 
upstream 5' CTCCGGCATGTGCAAAG 3' 
downstream 5' CGTAGATGGGCACAGTG 3' 
PCR conditions were 94 °C for 5 minutes, followed by 95 °C for 
45 seconds, 55 °C for 1 
minute and 72 °C for 1 minute for 35 cycles, and a final extension 
time of 72 °C for 10 
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minutes. 
Figure 20 shows the 460 bp fragment amplified from cDNA for the 13-actin gene in all 
tissues analysed. This showed that RNA had been successfully extracted from the tissues 
and, following treatment with reverse transcriptase, cDNA had been produced that could 
be amplified in PCR reactions. 
cDNA was subjected to PCR to amplify a 137 bp fragment that encompassed the 3' 
terminus of the APC gene and the transcribed region of the poly A sequence. To control 
for amplification of contaminating genomic DNA, which would also yield a PCR product 
of 137 bp, RNA prepared following the protocol in section 5.6.6.1, was not subject to 
reverse transcription. 
Primers were upstream 5' CAGCACAGAATCCAGTGGAAC 3' 
downstream 5' CACTGCATTCTAGTTGTGGTTTG 3' 
PCR conditions were 94 °C for 5 minutes, followed by 34 cycles of 94 °C, 58 °C and 72 °C 
all for 30 seconds, and a final extension time of 72 °C for 9 minutes. Figure 20a shows 
that a fragment of 137 bp was amplified from all tissues analysed and therefore RNA was 
being transcribed from the transgene. All controls, samples not subject to reverse 
transcription, were negative indicating that the bands seen are not a result of amplification 
of any contaminating DNA. 
5.6.7 Analysis of transgene positive embryonic fibroblasts 
To confirm that the DNA sequence between the loxP sites could be excised from the 
transgene in an eukaryotic system, transgene positive embryonic fibroblasts (EFs) were 
derived and infected with a replication deficient adenovirus that carried the gene encoding 
Cre- recombinase. To indicate that the adenovirus infection had been successful, EFs were 
also infected with a replicative deficient adenovirus carrying the 
13-galactosidase gene. The production of the bacterial enzyme p- galactosidase (I3-gal) can 
be detected using a chromogen substrate 5- bromo-4-chloro-3- indolyl- p- D- galactoside 
(X -gal). X -gal is cleaved by p- galactosidase releasing a blue indolyl derivative. 
In the 
following protocols, EFs were cultured and all incubations were carried out 
at 37 °C in a 
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5% CO2 humidified incubator unless stated otherwise. All solutions used were sterile. 
5.6.7.1 Derivation of Embryonic Fibroblasts 
A transgene positive male mouse was crossed with a transgene negative female. The 
mothers was sacrificed at 13 days post -coitum and the uterus removed and placed into a 
petri -dish containing PBS. Embryos were isolated from the uterus and the yolk sac and 
placenta of each embryo removed and discarded. Each embryo was decapitated and 
placed in 70% ethanol for approximately 2 minutes to reduce the risk of microbial 
contamination during culturing. Embryos were placed into sterile universals containing 
PBS and 2.5% trypsin and were then homogenised using dissecting scissors, and 
incubated for 15 minutes. Following incubation, 8 mis of EF culture medium (Appendix 
A) was added to each universal to neutralise the trypsin. The embryonic cells were 
centrifuged for 3 minutes at 1,100 rpm, the supernatant removed and the cells 
resuspended in 20 ml of EF culture medium and placed into a 75cm2 tissue culture flask 
(Costar). The flasks were incubated at 37°C in a 5% CO2 humidified incubator. 
5.6.7.2 Culturing, and freezing embryonic fibroblasts 
Embryonic fibroblasts were cultured until confluent and then harvested by trypsinisation. 
This involved aspirating off the culture medium and adding 5 mis of PBS containing 
0.25% trypsin and 0.02% EDTA to each flask. Flasks were incubated at RT for 
approximately 5 minutes (until the EFs had dissociated from the bottom of the flask) and 
the cell suspension was then pipetted into sterile universals. EFs were centrifuged for 5 
minutes at 1,100 rpm. The supernatant was removed and the cell pellet resuspended in 5 
mis of PBS. The number of cells per flask was determined by standard procedure using a 
haemocytometer. Some of these cells were stored for further experiments whilst DNA 
was extracted from the remaining cells (see below). 
5.6.7.3 Freezing embryonic fibroblasts 
For each embryo, 2 vials of EFs were frozen and stored for further experiments. 
The 
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following procedure was used; 1 X 106 cells were removed, pelleted by centrifugation at 
1,100 rpm and resuspended in 2 mis of EF freezing medium (Appendix A). One millilitre 
of the suspended cells was pipetted into each cryovial (Costar) and placed at 
-70 °C. 
5 6.7.4 DNA extraction and PCR protocol to determine the transgene status of embryonic 
fibroblasts 
DNA was isolated from EFs to determine transgene status. 1 x106 cells prepared as 
described in section 5.6.7.1 and 6.6.7.2, were centrifuged at 1,100 rpm and resuspended 
in 40011l of DNA lysis buffer (see appendix A). DNA extraction was carried out 
following the protocol in section 3.3.3, without methods for paraffin removal. Transgene 
status was determined using PCR, primers and conditions are shown in section 5.6.3.2. 
5.6.8 Excision of floxed APC cDNA in embryonic fibroblasts 
5.6.8.1 Adenovirus infection 
Embryonic fibroblasts derived from a transgene positive embryo were removed from 
-70°C. The cryovial was thawed rapidly by placing in warm water. Following thawing 
EFs were removed from the vial and placed in a sterile universal with 10 ml of EF culture 
medium (Appendix A). Cells were gently mixed by inverting the universal and then 
pelleted by centrifugation at 1,100 rpm for 5 minutes. The EFs were resuspended in 
another 10 ml of media and centrifuged again. This washing procedure was carried out to 
remove all traces of freezing medium as it contains DMSO which is toxic to the cells. The 
EFs were then resuspended into 1 ml of EF culture medium and the number of cells per 
flask determined by the use of a haemocytometer. Four x 105 cells were seeded into each 
of four 25cm2 tissue culture flasks, 4.75 ml of EF culture medium was added 
and flasks 
were incubated overnight to allow the cells to attach to the bottom of 
the flask. The 
following day the old EF medium was aspirated off and the following 
solutions, as stated 
in table 11, were applied to each flask in a volume of 1 ml of fresh EF 
medium. 
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Table 11: Infection of embryonic fibroblasts with adenovirus 
Flask 1 1.2 x 10 pfu of Adenovirus /Cre recombinase Demonstrate excision 
Flask 2 1.2 x 10' pfu of Adenovirus/ ß- galactosidase Control for excision 
Flask 3 1.2 x 10' pfu of adenovirus/ ß- galactosidase Demonstrate infection 
Flask 4 1 ml of EF culture medium Control for excision 
The multiplicity of infection (MOI) required to give a high percentage of adenovirus 
infection had previously been determined by Elizabeth Lovejoy to be 50 (ie 50 particle 
forming units (pfu) /cell). Therefore, when infecting 2.4 x 105 cells, 1.2 x 10' pfu of 
adenovirus was required. 
Flasks were incubated for 1 hour with occasional shaking. Following incubation, the EF 
medium was removed and 5 ml of fresh EF medium added to each flask. Flasks were 
incubated for 48 hours. After 48 hours, fibroblasts from flasks 1, 2 and 4 were harvested 
by trypsinisation and DNA extracted following the protocols outlined in section 5.6.7. 
Flask 3 was analysed to determine whether the adenovirus infection had been successful. 
Embryonic fibroblasts were washed twice with 5 mis of PBS. One millilitre of 
freshly 
prepared cell fixative (Appendix A) was added to the flask and incubated 
for 4 minutes. 
The fixative was removed and the flask was rinsed twice with 5 ml 
of PBS. Two 
millilitres of ß- galactosidase stain (Appendix A) was then added and the flask 
incubated 
overnight. The following day the stain was removed, 5 ml of PBS added 
and the cells 
were examined under the microscope. In virtually all of the 
EFs the blue indolyl 
derivative, which results from the cleavage of X -gal by J3- galactosidase, 
was noted. The 
derivative was present in both the cytoplasm and nuclei of EFs. 
I estimated that 80% of 
EFs had been infected by adenovirus carrying the ß- galactosidase 
gene. 
5.6.8.2 Detection of Cre recombinase mediated excision 
DNA was extracted from flasks 1, 2 and 4, as described 
in section 5.6.7.4. PCR was used 
to determine that Cre mediated excision had occurred. 
The DNA template derived 
from 
each flask was subjected to PCR to amplify the murine 
Apc gene to ensure that the 
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extracted DNA was amplifiable. PCR primers and conditions have previously been 
described in section 5.6.3.2. In all cases, the PCR was successful. 
The DNA was then subjected to PCR to detect the presence or absence of the transgene. 
The forward primer was situated in the transgene poly -A sequence and the downstream 
primer was the universal M13 reverse primer situated within the p -GEM plasmid part of 
the transgene. PCR primers and conditions have been previously described, see section 
5.6.3.2. If the APC transgene is present a 240 bp PCR product is produced, one would 
expect to see amplification of a 240 bp fragment in the two control flasks, flask 2 
(infected with adenovirus expressing 13-galactosidase) and flask 4 (not infected with 
adenovirus). No band was expected to be seen in Flask 1 that was infected with 
adenovirus expressing Cre recombinase as the sites for the primers would have been 
excised following Cre mediated recombination. A 240 bp fragment was detected 
following amplification of DNA derived from all 3 flasks, see figure 18b (i). As the 
fragment was detected in flask 1 this suggested that Cre mediated recombination had not 
occurred, or had not occurred in all cells. The latter is likely as I had previously estimated 
that 80% of embryonic fibroblasts were infected with adenovirus using this protocol (see 
section 5.6.8.1). Alternatively, this result may implicate reinsertion of the excised 
fragment (discussed in section 5.1.2.1). 
PCR was then used to detect excision of the DNA sequence that lies between the two 
loxP sites within the transgene. Primers used were the universal M13 forward and M13 
reverse primers (see section 5.4.2 and 5.4.3) situated at the 5' and 3' end of the linearised 
construct (AspE] ). If the APC cDNA were excised then a PCR product of 190 bp would 
be produced. If however, the sequence was not excised then the distance for the 
amplification would be greater than 13 kb and would not be detected by the PCR. 
The conditions for PCR were 94°C for 5 minutes, followed by 34 cycles of 95°C 
for 30 
seconds, 55°C for 30 seconds, 72°C 30 seconds. A final extension time of 
72°C for 8 
minutes was included. Following the PCR reaction, samples were 
electrophoresed 
through a 3% agarose gel. A 190 bp fragment was produced from 
the DNA template 
derived from flask one indicating that Cre mediated recombination 
had occurred. No 
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band was seen following amplification of DNA derived from the control flasks, flasks 2 
and 4. Results are shown in figure 18b (ii). 
This experiment has shown that Cre mediated excision is occurring between the two loxP 
sites within the APC transgene, however, from these experiments I can not determine 
with what efficiency excision is occurring. As the transgene has probably integrated into 
the mouse genome in a tandemly repeated array, the transgene may be lying in a tail to 
tail or head to head orientation. If this was the case then numerous possibilities exist for 
excision and inversion events, due to the orientation of the loxP sites. This experiment 
does not address this issue and will be discussed further in section 5.7. 
5.6.9 Summary of breeding program 
After 11 months, 155 mice had been generated. Thirty two had the genotype Tg +; Apc 
+i+, 
58 Tg -; Apc 
+/+, 43 Tg +; Apc 
+'1' 
and 22 Tg -; Apc + /M'°. Raw data are shown in Appendix 
E. 
Of the 32 Tg +; Apc 
+i 
+, three were culled for detection of transgene RNA (see section 
5.6.6) and 1 for the derivation of embryonic fibroblasts (see section 5.6.7). Three mice 
had died due to the mother not feeding. The age of the remaining 25 mice ranged from 
178 -305 days. To date these mice, who should overexpress APC, appear phenotypically 
normal. 
Forty -three mice had a genotype Tg +; Apc +u°. Four were culled for the production 
of 
embryos (see section 5.6.10), and one had died within one month; phenotypically 
this 
mouse was a runt. Twenty -two mice had the genotype Tg -; Apc +'°. Genotypes 
are 
shown in table 12. 
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Table 12: Summary of genotypes 
Genotype No. of 
Mice 
Comments Final No. 
of mice 
Tg +; Apc 
+1+ 32 Cull 3; detection of transgene 
RNA. 
Cull 1; derivation of embryonic 
fibroblasts. 
3 died; mother not feeding. 
25 
Tg -; Apc 
+i+ 58 58 
Tg +; Apc + 
/M`n 43 Cull 4; Analysis of embryos. 
1 died; runt. 
38 
Tg -; Apc 
+IMm 22 22 
Ideally, to determine whether the APC transgene could reduce or eliminate the phenotype 
seen in Apc +1`" mice, one could compare survival of Tg +; Apc +1'" and Tg -; Apc +'M'" 
mice. However, a direct comparison can not be made because the age and the genetic 
background of these mice vary, being either 75% or 87.5% C57BL /6. Previous studies 
have shown that the number and age at which the colonic adenomas appear is related to 
the genetic background (discussed in section 5.1.1). Therefore, the data are presented 
taking these two factors into account. Raw data are shown in Appendix E, and 
is 
summarised in table 13. Results included in this table are until 1s` May 1999. 
Maintenance 
of the transgenic colony and harvesting of the mice as from the 4`11 December 
1998 were 
carried out by Owen Sansom and Jason Reed. 
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Table 13: Analysis of Apc heterozygous mice. Figures represent the number of mice that 














198 0/1 0/1 
202 0/5 0/1 
207 0/4 
214 0/1 0/2 
221 0/1 
226 0/1 0/3 
231 0/1 0/2 
233 0/1 
237 0/2 1/2 Cull Mammary tumour/ 
adenomas aged 233 days 
241 1/1 0/2 Cull adenomas, aged 213 
days 
260 1/1 0/2 Cull adenomas aged 232 
days 
258 1/5 1/2 Tg+ Cull adenomas aged 
226 days 
Tg- Cull adenomas aged 
212 days 
265 0/1 
269 0/1 0/1 
0/1 Cull adenomas aged 281 
days 
286 1 /2 




Analysis of the data in table 13 suggests that the presence of the APC transgene does not 
result in the elimination or reduction in the frequency of the Apc + /min phenotype being 
detected. A total of 33 Apc 
+/Min 
mice on a 87.5% C57BL /6 background were analysed 
using the Chi squared test to determine whether there was a significant difference 
between the number of mice developing adenomas with the prescence or abscence of the 
APC transgene. Five out of 15 transgene positive mice were culled due to adenomas 
whilst 2/18 transgene negative mice were culled. No significant difference was found 
(x2= 2.418; p= 0.12). 
To determine whether the transgene could rescue the embryonic lethal phenotype 
associated with the homozygous Min genotype, transgene positive mice who were 
heterozygous for the Min allele were interbred. From such matings, one would expect 
75% of offspring to be transgene positive; of which 25% would be homozygous for the 
APC wildtype allele, 50% heterozygous for the Min allele and 25% homozygous for the 
Min allele. 
Forty eight mice were generated, one may expect to see 36 transgene positive mice of 
which 9 would be homozygous for the Apc wildtype allele; 18 heterozygous for the Min 
allele and 9 homozygous for the Min allele. In this study 38 mice were transgene positive, 
26 were heterozygotes (Apc + /M' ") whilst 12 were homozygous for the Apc wildtype allele 
(Apc + / ). No offspring were generated that were homozygous for the Min allele. Chi 
square test was used to determine whether there was a significant difference between the 
observed frequency of Tg+ Min homozygotes (0/48) versus the expected number of Tg+ 
Min homozygotes (9/48), results were statistically significant with x2= 11.08; p <0.001. 
Results are summarised in table 14. It appears that the APC transgene is unable 
to rescue 
Min/Min 
embryonic lethal phenotype associated with the Apc genotype. 
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Table 14: Analysis of Tg +; Apc +m''n crosses following the generation of 48 progeny 
Genotype Expected number (assuming 
no embryonic lethality) 
Actual number 
Tg+ 36 38 
Tg +; Apc ++ 9 12 







Tg- 12 10 
Tg -; Apc i + 3 5 
+ 
in Tg -; Apc 6 5 
Tg 
Mi in 3 0 
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5.6.10 Analysis of embryos to determine whether the APC transgene results in 
partial rescue of the embryonic lethal phenotype 
To determine whether the transgene could result in partial rescue, ie if transgene positive 
Apc Min/Min mice were viable for a longer period during development than that seen in Apc 
Min/Min (see section 5.1.1), matings were set up between Tg +; Apc +rn2'n mice. The date of 
coital activity was marked by the presence of a copulatory plug. At 8 dpc female mice 
were sacrificed by cervical dislocation and the uterus removed and placed into a petri dish 
containing PBS. Embryos were isolated from the uterus, numbered and placed in 70% 
ethanol. Using a dissection microscope, the yolk sac from each embryo was removed and 
placed into a sterile eppendorf. The placenta was discarded. All embryos within the litter 
were analysed by eye to determine whether any development abnormalities could be 
detected (carried out by Dr Alan Clarke). Following visual examination, the embryos 
were placed into 4% formalin prior to paraffin embedding. 
DNA was extracted from the yolk sacs and subjected to PCR to determine the transgene 
status of the embryo. Methods have been described previously in sections 5.6.7.4 and 
5.6.3.2. 
5.6.10.1 Results 
Twenty -one embryos were isolated from 4 females. Despite attempting to harvest 
embryos at 8 dpc, in some cases the embryos from litters were a couple of days older or 
younger. Two embryos were noted to exhibit exencephaly, the age of these embryos were 
day 9 and day 10. Eighteen embryos were transgene positive, of which 6 
were Apc 
wildtype and 12 were Apc heterozygotes. No embryos homozygous for the 
Min mutation 
were detected. There was a statistically significant difference between the 
observed (0/21) 
and expected (4/21) frequency of Apc Min homozygotes, (x2= 4.941; p <0.05). 
This result 
indicates that the APC transgene is not partially rescuing the 
Min homozygous 
phenotype. The genotypes of all embryos and the expected number 
of embryos for each 
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genotype are shown in table 15. Both mice exhibiting exencephaly had the genotype Tg +; 
A P 
+/Min 
Table 15: Genotypes of 21 embryos generated through mating Tg +; Apc +/Min mice. 
Genotype Expected number 
(assumming no embryonic 
lethality) 
Actual number 
Tg+ 16 18 
Tg +; Apc 
+1+ 
4 6 
Apc + m 8 12 
Tg +; Apc Min/Min 4 0 
Tg- 5 3 
Tg -; Apc 
+/+ 
1 1 
Tg -; Apc 
+/Min 3 2 
Tg -; Apc Min/Min 1 0 
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5.7 Discussion 
The APC transgene was successfully constructed and contained the APC cDNA sequence 
situated upstream of the SV40 poly A sequence. The expression of the transgene was 
driven by the promoter sequence of the murine Pgk gene; a gene that is ubiquitously 
expressed (McBurney et al., 1991; 1994; Sutherland el al., 1995). The APC cDNA, poly 
A and promoter sequences were flanked by loxP sites which lie in the same relative 
orientation in order to excise the intervening sequences following exposure to Cre 
recombinase (see section 5.1.2.1). Prior to injecting the transgene into oocytes for the 
production of transgenic mice, experiments were carried out to determine whether the 
DNA sequences, which lie between the two -loxP sites, could be excised in the presence 
of Cre -recombinase. This was carried out by transforming the transgene into a strain of 
E.Coli, which constitutively expresses Cre recombinase. Analysis of clones, which 
resulted from this transformation, showed that the DNA sequence between the loxP 
sequences could be efficiently excised from the transgene. No excision was seen 
following transformation of the incomplete transgene, which lacked one loxP site (see 
section 5.5.1). 
The transgene was injected into the pronuclei of 110 oocytes; this resulted in the 
production of 13 pups. The number of pups born was a lot lower than had been expected, 
one would expect approximately one third of injected oocytes to result in live pups, 
therefore the expected number would be 39 (Dr A Mackenzie, personal communication). 
The low number observed may be an indication that a threshold exists where 
overexpression of APC results in embryonic lethality (discussed further below). 
Of the 13 pups, six were lost due to water run outs within the cages, this occurred 
before 
the pups could be screened for the presence of the transgene. The remaining 
7 pups were 
screened and two were shown to be transgene positive. One of the transgene 
positive 
mice was very weak and subsequently died aged 4 weeks. This mouse 
may have been a 
runt. Alternatively death may have been a result of the transgene 
integrating and 
disrupting a critical gene, or due to the level of APC expression. 
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There is evidence to suggest that overexpression of APC results in a phenotype in 
developing mouse embryos. Chimeric transgenic mice have previously been generated 
which express APC cDNA in intestinal and stomach epithelial cell lineages from 
embryonic day 15 (Wong et al., 1996). Mice were viable and there was no significant 
difference in body weights between APC chimeras and normal mice. Analysis of the 
intestine epithelium revealed disordered cell migration. This phenotype was shown not to 
be caused by disruption in the levels of apoptosis or cellular proliferation, but was a result 
of disruption of cell adhesion, which resulted in the production of a non -adhesive 
migratory phenotype. It is still unclear how the APC protein regulates cell adhesion and 
cell migration. 
Cell adhesion plays a critical role in embryonic and organ development and maintenance 
of tissue integrity (Takeichi 1995; Gumbiner 1996; Vleminckx 1999). The current 
understanding of Apc's role in cell adhesion is discussed in section 2.7. Briefly, APC can 
bind to free ß- catenin, ß- catenin that is not already in a stable complex with cadherin at 
the cell membrane and form a complex with Axin. This complex is phosphorylated by 
GSK -3ß, and ß- catenin is targeted for degradation. One may propose that increased 
levels of APC may result in a decrease in cell adhesion, resulting from increased ß- catenin 
degradation and hence reduced (3- cateninlcadherin complexes. However, in the study by 
Wong and co- workers overexpression of APC in chimeras did not result in a decrease in 
ß- catenin levels. 
In vitro studies have shown that the APC protein associates with microtubules and is 
localised in punctate clusters near the ends of microtubules that protrude into actively 
migrating membrane structures, this suggests that APC has a role in microtubule 
dependent cell migration (see section 2.3.4). The importance of APC in cell migration 
has 
recently been elucidated by the analysis of the Min model, mice who harbour 
a mutation 
at codon 850 (Mahmoud et al., 1997). When compared to wildtype mice 
on the same 
genetic background, analysis of histologically normal intestinal epithelium 
exhibited 
elevated ß- catenin expression which was associated with decreased 
proliferation, 
decreased apoptosis and a decreased rate of enterocyte crypt -villus 
migration (Mahmoud 
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et al., 1997). 
It is likely that the level of APC expression will influence whether transgenic mice are 
viable. As the amount of APC expressed within each injected oocyte will vary, due to the 
transgene copy number, and to some extent, on the position of integration, then some 
mice may be viable and some may not. The level of expression may be such that a live 
pup is born but cannot survive. 
To determine the transgene copy number in the surviving mouse, Southern blot protocol 
was used. However, despite numerous attempts, the sensitivity of the procedure could 
not be increased sufficiently to detect less than 100 copies of the transgene per single 
copy of murine genome. The amount of genomic DNA analysed was increased from 
101.1g up to 60 µg, this a relatively large amount of DNA to be used for this protocol as it 
has been reported that a single -copy of a gene can be detected in 10µg of human DNA 
(Old and Primrose 1989). It is possible that during the extraction, the DNA was 
excessively sheared or may have been degraded so that large molecular weight fragments 
were not present. The APC transgene is a relatively large fragment of 13.2 kb. If this 
were the case then, following incubation of the DNA sample with the restriction 
endonuclease and subsequent electrophoresis through the agarose gel, the majority of the 
DNA would appear as low molecular weight DNA. This was not the case as an intense 
streak of DNA was seen along side the full length of the molecular weight markers. This 
result also indicated that the DNA was being successfully transferred onto the Nylon 
membrane. Future experiments need to be carried out to increase the sensitivity of this 
protocol, one may use a probe targeted at a different region of the transgene, or the 
hybridisation conditions and stringency washes could be varied. 
The failure to detect the APC transgene by Southern blot protocol also meant that 
I could 
not determine whether progeny generated during the breeding program 
were 
homozygous or heterozygous for the transgene. If the Southern blot protocol 
had been 
successful, mice heterozygous for the transgene could have been detected 
by a two -fold 
increase in the intensity of a 13.2 kb band detected by autoradiograph 
when compared to 
the heterozygous mouse DNA. 
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The transgene positive founder mouse was enrolled in a breeding program to establish 
transgene positive Apc Min homozygotes (Tg +; Apcmitilmin) on a pure bred C57BL /6 
background. Therefore, mating was carried out with the Min mouse (Apc +1M'°). During 
the program thirty -two Tg +; Apc mice were generated. Three of these mice were culled 
to determine whether RNA was being transcribed from the transgene. RNA was 
extracted from various tissues (tissues are listed in figure 20) and subjected to reverse 
transcription PCR. In all tissues tested (see figure 20), transgene specific RNA was 
detected, all negative controls were negative. One would expect to see expression within 
all tissues as the promoter sequence, derived from the Pgk gene, is ubiquitously expressed 
(McBurney et al., 1991; 1994; Sutherland et al., 1995). This experiment was not 
designed to determine the level of expression within each tissue, but this could be 
included in later experiments. 
To determine the presence of transgene specific protein, immunohistochemistry may be 
carried out using an antibody that recognises the human APC protein but not murine Apc 
protein. One such antibody is a commercially available (Oncogene research product, 
MA), in future studies this antibody could be optimised and used for the detection of the 
protein transcribed from the APC transgene. 
The three mice, which were culled to detect RNA production and the remaining 25 mice 
which overexpress APC, whose ages range from 178 to 305 days, appear phenotypically 
normal. As a previous study has shown that forced expression of APC within the intestine 
results in disordered migration of cells up the colonic crypt (Wong et al., 1996), one may 
expect a similar phenotype in mice from this study. Initial analysis of tissue sections taken 
from three mice with this genotype (Tg +; Apc 
+i 
+), showed no evidence of disordered 
migration within the colon. No histological changes were noted in any of the other tissues 
analysed (see figure 20 for tissues analysed). The transgene chimeric mice generated by 
Wong and co- workers, expressed APC cDNA under the control of a fatty acid binding 
protein gene promoter (Fabpl). The promoter has been extensively characterised 
in 
transgenic and chimeric transgenic animals and is shown to direct gene expression 
along 
the entire length of the crypt -villus (Kim et al., 1993; Hermiston and 
Gordon 1995; 
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Hermiston et al., 1996). Expression is initiated in proliferating crypt epithelial cells and is 
sustained as all lineages complete their migration- associated differentiation (Trahair et al., 
1989). Conversely, the Pgk promoter sequence is known to drive a high level of 
expression in proliferating cells and a lower level in more differentiated cells, therefore 
the level of expression is likely to decrease from crypt to villus. The difference in 
promoter activity between these two models may result in phenotypic differences. To 
conclude whether a phenotype is associated with expression of the APC transgene in this 
study more mice need to be analysed. Furthermore, as these mice were heterozygous for 
the transgene, homozygous mice need to be examined to determine whether in cases 
where twice as much APC protein is expressed (transgene specific ) a phenotype is 
exhibited. 
Mice on a pure bred C57BL /6 background, which are heterozygous for the Min allele, 
develop multiple colonic adenomas (average number 50) at approximately 5 months (155 
days) of age (see section 5.1.1). Symptoms of multiple adenomas, include anaemia (as 
determined by white feet), blood in the faeces and ultimately blockage of the colon. One 
aim of this study was to determine whether the presence of the APC transgene could 
reduce the number of adenomas and hence delay the onset or even completely eliminate 
this phenotype. As the age at which adenomas develop and the number of adenomas 
present per mouse has been shown to be dependent on the genetic background (see 
section 5.1.1) the data collected must be analysed according to the genetic background of 
the progeny, in this case either being 75% or 87.5% C57BL /6. 
To date, no mice on a 75% C57BL /6 background were culled due to illness. The 
age of 
these mice ranged from 177 -214 days and consisted of 23 Tg +; Apc 
+lM' mice and 3 
Tg -; Apc 
+im", 
mice. The low number of Tg negative mice prevents me from commenting 
on whether, in this group of animals, the transgene is having any effect. 
Thirty -three mice on an 87.5% C57BL /6 background were analysed 
(see table 13), this 
group consisted of 15 mice with the genotype Tg+ Apc +'° and 18 with the 
genotype 
Tg -; Apc + /M'° . To date, 7 mice have been culled due to illness, 
all exhibited symptoms of 
colonic adenomas and adenomas were detected in the small intestine 
following dissection. 
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The number of adenomas per mouse has not yet been determined. Statistical analysis has 
shown that there is no significant difference between the number of Tg +; Apc'Imin mice 
i /Mn 
(5/15) and Tg -;Apc mice (2/18) developing ademomas (x2= 2.418; p =0.12) These 
data therefore suggest that the transgene is not able to rescue the Apc +'n phenotype. 
The average age of death of transgene negative mice was 222 days, whilst for transgene 
positive animals it was 257 days. As expected, the age of death is greater than that seen 
on a pure C57BL /6 background. 
Elimination or reduction in the severity of the phenotype may only occur in transgene 
homozygotes, in this study progeny were derived either from interbreeding Tg +'-; Apc +/Min 
genotypes or Tg 
+/-; 
Apc +/M`n with Tg -/ -; Apc + /M'n mice. Therefore, the number of progeny 
which would be homozygous for the transgene would be less than 25% (estimated at <8). 
During the breeding program, 48 transgene positive mice were generated from 
interbreeding Tg 
+i 
-; Apc mice. The relative percentage of each possible genotype from 
these offspring, in the absence of embryonic lethality, would be expect to be 25% Apc 
+I+; 
50% Apc+fmin and 25% ApcM;nmm'n Twenty -five percent (12/48) were homozygous for the 
wildtype allele (Apc 
+i 
+), 54% (26/48) were heterozygotes (Apc +1`n). No offspring were 
generated that were homozygous for the Min allele. One may expect to see 
approximately 9 progeny with this genotype generated from such matings. Using a chi 
square test the difference between the expected and observed frequency is statistically 
significant 0C2= 11.08; p <0.001). Therefore, it appears that the APC transgene is unable to 
rescue the embryonic lethal phenotype associated with the Apc mi'n genotype. 
However, it may be necessary for the offspring to be homozygous for the transgene. One 
would expect 25% of progeny from these matings to have the genotype Tg 
+o, of which, 
25% would be homozygous for the Min allele. This equates to 12 Tg 
+' ++ 
mice, 3 of which 
would be predicted to be homozygous for the Min allele. In conclusion, 
more mice need 
to be generated to say with confidence that homozygosity for the 
transgene does not 
rescue the embryonic lethal Min phenotype. 
In previous studies embryos homozygous for the Apc Min allele 
show development 
abnormalities at 6.5 days post coitum (dpc), embryos fail 
to develop the primitive 
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ectoderm and die before day 8 gestation (see section 5.1.1). By mid gestation 
(approximately 10 dpc) homozygotes consist of a mass of trophoblast giant cells with an 
additional cluster of much smaller embryonic cells. To determine whether the transgene 
could result in a partial rescue of the embryonic phenotype, i.e. whether expression could 
increase embryonic viability, Tg+ Apc 
+im'n 
crosses were set up and the embryos harvested 
at 8 dpc. Twenty -one embryos were isolated from four females. Despite attempting to 
harvest embryos at 8 dpc, in some cases the embryos from litters were a couple of days 
older or younger. Eighteen out of the 21 embryos were transgene positive, of which 12 
were Apc heterozygotes and six were Apc wildtype. No embryos homozygous for the 
Min mutation were detected. One may predict from such mating, 5 embryos would be 
homozygous for the Min allele. Using statistics to analyse the observed number of mice 
(0/21) compared to the expected number mice (4/21) with this genotype, this result is 
statistically significant (x2= 4.941; p <0.05). These data suggest that the APC transgene is 
not able to partially rescue the Min embryonic lethal phenotype. 
Two embryos were shown to exhibit exencephaly, both of which had the genotype 
Tg +; Apc +imin. The age of these embryos was day 9 and day 10. Exencephaly has been 
noted to occur in a low percentage of embryos generated from Apc crosses (Dr J. 
Armstrong personal communication). It is therefore unclear whether this phenotype is a 
result of the presence of the transgene. To determine whether this is the case, more 
embryos need to be analysed and the relative frequency of exencephaly between 
transgene positive heterozygotes and transgene negative heterozygotes determined. 
The breeding program will be continued to increase the numbers of progeny which 
overexpress APC and the number of transgene positive and negative Apc heterozygotes. 
Ideally, all mice will be on the pure bred C57BL /6 background so that 
comparisons 
between the phenotypes exhibited by different genotypes can be 
made without the 
influence of modifier loci (see section 5.1.1). More embryos will 
be harvested to 
determine whether the transgene can result in partial rescue of the 
Apc 
Min/Min embryonic 
lethal phenotype and to conclude whether exencephaly is associated 
with the presence of 
the APC transgene. 
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Once a large colony of mice has been established and the mice fully characterised, 
experiments may be carried out to excise the transgene. Ideally, I hoped to see embryonic 
rescue or partial rescue of the homozygous Min phenotype, and subsequently the APC 
transgene could be excised in a temporal or tissue specific manner, and the role of APC in 
development or the adult tissue further elucidated. The Cre gene could be delivered using 
the replication deficient recombinant adenovirus (described in section 5.1.2.2b and 5.6.8), 
resulting in global or tissue specific APC excision, or following breeding with Cre 
transgenic mice. 
Within this department several transgenic mice which expresses Cre are available or are 
currently being developed. These include mice who express Cre specifically in lung tissue 
(under the control of a lung specific promoter), mammary tissue (under the control of the 
ß- lactoglobulin promoter, Seibert et al., 1997) and transgenic mice which express Cre 
specifically in the intestine and whose expression can be controlled in a temporal manner. 
In the latter case, expression is driven by the Cdx -1 promoter sequence (Meyer and 
Gruss, 1993). To confer temporal control of Cre expression, Cre is being expressed as a 
fusion protein with a mutant oestrogen receptor ligand- binding domain (see section 
5.1.2.2a). The mutated oestrogen receptor ligand- binding domain is insensitive to the 
endogenous hormone ß- oestradiol but still responsive to the synthetic oestrogen 
antagonist 4- OH- tamoxifen (Schwenk et al., 1998). 
Therefore, this APC transgenic mouse model has a great deal of potential. However, to 
date it has not been established whether a protein product is being produced from the 
transgene. Immunohistochemical studies are of high priority. It is possible that during in 
vitro manipulation of the APC cDNA, a mutation within the cDNA may have occurred. If 
it was such that this resulted in the production of a premature translation stop codon, 
then a truncated product may be produced. The human specific APC antibody which 
would be used (APC Ab -4, Oncogene research products) is raised to the carboxyl 
terminus of the protein and hence protein would not be detected. This antibody is not 
suitable for western blotting techniques so a truncated product could not be detected 
by 
this means. If no protein were detected following immunohistochemical analysis then 
the 
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next step would be to sequence the transgene. This is a very large sequence and would be 
expensive and time consuming. 
Another potential problem associated with this model is that human APC cDNA was 
used. Despite high homology between species (see section 2.5), this may result in a 
phenotype. Secondly, numerous transcripts have been shown to be produced from the 
APC gene as a result of alternative splicing (reviewed in section 2.2). Since the isolation 
of the APC cDNA sequence, which was used to generate this transgenic model (Groden 
et al., 1991), four exons have been identified which are situated upstream of the original 
exon 1. These exons are not present within the cDNA sequence. Splice variants 
generated from these additional exons have been shown to be present at elevated levels in 
postmitotic and terminally differentiated tissues (Santoro and Groden 1997) suggesting 
that different APC isoforms may be involved in the physiology of cell cycle cessation. In 
this model, no splice variants are produced and all APC exons (1 -15) are transcribed and 
translated, therefore,if different isoforms of APC specify various cellular functions, these 
specific functions may not be carried out in this model. 
Since the initiation of this project, Shibata and co- workers have published details of a 
floxed Apc transgenic mouse. Exon 14 of the Apc gene has been floxed and mice 
generated which are homozygous for this feature (Shibata et al., 1997). Delivery of Cre 
recombinase to these mice resulted in deletion of the loxP flanked exon 14 and also the 
introduction of a frame -shift mutation at codon 580. Protein produced from this gene 
would contain the homodimerisation domain and part of the armadillo repeats (see 
section 2.3), all downstream domains would be lost. Adenovirus encoding the Cre 
recombinase gene was delivered via enema to the intestine and resulted in the deletion of 
Apc exon 14 within the large intestine. Unfortunately, this delivery method was inefficient 
and only a small area of the intestine underwent Cre mediated excision. Within this 
area, 
the mice developed adenomas within approximately 4 weeks. This 
model will allow 
extensive analysis of the function of APC in both embryogenesis and the adult 
tissue. 
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Chapter 6: Summary 
APC is well established as a tumour suppressor gene and inactivation of the gene is 
associated with numerous types of cancer. Germline mutations within the APC gene 
predispose individuals to FAP, a disease whereby multiple adenomas develop within the 
colon predisposing the individual to colorectal cancer and in some instances extracolonic 
manifestations (Bodmer et al, 1987; Leppert et al., 1987; Dunlop et al., 1990). Analysis 
of subsequent tumours reveals mutation or loss of the remaining APC allele (Nishisho et 
al., 1991; Groden et al., 1991). Biallelic inactivation of the APC gene has also been 
reported in sporadic colorectal, gastric and hepatic cancers (Nishisho et al., 1991; 
Groden et al., 1991;Tamura et al., 1994; Oda et al., 1996; Imai et al., 1997). Mutations 
within the APC gene have also been detected in pancreatic, oesophageal and prostate 
cancers (Yashima et al., 1994; Horn et al., 1992a; Powell et al., 1994; Watanabe et al., 
1996; Gonzalez et al., 1997). It is currently unclear the precise role APC plays in 
carcinogenesis but the APC protein appears to have multiple functions within the cell, 
including the regulation of cell proliferation and differentiation, cell adhesion and 
signalling, and cell movement. 
The human APC gene is located at chromosome 5q21 (Kinzler et al., 1991a,ó; Joslyn el 
al., 1991). Several groups have reported genetic loss at this region within NSCLC 
(Ashton -Rickardt et al., 1991; D'Amico et al., 1992; Tsuchiya et al., 1992; Horn et al., 
1992a; Hosoe et al., 1994; Wieland and Bohm 1994, Fong et al., 1995). The frequency 
of loss varies between studies from 20 -71 %. The varying frequency of LOH may 
be a 
reflection of different histological types within cohorts as a number of studies 
have 
revealed that ADC and SCC exhibit different allelotypes. Furthermore 
varying 
frequencies of LOH may reflect tumour stage. 
Through the analysis of polymorphic sites within the APC gene and a 
second gene lying 
approximately within 500 kb downstream, the MCC (mutated 
in colorectal cancer) gene, 
I have determined the frequency of loss of heterozygosity 
(LOH) in a cohort of 
consecutive pulmonary ADC and SCC from Edinburgh 
Royal Infirmary. Loss of 
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heterozygosity was shown to occur in 46% (11/24) of SCC and 36% (16/44) of ADC. 
There was no significant difference between frequency of loss in these two histological 
subtypes. Analysis of tumours according to tumour stage, revealed that LOH was not 
associated with increasing tumour stage in SCC or ADC. Therefore, this result indicated 
that LOH at 5q21 is not associated with tumour progression in ADC or SCC. 
Subclassification of ADC into the site of origin; bronchial or parenchymal, revealed no 
significant difference in the frequency of LOH between these two subgroups or between 
the different tumour stages within each subgroup. 
There are currently no studies that identify the point at which LOH at 5q21 occurs in 
NSCLC. As several stages of premalignant lesions have been identified in the 
development of SCC, analysis would be relatively easy; however, such a study would not 
be so easy to conduct for ADC as premalignant lesions have been less well characterised. 
There is now extensive evidence to suggest that alveolar atypical hyperplastic lesions are 
precursor lesions to parenchymal ADC. These lesions may be studied to determine the 
frequency of LOH at 5q21 and the frequency compared to that seen in parenchymal 
ADC. No premalignant lesions for bronchial ADC have been identified. 
In the study described above, polymorphic sites within two genes, APC and MCC were 
analysed. In all cases that were informative for both genes; loss or retention was always 
seen in both genes, i.e. there were no cases showing discordance between the two genes, 
indicating that this was a minimum area of loss. In previous studies of NSCLC, a 
common region of chromosomal deletion at 5q21 has been identified. This region spans 
3 -5 megabases and harbours numerous genes including the tumour suppressor gene APC 
and the MCC gene. To date, of the genes identified and characterised within this region, 
the most likely candidate gene to be involved in NSCLC tumourigenesis is APC. 
According to Knudson's hypothesis, tumour suppressor genes act recessively 
at the 
cellular level so that both copies of the gene must be inactivated for growth 
suppressive 
functions to be eliminated (Knudson 1978). Therefore, demonstrating 
the loss of one 
APC allele in a proportion of tumours would not indicate loss of tumour 
suppression. The 
final aim of this initial investigation was to determine whether biallelic 
inactivation of the 
APC gene is a characteristic of pulmonary ADC and SCC. 
Extensive studies of several types of cancer have demonstrated 
mutations within the APC gene occur between codon 1286 -1513, 
cluster region, and that these mutations nearly always result in 
truncated protein product (See Laurent -Puig et al., 1998). 
In cases of NSCLC that exhibited LOH at 5q21, the mutation cluster region was 
examined for mutations. This was carried out using single strand conformational 
polymorphism analysis. No mutations were detected within the MCR of 30 tumours 
analysed. It is possible that mutations exist outside this region. As the majority of 
mutations within this gene have been shown to result in the truncation of the protein 
product, immunohistochemistry was carried out using an antibody raised to the carboxyl 
terminus of the APC protein. In all cases analysed (N =30), full length APC was shown to 
be present and the cytoplasmic and nuclear staining seen in normal tissue was also 
detected in the tumours. Therefore, using SSCP and immunohistochemistry there was no 
evidence of biallelic inactivation of the APC gene. One could state that mutations within 
the mutation cluster region are extremely rare in pulmonary ADC and SCC. Furthermore, 
if mutations occur in the APC gene they rarely result in the production of truncated APC 
protein. The detection of full length APC in these cases also suggests that epigenetic 
factors do not lead to loss of APC expression in these tumours. If the APC gene did play 
a role in lung carcinogenesis, one would expect individuals with germline mutations in the 
APC gene to have an increased risk of lung cancer and this is not the case. 
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that the majority of 
named the mutation 
the production of a 
The proto -oncogene K -RAS encodes a protein that functions as a guanosine diphosphate 
/ guanosine triphosphate (GDP /GTP) regulated switch, transducing extracellular stimuli to 
cytoplasmic signal transduction cascades. The K RAS gene can acquire transforming 
potential following point mutations that lead to amino acid changes at codons 
12, 13 or 
61 or through mutations at or near the GTP- binding domain, both of which 
result in 




The K -RAS gene is mutated in 25 -50% of ADC and the majority of mutations occur at 
codon 12 ( >90 %) (Rodenhuis et al., 1988; Slebos et al., 1989; Reynolds et al., 1991, 
Mitsudomi et al., 1991; Slebos et al., 1991; Mills et al., 1995; Keohauana el al., 1996; 
Graziono et al., 1999; Gealy et al., 1999). Mutations at codons 13 and 61 are relatively 
rare. Mutations at codon 12 are generally guanine to thymine (G -T) transversions 
(approximately 80 %), occurring at position 1 in 60% of tumours and position 2 in 15% 
of tumours. G -A transitions also occur, these are usually at position 2 (20% of tumours). 
Guanine to thymine transversions are typical of the production of DNA adducts at 
guanine residues and this mutation has been shown to be associated with the carcinogens 
derived from cigarette smoking. 
Previous investigations have reported that K -RAS mutations are not associated with 
tumour progression, and that mutation within this gene may be an early event in the 
development of pulmonary ADC, with mutation occurring prior to clonal expansion (Li et 
a1.,1994a). Due to the absence of recognised precursor lesions, it has been difficult to 
further define the timing ofK-RAS mutations in the development of pulmonary ADC. 
In this study, I determined that mutations at position 1 or 2 of codon 12 of the K -RAS 
gene occurred in 25% (16/65) of ADC in a cohort obtained from Edinburgh Royal 
infirmary. The majority of mutations were G -T transversions at position 1 (56 %; 9/16) 
whilst other mutations occured at a lower frequency; G -T transversions at position 2 of 
codon 12 occured in 38% (6/16) of cases and G -A transition at position 2 occured in 6% 
(1/16) of cases. The presence of K -RAS mutation did not increase significantly with 
tumour stage. These data, derived from the analysis of this cohort are similar to results 
obtained with previously published studies. 
Subclassification of ADC into bronchial and parenchymal origin showed that significantly 
more mutations were associated with ADC of parenchymal origin than of bronchial 
origin. This is the first reported genetic difference between these two histological 
subtypes and suggests that different genetic pathways are involved in the development 
of 
these tumours. It is interesting to note that like bronchial ADC, SCC and SCLC, 
that also 
arise in the central portion of the lung and are associated with smoking, are not 
frequently 
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characterised as having K -RAS mutations. 
Analysis of 32 areas of alveolar atypical hyperplasia (AAH), possible precursor lesions 
for parenchymal ADC, identified K -RAS mutations. Mutations were identified in sixteen 
patients, 10 of which harboured an ADC, revealed the presence of a codon 12 mutation 
in 5 lesions (16 %). Two positive lesions were identified in case 1, which contained 5 
lesions plus an ADC. No mutations were detected in the ADC and different mutations 
were detected within the two AAH lesions (G -A transition pos.1 and a G -T transversion 
at position 1 and 2). In case 7, one out of 6 AAH lesions harboured a K -RAS codon 12 
mutation, no mutation was detected in the corresponding ADC. In cases 13 and 15, 
which consisted of only one lesion and no ADC, mutations were also detected. 
The mutation spectrum seen within AAH lesions consisted of 7 cases of G -T 
transversions and only one lesion with G -A transitions. This mutation spectrum is 
consistent with mutations detected in parenchymal ADC further strengthening the 
proposal that AAH lesions are precursors of parenchymal ADC. These data also suggest 
that assuming AAH lesions are true preneoplastic lesions, mutations within K -RAS gene 
are a very early event in the development of parenchymal ADC. Since the initiation of this 
work, two studies have reported the presence of K -RAS mutations within areas of AAH. 
From the different genetic backgrounds of AAH lesions and corresponding ADC within 
patients analysed in this study, and the high percentage of G -T transversions, one may 
suggest that AAH lesions are independent entities, independent of ADC and of other 
lesions. These lesions may be a result of a phenomenon known as field carcinogenesis 
(Slaughter et al., 1953); in this case the carcinogen is likely to be cigarette smoke. 
Alternatively, multiple AAH lesions may be a result of spread of progeny from a single 
progenitor cell and mutation of the K -RAS gene is an additional genetic event, this 
phenomenon has been referred to as subclonal drift (Nowell, 1976). 
To further characterise the function of APC, an APC transgene was constructed. 
This 
transgene contains the human APC cDNA sequence whose expression is driven 
by the 
promoter sequence of the ubiquitously expressed murine phosphoglycerate kinase 
(Pgk) 
gene. These sequences are flanked by 2 loxP sites that lie in the same 
orientation thereby 
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enabling excision of the flanked sequence following exposure to Cre recombinase. 
Excision was demonstrated in a prokaryotic system. 
Transgene positive mice have been generated following microinjection of the transgene 
into the pronuclei of oocytes. The mice generated contained the APC transgene on a 
murine wildtype Apc background (Tg +; Apc +/+). Excision of the DNA sequence flanked 
by the loxP sites has been demonstrated in an eukaryotic system, using embryonic 
fibroblasts derived from transgene positive embryos. 
Analysis of mice with the genotype Tg +; Apc +1+ has shown that RNA is transcribed from 
the transgene. To date no phenotype has been noted in the mice that represent 
overexpression of APC. 
Transgene positive mice have been bred with Min mice (A p c +/M'" ); Min mice harbour a 
germline mutation that results in a truncated Apc protein at codon 850. Mice 
heterozygous for the truncated (Min) allele exhibit an FAP phenotype and develop 
numerous colonic adenomas. Homozygosity for the Min allele results in embryonic 
lethality. The aim of this part of the thesis was to determine whether the APC transgene 
could result in reduction in severity or elimination of the FAP phenotype exhibited by Apc 
+M'" mice. As the severity of the phenotype is modified by modifier loci, comparison of 
transgene positive and transgene negative Apc heterozygotes has been carried out 
between mice on the same genetic background. Until the colony has been established on a 
pure bred background, the numbers available for analysis are low. However, data from 
mice on the 87.5% C57BL /6 background have revealed that the APC transgene can not 
eliminate the development of multiple colonic adenomas and that there is no statistically 
significant differene in the frequency of the Apc 
+m,,, 
phenotype in transgene positive and 
transgene negative mice (x2= 2.418; p= 0.12). It also appears that the embryonic lethal 
phenotype can not be eliminated by APC transgene as there was a significant difference 
between the observed frequency of Tg+ Min homozygotes and the expected 
frequency. 
Expression of the transgene may result in partial rescue of embryonic lethality. 
To date a 
small number of embryos have been analysed and no Apc Min/M'" homozygotes 
have been 
detected, the results generated indicated that there is statistically 
significant difference in 
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the observed number of min homozyotes and expected number of Min homozygotes, data 
which indicates that the APC transgene is not able to result in partial rescue of the Min 
homozygote lethal phenotype. Two embryos were identified that exhibited exencephaly 
and both embryos had the genotype Tg +; Apc +/M'n. More embryos must be studied to 
determine whether this phenotype is associated with APC transgene expression. 
In these studies, the majority of mice and embryos generated are heterozygous for the 
APC transgene, further investigations need to be conducted to ascertain whether 
homozygosity for the transgene can firstly eliminate or reduce the Apc Min heterozygous 
phenotype. Secondly, if homozygosity for the transgene results in rescue or partial rescue 
of the Apc M`i'n embryonic lethal phenotype. 
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APPENDIX A: Solutions 
General Solutions 
TE 
10mM Tris (pH 8.0) 
1mM EDTA 
10 x TBE (tris- borate -EDTA buffer) 





pH to 7.4 and autoclaved 
(x10) gel loading buffer 











Preperation of 1L 
1) Dissolve 20g Tryptone, 5g Yeast Extract and 0.5g NaCl in 950m1 deionised water. 
2) Prepare a 250mM KC1 stock solution 
3) Add 10m1 of KC1 stock solution to the solution in step 1. 
3) Adjust pH to 7.0 with 5M NaOH, then bring volume to 980m1 with deionised water. 
4) Prepare 1M solution of MgCl2 
5) Autoclave both solutions 
6) Prepar a 2M solution of glucose and filter sterilise. 
7) Add 10m1 of filter sterilised 2M glucose solution and 10m1 MgCl2 solution to cooled 
autoclaved solution. 
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LB (Luria -Bertani) medium and plates 
1% Bacto- Tryptone 
0.5% Bacto -Yeast Extract 
1% NaC1 
pH7.0 
Medium: Preperation of 1L 
1) Dissolve 10g Bacto -Tryptone, 5g Bacto -Yeast Extract and 10g NaC1 in 950m1 deionised 
water. 
2) Adjust pH to 7.0 with NaOH and ajust volume to 1L 
3) Autoclave and allow to cool to 55 °C and add antibiotic if needed 
4) Store at RT or at 4 °C. 
LB plates 
1) Prepare LB medium as above, once cooled to 55 °C, add antibiotic (stock solution of ampicilin 
to a final concentration of 50.tg/ml) and pour into 10cm plates. 
2) Allow to harden, then invert and store at 4 °C 
Ampicillin Stock solution 100mg/m1 
1) Dissolve 10g of Amicillin into 10ml of sterile deionised water 
2) Aliquote into 500u1 and store at -20 °C 
X -gal stock solution 40mg/m1 
1) Dissolve 400mg X -gal in 10m1 dimethylformamide 
2) Protect from light by storing in a brown bottle at -20 °C 
To add to previously made agar plates, pipette 4Oµ1 of stock solution onto each plate, 




10mM Tris -HCI pH 8.3 
50mM KC1 
0.45% (v /v) Tween -20 
2.5mM MgCl2 
Single Strand Conformational Polymorphism 
Denaturing solution Stop Solution 
0.5M NaOH 95% formamide 
10mM EDTA 10mM EDTA (pH 8) 
0.01% (w /v) bromophenol blue 




0.2M Tris -HCI pH 7.6 
0.01M imidazole 
0.05% (v /v) hydrogen peroxide 
Sequencing 
(2x) Binding Wash 
10mM Tris -HCI (pH 7.5) 
1mM EDTA 
2.0M NaC1 
plasmid reaction buffer 
1.0M Tris -HC1 pH 7.5 
100mM MgC12 
250mM NaC1 
Sequencing Stop Solution 
95% formamide 
10mM EDTA (pH 8) 
0.01% (w /v) bromophenol blue 
0.01% (w /v) xylene cyanol 
Ligations 
(5x) Reaction Buffer 




25% polyethylene glycol -8000 
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Reaction Buffer 







6% Sequencing Gel 
6% acrylamide:bisacrylamide (40:1) 
8M Urea 
1xTBE 
1µI 25% ammonium persulphate per ml of gel 
111.1 TEMED per ml gel 
10 X Ligation Buffer 
60Mm Tris -HCL, pH7.5 
60mM MgC12 
50mM NaC1 





Wizard Mini Prep Solutions 
Cell resuspension buffer 
50mM Tris-HC1 (pH 7.5) 
10mM EDTA 
100µg/ml RNase A 
Neutralising Solution 




0.3 M Sodium Citrate pH 7.0 
Denhardts Reagent (100x) 
2% (w /v) Ficoll 
2% (w /v) Polyvinyl pyrollidone 
2% (w /v) Bovine serum albumin (Fraction V) 
Stringency wash 1 
2x SSC 
0.1% SDS 
Stringency wash 3 
0.1xSSC 
0.1% SDS 




80mM potassium acetate 
8.3mM Tris -HC1 pH 7.5 
40µM EDTA 
55% (v /v) ethanol 
Pre -Hybridisation solution 
6 X SSC 
5 X Denhardt's 
17mM SDS 
High Prime Mix 
4 units of Klenow polymerase 
0.125 mM of each of dATP, dGTP, dTTP 
5x reaction buffer in 50% glycerol 





DEPC treated water 
0.01% (w /v) diethylpyrocarbonate (DEPC) in double distilled water 
Stand overnight at room temperature 
Autoclave 
10x DNase reaction buffer 




Embryonic fibroblast Culture medium 
MEM Glasgow BHK -21 (Life technologies, 
UK) 
5% fetal calf serum 
5% neonatal calf serum 
1mM MEM non -essential amino acids (Life 
Technologies) 
1mM of sodium pyrutate (Gibco, UK) 
Cell fixative 
0.05% gluteraldehyde in PBS 
25% stock solution was stored at -20 °C and 
diluted 1/500 in PBS prior to use. 
Embryonic Fibroblast freezing medium 
25% fetal calf serum 
25% normal calf serum 







1 mg/m1 x-gal. 
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Appendix B: Suppliers 










Bio -Rad Laboratories Ltd. Boehringer Manheim UK 








Dako Ltd Dynal UK Ltd 




HP 11 2HT 
Station House 








WS 14 OEE 
Gibco (BRL). 
Life Technologies Ltd. 
3 Fountain Drive 
Paisley 
PA4 9RF 
Hybaid Ltd Hoefer Ltd 
111 -113 Waldegrave Road 
Teddington 
Middlessex 
TW 11 8LL 
Croft Road 




Invitrogen BV Kodak Ltd 




36 Clifton Road Cambridge 
CB 1 4ZR 
New England Biolabs (UK) Ltd. Oncogene Research Products 






Oswell DNA Service Pharmacia Biotech 
Dept. of Chemistry 
University of Edinburgh 
Kings Buildings 
West Mains Road 
Edinburgh 




Promega UK Ltd Quiagen Ltd 
Delta House, 
Chilworth Research Centre, 
Southampton. 
SO16 7NS 












1101 CB Amsterdam Zuidoost 
The Netherlands 
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APPENDIX C: NSCLC database; analysis of LOH at 5q21 
Abbreviations 
B.ADC- bronchial adenocarcinoma P. ADC- parenchymal adenocarcinoma 
SCC -squamous cell carcinoma 
NI- non -informative IRET- Informative retained 
ILOH- informative loss of heterozygosity 
Al/a2- allelel/allele 2 
CASE UB NO. AGE SEX TNM HISTOLOGY APC 3' APC EX.11 MCC EX.10 MCC 3' 
1 84/00950 65 F T2N2 B. ADC NI IRET NI IRET 
2 84/01170 83 M T1NO P. ADC IRET NT NI IRET 
3 84/01687 65 F T2NO ADC NT IRET NI IRET 
4 84/01742 66 M T2NO ADC ILOHa1 ILOHa2 NI NI 
5 84/03245 68 M T1 NO P. ADC ILOHa2 NT ILOHa1 
NT 
6 84/03801 54 M T2N1 P. ADC NT IRET NT 
IRET 
7 84/03921 50 F T2NO ADC NT IRET NI 
IRET 
8 84/09939 F T2NO B. ADC ILOHa2 NI 
ILOHa1 NT 
9 84/10202 58 F T2N1 P. ADC NI NI 
IRET NI 
10 84/14695 65 F T3N1 ADC ILOHa1 ILOHa2 
NI ILOHa2 
11 84/16024 50 F T2N2 ADC NI NI 
NI IRET 
12 84/16468 71 M T2NO ADC NI 
NI ILOHa1 ILOHa1 
13 85/05898 62 F T2N1 P. ADC NT 
NT ILOHa2 ILOHa1 
14 85/07275 69 F T2NO B. ADC NT 
ILOHa1 ILOHa2 NI 
15 85/17016 62 F T1 NO T1 P. ADC T1 IRET 
NT T1 IRET NT 
T2NO T2 adenosquame T2 ILOHa2 T2 ILOHa1 
16 89/25140 69 F T2N2 SCC IRET 
IRET IRET NT 
17 89/25506 57 M T2N2 ADC IRET 
NI NI NI 
18 89/26713 68 M T2NO P. ADC 
IRET IRET IRET IRET 
19 89/27480 60 M T2NO P. ADC 
IRET IRET NI IRET 
20 89/28300 56 M T2N1 SCC 
ILOHa2 ILOHa1 NI NI 
21 89/29807 45 F T3NO ADC 
IRET NI NT IRET 
22 90/00047 59 M T2NO SCC 
ILOHa1 ILOHa2 ILOHa2 NT 
23 90/00413 46 M T1 NO P. 
ADC NI NI NI NI 
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24 90/00417 69 M T2NO SCC NI NI NI IRET 
25 90/00690 57 M T3NO ADC NI NI NI IRET 
26 90/00724 63 F T2NO B.ADC NT IRET IRET NT 
27 90/01327 58 M T2NO ADC IRET IRET NI NI 
28 90/02125 56 M T2NO SCC NI NI NI NI 
29 90/02162 70 F T2N1 ADC NT ILOHa2 ILOHa2 ILOHa2 
30 90/02257 62 M T2N1 SCC NT IRET IRET NT 
31 90/02501 76 M T2NO SCC IRET IRET IRET IRET 
32 90/02736 75 M T2N1 P. ADC NT IRET IRET NT 
33 90/02956 72 M T3NO SCC NT IRETx2 NIx2 IRETX2 
34 90/03496 66 M T2N2 SCC NI ILOHa2 NI ILOHa1 
35 90/03498 63 M T3N2 T1 P. ADC IRET X2 IRETX2 IRETX2 IRETX2 
T2 SCC 
36 90/03739 68 M T2N1 SCC NI NI NI NI 
37 90/03971 75 M T2N1 P. ADC NT ILOHa2 NI ILOHa1 
38 90/04074 74 M T2N1 SCC ILOHa1 ILOHa2 NI NI 
39 90/04564 53 M T2NO P. ADC NI NI NI IRET 
40 90/04759 70 M T2NO SCC ILOHa1 NI ILOHa2 ILOHa2 
41 90/05104 63 M ADC NIx2 TIILOHa2 NIx2 NI 
T2 RET 
42 90/07250 66 M T2NO ADC IRET IRET IRET NT 
43 90/07387 57 M T3N2 ADC IRET NI IRET NT 
44 90/08639 64 M T2NO ADC ILOHa1 ILOHa2 NI NI 
45 90/09521 69 M T3NO ADC ILOHa2 NI ILOHa1 NT 
46 90/10230 51 F T2NO P. ADC ILOHa2 NI ILOHa2 NT 
47 90/11758 69 M T2NO B.ADC IRET NI NI NI 
48 90/14151 64 M T2NO ADC NT NI NI NI 
49 90/14771 55 M T2NO B. ADC NT IRET NI 
IRET 
50 90/17878 62 F T1 NO ADC IRET NI IRET 
NT 
51 90/17920 66 M T1N1 SCC NI IRET IRET 
NI 
52 90/18877 70 M T2N1 P. ADC IRET NT NI 
IRET 
53 90/21957 66 F T2N1 P. ADC IRET IRET 
IRET NT 
54 90/22073 73 F T2NO ADC NI NI 
IRET IRET 
55 90/22081 66 F T2NO ADC NI NI 
IRET NI 
56 90/22482 51 M T3N2 P. ADC ILOHa2 
ILOHa2 NI ILOHa2 
57 90/22711 49 F Ti NO P. ADC NT IRET 
IRET NT 
58 90/23269 66 F T2N2 ADC NI 
ILOHa2 NI NI 
59 90/23653 67 M T2NO B.ADC IRET 
NT NI IRET 
60 90/24563 69 M T3N2 ADC ILOHa2 
NT ILOHa2 NT 
61 90/25526 53 M T2N1 ADC 
IRET IRET NI NI 
62 90/257941 71 M T2NO ADC 
ILOHa1 ILOHa2 ILOHa2 NT 
63 90/26831 64 F T3N2 ADC 
NI NI IRET NI 
64 90/27759 74 M T2NO P. ADC 
NI IRET NI NI 
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65 90/27957 71 M T2N1 SCC IRET M NI IRET 
66 90/27988 63 M T2NO SCC NI NI NI NT 
67 90/28125 63 M T2NO SCC NI NI NI ILOHa1 
68 91/00297 63 M T2NO SCC NI IRET NI IRET 
69 91/00486 82 M T2N1 SCC NI NI ILOHa1 ILOHa1 
70 91/01945 75 M T1N0 P. ADC IRET IRET IRET IRET 
71 91/02175 54 F T2N2 ADC NI NI NI NI 
72 91/02882 73 M T2NO SCC NI NI ILOHa2 ILOHa2 
73 91/04010 79 M T2NO B. ADC ILOHa1 ILOH NI NI 
74 91/05849 67 M T1N0 SCC NI IRET NI 
NI 
75 91/06104 37 M T2NO SCC NI NI NI 
NI 
76 91/06385 64 M T3NO SCC NI NI IRET 
NI 
77 91/07148 59 M T2NO P. ADC IRET IRET NI 
IRET 
78 91/0665 61 F T2NO SCC IRET IRET NI 
NI 
79 91/07238 55 M T2NO P. ADC NI NI ILOHa1 
NI 
80 91/07877 66 M T2NO SCC NI NI ILOHa1 
ILOHa1 
81 91/08090 51 M T2N2 SCC ILOHa1 ILOHa2 NI 
NI 
82 91/08381 57 F T3N2 SCC ILOHa1 ILOHa2 
NI ILOHa2 
83 91/08444 63 M T2NO ADC IRET IRET 
NT NT 
84 91/08748 46 M T2N1 SCC IRET NI 
NI NI 
85 91/08925 67 M T1N1 SCC IRET IRET 
IRET IRET 
86 91/09054 59 M T2NO P. ADC IRET IRET 
NI NI 
87 91/09159 60 M T2N2 SCC IRET 
NI IRET NI 
88 91/09363 84 M T2N1 P. ADC ILOHa1 
NI NI ILOHa1 
89 91/09369 73 M T2NO SCC ILOHa2 
NI ILOHa1 NT 
90 91/09534 76 F T2NO SCC IRET 
IRET IRET NI 
91 91/09940 79 M T2NO SCC IRET 
IRET NI NI 
92 91/10095 63 M T3N1 P. ADC IRET 
IRET IRET NT 
93 94/00111 72 F T2NO B. ADC 
NI NI ILOHa1 NI 
94 94/01642 58 F T3N0/ ADC )C2 
IRET NI Nb2 IRET 
T1 NO 
95 94/02910 64 M T2N1 B. ADC 
NI IRET NI NI 
96 94/04401 66 M T2NO B. ADC 
ILOHa2 ILOHa1 NI NI 
97 94/04621 60 M T2NO B. ADC 
NI ILOHa2 NI ILOHa2 
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Appendix D: NSCLC database; analysis of K -RAS muations in 
ADC 
Abbreviations 
B.ADC- bronchial adenocarcinoma P. ADC- parenchymal adenocarcinoma 
CASE UB NO. AGE SEX TNM HISTOLOGY K -RAS 
codon 12 
Mutation 
1 84/00950 65 F T2N2 B. ADC 
2 84/01170 83 M T1 NO P. ADC 
3 84/01687 65 F T2NO ADC - 
4 84/01742 66 M T2NO ADC 
5 84/03245 68 M Ti NO P. ADC - 
6 84/03801 54 M T2N1 P. ADC 
7 84/03921 50 F T2NO ADC - 
8 84/09939 F T2NO B. ADC 
9 84/10202 58 F T2N1 P. ADC 
10 84/14695 65 F T3N1 ADC 
11 84/16024 50 F T2N2 ADC + G -T pos 2 
12 84/16468 71 M T2NO ADC + G -T pos.1 
13 85/05898 62 F T2N1 P. ADC 
14 85/07275 69 F T2NO B. ADC - 
15 85/17016 62 F T1 NO T1 P. ADC T1 + G -T pos.1 
T2NO T2 adenosquame T2 - 
17 89/25506 57 M T2N2 ADC - 
18 89/26713 68 M T2NO P. ADC + G -T pos.1 
19 89/27480 60 M T2NO P. ADC + G -T pos.2 
21 89/29807 45 F T3NO ADC 
23 90/00413 46 M Ti NO P. ADC + G -T pos. 2 
25 90/00690 57 M T3NO ADC 
26 90/00724 63 F T2NO B.ADC - 
27 90/01327 58 M T2NO ADC 
29 90/02162 70 F T2N1 ADC + 
G -T pos 1 
32 90/02736 75 M T2N1 P. ADC 
35 90/03498 63 M T3N2 P. ADC + 
G -T pos. 1 
37 90/03971 75 M T2N1 P. ADC 
39 90/04564 53 M T2NO P. ADC 
+ G -T pos.1 
41 90/05104 63 M ADC - 
42 90/07250 66 M T2NO ADC 
+ G -T pos.1 
43 90/07387 57 M T3N2 ADC 
44 90/08639 64 M T2NO ADC 
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45 90/09521 69 M T3NO ADC - 
46 90/10230 51 F T2NO P. ADC - 
47 90/11758 69 M T2NO B.ADC 
48 90/14151 64 M T2NO ADC - 
49 90/14771 55 M T2NO B.ADC - 
50 90/17878 62 F T1 NO ADC 
52 90/18877 70 M T2N1 P. ADC 
53 90/21957 66 F T2N1 P. ADC 
54 90/22073 73 F T2NO ADC 
55 90/22081 66 F T2NO ADC + G -T pos.2 
56 90/22482 51 M T3N2 P. ADC 
57 90/22711 49 F T1 NO P. ADC + G -T pos. 1 
58 90/23269 66 F T2N2 ADC 
59 90/23653 67 M T2NO B.ADC 
60 90/24563 69 M T3N2 ADC 
61 90/25526 53 M T2N1 ADC 
62 90/257941 71 M T2NO ADC 
63 90/26831 64 F T3N2 ADC 
64 90/27759 74 M T2NO P. ADC 
70 91/01945 75 M T1NO P. ADC 
71 91/02175 54 F T2N2 ADC 
73 91/04010 79 M T2NO B. ADC 
77 91/07148 59 M T2NO P. ADC 
+ G -A pos.2 
79 91/07238 55 M T2NO P. ADC 
+ G -T pos.2 
83 91/08444 63 M T2N0 ADC - 
86 91/09054 59 M T2N0 P. ADC 
88 91/09363 84 M T2N1 P. ADC 
+ G -T pos. 1 
92 91/10095 63 M T3N1 P. ADC 
93 94/00111 72 F T2NO 
B. ADC 
94 94/01642 58 F T3NO/T1 
ADC x2 T1- G -T pos.1 
NO T2 
+ 
95 94/02910 64 M T2N1 B. ADC 
96 94/04401 66 M T2NO B. ADC 
97 94/04621 60 M T2NO B. ADC 
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Appendix E: Database for murine breeding program 
Abbreviations: WT- wildtype; Tg- Transgene; D.O.B- date of birth ; NEG -negative; 
MIN (genotype Apc +' -) 
No. Sex Apc Tg Mating D.O.B Comments 
Founder 
CC 
F WT POSITIVE Micro -injection 
1 M WT NEG CC X MIN 10.03.98 
2 M WT POSITIVE CC X MIN 10.03.98 
3 M WT NEG CC X MIN 30.3.98 
4 M WT POSITIVE CC X MIN 30.3.98 Cull for Tg expression experiments 
5 F WT NEG CC X MIN 30.3.98 
6 M WT POSITIVE CC X MIN 30.3.98 Cull for Tg expression experiments 
7 F WT NEG CC X MIN 30.3.98 
8 M WT NEG CC X MIN 30.3.98 
9 M WT NEG CC X MIN 30.3.98 
10 F HET POSITIVE CC X MIN 30.3.98 Cull 26.2.99 ill /colonic adenomas 
11 M WT POSITIVE CC X MIN 30.3.98 Cull for Tg expression experiments 
12 M WT NEG CC X MIN 30.3.98 
13 F WT NEG 2 X MIN 14.05.98 Found dead 16.06.98: Runt 
14 M WT NEG 2 X MIN 14.05.98 
15 F WT NEG 2 X MIN 14.05.98 
16 M WT POSITIVE 2 X MIN 19.05.98 
17 M HET NEG 2 X MIN 19.05.98 
18 M HET POSITIVE 2 X MIN 19.05.98 Cull 26.2.99 ill /colonic adenomas 
19 M HET POSITIVE 2 X MIN 19.05.98 
20 F WT POSITIVE 2 X MIN 01.06.98 Breed with Mgb -c 2 20.07.98 for Efs 
21 M WT NEG 2 X MIN 01.06.98 
22 M HET NEG 2 X MIN 01.06.98 
23 F WT NEG 2 X MIN 01.06.98 
24 F HET POSITIVE 2 X MIN 01.06.98 
25 F WT NEG 2 X MIN 01.06.98 Found dead 06.07.98 (no adenomas) 
26 M HET NEG CC X MIN 05.06.98 
27 M WT NEG CC X MIN 05.06.98 
28 F WT NEG CC X MIN 05.06.98 Found dead 06.07.98 (no adenomas) 
29 F WT NEG CC X MIN 05.06.98 Found dead 30.6.98 (no adenomas) 
30 F WT NEG CC X MIN 05.06.98 
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31 F WT NEG CC X MIN 05.06.98 
32 M WT NEG CC X MIN 05.06.98 
33 M WT NEG CC X MIN 05.06.98 
34 F WT NEG CC X MIN 05.06.98 
35 M WT NEG CC X MIN 05.06.98 
36 F WT NEG CC X MIN 05.06.98 Found dead 06.07.98 (no adenomas) 
37 F WT NEG 11 X MIN (X3) 06.06.98 
38 M WT NEG 11 X MIN (X3) 06.06.98 
39 F WT NEG 11 X MIN (X3) 06.06.98 
40 M WT NEG 11 X MIN (X3) 06.06.98 
41 F WT NEG 11 X MIN (X3) 06.06.98 
42 F WT NEG 11 X MIN (X3) 06.06.98 
43 M WT NEG 4 X MIN (X3) 08.06.98 
44 M WT NEG 4 X MIN (x3) 08.06.98 
45 M WT NEG 4 X MIN (x3) 08.06.98 
46 M WT NEG 4 X MIN (x3) 08.06.98 
47 F WT NEG 4 X MIN (x3) 08.06.98 
48 F WT NEG 4 X MIN (x3) 08.06.98 
49 M WT NEG 4 X MIN (x3) 08.06.98 
50 M WT NEG 4 X MIN (x3) 08.06.98 
51 F WT NEG 4 X MIN (x3) 08.06.98 
52 M WT POSITIVE 4 X MIN (x3) 15.06.98 
53 M WT NEG 4 X MIN (x3) 15.06.98 
54 M HET POSITIVE 11 X MIN (x3) 12.06.98 
55 M HET POSITIVE 11 X MIN (x3) 12.06.98 Cull 02.2.99 ill /colonic adenomas 
56 M HET NEG 11 X MIN (x3)) 12.06.98 Cull 19.01.99 ill /colonic adenomas 
57 F WT NEG 11 X MIN (x3) 12.06.98 
58 F HET NEG 11 X MIN (x3) 12.06.98 
59 M HET POSITIVE 11 X MIN (x3) 12.06.98 
60 F HET POSITIVE 11 X MIN (x3) 12.06.98 
61 F WT NEG 11 X MIN (x3) 12.06.98 
62 F HET POSITIVE 11 X MIN (X3) 12.06.98 
63 F HET NEG 2 X MIN 10.06.98 
64 M WT NEG 2 X MIN 10.06.98 
65 M HET NEG 2 X MIN 10.06.98 
66 F WT POSITIVE 2 X MIN 10.06.98 
67 F HET POSITIVE 2 X MIN 10.06.98 Cull 02.2.99 ill /colonic adenomas 
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68 F WT POSITIVE 2 X MIN 10.06.98 
69 F WT POSITIVE 2 X MIN 10.06.98 
70 F WT POSITIVE 2 X MIN 10.06.98 
71 F WT POSITIVE 2 X MIN 10.06.98 
72 F WT NEG 2 X MIN 10.06.98 
73 M WT NEG 2 X MIN 10.06.98 
74 M WT NEG 10 X MIN 29.06.98 
75 F HET NEG 10 X MIN 29.06.98 
76 F WT NEG 10 X MIN 29.06.98 
77 M HET NEG 10 X MIN 29.06.98 
78 F HET POSITIVE 10 X MIN 29.06.98 Cull 02.2.99 ill /colonic adenomas 
79 M HET NEG 11 X MIN (X3) 03.07.98 
80 M WT NEG 11 X MIN (X3) 03.07.98 
81 F HET NEG 11 X MIN (X3) 03.07.98 Cull 26/2/99: Mammary tumours/ colonic 
adenomas 
82 M HET POSITIVE 11 X MIN (X3) 03.07.98 
83 F HET POSITIVE 11 X MIN (X3) 03.07.98 
84 F HET NEG 4 X MIN (X3) 9/07/98 
85 F WT NEG 4 X MIN (X3) 09.07.98 
86 F HET NEG 4 X MIN (x3) 09.07.98 
87 M HET POSITIVE 4 X MIN (x3) 09.07.98 
88 M HET NEG 4 X MIN (X3) 09.07.98 
89 M WT NEG 4 X MIN (X3) 09.07.98 
90 M WT POSITIVE 4 X MIN (X3) 09.07.98 
91 F WT POSITIVE 4 X MIN (X3) 09.07.98 
92 M WT POSITIVE 11 X MIN (X3) 14.07.98 
93 F WT NEG 11 X MIN X3) 14.07.98 
94 M HET NEG 11 X MIN (X3) 14.07.98 
95 M HET NEG 11 X MIN (X3) 14.07.98 
96 F WT NEG 11 X MIN (X3) 14.07.98 
97 F WT POSITIVE 11 X MIN(X3) 14.07.98 
98 M HET POSITIVE 11 X MIN (X3) 14.07.98 
99 M WT NEG 11 X MIN (X3) 14.07.98 
100 M HET NEG 11 X MIN (X3) 14.07.98 
101 M WT NEG 10 X 18 19.08.98 
102 F HET POSITIVE 10 X 18 19.08.99 Mate with 18 for embryos 
103 M WT NEG 10 X 18 19.08.99 
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104 F HET NEG 10 X 18 19.08.98 
105 F HET POSITIVE 10 X 18 19.08.98 Mate with 18 for embryos 
106 F HET POSITIVE 10 X 18 19.08.98 Mate with 18 for embryos 
107 M HET NEG 55 X 62 26.08.98 
108 M HET POSITIVE 55 X 62 26.08.98 
109 M HET NEG 55 X 62 26.08.98 
110 F WT POSITIVE 55 X 62 26.08.98 
111 F HET POSITIVE 55 X 62 26.08.98 Mate with 18 for embryos 
112 M WT NEG 59 X 67 02.09.98 
113 M WT NEG 59 X 67 02.09.98 
114 M HET POSITIVE 59 X 67 02.09.98 
115 M WT POSITIVE 59 X 67 02.09.98 
116 M HET POSITIVE 59 X 67 02.09.98 
117 M HET POSITIVE 59 X 67 02.09.98 
118 F HET POSITIVE 59 X 67 02.09.98 
119 F HET POSITIVE 54 X 60 07.09.98 
120 M HET POSITIVE 54 X 60 07.09.98 
121 M HET POSITIVE 54 X 60 07.09.98 
122 F HET POSITIVE 54 X 60 07.09.98 
123 F HET NEG 54 X 60 07.09.98 
124 F HET POSITIVE 19 X 24 07.09.98 
125 F WT POSITIVE 19 X 24 07.09.98 
127 F WT POSITIVE 19 X 24 07.09.98 
127 F WT NEG 19 X 24 07.09.98 
128 F WT POSITIVE 10 X 18 11.09.98 
129 M WT POSITIVE 10 X 18 11.09.98 
130 F HET NEG 10 X 18 11.09.98 
131 M WT POSITIVE 10 X 18 11.09.98 
132 M WT POSITIVE 10 X 18 11.09.98 
133 F HET POSITIVE 10 X 18 11.09.98 
134 M WT POSITIVE 10 X 18 11.09.98 
135 F HET POSITIVE 55 X 62 20.09.98 
136 F HET POSITIVE 55 X 62 20.09.98 
137 M WT POSITIVE 55 X 62 20.09.98 
138 F HET POSITIVE 55 X 62 20.09.98 
139 F HET POSITIVE 55 X 62 20.09.98 
140 M HET POSITIVE 55 X 62 20.09.98 
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141 F HET POSITIVE 55 X 62 20.09.98 Found dead 20.10.98: Runt 
142 F WT POSITIVE 55 X 62 20.09.98 
143 M HET POSITIVE 91 X MIN 23.09.98 
144 M WT POSITIVE 91 X MIN 23.09.98 Found dead 20.10.98 mother not feeding 
145 F WT POSITIVE 91 X MIN 23.09.98 Found dead 20.10.98 mother not feeding 
146 F WT POSITIVE 91 X MIN 23.09.98 Found dead 20.10.98 mother not feeding 
147 F WT POSITIVE 91 X MIN 23.09.98 
148 M WT NEG 91 X MIN 23.09.98 
149 M HET POSITIVE 91 X MIN 23.09.98 
150 M HET POSITIVE 54 X 60 01.10.98 
151 M WT POSITIVE 54 X 60 01.10.98 
152 M HET POSITIVE 54 X 60 01.10.98 
153 M HET POSITIVE 54 X 60 01.10.98 
154 M HET POSITIVE 59 X 67 02.10.98 
155 F HET POSITIVE 59 X 67 02.10.98 
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SUMMARY 
Four genetic polymorphisms in the APC and MCC genes at chromosome 5q21 were analysed for loss of heterozygosity (LOH) in 97 
squamous carcinomas and adenocarcinomas of the lung. LOH was identified in at least two polymorphic loci in 41 percent of 
nnative cases. There was no significant difference in the frequency of LOH between squamous carcinomas and adenocarcinomas. 
the adenocarcinoma group, however, LOH appeared to be more common in tumours having a bronchial origin (5/9; 56 per cent) 
n in parenchymal adenocarcinoma (6/21; 29 per cent). All 32 tumours showing LOH at one or more polymorphic sites were examined 
r mutations in the mutation cluster region (MCR) of APC by single -strand conformational polymorphism (SSCP) analysis. Mutations 
ere not detected in any of these cases. We therefore propose that it is likely that a tumour suppressor gene on 5q other than APC is 
ohed in the pathogenesis of lung cancer. 
woRDS- non -small cell lung cancer; adenocarcinoma; squamous carcinoma; APC; MCC 
INTRODUCTION 
Lung cancer is characterized by a greater hetero- 
Lneity of morphological appearances than the other 
caiicommon 
visceral malignancies.' Eight histological 
classes of primary pulmonary malignancy are described 
® the World Health Organisation (WHO) classification 
if lung tumours.2 From the therapeutic and prognostic 
viewpoint, the prime distinction to be made is between 
small cell lung cancer (SCLC) and non -small cell lung 
er ( NSCLC), with the former having a poorer 
clinical outlook. A variety of molecular lesions have 
ten described in lung cancer, some of which show 
lorrelation with histological classification. Thus, ampli- 
n tBtion of c -myc is often associated with SCLC, while 
r -ras mutations and increased expression of c- erbB -2 
Ire seen in NSCLC, particularly adenocarcinoma.3,4 
Recently there have been a number of reports of 
genetic losses at chromosome 5q in lung carcinomas.54 
Most attention has been paid to SCLC, in which such 
esses are described in about 80 per cent of cases, but 
other groups, including our own, have shown losses at 
ki in NSCLC.5,8 Consistent loss of genetic material at a 
rticular chromosomal arm in a neoplasm is evidence 
It the presence of a tumour suppressor gene at that site. 
''though other loci on 5q may be implicated, 5q21 is a 
Prime candidate region, as it contains the tumour sup- 
Pressor gene APC (adenomatous polyposis coli) and the 
Bndidate tumour suppressor gene MCC (mutated in 
colorectal cancer). APC in particular is an important 
Addressee for correspondence: C. A Cooper, Sir Alastair Currie 
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CCC 0022_3417/96/090033 -05 
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and relatively well- characterized tumour suppressor 
gene, which is implicated in hereditary and acquired 
colorectal cancer and also in some other neoplasms.° 
The function of APC is not fully understood. It 
associates with plakoglobin and ß- catenin and may 
be involved in the regulation of epithelial cell -cell 
adhesion.10 Through binding to these proteins, it may 
also influence a Wnt -J- stimulated cell- signalling path- 
way, controlling the differentiation fate of epithelial 
cells.11,12 In vitro APC protein also acts as a microtubule 
binding protein and enhances microtubule polymeriz- 
ation.13,14 It is unknown if APC plays a role in lung 
cancer and there is no increased incidence of lung cancer 
in patients with familial adenomatous polyposis (FAP), 
but we have recently shown that the APC protein is 
normally expressed in respiratory epithelium.15 
The aims of the present study were to determine the 
frequency of 5q21 involvement in NSCLC and in par- 
ticular to determine the relative occurrence of loss in 
squamous carcinoma and adenocarcinoma, the 
most 
common forms of NSCLC, as there is emerging evidence 
that there may be significant differences in the allelo- 
types of these neoplasms.16 These differences 
may be of 
practical significance, since epidemiological 
investi- 
gations have shown that the relative incidences 
of these 
tumours are changing with adenocarcinoma 
becoming 
more prevalent.17 This shift in the histological 
profile of 
lung cancer has led some authors to 
re- evaluate the 
WHO classification, which recognizes 
several morpho- 
logical subtypes of adenocarcinoma, 
but has not been 
shown to be of prognostic or biological 
significance. It 
has been suggested that a more clinically 
relevant dis- 
tinction can be drawn between adenocarcinomas 
having 
origin (like squamous carcinoma 
and SCLC) from large 
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airways and those arising in the distal lung parenchyma, 
from bronchiolar and alveolar lining cells.18 A compari- 
son between the bronchial and parenchymal groups of 
adenocarcinomas was therefore included in the study. 
Our strategy was to determine the frequency of LOH 
at four polymorphic loci in APC and MCC in a series of 
surgically resected NSCLC cases. LOH at the appropri- 
ate genetic locus is not, of itself, sufficient evidence to 
implicate a particular tumour suppressor gene in the 
pathogenesis of a neoplasm. The widely accepted multi- 
stage model of carcinogenesis predicts that development 
of neoplasia requires the remaining copy of the gene 
to be mutated or otherwise inactivated.9 Mutations in 
the APC gene have been detected in a number of 
tumours, including those of the colon, pancreas, and 
stomach.9'19,2o The majority of mutations have been 
found in the first half of the gene's coding sequence, 
two -thirds of somatic mutations in colorectal tumours 
being restricted to a region called the mutation cluster 
region (MCR), between codons 1286 and 1513.21 We 
therefore decided to use an established single- strand 
conformational polymorphism (SSCP) technique to 
screen for mutations in the MCR of the remaining APC 
allele of those cases showing LOH at 5g21. 
MATERIALS AND METHODS 
Cases and tissue samples 
DNA was extracted from paraffin blocks of 97 surgi- 
cal resections (lobectomy and pneumonectomy) for pri- 
mary squamous cell carcinoma or adenocarcinoma of 
the lung, using standard methods.22 Separate samples 
were taken from each case to include tumour and 
non -tumour (usually uninvolved lymph node) tissue. 
The tumour samples were dissected from 10 pm sections 
under histological guidance, to minimize stromal/ 
inflammatory cell contamination. Cases included were 
chosen as follows: 32 consecutive squamous carcinomas, 
58 consecutive adenocarcinomas, and 7 additional non - 
randomly selected adenocarcinomas, all of bronchial 
type. The latter were included because our experience 
has shown that bronchial adenocarcinomas are rather 
less common than those arising in the pulmonary paren- 
chyma.23 Adenocarcinomas were allocated, on the basis 
of macroscopic and histopathological appearances, into 
parenchymal or bronchial subtypes, with an additional 
category for neoplasms of uncertain or mixed histo- 
genesis. Parenchymal carcinomas were defined by lack 
of a bronchial origin and by a lepidic' growth pattern. 
Cytologically, they were composed of cells resembling 
type 2 pneumocytes, clara cells (`tongue- shaped' cells),17 
or mucus cells. The bronchial adenocarcinomas showed 
obvious origin from and disruption of bronchial mucosa 
and tended to have an acinar or papillary pattern. 
LOH in APC and MCC genes 
LOH for each tumour was determined using polymer - 
ase chain reaction (PCR) amplification of intragenic 
sequences containing known polymorphic sites within 
the APC and MCC genes. Restriction fragment length 
1 









Fig. 1 -Two samples analysed by PCR amplification of the naturally - 
occurring length polymorphism at MCC exon 10. In each case, the 
`normal' DNA sample (reactive lymph node) is shown in lane N. Both 
patients are heterozygous for this locus, indicated by Al (175) and A2 
(161) base -pairs. The corresponding tumour samples (T) show loss of incube A2 in patient 1 (LOH). Heterozygosity is retained in patient 2. Lane M 







polymorphisms (RFLPs) in the 3' untranslated region 
(UTR)24 and exon 11 of the APC gene25 and a RFLP in 
the 3'UTR of MCC26 were analysed using enzymes 
Sspl, Rsal , and Mael1l , respectively. A fourth poly- 
morphism, a length polymorphism in MCC exon 10,27 
was also analysed. Conditions and primers have been 
previously published28 with the exception of a new 
APC 3' UTR primer. Here the upstream primer was 
replaced with a new primer (5' GAAGAGACTGCA 
ATGTCTAAGAA 3') to produce a smaller 318 bp PCR 
product, which was easier to amplify from archival 
paraffin- embedded tissues. A control DNA fragment 
containing the appropriate restriction site was added to 
the APC exon 11 (Rsal) and the MCC 3'UTR (Maelll ) 
digests to ensure complete restriction enzyme cleavage. 
The digested PCR products were run on agarose or 
polyacrylamide gels and stained with ethidium bromide. 
LOH at a given locus was defined by a reduction in the 
intensity of an allele band of the tumour in comparison 
with its corresponding normal (Fig. 1). Cases polymor- 
phic at two or more loci were subjected to statistical 
analysis. 
SSCP analysis of the MCR of the APC 
All cases showing LOH at 5q21 were screened for 
APC mutations. DNA fragments were amplified by 
PCR (Table I). Some of the primers used have pre- 
viously been published.29 Cycling conditions consisted 
of an initial denaturation step of 5 min at 94 °C, followed 
by 36 cycles of 30 s denaturation at 94 °C, 30 s at the 
appropriate annealing temperature (see Table I), and 
60 s extension at 72 °C, with a final extension step of 
10 min at 72 °C. One microlitre of denaturing solution 
(0.5 M NaOH, 10 mM EDTA) was added to 5 pl of PCR 
product. Samples were incubated for 5 min at 50 °C, then 
3 ,ul of stop solution [95 per cent formamide, 10 mM 
EDTA (pH 8), 0.01 per cent bromophenol blue, 0.01 
per 
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5q21 IN LUNG CANCER 
Table I- Sections of APC MCR for SSCP analysis 
Nucleotide Product 













4132-4423 291 CAGGAGACCCCACTCATGTT 
CAGCATTTACTGCAGCTTGC 






incubation. Nine microlitres of sample was loaded onto 
a non- denaturirT MDE gel (AT Biochem, PA, U.S.A.) 
containing 5 per cent glycerol in 1X TBE and run at 
25 °C at 25 W. Gels were subsequently silver- stained 
according to the manufacturer's instructions (Bio -rad 
Laboratories Ltd., U.K.). Colorectal adenocarcinoma 
cases previously shown to harbour mutations in the 
MCR of APC were included as positive controls. 
RESULTS 
APC/MCC LOH in NSCLC 
A total of 97 NSCLC cases were studied for LOH 
within the APC and MCC genes. Sixty -four of the 90 
consecutive tumours were informative at two or more 
loci (41 adenocarcinoma, 23 squamous carcinomas). 
LOH was seen in 37 per cent (15/41) of adenocarcinomas 
and 48 per cent (11/23) of squamous carcinomas, giving 
an overall LOH of 41 per cent in our informative 
NSCLC cases. Statistical analysis indicated no signifi- 
cant difference in the frequency of LOH between 
squamous carcinomas and adenocarcinomas ( 2= 0.772, 
df =1; P <0.2). 
Within the adenocarcinoma category, which included 
the additional non -randomly selected bronchial adeno- 
carcinomas, there appeared to be a difference between 
tumours of bronchial and parenchymal origin, with 5/9 
(56 per cent) informative adenocarcinomas arising in the 
bronchus showing LOH, while parenchymal cancers 
showed LOH in 6/21 cases (29 per cent). This difference 
falls short of significance at the 5 per cent level. Sixteen 
adenocarcinomas could not be clearly described as aris- 
ing in the bronchus or the parenchyma. LOH was seen 
in eight (50 per cent) of these tumours. 
There was no relationship between LOH and tumour 
stage. In all cases that were informative for polymor- 
phisms in both genes analysed, loss or retention was 
always seen in both APC and MCC; there were no cases 
showing discordance between the two genes. 
Mutation analysis of the APC gene by SSCP 
Thirty -two lung cancer cases were screened for 
mutations in the MCR of APC by SSCP. This group 
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consisted of 21 adenocarcinomas and 11 squamous 
carcinomas. The adenocarcinoma group included five 
non -randomly selected cases of bronchial origin and one 
case of parenchymal origin which showed LOH at one 
or more polymorphic loci. In no case was there a 
difference in the pattern of band mobility between 
control and tumour DNA, providing strong evidence 
against the presence of APC mutation in any of these 
NSCLC cases. 
DISCUSSION 
The long arm of chromosome 5 has recently been the 
focus of much attention in tumour biology. Particular 
attention has been paid to the 5g21 region, the locus of 
APC, the gene responsible for FAP.25 LOH at 5821 has 
been described in a variety of neoplasms including 
carcinomas of the colorectum, stomach, pancreas, 
oesophagus, and kidney.19'28'3 ° -s2 In the present study, 
we have shown that LOH at 5821 is also a feature of 
some 41 per cent of randomly selected NSCLC cases, a 
higher percentage than in a recently published study," 
and that NSCLC exhibiting LOH is not associated with 
mutation of the recognized MCR of APC. 
The APC gene has previously been shown to exhibit 
LOH in various tumour types and a significant mutation 
rate in the MCR of this gene has been described 
in carcinomas of the colorectum, pancreas, and 
stomach.9'19.2o One previous study has looked at a very 
limited series of lung cancers, finding no evidence of 
mutation in seven neoplasms showing genetic loss at this 
locus.19 Our 32 cases showing LOH were screened using 
SSCP and no mutations were detected in the MCR. To 
compute the probability that such a result might have 
been obtained by chance, we used the following logic. In 
sporadic colorectal cancer, more than 60 per cent of 
mutations occur in the MCR, but analysis of these 
colorectal tumours using the SSCP technique has 
detected mutations in only 50 per cent of cases.21 
Therefore it appears that SSCP is detecting approxi- 
mately 80 per cent of mutations. If mutations in the 
MCR of the APC gene were detected as frequently in 
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NSCLC as in colorectal tumours (50 per cent), then the 
probability of obtaining a negative result in our SSCP 
analysis could be calculated by 0.532= 2.33 -10. Simi- 
larly, there is 95 per cent probability that the prevalence 
of detectable mutations is less than 9 per cent. This is 
calculated by taking the statistical confidence limit of 
P <0.05 and solving for x in the equation (1 - x)32 =0.05; 
x= 0.09). This is strong evidence against the involvement 
of the gene in pulmonary carcinogenesis, a finding which 
is consistent with tumour epidemiology, since there is no 
increase in incidence of lung cancer in FAP patients. 
The MCC gene at 5q21 has been described as a 
potentially important tumour suppressor gene. MCC 
was originally identified in colorectal cancer, but more 
recent mutation analysis by SSCP has failed to show 
mutations in a series of 80 carcinomas of the large 
bowel.28 We know of no reports of MCC mutation 
outside the colorectum and it therefore seems increas- 
ingly likely that the status of MCC as a tumour suppres- 
sor gene is in some doubt. Further investigation of this 
association will be necessary, as is a detailed mapping of 
losses at 5q, to localize any other possible tumour 
suppressor genes. Interestingly, a recent study has shown 
that LOH at a novel locus (del 27) lying centromeric to 
5q21 is seen in a high proportion of lung cancers.33 
The few previous reports of genetic losses at 5g21 in 
lung cancer have largely concentrated on SCLC.6'7 A 
recently published study showed LOH in 29 per cent of 
informative NSCLC cases with a marginal but signifi- 
cant difference in the frequency of LOH between 
squamous carcinoma and adenocarcinoma, the former 
being the more frequent.8 Our larger study suggests a 
higher incidence of LOH in NSCLC (41 per cent) but no 
difference in LOH between squamous carcinoma and 
adenocarcinoma. 
Recently there has been accumulating evidence of a 
shift in the histological pattern of pulmonary neoplasia, 
with a relative increase in the proportion of adenocarci- 
nomas, particularly when compared with squamous 
carcinomas and SCLC.9 The recent rise in the incidence 
of adenocarcinomas has been noted particularly to 
involve those arising in the periphery of the lung.34 
Morphological and immunohistochemical studies have 
shown that there may be biological differences between 
adenocarcinomas of bronchial compared with those of 
parenchymal origin. The latter arise on a background 
of alveolar atypical hyperplasia, with demonstrable 
increase in expression of the products of the p53 and 
c- erbB -2 genes.35 It is also evident that adenocarcinomas 
of bronchial origin have a distinctly poorer clinical 
prognosis.18 Our demonstration that LOH at 5q21 
appears to be associated more with bronchial than 
parenchymal adenocarcinomas is intriguing and may, if 
confirmed in a larger series, provide further biological 
support for the proposed subclassification of adenocar- 
cinomas. It may be that LOH at 5q21 is associated with 
the common bronchial neoplasms of all types (squamous 
carcinoma, adenocarcinoma, and SCLC) and is of lesser 
importance in the increasingly frequent parenchymal 
adenocarcinoma. 
We conclude that LOH at 5g21 is more common 
in SCLC than in NSCLC, with no difference in the 
frequency of LOH between adenocarcinomas and 
squamous carcinomas. LOH was detected more fre- 
quently in adenocarcinomas of parenchymal rather than 
bronchial origin, although these results do not reach 
statistical significance. Finally, it seems unlikely that 
APC plays an important role in NSCLC. 
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THE PATTERN OF K -ras MUTATION IN PULMONARY 
ADENOCARCINOMA DEFINES A NEW PATHWAY OF 
TUMOUR DEVELOPMENT IN THE HUMAN LUNG 
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SUMMARY 
Codon 12 of the K -ras oncogene was screened for mutations in 65 surgically -resected primary pulmonary adenocarcinomas and in 32 
tissue foci of alveolar atypical hyperplasia (AAH) by a polymerase chain reaction (PCR) -based method. Mutations in either position I 
or position 2 of codon 12 were detected in 16 tumours (25 per cent). When analysed by site of origin, mutations were seen in 9/26 (35 
per cent) parenchymal and in 0 /12 bronchial adenocarcinomas (P <0.02). K -ras mutations were seen in five AAH lesions from four 
patients. DNA sequencing showed that the great majority of mutations in both adenocarcinomas and AAH were G-T transversions. 
These findings provide support for the classification of pulmonary adenocarcinomas into bronchial and parenchymal subtypes and also 
provide molecular evidence to support the importance of AAH in the development of parenchymal cancers. © 1997 by John Wiley & 
Sons, Ltd. 
J. Pathol. 181: 401 -404, 1997. 
No. of Figures: 2. No. of Tables: 1. No. of References: 17. 
KEY WORDS -lung neoplasms; adenocarcinoma; K -ras; alveolar atypical hyperplasia 
INTRODUCTION 
Important epidemiological and biological features dis- 
Itinguish adenocarcinoma of the lung from other corn- 
mon malignancies arising at this site.1 Little is known for 
certain concerning the histogenesis of adenocarcinoma, 
however, and the morphological classification is some- 
what controversial. The World Health Organisation 
classification of lung cancer recognizes several histologi- 
cal subtypes of primary pulmonary adenocarcinoma but 
has been widely criticized as poorly reproducible and 
lacking a clinical or biological basis.2,3 One alternative 
(classification is based on recognition of the differences 
between those adenocarcinomas taking origin (like 
squamous and small cell tumours) from the bronchi and 
those (the majority) developing in the distal paren- 
chyma.3 We have previously proposed that parenchymal 
adenocarcinomas may arise on a background of alveolar 
atypical hyperplasia (AAH).4 These lesions are charac- 
terized by distinct cytological atypia and have also 
recently been described in other populations, particu- 
larly in North America and Japan.5,6 AAH has been 
shown to have abnormal cytometric DNA profiles and 
to show immunohistochemical evidence of abnormal 
expression of the p53 and c- erb -B2 gene products.7'8 
Mutations in codon 1,2 of the K -ras oncogene have 
been shown to occur in between approximately 10 and 
40 per cent of pulmonary adenocarcinomas.9 -" It has 
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Ninewells Hospital and Medical School, Dundee DD1 9SY, U.K. 
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been suggested that the presence of mutation may be a 
marker of an adverse prognosis in these neoplasms)" I 
One study in a Japanese population has suggested that 
K -ras mutations are associated with tumour dilTeren- 
tiation, being seen more often in mutinous than in other 
types of adenocarcinoma.12 It is, as yet, unclear whether 
there are differences in the occurrence of mutation 
between bronchial and parenchymal adenocarcinomas. 
The aims of the present study were to determine 
whether the K -ras mutation associates predominantly 
with one or other subtype and to investigate the occur- 
rence of these mutations in the potentially premalignant 
lesions of AAH. 
MATERIALS AND METHODS 
Tissue samples 
All cases included in this study have previously been 
reported in an investigation of loss of heterozygosity at 
chromosome 5g21 in lung cancer.13 DNA was extracted 
from tumour -containing paraffin blocks of 65 surgically 
resected primary adenocarcinomas of lung using pre- 
viously described methods.13 Tumour samples were 
selected so as to minimize stromal and inflammatory 
contamination. Non- tumour (control) DNA was 
extracted from uninvolved lymph node tissue. The series 
of 65 comprised 58 consecutive resected adenocarcino- 
mas, 26 (45 per cent) being of parenchymal type, 5 (9 per 
cent) showing a bronchial origin, and 27 (47 per cent) 
that could not be accurately classified. Seven additional 
bronchial adenocarcinomas were included as these 
lesions are, in our experience, somewhat less common 
Received 24 July /996 
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Fig. 1 -A focus of AAH. The normal pulmonary parenchymal 
architecture is retained but shows alveolar wall thickening. The lesion 
is lined by a population of plump, cytologically atypical cells morpho- 
logically resembling type II alveolar lining cells. This particular lesion 
measured 2.5 mm in maximum dimension and harboured a G -T 
transversion at position 1 of codon 12 of K-ras 
than parenchymal carcinomas.13 Classification of the 
adenocarcinomas into bronchial and parenchymal sub- 
types was based on review of macroscopic and histologi- 
cal features. The parenchymal tumours were defined by 
a lipidic growth pattern and contained significant popu- 
lations of cells resembling type 2 alveolar lining cells or 
Clara cells.3 Bronchial adenocarcinomas were centred 
on, and frequently disrupted, large airways and tended 
to show an acinar or papillary pattern. Tumours not 
clearly fitting either of these categories, often larger, 
poorly differentiated neoplasms, were considered 
separately as of uncertain or mixed histogenesis. 
AAH was sought in non -tumour parenchyma of all 
cases included in this study (Fig. 1). Alveolar cell 
hyperplasia or atypic found in direct continuity with 
obvious tumour was not classified as AAH. Material 
used in a previous investigation was reviewed and 
included where sufficient AAH tissue was available.8 
Sections of the AAH were cut at 10 ,um, dewaxed, and 
stained with eosin. The slides were examined under the 
microscope and areas of AAH marked and removed by 
microdissection. DNA was extracted into a volume of 
50 -100pl of lysis buffer, depending on the size of the 
AAH lesion. The lysis buffer comprised 10 mm Tris at 
pH 8.3, 50 mm KC1, 0.45 per cent (v /v) Tween 20, and 
2.5 mm MgC12 containing 1.25 mg/ml proteinase K. 
Screening for K -ras codon 12 mutations 
Polymerase chain reaction (PCR) was applied to 
tumour and normal DNA to amplify a 157 base pair 
(bp) product encompassing codon 12 of the K -ras gene. 
The primers used incorporated mismatches designed to 
create two BstNl 1 restriction endonuclease sites in the 
normal gene.14 One of these cleavage sites was within the 
3' primer; it acted as a control for complete BstNl 
digestion and generated a 14 bp fragment. The 5' primer, 
within exon 1, contained a cytosine substitution corre- 
sponding to the first position of codon 11, thus creating 
a BstN 1 recognition site extending into positions 1 and 2 
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Fig. 2- Detection and sequencing of K -ras mutations. (a) Paired 
tumour (T) and normal (N) samples are run against uncut PCR 
product (U) and molecular weight markers (M). Case 1 shows 
complete cleavage of the tumour DNA but with loss of the BstNl 
restriction site extending into codon 12, thus generating a `mutated' 
band of 143 bp. Case 2 shows no evidence of mutation. (b) Sequencing 
gel showing a G -T transversion at position 1 of codon 12 (arrowed) 
of codon 12 which are outside the primer sequences. 
Mutations in either of the first two positions of codon 12 
result in loss of this restriction site and can thus be 
identified by gel electrophoresis. 
PCRs were carried out in 100 ,u1 volumes containing 
10 ,al of DNA, 0-5 ,um of each primer, 1.5 mM MgC12, 
0.2 mm of each dNTP, and 2.5 units of Taq polymerase 
(Gibco BRL, U.K.) made up in PCR buffer (Gibco 
BRL, U.K.). Cycling conditions were as follows: an 
initial denaturation step of 5 min at 94 °C followed by 
30-38 cycles of 30 s denaturation at 94 °C, annealing at 
55 °C, and extension at 72 °C, with a final extension step 
of 10 min at 72 °C. Following amplification, 20µ1 of 
PCR product was digested at 60 °C overnight with 10 
units of BstNI [New England Biolabs (U.K.) Ltd.]. 
Digested PCR products were run on a 3 per cent agarose 
gel stained with ethidium bromide and sizes compared 
with molecular weight markers. Samples which did not 
contain codon 12 mutations generated 114 bp frag- 
ments whilst mutated samples, having lost the second 
BstNl restriction site, yielded larger fragments at 143 bp 
(Fig. 2). 
Sequencing K -ras mutations 
Samples shown to carry a mutation at codon 12 were 
analysed by sequencing. Tumour and normal samples 
were amplified by PCR using a biotinylated exon 
1 
primer 5'GACTGAATATAAACTTGTGG3' and 
the 
previous intron 1 3' primer. Cycling conditions were 
as 






























































K -ras IN PULMONARY ADENOCARCINOMA 
Table I -K -ras mutational analysis in alveolar atypical hyper - 
plasia (AAH) in 16 patients. K -ras mut refers to the presence 
or absence of abnormal bands on BstN 1 digests. The normal 
codon 12 sequence is GGT 






























12 12a eod 
13 13a TGT 
14 14a 
15 15a TGT 
16 16a 
streptavidin- coated magnetic beads (Dynal, Norway) 
and sequenced using the Sequenase version II sequenc- 
ing kit (Amersham International, U.K.). 
In some AAH lesions, possibly because of a high 
`background' of wild -type K -ras, mutations were only 
indistinctly visible on both the BstN1 and the sequenc- 
ing gels. In these cases (la, lb, 15a of Table I) a further 
PCR was included to enrich for the mutant allele. 
BstNl- digested samples were amplified using the bio- 
tinylated exon 1 primer and a new downstream primer in 
exon 1 (5'CTCTATTGTTGGATCATATT 3'). Ampli- 
fied samples were then sequenced as before. The unusual 
pattern of mutation seen in lesions la and lb (Table I) 
was confirmed by cloning the PCR product (Original 
TA Cloning Kit, Invitrogen) and sequencing again as 
before. 
RESULTS 
The BstN 1 assay for K -ras mutation was successfully 
Ipplied to all 65 adenocarcinomas. Mutations in codon 
1997 by John Wiley & Sons, Ltd. 
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12 of the gene were detected in 16 cases (25 per cent). 
DNA sequencing showed that nine tumours had G -T 
transversions at position 1; G -T transversions at pos- 
ition 2 were seen in six cases; and one had a G -A 
transition at position 2 (Fig. 2). There was a strong 
relationship between tumour subtype and presence of 
K -ras mutation, with 9/26 (35 per cent) parenchymal 
lesions showing mutation while none of the 12 bronchial 
adenocarcinomas had evidence of codon 12 abnormality 
(P= 0.019, Fisher's exact test). The mutation incidence in 
the unclassified tumours (7/27, 26 per cent) was the same 
as for the series as a whole. 
Foci of AAH were available from 16 patients yielding 
a total of 32 lesions, with between one and six distinct 
foci per case (mean 2.0). The results of the mutational 
analysis on these lesions are summarized in Table I. 
Evidence of K -ras mutation was seen in five AAH (15 
per cent) from four patients. One of these patients had 
an associated adenocarcinoma. This was not mutated. 
AAH mutations were confirmed by sequencing (Table I) 
showing in general a similar pattern to adenocarcinomas 
but with one unusual lesion showing G -T transversions 
at both positions 1 and 2 of codon 12. This mutation 
was confirmed by cloning. 
DISCUSSION 
Classification of primary pulmonary adenocarcino- 
mas into parenchymal and bronchial subtypes has been 
advocated as a clinically relevant distinction, with the 
latter having a worse prognosis.3 Histologically, bron- 
chial adenocarcinomas share morphological features 
with either the normal bronchial lining cells or the cells 
of bronchial glands, while parenchymal cancers fre- 
quently show alveolar lining or Clara cell differen- 
tiation.3 In a previous study, we have shown that loss of 
heterozygosity at chromosome 5g21, although occur- 
ring in a proportion of both tumour types, appears to 
be more common in tumours of bronchial than paren- 
chymal origin.13 Here we have analysed the same 
tumours and have demonstrated a significant difference 
in the frequency of K -ras codon 12 mutations between 
the two subtypes, K -ras mutations being present in 
about one -third of adenocarcinomas arising in the 
parenchyma but not detected in bronchial adenocarci- 
nomas. We have compared the results of the studies and 
have found no evidence of a relationship between K -ras 
mutation status and retention or loss of heterozygosity 
at 5q. There is now clear evidence for a genetic differ- 
ence between the two subtypes of adenocarcinoma. 
Although we believe this to be the first unequivocal 
demonstration of this difference, it is interesting to note 
that, in other reported studies in lung tumours, the 
incidence of K -ras codon 12 mutations varies from 10 
to 40 per cent, perhaps reflecting different ratios of 
bronchial to parenchymal adenocarcinomas included 
in these studies.9 -12 
The data also support the proposal that parenchymal 
(but not bronchial) adenocarcinomas derive from AAH, 
since this shares with parenchymal adenocarcinoma a 
predilection for clonal expansion of cells bearing 
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mutated K -ras. Foci of hyperplasia of atypical alveolar 
lining cells, usually with an associated expansion of the 
interstitial connective tissue, have been noted for at least 
30 years but it is only recently that the significance of 
these lesions as putative progenitors of parenchymal 
adenocarcinoma has been emphasized.4.8,15 Initial sus- 
picion that AAH is a premalignant phenotype was on 
morphological criteria but this has been heightened by 
immunohistochemical evidence of expression of prolifer- 
ation antigens and of the c- erb -B2 and stabilized p53 
proteins.4,8 Our demonstration of mutations in codon 12 
of the K -ras oncogene is unequivocal molecular proof of 
genetic abnormality in AAH and confirms a recently 
published study describing K -ras mutations in 16/41 
AAH.16 
Finally, the nature of the mutations in K -ras gives 
some clue to the underlying carcinogenic process in 
AAH and parenchymal adenocarcinomas of the lung. 
Sequence analysis revealed that 94 per cent of mutations 
were G -T transversions, a predominance reflected in 
other point mutations in cancer -related genes in respir- 
atory epithelium.17 This type of mutation is entirely 
consistent with origin from mismatched nucleotides 
inserted in attempted repair of deoxyguanosine oxi- 
dation metabolites, presumably generated by exposure 
to inhaled carcinogens. Our data also clearly show 
that separate foci of AAH within the lung are geneti- 
cally distinct with respect to K -ras mutation. Several 
patients had both mutated and non -mutated AAH 
(Table I). One had a mutated AAH but no evidence of 
mutation in the co- existing adenocarcinoma. Interest- 
ingly, one individual (patient 1, Table I) harboured two 
AAH lesions with different K -ras mutations, one of 
which was a double G -T transversion involving pos- 
itions 1 and 2 of codon 12. These associations would 
tend to refute early speculation that AAH lesions might 
possibly represent intrapulmonary spread of primary 
adenocarcinoma and further strengthen the puta- 
tive role of AAH as an independent neoplastic pro- 
liferation and a possible precursor of parenchymal 
adenocarcinoma. 
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